id	sid	tid	token	lemma	pos
aiua-12307	1	1	stesura	stesura	PROPN
aiua-12307	1	2	seveso	seveso	PROPN
aiua-12307	1	3	archivio	archivio	PROPN
aiua-12307	1	4	italiano	italiano	X
aiua-12307	1	5	di	di	X
aiua-12307	1	6	urologia	urologia	PROPN
aiua-12307	1	7	e	e	PROPN
aiua-12307	1	8	andrologia	andrologia	NOUN
aiua-12307	1	9	2024	2024	NUM
aiua-12307	1	10	;	;	PUNCT
aiua-12307	1	11	96(2):12307	96(2):12307	NUM
aiua-12307	1	12	1	1	NUM
aiua-12307	1	13	review	review	NOUN
aiua-12307	1	14	introduction	introduction	NOUN
aiua-12307	1	15	the	the	DET
aiua-12307	1	16	immune	immune	ADJ
aiua-12307	1	17	system	system	NOUN
aiua-12307	1	18	plays	play	VERB
aiua-12307	1	19	a	a	DET
aiua-12307	1	20	vital	vital	ADJ
aiua-12307	1	21	role	role	NOUN
aiua-12307	1	22	in	in	ADP
aiua-12307	1	23	preventing	prevent	VERB
aiua-12307	1	24	and	and	CCONJ
aiua-12307	1	25	defending	defend	VERB
aiua-12307	1	26	against	against	ADP
aiua-12307	1	27	cancer	cancer	NOUN
aiua-12307	1	28	.	.	PUNCT
aiua-12307	2	1	in	in	ADP
aiua-12307	2	2	recent	recent	ADJ
aiua-12307	2	3	years	year	NOUN
aiua-12307	2	4	,	,	PUNCT
aiua-12307	2	5	significant	significant	ADJ
aiua-12307	2	6	advances	advance	NOUN
aiua-12307	2	7	have	have	AUX
aiua-12307	2	8	been	be	AUX
aiua-12307	2	9	made	make	VERB
aiua-12307	2	10	in	in	ADP
aiua-12307	2	11	understanding	understand	VERB
aiua-12307	2	12	the	the	DET
aiua-12307	2	13	immune	immune	ADJ
aiua-12307	2	14	system	system	NOUN
aiua-12307	2	15	and	and	CCONJ
aiua-12307	2	16	its	its	PRON
aiua-12307	2	17	role	role	NOUN
aiua-12307	2	18	in	in	ADP
aiua-12307	2	19	cancer	cancer	NOUN
aiua-12307	2	20	.	.	PUNCT
aiua-12307	3	1	immunotherapy	immunotherapy	NOUN
aiua-12307	3	2	is	be	AUX
aiua-12307	3	3	the	the	DET
aiua-12307	3	4	golden	golden	ADJ
aiua-12307	3	5	child	child	NOUN
aiua-12307	3	6	of	of	ADP
aiua-12307	3	7	medical	medical	ADJ
aiua-12307	3	8	oncology	oncology	NOUN
aiua-12307	3	9	and	and	CCONJ
aiua-12307	3	10	a	a	DET
aiua-12307	3	11	new	new	ADJ
aiua-12307	3	12	approach	approach	NOUN
aiua-12307	3	13	to	to	ADP
aiua-12307	3	14	cancer	cancer	NOUN
aiua-12307	3	15	treatment	treatment	NOUN
aiua-12307	3	16	(	(	PUNCT
aiua-12307	3	17	1	1	NUM
aiua-12307	3	18	)	)	PUNCT
aiua-12307	3	19	.	.	PUNCT
aiua-12307	4	1	the	the	DET
aiua-12307	4	2	origin	origin	NOUN
aiua-12307	4	3	of	of	ADP
aiua-12307	4	4	immunotherapy	immunotherapy	NOUN
aiua-12307	4	5	in	in	ADP
aiua-12307	4	6	urological	urological	ADJ
aiua-12307	4	7	cancers	cancer	NOUN
aiua-12307	4	8	was	be	AUX
aiua-12307	4	9	found	find	VERB
aiua-12307	4	10	in	in	ADP
aiua-12307	4	11	1976	1976	NUM
aiua-12307	4	12	by	by	ADP
aiua-12307	4	13	morales	morale	NOUN
aiua-12307	4	14	et	et	PROPN
aiua-12307	4	15	al	al	PROPN
aiua-12307	4	16	.	.	PUNCT
aiua-12307	5	1	it	it	PRON
aiua-12307	5	2	started	start	VERB
aiua-12307	5	3	with	with	ADP
aiua-12307	5	4	the	the	DET
aiua-12307	5	5	introduction	introduction	NOUN
aiua-12307	5	6	of	of	ADP
aiua-12307	5	7	bacillus	bacillus	NOUN
aiua-12307	5	8	calmette	calmette	NOUN
aiua-12307	5	9	-	-	PUNCT
aiua-12307	5	10	gueren	gueren	PROPN
aiua-12307	5	11	(	(	PUNCT
aiua-12307	5	12	bcg	bcg	PROPN
aiua-12307	5	13	)	)	PUNCT
aiua-12307	5	14	treatment	treatment	NOUN
aiua-12307	5	15	for	for	ADP
aiua-12307	5	16	superficial	superficial	ADJ
aiua-12307	5	17	bladder	bladder	NOUN
aiua-12307	5	18	cancer	cancer	NOUN
aiua-12307	5	19	(	(	PUNCT
aiua-12307	5	20	bc	bc	PROPN
aiua-12307	5	21	)	)	PUNCT
aiua-12307	5	22	(	(	PUNCT
aiua-12307	5	23	2	2	NUM
aiua-12307	5	24	)	)	PUNCT
aiua-12307	5	25	.	.	PUNCT
aiua-12307	6	1	this	this	DET
aiua-12307	6	2	development	development	NOUN
aiua-12307	6	3	was	be	AUX
aiua-12307	6	4	followed	follow	VERB
aiua-12307	6	5	by	by	ADP
aiua-12307	6	6	the	the	DET
aiua-12307	6	7	introduction	introduction	NOUN
aiua-12307	6	8	of	of	ADP
aiua-12307	6	9	cytokines	cytokine	NOUN
aiua-12307	6	10	such	such	ADJ
aiua-12307	6	11	as	as	ADP
aiua-12307	6	12	interferon	interferon	NOUN
aiua-12307	6	13	and	and	CCONJ
aiua-12307	6	14	interleukin-2	interleukin-2	NOUN
aiua-12307	6	15	(	(	PUNCT
aiua-12307	6	16	il-2	il-2	NUM
aiua-12307	6	17	)	)	PUNCT
aiua-12307	6	18	in	in	ADP
aiua-12307	6	19	the	the	DET
aiua-12307	6	20	treatment	treatment	NOUN
aiua-12307	6	21	of	of	ADP
aiua-12307	6	22	metastatic	metastatic	ADJ
aiua-12307	6	23	renal	renal	ADJ
aiua-12307	6	24	cell	cell	NOUN
aiua-12307	6	25	carcinoma	carcinoma	NOUN
aiua-12307	6	26	(	(	PUNCT
aiua-12307	6	27	mrcc	mrcc	NOUN
aiua-12307	6	28	)	)	PUNCT
aiua-12307	6	29	.	.	PUNCT
aiua-12307	7	1	one	one	NUM
aiua-12307	7	2	of	of	ADP
aiua-12307	7	3	the	the	DET
aiua-12307	7	4	first	first	ADJ
aiua-12307	7	5	reports	report	NOUN
aiua-12307	7	6	demonstrating	demonstrate	VERB
aiua-12307	7	7	the	the	DET
aiua-12307	7	8	potential	potential	ADJ
aiua-12307	7	9	application	application	NOUN
aiua-12307	7	10	of	of	ADP
aiua-12307	7	11	immune	immune	ADJ
aiua-12307	7	12	modulation	modulation	NOUN
aiua-12307	7	13	in	in	ADP
aiua-12307	7	14	cancer	cancer	NOUN
aiua-12307	7	15	treatment	treatment	NOUN
aiua-12307	7	16	was	be	AUX
aiua-12307	7	17	in	in	ADP
aiua-12307	7	18	1984	1984	NUM
aiua-12307	7	19	,	,	PUNCT
aiua-12307	7	20	when	when	SCONJ
aiua-12307	7	21	the	the	DET
aiua-12307	7	22	administration	administration	NOUN
aiua-12307	7	23	of	of	ADP
aiua-12307	7	24	il-2	il-2	PROPN
aiua-12307	7	25	in	in	ADP
aiua-12307	7	26	a	a	DET
aiua-12307	7	27	patient	patient	NOUN
aiua-12307	7	28	diagnosed	diagnose	VERB
aiua-12307	7	29	with	with	ADP
aiua-12307	7	30	melanoma	melanoma	NOUN
aiua-12307	7	31	reduced	reduce	VERB
aiua-12307	7	32	the	the	DET
aiua-12307	7	33	tumour	tumour	NOUN
aiua-12307	7	34	burden	burden	NOUN
aiua-12307	7	35	.	.	PUNCT
aiua-12307	8	1	this	this	DET
aiua-12307	8	2	report	report	NOUN
aiua-12307	8	3	has	have	AUX
aiua-12307	8	4	since	since	SCONJ
aiua-12307	8	5	led	lead	VERB
aiua-12307	8	6	to	to	ADP
aiua-12307	8	7	significant	significant	ADJ
aiua-12307	8	8	interest	interest	NOUN
aiua-12307	8	9	in	in	ADP
aiua-12307	8	10	the	the	DET
aiua-12307	8	11	field	field	NOUN
aiua-12307	8	12	of	of	ADP
aiua-12307	8	13	immunology	immunology	NOUN
aiua-12307	8	14	and	and	CCONJ
aiua-12307	8	15	its	its	PRON
aiua-12307	8	16	role	role	NOUN
aiua-12307	8	17	in	in	ADP
aiua-12307	8	18	managing	manage	VERB
aiua-12307	8	19	various	various	ADJ
aiua-12307	8	20	malignancies	malignancy	NOUN
aiua-12307	8	21	(	(	PUNCT
aiua-12307	8	22	3	3	NUM
aiua-12307	8	23	)	)	PUNCT
aiua-12307	8	24	.	.	PUNCT
aiua-12307	9	1	in	in	ADP
aiua-12307	9	2	2010	2010	NUM
aiua-12307	9	3	,	,	PUNCT
aiua-12307	9	4	it	it	PRON
aiua-12307	9	5	joined	join	VERB
aiua-12307	9	6	the	the	DET
aiua-12307	9	7	field	field	NOUN
aiua-12307	9	8	of	of	ADP
aiua-12307	9	9	prostate	prostate	NOUN
aiua-12307	9	10	cancer	cancer	NOUN
aiua-12307	9	11	immunotherapy	immunotherapy	NOUN
aiua-12307	9	12	with	with	ADP
aiua-12307	9	13	the	the	DET
aiua-12307	9	14	approval	approval	NOUN
aiua-12307	9	15	of	of	ADP
aiua-12307	9	16	the	the	DET
aiua-12307	9	17	autologous	autologous	ADJ
aiua-12307	9	18	cancer	cancer	NOUN
aiua-12307	9	19	vaccine	vaccine	NOUN
aiua-12307	9	20	sipuleucel	sipuleucel	NOUN
aiua-12307	9	21	-	-	PUNCT
aiua-12307	9	22	t.	t.	NOUN
aiua-12307	9	23	more	more	ADV
aiua-12307	9	24	recently	recently	ADV
aiua-12307	9	25	,	,	PUNCT
aiua-12307	9	26	immune	immune	ADJ
aiua-12307	9	27	checkpoint	checkpoint	NOUN
aiua-12307	9	28	inhibitors	inhibitor	NOUN
aiua-12307	9	29	(	(	PUNCT
aiua-12307	9	30	icis	icis	NOUN
aiua-12307	9	31	)	)	PUNCT
aiua-12307	9	32	have	have	AUX
aiua-12307	9	33	been	be	AUX
aiua-12307	9	34	introduced	introduce	VERB
aiua-12307	9	35	with	with	ADP
aiua-12307	9	36	striking	striking	ADJ
aiua-12307	9	37	results	result	NOUN
aiua-12307	9	38	for	for	ADP
aiua-12307	9	39	urology	urology	NOUN
aiua-12307	9	40	-	-	PUNCT
aiua-12307	9	41	specific	specific	ADJ
aiua-12307	9	42	malignancies	malignancy	NOUN
aiua-12307	9	43	.	.	PUNCT
aiua-12307	10	1	the	the	DET
aiua-12307	10	2	introduction	introduction	NOUN
aiua-12307	10	3	of	of	ADP
aiua-12307	10	4	icis	icis	PROPN
aiua-12307	10	5	over	over	ADP
aiua-12307	10	6	the	the	DET
aiua-12307	10	7	past	past	ADJ
aiua-12307	10	8	decade	decade	NOUN
aiua-12307	10	9	has	have	AUX
aiua-12307	10	10	led	lead	VERB
aiua-12307	10	11	to	to	ADP
aiua-12307	10	12	significant	significant	ADJ
aiua-12307	10	13	advances	advance	NOUN
aiua-12307	10	14	in	in	ADP
aiua-12307	10	15	cancer	cancer	NOUN
aiua-12307	10	16	treatment	treatment	NOUN
aiua-12307	10	17	.	.	PUNCT
aiua-12307	11	1	recent	recent	ADJ
aiua-12307	11	2	advances	advance	NOUN
aiua-12307	11	3	in	in	ADP
aiua-12307	11	4	immunotherapy	immunotherapy	NOUN
aiua-12307	11	5	treatment	treatment	NOUN
aiua-12307	11	6	promise	promise	NOUN
aiua-12307	11	7	to	to	PART
aiua-12307	11	8	significantly	significantly	ADV
aiua-12307	11	9	transform	transform	VERB
aiua-12307	11	10	the	the	DET
aiua-12307	11	11	field	field	NOUN
aiua-12307	11	12	of	of	ADP
aiua-12307	11	13	uro	uro	NOUN
aiua-12307	11	14	-	-	PUNCT
aiua-12307	11	15	oncology	oncology	NOUN
aiua-12307	11	16	.	.	PUNCT
aiua-12307	12	1	in	in	ADP
aiua-12307	12	2	this	this	DET
aiua-12307	12	3	review	review	NOUN
aiua-12307	12	4	,	,	PUNCT
aiua-12307	12	5	we	we	PRON
aiua-12307	12	6	aimed	aim	VERB
aiua-12307	12	7	to	to	PART
aiua-12307	12	8	summarize	summarize	VERB
aiua-12307	12	9	the	the	DET
aiua-12307	12	10	use	use	NOUN
aiua-12307	12	11	of	of	ADP
aiua-12307	12	12	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	12	13	agents	agent	NOUN
aiua-12307	12	14	in	in	ADP
aiua-12307	12	15	treating	treat	VERB
aiua-12307	12	16	urothelial	urothelial	ADJ
aiua-12307	12	17	,	,	PUNCT
aiua-12307	12	18	renal	renal	ADJ
aiua-12307	12	19	and	and	CCONJ
aiua-12307	12	20	prostate	prostate	NOUN
aiua-12307	12	21	cancer	cancer	NOUN
aiua-12307	12	22	in	in	ADP
aiua-12307	12	23	the	the	DET
aiua-12307	12	24	light	light	NOUN
aiua-12307	12	25	of	of	ADP
aiua-12307	12	26	clinical	clinical	ADJ
aiua-12307	12	27	studies	study	NOUN
aiua-12307	12	28	.	.	PUNCT
aiua-12307	13	1	urothelial	urothelial	ADJ
aiua-12307	13	2	carcinoma	carcinoma	ADJ
aiua-12307	13	3	urothelial	urothelial	ADJ
aiua-12307	13	4	carcinoma	carcinoma	NOUN
aiua-12307	13	5	can	can	AUX
aiua-12307	13	6	occur	occur	VERB
aiua-12307	13	7	along	along	ADP
aiua-12307	13	8	the	the	DET
aiua-12307	13	9	entire	entire	ADJ
aiua-12307	13	10	urothelium	urothelium	NOUN
aiua-12307	13	11	,	,	PUNCT
aiua-12307	13	12	which	which	PRON
aiua-12307	13	13	anatomically	anatomically	ADV
aiua-12307	13	14	extends	extend	VERB
aiua-12307	13	15	from	from	ADP
aiua-12307	13	16	the	the	DET
aiua-12307	13	17	kidney	kidney	NOUN
aiua-12307	13	18	to	to	ADP
aiua-12307	13	19	the	the	DET
aiua-12307	13	20	urethra	urethra	NOUN
aiua-12307	13	21	.	.	PUNCT
aiua-12307	14	1	urothelial	urothelial	ADJ
aiua-12307	14	2	carcinomas	carcinoma	NOUN
aiua-12307	14	3	can	can	AUX
aiua-12307	14	4	generally	generally	ADV
aiua-12307	14	5	be	be	AUX
aiua-12307	14	6	examined	examine	VERB
aiua-12307	14	7	under	under	ADP
aiua-12307	14	8	two	two	NUM
aiua-12307	14	9	main	main	ADJ
aiua-12307	14	10	headings	heading	NOUN
aiua-12307	14	11	:	:	PUNCT
aiua-12307	14	12	upper	upper	ADJ
aiua-12307	14	13	urinary	urinary	ADJ
aiua-12307	14	14	tract	tract	NOUN
aiua-12307	14	15	urothelial	urothelial	ADJ
aiua-12307	14	16	carcinomas	carcinoma	NOUN
aiua-12307	14	17	(	(	PUNCT
aiua-12307	14	18	utuc	utuc	NOUN
aiua-12307	14	19	)	)	PUNCT
aiua-12307	14	20	and	and	CCONJ
aiua-12307	14	21	lower	low	ADJ
aiua-12307	14	22	urinary	urinary	ADJ
aiua-12307	14	23	tract	tract	NOUN
aiua-12307	14	24	urothelial	urothelial	ADJ
aiua-12307	14	25	carcinomas	carcinoma	NOUN
aiua-12307	14	26	.	.	PUNCT
aiua-12307	15	1	it	it	PRON
aiua-12307	15	2	is	be	AUX
aiua-12307	15	3	often	often	ADV
aiua-12307	15	4	not	not	PART
aiua-12307	15	5	possible	possible	ADJ
aiua-12307	15	6	to	to	PART
aiua-12307	15	7	evaluate	evaluate	VERB
aiua-12307	15	8	these	these	DET
aiua-12307	15	9	two	two	NUM
aiua-12307	15	10	main	main	ADJ
aiua-12307	15	11	topics	topic	NOUN
aiua-12307	15	12	independently	independently	ADV
aiua-12307	15	13	.	.	PUNCT
aiua-12307	16	1	bc	bc	PROPN
aiua-12307	16	2	accounts	account	VERB
aiua-12307	16	3	for	for	ADP
aiua-12307	16	4	90	90	NUM
aiua-12307	16	5	-	-	SYM
aiua-12307	16	6	95	95	NUM
aiua-12307	16	7	%	%	NOUN
aiua-12307	16	8	of	of	ADP
aiua-12307	16	9	urothelial	urothelial	ADJ
aiua-12307	16	10	carcinomas	carcinoma	NOUN
aiua-12307	16	11	,	,	PUNCT
aiua-12307	16	12	utuc	utuc	NOUN
aiua-12307	16	13	accounts	account	VERB
aiua-12307	16	14	for	for	ADP
aiua-12307	16	15	5	5	NUM
aiua-12307	16	16	-	-	SYM
aiua-12307	16	17	10	10	NUM
aiua-12307	16	18	%	%	NOUN
aiua-12307	16	19	,	,	PUNCT
aiua-12307	16	20	and	and	CCONJ
aiua-12307	16	21	urethral	urethral	ADJ
aiua-12307	16	22	cancer	cancer	NOUN
aiua-12307	16	23	accounts	account	VERB
aiua-12307	16	24	for	for	ADP
aiua-12307	16	25	1	1	NUM
aiua-12307	16	26	%	%	NOUN
aiua-12307	16	27	(	(	PUNCT
aiua-12307	16	28	4	4	NUM
aiua-12307	16	29	)	)	PUNCT
aiua-12307	16	30	.	.	PUNCT
aiua-12307	17	1	today	today	NOUN
aiua-12307	17	2	,	,	PUNCT
aiua-12307	17	3	in	in	ADP
aiua-12307	17	4	most	most	ADJ
aiua-12307	17	5	studies	study	NOUN
aiua-12307	17	6	on	on	ADP
aiua-12307	17	7	the	the	DET
aiua-12307	17	8	role	role	NOUN
aiua-12307	17	9	of	of	ADP
aiua-12307	17	10	immunotherapy	immunotherapy	NOUN
aiua-12307	17	11	in	in	ADP
aiua-12307	17	12	urothelial	urothelial	ADJ
aiua-12307	17	13	carcinoma	carcinoma	NOUN
aiua-12307	17	14	,	,	PUNCT
aiua-12307	17	15	bc	bc	PROPN
aiua-12307	17	16	and	and	CCONJ
aiua-12307	17	17	utuc	utuc	NOUN
aiua-12307	17	18	have	have	AUX
aiua-12307	17	19	been	be	AUX
aiua-12307	17	20	evaluated	evaluate	VERB
aiua-12307	17	21	together	together	ADV
aiua-12307	17	22	.	.	PUNCT
aiua-12307	18	1	bc	bc	PROPN
aiua-12307	18	2	is	be	AUX
aiua-12307	18	3	the	the	DET
aiua-12307	18	4	10th	10th	ADJ
aiua-12307	18	5	most	most	ADV
aiua-12307	18	6	common	common	ADJ
aiua-12307	18	7	cancer	cancer	NOUN
aiua-12307	18	8	in	in	ADP
aiua-12307	18	9	the	the	DET
aiua-12307	18	10	entire	entire	ADJ
aiua-12307	18	11	population	population	NOUN
aiua-12307	18	12	and	and	CCONJ
aiua-12307	18	13	the	the	DET
aiua-12307	18	14	7th	7th	ADJ
aiua-12307	18	15	most	most	ADV
aiua-12307	18	16	common	common	ADJ
aiua-12307	18	17	cancer	cancer	NOUN
aiua-12307	18	18	in	in	ADP
aiua-12307	18	19	men	man	NOUN
aiua-12307	18	20	.	.	PUNCT
aiua-12307	19	1	bc	bc	PROPN
aiua-12307	19	2	is	be	AUX
aiua-12307	19	3	responsible	responsible	ADJ
aiua-12307	19	4	for	for	ADP
aiua-12307	19	5	2.1	2.1	NUM
aiua-12307	19	6	%	%	NOUN
aiua-12307	19	7	of	of	ADP
aiua-12307	19	8	cancer	cancer	NOUN
aiua-12307	19	9	-	-	PUNCT
aiua-12307	19	10	related	relate	VERB
aiua-12307	19	11	deaths	death	NOUN
aiua-12307	19	12	and	and	CCONJ
aiua-12307	19	13	is	be	AUX
aiua-12307	19	14	the	the	DET
aiua-12307	19	15	13th	13th	ADJ
aiua-12307	19	16	deadliest	deadly	ADJ
aiua-12307	19	17	cancer	cancer	NOUN
aiua-12307	19	18	(	(	PUNCT
aiua-12307	19	19	5	5	NUM
aiua-12307	19	20	)	)	PUNCT
aiua-12307	19	21	.	.	PUNCT
aiua-12307	20	1	at	at	ADP
aiua-12307	20	2	the	the	DET
aiua-12307	20	3	time	time	NOUN
aiua-12307	20	4	of	of	ADP
aiua-12307	20	5	initial	initial	ADJ
aiua-12307	20	6	diagnoimmunotherapy	diagnoimmunotherapy	NOUN
aiua-12307	20	7	is	be	AUX
aiua-12307	20	8	defined	define	VERB
aiua-12307	20	9	as	as	ADP
aiua-12307	20	10	a	a	DET
aiua-12307	20	11	therapeutic	therapeutic	ADJ
aiua-12307	20	12	approach	approach	NOUN
aiua-12307	20	13	that	that	PRON
aiua-12307	20	14	targets	target	VERB
aiua-12307	20	15	or	or	CCONJ
aiua-12307	20	16	manipulates	manipulate	VERB
aiua-12307	20	17	the	the	DET
aiua-12307	20	18	immune	immune	ADJ
aiua-12307	20	19	system	system	NOUN
aiua-12307	20	20	.	.	PUNCT
aiua-12307	21	1	a	a	DET
aiua-12307	21	2	deeper	deep	ADJ
aiua-12307	21	3	understanding	understanding	NOUN
aiua-12307	21	4	of	of	ADP
aiua-12307	21	5	the	the	DET
aiua-12307	21	6	cellular	cellular	ADJ
aiua-12307	21	7	and	and	CCONJ
aiua-12307	21	8	molecular	molecular	ADJ
aiua-12307	21	9	composition	composition	NOUN
aiua-12307	21	10	of	of	ADP
aiua-12307	21	11	the	the	DET
aiua-12307	21	12	tumour	tumour	NOUN
aiua-12307	21	13	environment	environment	NOUN
aiua-12307	21	14	,	,	PUNCT
aiua-12307	21	15	as	as	ADV
aiua-12307	21	16	well	well	ADV
aiua-12307	21	17	as	as	ADP
aiua-12307	21	18	the	the	DET
aiua-12307	21	19	mechanisms	mechanism	NOUN
aiua-12307	21	20	controlling	control	VERB
aiua-12307	21	21	the	the	DET
aiua-12307	21	22	immune	immune	ADJ
aiua-12307	21	23	system	system	NOUN
aiua-12307	21	24	,	,	PUNCT
aiua-12307	21	25	has	have	AUX
aiua-12307	21	26	made	make	VERB
aiua-12307	21	27	possible	possible	ADJ
aiua-12307	21	28	the	the	DET
aiua-12307	21	29	development	development	NOUN
aiua-12307	21	30	and	and	CCONJ
aiua-12307	21	31	clinical	clinical	ADJ
aiua-12307	21	32	investigation	investigation	NOUN
aiua-12307	21	33	of	of	ADP
aiua-12307	21	34	many	many	ADJ
aiua-12307	21	35	innovative	innovative	ADJ
aiua-12307	21	36	cancer	cancer	NOUN
aiua-12307	21	37	therapies	therapy	NOUN
aiua-12307	21	38	.	.	PUNCT
aiua-12307	22	1	historically	historically	ADV
aiua-12307	22	2	,	,	PUNCT
aiua-12307	22	3	immunotherapy	immunotherapy	NOUN
aiua-12307	22	4	has	have	AUX
aiua-12307	22	5	played	play	VERB
aiua-12307	22	6	an	an	DET
aiua-12307	22	7	essential	essential	ADJ
aiua-12307	22	8	role	role	NOUN
aiua-12307	22	9	in	in	ADP
aiua-12307	22	10	treating	treat	VERB
aiua-12307	22	11	urologic	urologic	ADJ
aiua-12307	22	12	malignancies	malignancy	NOUN
aiua-12307	22	13	,	,	PUNCT
aiua-12307	22	14	while	while	SCONJ
aiua-12307	22	15	in	in	ADP
aiua-12307	22	16	the	the	DET
aiua-12307	22	17	modern	modern	ADJ
aiua-12307	22	18	era	era	NOUN
aiua-12307	22	19	,	,	PUNCT
aiua-12307	22	20	the	the	DET
aiua-12307	22	21	development	development	NOUN
aiua-12307	22	22	of	of	ADP
aiua-12307	22	23	immune	immune	ADJ
aiua-12307	22	24	checkpoint	checkpoint	NOUN
aiua-12307	22	25	inhibitors	inhibitor	NOUN
aiua-12307	22	26	(	(	PUNCT
aiua-12307	22	27	icis	icis	NOUN
aiua-12307	22	28	)	)	PUNCT
aiua-12307	22	29	has	have	AUX
aiua-12307	22	30	been	be	AUX
aiua-12307	22	31	critical	critical	ADJ
aiua-12307	22	32	to	to	ADP
aiua-12307	22	33	urology	urology	NOUN
aiua-12307	22	34	.	.	PUNCT
aiua-12307	23	1	urothelial	urothelial	ADJ
aiua-12307	23	2	carcinoma	carcinoma	NOUN
aiua-12307	23	3	is	be	AUX
aiua-12307	23	4	a	a	DET
aiua-12307	23	5	common	common	ADJ
aiua-12307	23	6	type	type	NOUN
aiua-12307	23	7	of	of	ADP
aiua-12307	23	8	cancer	cancer	NOUN
aiua-12307	23	9	in	in	ADP
aiua-12307	23	10	the	the	DET
aiua-12307	23	11	genitourinary	genitourinary	ADJ
aiua-12307	23	12	system	system	NOUN
aiua-12307	23	13	,	,	PUNCT
aiua-12307	23	14	and	and	CCONJ
aiua-12307	23	15	treatment	treatment	NOUN
aiua-12307	23	16	strategies	strategy	NOUN
aiua-12307	23	17	in	in	ADP
aiua-12307	23	18	this	this	DET
aiua-12307	23	19	area	area	NOUN
aiua-12307	23	20	are	be	AUX
aiua-12307	23	21	constantly	constantly	ADV
aiua-12307	23	22	evolving	evolve	VERB
aiua-12307	23	23	.	.	PUNCT
aiua-12307	24	1	intravesical	intravesical	ADJ
aiua-12307	24	2	and	and	CCONJ
aiua-12307	24	3	systemic	systemic	ADJ
aiua-12307	24	4	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	24	5	agents	agent	NOUN
aiua-12307	24	6	have	have	AUX
aiua-12307	24	7	begun	begin	VERB
aiua-12307	24	8	to	to	PART
aiua-12307	24	9	be	be	AUX
aiua-12307	24	10	used	use	VERB
aiua-12307	24	11	increasingly	increasingly	ADV
aiua-12307	24	12	frequently	frequently	ADV
aiua-12307	24	13	in	in	ADP
aiua-12307	24	14	treating	treat	VERB
aiua-12307	24	15	urothelial	urothelial	ADJ
aiua-12307	24	16	carcinoma	carcinoma	NOUN
aiua-12307	24	17	.	.	PUNCT
aiua-12307	25	1	these	these	DET
aiua-12307	25	2	agents	agent	NOUN
aiua-12307	25	3	increase	increase	VERB
aiua-12307	25	4	the	the	DET
aiua-12307	25	5	anti	anti	ADJ
aiua-12307	25	6	-	-	ADJ
aiua-12307	25	7	tumour	tumour	ADJ
aiua-12307	25	8	response	response	NOUN
aiua-12307	25	9	by	by	ADP
aiua-12307	25	10	affecting	affect	VERB
aiua-12307	25	11	the	the	DET
aiua-12307	25	12	body	body	NOUN
aiua-12307	25	13	's	's	PART
aiua-12307	25	14	defence	defence	NOUN
aiua-12307	25	15	mechanisms	mechanism	NOUN
aiua-12307	25	16	.	.	PUNCT
aiua-12307	26	1	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	26	2	agents	agent	NOUN
aiua-12307	26	3	used	use	VERB
aiua-12307	26	4	in	in	ADP
aiua-12307	26	5	urothelial	urothelial	ADJ
aiua-12307	26	6	carcinoma	carcinoma	NOUN
aiua-12307	26	7	include	include	VERB
aiua-12307	26	8	various	various	ADJ
aiua-12307	26	9	options	option	NOUN
aiua-12307	26	10	such	such	ADJ
aiua-12307	26	11	as	as	ADP
aiua-12307	26	12	bcg	bcg	PROPN
aiua-12307	26	13	,	,	PUNCT
aiua-12307	26	14	interferon	interferon	ADJ
aiua-12307	26	15	,	,	PUNCT
aiua-12307	26	16	anti	anti	ADJ
aiua-12307	26	17	-	-	ADJ
aiua-12307	26	18	pd-1	pd-1	ADJ
aiua-12307	26	19	(	(	PUNCT
aiua-12307	26	20	pembrolizumab	pembrolizumab	NOUN
aiua-12307	26	21	,	,	PUNCT
aiua-12307	26	22	nivolumab	nivolumab	NOUN
aiua-12307	26	23	)	)	PUNCT
aiua-12307	26	24	and	and	CCONJ
aiua-12307	26	25	anti	anti	ADJ
aiua-12307	26	26	-	-	ADJ
aiua-12307	26	27	pd	pd	ADJ
aiua-12307	26	28	-	-	PUNCT
aiua-12307	26	29	l1	l1	PROPN
aiua-12307	26	30	(	(	PUNCT
aiua-12307	26	31	atezolizumab	atezolizumab	PROPN
aiua-12307	26	32	,	,	PUNCT
aiua-12307	26	33	avelumab	avelumab	ADJ
aiua-12307	26	34	,	,	PUNCT
aiua-12307	26	35	durvalumab	durvalumab	NOUN
aiua-12307	26	36	)	)	PUNCT
aiua-12307	26	37	.	.	PUNCT
aiua-12307	27	1	renal	renal	ADJ
aiua-12307	27	2	cell	cell	NOUN
aiua-12307	27	3	carcinoma	carcinoma	NOUN
aiua-12307	27	4	(	(	PUNCT
aiua-12307	27	5	rcc	rcc	PROPN
aiua-12307	27	6	)	)	PUNCT
aiua-12307	27	7	has	have	AUX
aiua-12307	27	8	been	be	AUX
aiua-12307	27	9	known	know	VERB
aiua-12307	27	10	for	for	ADP
aiua-12307	27	11	many	many	ADJ
aiua-12307	27	12	years	year	NOUN
aiua-12307	27	13	as	as	ADP
aiua-12307	27	14	a	a	DET
aiua-12307	27	15	tumour	tumour	NOUN
aiua-12307	27	16	with	with	ADP
aiua-12307	27	17	unique	unique	ADJ
aiua-12307	27	18	sensitivity	sensitivity	NOUN
aiua-12307	27	19	to	to	ADP
aiua-12307	27	20	immunotherapies	immunotherapy	NOUN
aiua-12307	27	21	.	.	PUNCT
aiua-12307	28	1	the	the	DET
aiua-12307	28	2	recent	recent	ADJ
aiua-12307	28	3	emergence	emergence	NOUN
aiua-12307	28	4	of	of	ADP
aiua-12307	28	5	icis	icis	NOUN
aiua-12307	28	6	that	that	PRON
aiua-12307	28	7	block	block	VERB
aiua-12307	28	8	pd-1	pd-1	ADP
aiua-12307	28	9	/	/	SYM
aiua-12307	28	10	pd	pd	NOUN
aiua-12307	28	11	-	-	PROPN
aiua-12307	28	12	l1	l1	PROPN
aiua-12307	28	13	(	(	PUNCT
aiua-12307	28	14	pembrolizumab	pembrolizumab	NOUN
aiua-12307	28	15	,	,	PUNCT
aiua-12307	28	16	nivolumab	nivolumab	NOUN
aiua-12307	28	17	,	,	PUNCT
aiua-12307	28	18	atezolizumab	atezolizumab	NOUN
aiua-12307	28	19	)	)	PUNCT
aiua-12307	28	20	or	or	CCONJ
aiua-12307	28	21	ctla4	ctla4	NOUN
aiua-12307	28	22	(	(	PUNCT
aiua-12307	28	23	ipilimumab	ipilimumab	ADV
aiua-12307	28	24	)	)	PUNCT
aiua-12307	28	25	signalling	signal	VERB
aiua-12307	28	26	pathways	pathway	NOUN
aiua-12307	28	27	has	have	AUX
aiua-12307	28	28	reestablished	reestablish	VERB
aiua-12307	28	29	systemic	systemic	ADJ
aiua-12307	28	30	immunotherapy	immunotherapy	NOUN
aiua-12307	28	31	as	as	ADP
aiua-12307	28	32	central	central	ADJ
aiua-12307	28	33	to	to	ADP
aiua-12307	28	34	the	the	DET
aiua-12307	28	35	treatment	treatment	NOUN
aiua-12307	28	36	of	of	ADP
aiua-12307	28	37	advanced	advanced	ADJ
aiua-12307	28	38	rcc	rcc	PROPN
aiua-12307	28	39	.	.	PUNCT
aiua-12307	29	1	in	in	ADP
aiua-12307	29	2	light	light	NOUN
aiua-12307	29	3	of	of	ADP
aiua-12307	29	4	randomized	randomized	ADJ
aiua-12307	29	5	clinical	clinical	ADJ
aiua-12307	29	6	trials	trial	NOUN
aiua-12307	29	7	conducted	conduct	VERB
aiua-12307	29	8	with	with	ADP
aiua-12307	29	9	increasing	increase	VERB
aiua-12307	29	10	interest	interest	NOUN
aiua-12307	29	11	in	in	ADP
aiua-12307	29	12	the	the	DET
aiua-12307	29	13	application	application	NOUN
aiua-12307	29	14	of	of	ADP
aiua-12307	29	15	immunotherapies	immunotherapy	NOUN
aiua-12307	29	16	in	in	ADP
aiua-12307	29	17	the	the	DET
aiua-12307	29	18	adjuvant	adjuvant	ADJ
aiua-12307	29	19	setting	setting	NOUN
aiua-12307	29	20	,	,	PUNCT
aiua-12307	29	21	combination	combination	NOUN
aiua-12307	29	22	therapies	therapy	NOUN
aiua-12307	29	23	(	(	PUNCT
aiua-12307	29	24	nivolumab	nivolumab	NOUN
aiua-12307	29	25	/	/	SYM
aiua-12307	29	26	ipilimumab	ipilimumab	NOUN
aiua-12307	29	27	,	,	PUNCT
aiua-12307	29	28	nivolumab	nivolumab	NOUN
aiua-12307	29	29	/	/	SYM
aiua-12307	29	30	cabozantinib	cabozantinib	ADV
aiua-12307	29	31	,	,	PUNCT
aiua-12307	29	32	pembrolizumab	pembrolizumab	NOUN
aiua-12307	29	33	/	/	SYM
aiua-12307	29	34	axitinib	axitinib	NOUN
aiua-12307	29	35	,	,	PUNCT
aiua-12307	29	36	pembrolizumab	pembrolizumab	NOUN
aiua-12307	29	37	/	/	SYM
aiua-12307	29	38	lenvantinib	lenvantinib	NOUN
aiua-12307	29	39	)	)	PUNCT
aiua-12307	29	40	have	have	AUX
aiua-12307	29	41	become	become	VERB
aiua-12307	29	42	the	the	DET
aiua-12307	29	43	standard	standard	ADJ
aiua-12307	29	44	first	first	ADJ
aiua-12307	29	45	-	-	PUNCT
aiua-12307	29	46	line	line	NOUN
aiua-12307	29	47	treatment	treatment	NOUN
aiua-12307	29	48	of	of	ADP
aiua-12307	29	49	metastatic	metastatic	ADJ
aiua-12307	29	50	rcc	rcc	PROPN
aiua-12307	29	51	.	.	PUNCT
aiua-12307	30	1	prostate	prostate	NOUN
aiua-12307	30	2	cancer	cancer	NOUN
aiua-12307	30	3	is	be	AUX
aiua-12307	30	4	in	in	ADP
aiua-12307	30	5	the	the	DET
aiua-12307	30	6	immunologically	immunologically	ADV
aiua-12307	30	7	"	"	PUNCT
aiua-12307	30	8	cold	cold	ADJ
aiua-12307	30	9	"	"	PUNCT
aiua-12307	30	10	tumour	tumour	NOUN
aiua-12307	30	11	category	category	NOUN
aiua-12307	30	12	;	;	PUNCT
aiua-12307	30	13	on	on	ADP
aiua-12307	30	14	the	the	DET
aiua-12307	30	15	contrary	contrary	NOUN
aiua-12307	30	16	,	,	PUNCT
aiua-12307	30	17	in	in	ADP
aiua-12307	30	18	recent	recent	ADJ
aiua-12307	30	19	years	year	NOUN
aiua-12307	30	20	,	,	PUNCT
aiua-12307	30	21	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	30	22	agents	agent	NOUN
aiua-12307	30	23	have	have	AUX
aiua-12307	30	24	come	come	VERB
aiua-12307	30	25	to	to	ADP
aiua-12307	30	26	the	the	DET
aiua-12307	30	27	fore	fore	NOUN
aiua-12307	30	28	as	as	ADP
aiua-12307	30	29	an	an	DET
aiua-12307	30	30	essential	essential	ADJ
aiua-12307	30	31	area	area	NOUN
aiua-12307	30	32	in	in	ADP
aiua-12307	30	33	the	the	DET
aiua-12307	30	34	treatment	treatment	NOUN
aiua-12307	30	35	of	of	ADP
aiua-12307	30	36	this	this	DET
aiua-12307	30	37	disease	disease	NOUN
aiua-12307	30	38	.	.	PUNCT
aiua-12307	31	1	especially	especially	ADV
aiua-12307	31	2	in	in	ADP
aiua-12307	31	3	the	the	DET
aiua-12307	31	4	treatment	treatment	NOUN
aiua-12307	31	5	of	of	ADP
aiua-12307	31	6	castration	castration	NOUN
aiua-12307	31	7	-	-	PUNCT
aiua-12307	31	8	resistant	resistant	ADJ
aiua-12307	31	9	prostate	prostate	NOUN
aiua-12307	31	10	cancer	cancer	NOUN
aiua-12307	31	11	,	,	PUNCT
aiua-12307	31	12	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	31	13	agents	agent	NOUN
aiua-12307	31	14	constitute	constitute	VERB
aiua-12307	31	15	an	an	DET
aiua-12307	31	16	alternative	alternative	ADJ
aiua-12307	31	17	treatment	treatment	NOUN
aiua-12307	31	18	method	method	NOUN
aiua-12307	31	19	besides	besides	SCONJ
aiua-12307	31	20	androgen	androgen	NOUN
aiua-12307	31	21	deprivation	deprivation	NOUN
aiua-12307	31	22	therapy	therapy	NOUN
aiua-12307	31	23	and	and	CCONJ
aiua-12307	31	24	chemotherapy	chemotherapy	NOUN
aiua-12307	31	25	.	.	PUNCT
aiua-12307	32	1	ipilimumab	ipilimumab	PROPN
aiua-12307	32	2	,	,	PUNCT
aiua-12307	32	3	nivolumab	nivolumab	NOUN
aiua-12307	32	4	,	,	PUNCT
aiua-12307	32	5	pembrolizumab	pembrolizumab	NOUN
aiua-12307	32	6	,	,	PUNCT
aiua-12307	32	7	atezolizumab	atezolizumab	NOUN
aiua-12307	32	8	,	,	PUNCT
aiua-12307	32	9	and	and	CCONJ
aiua-12307	32	10	sipuleucel	sipuleucel	PROPN
aiua-12307	32	11	t	t	PROPN
aiua-12307	32	12	(	(	PUNCT
aiua-12307	32	13	vaccine	vaccine	NOUN
aiua-12307	32	14	-	-	PUNCT
aiua-12307	32	15	based	base	VERB
aiua-12307	32	16	)	)	PUNCT
aiua-12307	32	17	are	be	AUX
aiua-12307	32	18	promising	promise	VERB
aiua-12307	32	19	alternative	alternative	ADJ
aiua-12307	32	20	treatment	treatment	NOUN
aiua-12307	32	21	options	option	NOUN
aiua-12307	32	22	.	.	PUNCT
aiua-12307	33	1	considering	consider	VERB
aiua-12307	33	2	ongoing	ongoing	ADJ
aiua-12307	33	3	randomized	randomized	ADJ
aiua-12307	33	4	clinical	clinical	ADJ
aiua-12307	33	5	trials	trial	NOUN
aiua-12307	33	6	,	,	PUNCT
aiua-12307	33	7	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	33	8	agents	agent	NOUN
aiua-12307	33	9	promise	promise	VERB
aiua-12307	33	10	to	to	PART
aiua-12307	33	11	transform	transform	VERB
aiua-12307	33	12	the	the	DET
aiua-12307	33	13	uro	uro	NOUN
aiua-12307	33	14	-	-	PUNCT
aiua-12307	33	15	oncology	oncology	NOUN
aiua-12307	33	16	field	field	NOUN
aiua-12307	33	17	significantly	significantly	ADV
aiua-12307	33	18	.	.	PUNCT
aiua-12307	34	1	in	in	ADP
aiua-12307	34	2	this	this	DET
aiua-12307	34	3	review	review	NOUN
aiua-12307	34	4	,	,	PUNCT
aiua-12307	34	5	we	we	PRON
aiua-12307	34	6	aimed	aim	VERB
aiua-12307	34	7	to	to	PART
aiua-12307	34	8	summarize	summarize	VERB
aiua-12307	34	9	the	the	DET
aiua-12307	34	10	role	role	NOUN
aiua-12307	34	11	of	of	ADP
aiua-12307	34	12	immunotherapy	immunotherapy	NOUN
aiua-12307	34	13	in	in	ADP
aiua-12307	34	14	urothelial	urothelial	ADJ
aiua-12307	34	15	,	,	PUNCT
aiua-12307	34	16	renal	renal	ADJ
aiua-12307	34	17	and	and	CCONJ
aiua-12307	34	18	prostate	prostate	NOUN
aiua-12307	34	19	cancer	cancer	NOUN
aiua-12307	34	20	in	in	ADP
aiua-12307	34	21	the	the	DET
aiua-12307	34	22	light	light	NOUN
aiua-12307	34	23	of	of	ADP
aiua-12307	34	24	randomized	randomized	ADJ
aiua-12307	34	25	clinical	clinical	ADJ
aiua-12307	34	26	trials	trial	NOUN
aiua-12307	34	27	.	.	PUNCT
aiua-12307	35	1	key	key	ADJ
aiua-12307	35	2	words	word	NOUN
aiua-12307	35	3	:	:	PUNCT
aiua-12307	35	4	urological	urological	ADJ
aiua-12307	35	5	cancers	cancer	NOUN
aiua-12307	35	6	;	;	PUNCT
aiua-12307	35	7	immunotherapy	immunotherapy	NOUN
aiua-12307	35	8	;	;	PUNCT
aiua-12307	35	9	clinical	clinical	ADJ
aiua-12307	35	10	trials	trial	NOUN
aiua-12307	35	11	.	.	PUNCT
aiua-12307	35	12	submitted	submit	VERB
aiua-12307	35	13	24	24	NUM
aiua-12307	35	14	january	january	PROPN
aiua-12307	35	15	2024	2024	NUM
aiua-12307	35	16	;	;	PUNCT
aiua-12307	35	17	accepted	accept	VERB
aiua-12307	35	18	10	10	NUM
aiua-12307	35	19	february	february	NOUN
aiua-12307	35	20	2024	2024	NUM
aiua-12307	35	21	the	the	DET
aiua-12307	35	22	role	role	NOUN
aiua-12307	35	23	of	of	ADP
aiua-12307	35	24	immunotherapy	immunotherapy	NOUN
aiua-12307	35	25	in	in	ADP
aiua-12307	35	26	urological	urological	ADJ
aiua-12307	35	27	cancers	cancer	NOUN
aiua-12307	35	28	efe	efe	NOUN
aiua-12307	35	29	bosnali	bosnali	VERB
aiua-12307	35	30	1	1	NUM
aiua-12307	35	31	,	,	PUNCT
aiua-12307	35	32	enes	enes	PROPN
aiua-12307	35	33	malik	malik	PROPN
aiua-12307	35	34	akdas	akdas	PROPN
aiua-12307	35	35	2	2	NUM
aiua-12307	35	36	,	,	PUNCT
aiua-12307	35	37	engin	engin	PROPN
aiua-12307	35	38	telli	telli	NOUN
aiua-12307	35	39	2	2	NUM
aiua-12307	35	40	,	,	PUNCT
aiua-12307	35	41	kerem	kerem	PROPN
aiua-12307	35	42	teke	teke	PROPN
aiua-12307	35	43	2	2	NUM
aiua-12307	35	44	,	,	PUNCT
aiua-12307	35	45	onder	onder	PROPN
aiua-12307	35	46	kara	kara	PROPN
aiua-12307	35	47	2	2	NUM
aiua-12307	35	48	1	1	NUM
aiua-12307	35	49	department	department	NOUN
aiua-12307	35	50	of	of	ADP
aiua-12307	35	51	urology	urology	NOUN
aiua-12307	35	52	,	,	PUNCT
aiua-12307	35	53	university	university	NOUN
aiua-12307	35	54	of	of	ADP
aiua-12307	35	55	health	health	PROPN
aiua-12307	35	56	sciences	sciences	PROPN
aiua-12307	35	57	,	,	PUNCT
aiua-12307	35	58	derince	derince	NOUN
aiua-12307	35	59	training	training	NOUN
aiua-12307	35	60	and	and	CCONJ
aiua-12307	35	61	research	research	NOUN
aiua-12307	35	62	hospital	hospital	NOUN
aiua-12307	35	63	,	,	PUNCT
aiua-12307	35	64	kocaeli	kocaeli	ADJ
aiua-12307	35	65	,	,	PUNCT
aiua-12307	35	66	turkey	turkey	PROPN
aiua-12307	35	67	;	;	PUNCT
aiua-12307	35	68	2	2	NUM
aiua-12307	35	69	department	department	NOUN
aiua-12307	35	70	of	of	ADP
aiua-12307	35	71	urology	urology	NOUN
aiua-12307	35	72	,	,	PUNCT
aiua-12307	35	73	school	school	NOUN
aiua-12307	35	74	of	of	ADP
aiua-12307	35	75	medicine	medicine	NOUN
aiua-12307	35	76	,	,	PUNCT
aiua-12307	35	77	kocaeli	kocaeli	PROPN
aiua-12307	35	78	university	university	PROPN
aiua-12307	35	79	,	,	PUNCT
aiua-12307	35	80	turkey	turkey	PROPN
aiua-12307	35	81	.	.	PUNCT
aiua-12307	36	1	doi	doi	NOUN
aiua-12307	36	2	:	:	PUNCT
aiua-12307	36	3	10.4081	10.4081	NUM
aiua-12307	36	4	/	/	SYM
aiua-12307	36	5	aiua.2024.12307	aiua.2024.12307	NOUN
aiua-12307	36	6	summary	summary	VERB
aiua-12307	36	7	archivio	archivio	NOUN
aiua-12307	36	8	italiano	italiano	X
aiua-12307	36	9	di	di	X
aiua-12307	36	10	urologia	urologia	PROPN
aiua-12307	36	11	e	e	PROPN
aiua-12307	36	12	andrologia	andrologia	NOUN
aiua-12307	36	13	2024	2024	NUM
aiua-12307	36	14	;	;	PUNCT
aiua-12307	36	15	96(2):12307	96(2):12307	NUM
aiua-12307	36	16	e.	e.	PROPN
aiua-12307	36	17	bosnali	bosnali	PROPN
aiua-12307	36	18	,	,	PUNCT
aiua-12307	36	19	e.	e.	PROPN
aiua-12307	36	20	malik	malik	PROPN
aiua-12307	36	21	akdas	akdas	PROPN
aiua-12307	36	22	,	,	PUNCT
aiua-12307	36	23	e.	e.	PROPN
aiua-12307	36	24	telli	telli	PROPN
aiua-12307	36	25	,	,	PUNCT
aiua-12307	36	26	k.	k.	PROPN
aiua-12307	36	27	teke	teke	PROPN
aiua-12307	36	28	,	,	PUNCT
aiua-12307	36	29	o.	o.	PROPN
aiua-12307	36	30	kara	kara	PROPN
aiua-12307	36	31	2	2	NUM
aiua-12307	36	32	sis	sis	NOUN
aiua-12307	36	33	,	,	PUNCT
aiua-12307	36	34	75	75	NUM
aiua-12307	36	35	%	%	NOUN
aiua-12307	36	36	of	of	ADP
aiua-12307	36	37	the	the	DET
aiua-12307	36	38	patients	patient	NOUN
aiua-12307	36	39	are	be	AUX
aiua-12307	36	40	diagnosed	diagnose	VERB
aiua-12307	36	41	with	with	ADP
aiua-12307	36	42	non	non	ADJ
aiua-12307	36	43	-	-	ADJ
aiua-12307	36	44	muscleinvasive	muscleinvasive	ADJ
aiua-12307	36	45	bladder	bladder	NOUN
aiua-12307	36	46	cancer	cancer	NOUN
aiua-12307	36	47	(	(	PUNCT
aiua-12307	36	48	nmibc	nmibc	ADJ
aiua-12307	36	49	)	)	PUNCT
aiua-12307	36	50	(	(	PUNCT
aiua-12307	36	51	ta	ta	PROPN
aiua-12307	36	52	,	,	PUNCT
aiua-12307	36	53	t1	t1	NOUN
aiua-12307	36	54	,	,	PUNCT
aiua-12307	36	55	cis	cis	NOUN
aiua-12307	36	56	)	)	PUNCT
aiua-12307	36	57	and	and	CCONJ
aiua-12307	36	58	25	25	NUM
aiua-12307	36	59	%	%	NOUN
aiua-12307	36	60	with	with	ADP
aiua-12307	36	61	muscle	muscle	NOUN
aiua-12307	36	62	-	-	PUNCT
aiua-12307	36	63	invasive	invasive	ADJ
aiua-12307	36	64	bladder	bladder	NOUN
aiua-12307	36	65	cancer	cancer	NOUN
aiua-12307	36	66	(	(	PUNCT
aiua-12307	36	67	mibc	mibc	PROPN
aiua-12307	36	68	)	)	PUNCT
aiua-12307	36	69	(	(	PUNCT
aiua-12307	36	70	t2	t2	NOUN
aiua-12307	36	71	-	-	PUNCT
aiua-12307	36	72	t4	t4	PROPN
aiua-12307	36	73	)	)	PUNCT
aiua-12307	36	74	(	(	PUNCT
aiua-12307	36	75	6	6	NUM
aiua-12307	36	76	)	)	PUNCT
aiua-12307	36	77	.	.	PUNCT
aiua-12307	37	1	utuc	utuc	PROPN
aiua-12307	37	2	is	be	AUX
aiua-12307	37	3	a	a	DET
aiua-12307	37	4	malignant	malignant	ADJ
aiua-12307	37	5	change	change	NOUN
aiua-12307	37	6	in	in	ADP
aiua-12307	37	7	urothelial	urothelial	ADJ
aiua-12307	37	8	cells	cell	NOUN
aiua-12307	37	9	extending	extend	VERB
aiua-12307	37	10	from	from	ADP
aiua-12307	37	11	the	the	DET
aiua-12307	37	12	renal	renal	ADJ
aiua-12307	37	13	pelvis	pelvi	NOUN
aiua-12307	37	14	and	and	CCONJ
aiua-12307	37	15	calyces	calyx	NOUN
aiua-12307	37	16	to	to	ADP
aiua-12307	37	17	the	the	DET
aiua-12307	37	18	ureteral	ureteral	ADJ
aiua-12307	37	19	orifice	orifice	NOUN
aiua-12307	37	20	.	.	PUNCT
aiua-12307	38	1	the	the	DET
aiua-12307	38	2	exact	exact	ADJ
aiua-12307	38	3	incidence	incidence	NOUN
aiua-12307	38	4	of	of	ADP
aiua-12307	38	5	utuc	utuc	NOUN
aiua-12307	38	6	is	be	AUX
aiua-12307	38	7	challenging	challenge	VERB
aiua-12307	38	8	to	to	PART
aiua-12307	38	9	determine	determine	VERB
aiua-12307	38	10	because	because	SCONJ
aiua-12307	38	11	it	it	PRON
aiua-12307	38	12	is	be	AUX
aiua-12307	38	13	often	often	ADV
aiua-12307	38	14	associated	associate	VERB
aiua-12307	38	15	with	with	ADP
aiua-12307	38	16	renal	renal	ADJ
aiua-12307	38	17	pelvis	pelvi	NOUN
aiua-12307	38	18	and	and	CCONJ
aiua-12307	38	19	ureteral	ureteral	ADJ
aiua-12307	38	20	malignancies	malignancy	NOUN
aiua-12307	38	21	;	;	PUNCT
aiua-12307	38	22	they	they	PRON
aiua-12307	38	23	are	be	AUX
aiua-12307	38	24	reported	report	VERB
aiua-12307	38	25	in	in	ADP
aiua-12307	38	26	a	a	DET
aiua-12307	38	27	single	single	ADJ
aiua-12307	38	28	category	category	NOUN
aiua-12307	38	29	as	as	ADP
aiua-12307	38	30	renal	renal	ADJ
aiua-12307	38	31	tumours	tumour	NOUN
aiua-12307	38	32	(	(	PUNCT
aiua-12307	38	33	7	7	NUM
aiua-12307	38	34	)	)	PUNCT
aiua-12307	38	35	.	.	PUNCT
aiua-12307	39	1	the	the	DET
aiua-12307	39	2	estimated	estimate	VERB
aiua-12307	39	3	incidence	incidence	NOUN
aiua-12307	39	4	of	of	ADP
aiua-12307	39	5	utuc	utuc	NOUN
aiua-12307	39	6	in	in	ADP
aiua-12307	39	7	western	western	ADJ
aiua-12307	39	8	countries	country	NOUN
aiua-12307	39	9	is	be	AUX
aiua-12307	39	10	2/100,000	2/100,000	NUM
aiua-12307	39	11	cases	case	NOUN
aiua-12307	39	12	per	per	ADP
aiua-12307	39	13	year	year	NOUN
aiua-12307	39	14	,	,	PUNCT
aiua-12307	39	15	and	and	CCONJ
aiua-12307	39	16	its	its	PRON
aiua-12307	39	17	incidence	incidence	NOUN
aiua-12307	39	18	is	be	AUX
aiua-12307	39	19	highest	high	ADJ
aiua-12307	39	20	between	between	ADP
aiua-12307	39	21	the	the	DET
aiua-12307	39	22	ages	age	NOUN
aiua-12307	39	23	of	of	ADP
aiua-12307	39	24	70	70	NUM
aiua-12307	39	25	and	and	CCONJ
aiua-12307	39	26	90	90	NUM
aiua-12307	39	27	(	(	PUNCT
aiua-12307	39	28	8)	8)	NUM
aiua-12307	39	29	.	.	PUNCT
aiua-12307	40	1	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	40	2	agents	agent	NOUN
aiua-12307	40	3	used	use	VERB
aiua-12307	40	4	in	in	ADP
aiua-12307	40	5	urothelial	urothelial	ADJ
aiua-12307	40	6	carcinoma	carcinoma	NOUN
aiua-12307	40	7	(	(	PUNCT
aiua-12307	40	8	intravesical	intravesical	ADJ
aiua-12307	40	9	and	and	CCONJ
aiua-12307	40	10	systemic	systemic	ADJ
aiua-12307	40	11	)	)	PUNCT
aiua-12307	40	12	the	the	DET
aiua-12307	40	13	main	main	ADJ
aiua-12307	40	14	goal	goal	NOUN
aiua-12307	40	15	of	of	ADP
aiua-12307	40	16	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	40	17	agents	agent	NOUN
aiua-12307	40	18	is	be	AUX
aiua-12307	40	19	to	to	PART
aiua-12307	40	20	increase	increase	VERB
aiua-12307	40	21	the	the	DET
aiua-12307	40	22	anti	anti	ADJ
aiua-12307	40	23	-	-	ADJ
aiua-12307	40	24	tumour	tumour	ADJ
aiua-12307	40	25	response	response	NOUN
aiua-12307	40	26	by	by	ADP
aiua-12307	40	27	acting	act	VERB
aiua-12307	40	28	on	on	ADP
aiua-12307	40	29	the	the	DET
aiua-12307	40	30	body	body	NOUN
aiua-12307	40	31	's	's	PART
aiua-12307	40	32	defence	defence	NOUN
aiua-12307	40	33	cells	cell	NOUN
aiua-12307	40	34	.	.	PUNCT
aiua-12307	41	1	the	the	DET
aiua-12307	41	2	main	main	ADJ
aiua-12307	41	3	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	41	4	agents	agent	NOUN
aiua-12307	41	5	used	use	VERB
aiua-12307	41	6	in	in	ADP
aiua-12307	41	7	urothelial	urothelial	ADJ
aiua-12307	41	8	carcinoma	carcinoma	NOUN
aiua-12307	41	9	are	be	AUX
aiua-12307	41	10	;	;	PUNCT
aiua-12307	41	11	•	•	PRON
aiua-12307	41	12	bcg	bcg	PROPN
aiua-12307	41	13	}	}	PUNCT
aiua-12307	41	14	bc	bc	PROPN
aiua-12307	41	15	(	(	PUNCT
aiua-12307	41	16	intravesical	intravesical	ADJ
aiua-12307	41	17	therapy	therapy	NOUN
aiua-12307	41	18	)	)	PUNCT
aiua-12307	42	1	•	•	NOUN
aiua-12307	42	2	interferon	interferon	ADJ
aiua-12307	42	3	•	•	NUM
aiua-12307	42	4	anti	anti	ADJ
aiua-12307	42	5	-	-	ADJ
aiua-12307	42	6	pd-1	pd-1	ADJ
aiua-12307	42	7	(	(	PUNCT
aiua-12307	42	8	pembrolizumab	pembrolizumab	NOUN
aiua-12307	42	9	,	,	PUNCT
aiua-12307	42	10	nivolumab)}bc	nivolumab)}bc	ADJ
aiua-12307	42	11	and	and	CCONJ
aiua-12307	42	12	utuc•	utuc•	ADJ
aiua-12307	42	13	anti	anti	ADJ
aiua-12307	42	14	-	-	ADJ
aiua-12307	42	15	pd	pd	ADJ
aiua-12307	42	16	-	-	PUNCT
aiua-12307	42	17	l1	l1	PROPN
aiua-12307	42	18	(	(	PUNCT
aiua-12307	42	19	atezolizumab	atezolizumab	PROPN
aiua-12307	42	20	,	,	PUNCT
aiua-12307	42	21	avelumab	avelumab	ADJ
aiua-12307	42	22	,	,	PUNCT
aiua-12307	42	23	(	(	PUNCT
aiua-12307	42	24	systemic	systemic	ADJ
aiua-12307	42	25	treatment	treatment	NOUN
aiua-12307	42	26	)	)	PUNCT
aiua-12307	42	27	durvalumab	durvalumab	PROPN
aiua-12307	42	28	)	)	PUNCT
aiua-12307	42	29	the	the	DET
aiua-12307	42	30	most	most	ADV
aiua-12307	42	31	frequently	frequently	ADV
aiua-12307	42	32	and	and	CCONJ
aiua-12307	42	33	longest	long	ADV
aiua-12307	42	34	-	-	PUNCT
aiua-12307	42	35	used	use	VERB
aiua-12307	42	36	method	method	NOUN
aiua-12307	42	37	of	of	ADP
aiua-12307	42	38	immunotherapy	immunotherapy	NOUN
aiua-12307	42	39	in	in	ADP
aiua-12307	42	40	urothelial	urothelial	ADJ
aiua-12307	42	41	carcinoma	carcinoma	NOUN
aiua-12307	42	42	is	be	AUX
aiua-12307	42	43	intravesical	intravesical	ADJ
aiua-12307	42	44	bcg	bcg	PROPN
aiua-12307	42	45	treatment	treatment	NOUN
aiua-12307	42	46	in	in	ADP
aiua-12307	42	47	bc	bc	PROPN
aiua-12307	42	48	.	.	PROPN
aiua-12307	43	1	bcg	bcg	PROPN
aiua-12307	43	2	stimulates	stimulate	VERB
aiua-12307	43	3	the	the	DET
aiua-12307	43	4	immune	immune	ADJ
aiua-12307	43	5	system	system	NOUN
aiua-12307	43	6	in	in	ADP
aiua-12307	43	7	two	two	NUM
aiua-12307	43	8	separate	separate	ADJ
aiua-12307	43	9	ways	way	NOUN
aiua-12307	43	10	.	.	PUNCT
aiua-12307	44	1	first	first	ADV
aiua-12307	44	2	,	,	PUNCT
aiua-12307	44	3	it	it	PRON
aiua-12307	44	4	enhances	enhance	VERB
aiua-12307	44	5	the	the	DET
aiua-12307	44	6	anti	anti	ADJ
aiua-12307	44	7	-	-	ADJ
aiua-12307	44	8	tumour	tumour	ADJ
aiua-12307	44	9	response	response	NOUN
aiua-12307	44	10	via	via	ADP
aiua-12307	44	11	toll	toll	NOUN
aiua-12307	44	12	-	-	PUNCT
aiua-12307	44	13	like	like	ADJ
aiua-12307	44	14	receptors	receptor	NOUN
aiua-12307	44	15	,	,	PUNCT
aiua-12307	44	16	inflammatory	inflammatory	ADJ
aiua-12307	44	17	cytokines	cytokine	NOUN
aiua-12307	44	18	,	,	PUNCT
aiua-12307	44	19	and	and	CCONJ
aiua-12307	44	20	tumour	tumour	NOUN
aiua-12307	44	21	necrosis	necrosis	NOUN
aiua-12307	44	22	factors	factor	NOUN
aiua-12307	44	23	.	.	PUNCT
aiua-12307	45	1	secondly	secondly	ADV
aiua-12307	45	2	,	,	PUNCT
aiua-12307	45	3	it	it	PRON
aiua-12307	45	4	increases	increase	VERB
aiua-12307	45	5	the	the	DET
aiua-12307	45	6	immune	immune	ADJ
aiua-12307	45	7	response	response	NOUN
aiua-12307	45	8	against	against	ADP
aiua-12307	45	9	the	the	DET
aiua-12307	45	10	tumour	tumour	NOUN
aiua-12307	45	11	by	by	ADP
aiua-12307	45	12	stimulating	stimulate	VERB
aiua-12307	45	13	cd4	cd4	PROPN
aiua-12307	45	14	+	+	PROPN
aiua-12307	45	15	t	t	PROPN
aiua-12307	45	16	helper	helper	NOUN
aiua-12307	45	17	cells	cell	NOUN
aiua-12307	45	18	.	.	PUNCT
aiua-12307	46	1	in	in	ADP
aiua-12307	46	2	addition	addition	NOUN
aiua-12307	46	3	to	to	ADP
aiua-12307	46	4	these	these	DET
aiua-12307	46	5	mechanisms	mechanism	NOUN
aiua-12307	46	6	,	,	PUNCT
aiua-12307	46	7	bcg	bcg	PROPN
aiua-12307	46	8	is	be	AUX
aiua-12307	46	9	cytotoxic	cytotoxic	ADJ
aiua-12307	46	10	against	against	ADP
aiua-12307	46	11	tumour	tumour	NOUN
aiua-12307	46	12	cells	cell	NOUN
aiua-12307	46	13	(	(	PUNCT
aiua-12307	46	14	9	9	NUM
aiua-12307	46	15	)	)	PUNCT
aiua-12307	46	16	.	.	PUNCT
aiua-12307	47	1	interferon	interferon	PROPN
aiua-12307	47	2	is	be	AUX
aiua-12307	47	3	an	an	DET
aiua-12307	47	4	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	47	5	agent	agent	NOUN
aiua-12307	47	6	that	that	PRON
aiua-12307	47	7	can	can	AUX
aiua-12307	47	8	be	be	AUX
aiua-12307	47	9	used	use	VERB
aiua-12307	47	10	alone	alone	ADJ
aiua-12307	47	11	or	or	CCONJ
aiua-12307	47	12	in	in	ADP
aiua-12307	47	13	combination	combination	NOUN
aiua-12307	47	14	with	with	ADP
aiua-12307	47	15	bcg	bcg	PROPN
aiua-12307	47	16	.	.	PUNCT
aiua-12307	48	1	its	its	PRON
aiua-12307	48	2	mechanism	mechanism	NOUN
aiua-12307	48	3	of	of	ADP
aiua-12307	48	4	action	action	NOUN
aiua-12307	48	5	is	be	AUX
aiua-12307	48	6	lymphocyte	lymphocyte	ADJ
aiua-12307	48	7	activation	activation	NOUN
aiua-12307	48	8	and	and	CCONJ
aiua-12307	48	9	strengthening	strengthening	NOUN
aiua-12307	48	10	of	of	ADP
aiua-12307	48	11	the	the	DET
aiua-12307	48	12	t	t	PROPN
aiua-12307	48	13	-	-	PUNCT
aiua-12307	48	14	helper	helper	NOUN
aiua-12307	48	15	type	type	NOUN
aiua-12307	48	16	i	i	PRON
aiua-12307	48	17	immune	immune	ADJ
aiua-12307	48	18	response	response	NOUN
aiua-12307	48	19	(	(	PUNCT
aiua-12307	48	20	10	10	NUM
aiua-12307	48	21	)	)	PUNCT
aiua-12307	48	22	.	.	PUNCT
aiua-12307	49	1	nowadays	nowadays	ADV
aiua-12307	49	2	,	,	PUNCT
aiua-12307	49	3	systemic	systemic	ADJ
aiua-12307	49	4	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	49	5	agents	agent	NOUN
aiua-12307	49	6	are	be	AUX
aiua-12307	49	7	increasingly	increasingly	ADV
aiua-12307	49	8	used	use	VERB
aiua-12307	49	9	to	to	PART
aiua-12307	49	10	treat	treat	VERB
aiua-12307	49	11	urothelial	urothelial	ADJ
aiua-12307	49	12	carcinoma	carcinoma	NOUN
aiua-12307	49	13	.	.	PUNCT
aiua-12307	50	1	this	this	DET
aiua-12307	50	2	group	group	NOUN
aiua-12307	50	3	of	of	ADP
aiua-12307	50	4	drugs	drug	NOUN
aiua-12307	50	5	acts	act	VERB
aiua-12307	50	6	through	through	ADP
aiua-12307	50	7	pd-1	pd-1	ADP
aiua-12307	50	8	and	and	CCONJ
aiua-12307	50	9	pd	pd	PROPN
aiua-12307	50	10	-	-	PUNCT
aiua-12307	50	11	l1	l1	PROPN
aiua-12307	50	12	receptors	receptor	NOUN
aiua-12307	50	13	.	.	PUNCT
aiua-12307	51	1	the	the	DET
aiua-12307	51	2	interaction	interaction	NOUN
aiua-12307	51	3	between	between	ADP
aiua-12307	51	4	pd-1	pd-1	ADJ
aiua-12307	51	5	and	and	CCONJ
aiua-12307	51	6	pd	pd	PROPN
aiua-12307	51	7	-	-	PUNCT
aiua-12307	51	8	l1	l1	PROPN
aiua-12307	51	9	triggers	trigger	NOUN
aiua-12307	51	10	immune	immune	ADJ
aiua-12307	51	11	suppressive	suppressive	ADJ
aiua-12307	51	12	mechanisms	mechanism	NOUN
aiua-12307	51	13	when	when	SCONJ
aiua-12307	51	14	t	t	NOUN
aiua-12307	51	15	cells	cell	NOUN
aiua-12307	51	16	encounter	encounter	VERB
aiua-12307	51	17	tumour	tumour	NOUN
aiua-12307	51	18	cells	cell	NOUN
aiua-12307	51	19	.	.	PUNCT
aiua-12307	52	1	in	in	ADP
aiua-12307	52	2	this	this	DET
aiua-12307	52	3	way	way	NOUN
aiua-12307	52	4	,	,	PUNCT
aiua-12307	52	5	pd	pd	PROPN
aiua-12307	52	6	-	-	PROPN
aiua-12307	52	7	l1	l1	PROPN
aiua-12307	52	8	checkpoint	checkpoint	NOUN
aiua-12307	52	9	blockade	blockade	NOUN
aiua-12307	52	10	may	may	AUX
aiua-12307	52	11	interfere	interfere	VERB
aiua-12307	52	12	with	with	ADP
aiua-12307	52	13	tumour	tumour	NOUN
aiua-12307	52	14	/	/	SYM
aiua-12307	52	15	immune	immune	ADJ
aiua-12307	52	16	cell	cell	NOUN
aiua-12307	52	17	interactions	interaction	NOUN
aiua-12307	52	18	for	for	ADP
aiua-12307	52	19	some	some	DET
aiua-12307	52	20	tumours	tumour	NOUN
aiua-12307	52	21	and	and	CCONJ
aiua-12307	52	22	thus	thus	ADV
aiua-12307	52	23	improve	improve	VERB
aiua-12307	52	24	anti	anti	ADJ
aiua-12307	52	25	-	-	ADJ
aiua-12307	52	26	tumour	tumour	ADJ
aiua-12307	52	27	immune	immune	ADJ
aiua-12307	52	28	responses	response	NOUN
aiua-12307	52	29	.	.	PUNCT
aiua-12307	53	1	there	there	PRON
aiua-12307	53	2	are	be	VERB
aiua-12307	53	3	four	four	NUM
aiua-12307	53	4	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	53	5	agents	agent	NOUN
aiua-12307	53	6	approved	approve	VERB
aiua-12307	53	7	by	by	ADP
aiua-12307	53	8	the	the	DET
aiua-12307	53	9	food	food	NOUN
aiua-12307	53	10	and	and	CCONJ
aiua-12307	53	11	drug	drug	PROPN
aiua-12307	53	12	administration	administration	PROPN
aiua-12307	53	13	(	(	PUNCT
aiua-12307	53	14	fda	fda	PROPN
aiua-12307	53	15	)	)	PUNCT
aiua-12307	53	16	for	for	ADP
aiua-12307	53	17	use	use	NOUN
aiua-12307	53	18	in	in	ADP
aiua-12307	53	19	patients	patient	NOUN
aiua-12307	53	20	diagnosed	diagnose	VERB
aiua-12307	53	21	with	with	ADP
aiua-12307	53	22	metastatic	metastatic	ADJ
aiua-12307	53	23	urothelial	urothelial	ADJ
aiua-12307	53	24	carcinoma	carcinoma	NOUN
aiua-12307	53	25	(	(	PUNCT
aiua-12307	53	26	muc	muc	X
aiua-12307	53	27	)	)	PUNCT
aiua-12307	53	28	and	and	CCONJ
aiua-12307	53	29	progressing	progress	VERB
aiua-12307	53	30	following	follow	VERB
aiua-12307	53	31	platinum	platinum	NOUN
aiua-12307	53	32	-	-	PUNCT
aiua-12307	53	33	based	base	VERB
aiua-12307	53	34	chemotherapy	chemotherapy	NOUN
aiua-12307	53	35	(	(	PUNCT
aiua-12307	53	36	ct	ct	NOUN
aiua-12307	53	37	)	)	PUNCT
aiua-12307	53	38	(	(	PUNCT
aiua-12307	53	39	pembrolizumab	pembrolizumab	NOUN
aiua-12307	53	40	,	,	PUNCT
aiua-12307	53	41	nivolumab	nivolumab	NOUN
aiua-12307	53	42	,	,	PUNCT
aiua-12307	53	43	atezolizumab	atezolizumab	PROPN
aiua-12307	53	44	,	,	PUNCT
aiua-12307	53	45	avelumab	avelumab	NOUN
aiua-12307	53	46	)	)	PUNCT
aiua-12307	53	47	.	.	PUNCT
aiua-12307	54	1	pembrolizumab	pembrolizumab	NOUN
aiua-12307	54	2	in	in	ADP
aiua-12307	54	3	light	light	NOUN
aiua-12307	54	4	of	of	ADP
aiua-12307	54	5	the	the	DET
aiua-12307	54	6	data	datum	NOUN
aiua-12307	54	7	obtained	obtain	VERB
aiua-12307	54	8	from	from	ADP
aiua-12307	54	9	the	the	DET
aiua-12307	54	10	keynote-057	keynote-057	NOUN
aiua-12307	54	11	trial	trial	NOUN
aiua-12307	54	12	in	in	ADP
aiua-12307	54	13	phase	phase	NOUN
aiua-12307	54	14	ii	ii	PROPN
aiua-12307	54	15	,	,	PUNCT
aiua-12307	54	16	the	the	DET
aiua-12307	54	17	fda	fda	PROPN
aiua-12307	54	18	approved	approve	VERB
aiua-12307	54	19	the	the	DET
aiua-12307	54	20	use	use	NOUN
aiua-12307	54	21	of	of	ADP
aiua-12307	54	22	pembrolizumab	pembrolizumab	NOUN
aiua-12307	54	23	in	in	ADP
aiua-12307	54	24	2020	2020	NUM
aiua-12307	54	25	for	for	ADP
aiua-12307	54	26	the	the	DET
aiua-12307	54	27	treatment	treatment	NOUN
aiua-12307	54	28	of	of	ADP
aiua-12307	54	29	bcg	bcg	NOUN
aiua-12307	54	30	-	-	PUNCT
aiua-12307	54	31	refractory	refractory	NOUN
aiua-12307	54	32	high	high	ADJ
aiua-12307	54	33	-	-	PUNCT
aiua-12307	54	34	risk	risk	NOUN
aiua-12307	54	35	,	,	PUNCT
aiua-12307	54	36	nmibc	nmibc	ADJ
aiua-12307	54	37	-	-	ADJ
aiua-12307	54	38	diagnosed	diagnose	VERB
aiua-12307	54	39	patients	patient	NOUN
aiua-12307	54	40	who	who	PRON
aiua-12307	54	41	are	be	AUX
aiua-12307	54	42	not	not	PART
aiua-12307	54	43	suitable	suitable	ADJ
aiua-12307	54	44	for	for	ADP
aiua-12307	54	45	radical	radical	ADJ
aiua-12307	54	46	cystectomy	cystectomy	NOUN
aiua-12307	54	47	or	or	CCONJ
aiua-12307	54	48	who	who	PRON
aiua-12307	54	49	refuse	refuse	VERB
aiua-12307	54	50	radical	radical	ADJ
aiua-12307	54	51	cystectomy	cystectomy	NOUN
aiua-12307	54	52	(	(	PUNCT
aiua-12307	54	53	11	11	NUM
aiua-12307	54	54	)	)	PUNCT
aiua-12307	54	55	.	.	PUNCT
aiua-12307	55	1	this	this	DET
aiua-12307	55	2	study	study	NOUN
aiua-12307	55	3	showed	show	VERB
aiua-12307	55	4	that	that	SCONJ
aiua-12307	55	5	pembrolizumab	pembrolizumab	NOUN
aiua-12307	55	6	treatment	treatment	NOUN
aiua-12307	55	7	has	have	VERB
aiua-12307	55	8	acceptable	acceptable	ADJ
aiua-12307	55	9	response	response	NOUN
aiua-12307	55	10	rates	rate	NOUN
aiua-12307	55	11	in	in	ADP
aiua-12307	55	12	first	first	ADJ
aiua-12307	55	13	-	-	PUNCT
aiua-12307	55	14	line	line	NOUN
aiua-12307	55	15	treatment	treatment	NOUN
aiua-12307	55	16	in	in	ADP
aiua-12307	55	17	patients	patient	NOUN
aiua-12307	55	18	with	with	ADP
aiua-12307	55	19	locally	locally	ADV
aiua-12307	55	20	advanced	advanced	ADJ
aiua-12307	55	21	or	or	CCONJ
aiua-12307	55	22	metastatic	metastatic	ADJ
aiua-12307	55	23	urothelial	urothelial	ADJ
aiua-12307	55	24	cancer	cancer	NOUN
aiua-12307	55	25	with	with	ADP
aiua-12307	55	26	high	high	ADJ
aiua-12307	55	27	comorbidity	comorbidity	NOUN
aiua-12307	55	28	rates	rate	NOUN
aiua-12307	55	29	who	who	PRON
aiua-12307	55	30	can	can	AUX
aiua-12307	55	31	not	not	PART
aiua-12307	55	32	receive	receive	VERB
aiua-12307	55	33	platinumbased	platinumbase	VERB
aiua-12307	55	34	ct	ct	PROPN
aiua-12307	55	35	.	.	PUNCT
aiua-12307	56	1	use	use	NOUN
aiua-12307	56	2	with	with	ADP
aiua-12307	56	3	this	this	DET
aiua-12307	56	4	indication	indication	NOUN
aiua-12307	56	5	was	be	AUX
aiua-12307	56	6	approved	approve	VERB
aiua-12307	56	7	by	by	ADP
aiua-12307	56	8	the	the	DET
aiua-12307	56	9	fda	fda	PROPN
aiua-12307	56	10	in	in	ADP
aiua-12307	56	11	2017	2017	NUM
aiua-12307	56	12	(	(	PUNCT
aiua-12307	56	13	12	12	NUM
aiua-12307	56	14	)	)	PUNCT
aiua-12307	56	15	.	.	PUNCT
aiua-12307	57	1	in	in	ADP
aiua-12307	57	2	a	a	DET
aiua-12307	57	3	phase	phase	NOUN
aiua-12307	57	4	ii	ii	NOUN
aiua-12307	57	5	trial	trial	NOUN
aiua-12307	57	6	(	(	PUNCT
aiua-12307	57	7	pure-01	pure-01	PROPN
aiua-12307	57	8	)	)	PUNCT
aiua-12307	57	9	conducted	conduct	VERB
aiua-12307	57	10	on	on	ADP
aiua-12307	57	11	patients	patient	NOUN
aiua-12307	57	12	diagnosed	diagnose	VERB
aiua-12307	57	13	with	with	ADP
aiua-12307	57	14	mibc	mibc	PROPN
aiua-12307	57	15	,	,	PUNCT
aiua-12307	57	16	regardless	regardless	ADV
aiua-12307	57	17	of	of	ADP
aiua-12307	57	18	their	their	PRON
aiua-12307	57	19	suitability	suitability	NOUN
aiua-12307	57	20	for	for	ADP
aiua-12307	57	21	platinum	platinum	NOUN
aiua-12307	57	22	-	-	PUNCT
aiua-12307	57	23	based	base	VERB
aiua-12307	57	24	ct	ct	PROPN
aiua-12307	57	25	,	,	PUNCT
aiua-12307	57	26	pembrolizumab	pembrolizumab	NOUN
aiua-12307	57	27	neoadjuvant	neoadjuvant	ADJ
aiua-12307	57	28	therapy	therapy	NOUN
aiua-12307	57	29	alone	alone	ADV
aiua-12307	57	30	has	have	AUX
aiua-12307	57	31	been	be	AUX
aiua-12307	57	32	shown	show	VERB
aiua-12307	57	33	to	to	PART
aiua-12307	57	34	reduce	reduce	VERB
aiua-12307	57	35	tumour	tumour	NOUN
aiua-12307	57	36	downstaging	downstaging	NOUN
aiua-12307	57	37	at	at	ADP
aiua-12307	57	38	radical	radical	ADJ
aiua-12307	57	39	cystectomy	cystectomy	NOUN
aiua-12307	57	40	pathology	pathology	NOUN
aiua-12307	57	41	(	(	PUNCT
aiua-12307	57	42	13	13	NUM
aiua-12307	57	43	)	)	PUNCT
aiua-12307	57	44	.	.	PUNCT
aiua-12307	58	1	another	another	DET
aiua-12307	58	2	study	study	NOUN
aiua-12307	58	3	showed	show	VERB
aiua-12307	58	4	that	that	SCONJ
aiua-12307	58	5	adding	add	VERB
aiua-12307	58	6	pembrolizumab	pembrolizumab	NOUN
aiua-12307	58	7	to	to	ADP
aiua-12307	58	8	platinum	platinum	NOUN
aiua-12307	58	9	-	-	PUNCT
aiua-12307	58	10	based	base	VERB
aiua-12307	58	11	ct	ct	NOUN
aiua-12307	58	12	in	in	ADP
aiua-12307	58	13	neoadjuvant	neoadjuvant	ADJ
aiua-12307	58	14	treatment	treatment	NOUN
aiua-12307	58	15	improved	improve	VERB
aiua-12307	58	16	pathological	pathological	ADJ
aiua-12307	58	17	response	response	NOUN
aiua-12307	58	18	rates	rate	NOUN
aiua-12307	58	19	(	(	PUNCT
aiua-12307	58	20	14	14	NUM
aiua-12307	58	21	)	)	PUNCT
aiua-12307	58	22	.	.	PUNCT
aiua-12307	59	1	in	in	ADP
aiua-12307	59	2	another	another	DET
aiua-12307	59	3	study	study	NOUN
aiua-12307	59	4	,	,	PUNCT
aiua-12307	59	5	the	the	DET
aiua-12307	59	6	effectiveness	effectiveness	NOUN
aiua-12307	59	7	of	of	ADP
aiua-12307	59	8	maintenance	maintenance	NOUN
aiua-12307	59	9	treatment	treatment	NOUN
aiua-12307	59	10	with	with	ADP
aiua-12307	59	11	pembrolizumab	pembrolizumab	NOUN
aiua-12307	59	12	was	be	AUX
aiua-12307	59	13	evaluated	evaluate	VERB
aiua-12307	59	14	in	in	ADP
aiua-12307	59	15	patients	patient	NOUN
aiua-12307	59	16	who	who	PRON
aiua-12307	59	17	were	be	AUX
aiua-12307	59	18	given	give	VERB
aiua-12307	59	19	platinum	platinum	NOUN
aiua-12307	59	20	-	-	PUNCT
aiua-12307	59	21	based	base	VERB
aiua-12307	59	22	ct	ct	NOUN
aiua-12307	59	23	in	in	ADP
aiua-12307	59	24	first	first	ADJ
aiua-12307	59	25	-	-	PUNCT
aiua-12307	59	26	line	line	NOUN
aiua-12307	59	27	treatment	treatment	NOUN
aiua-12307	59	28	and	and	CCONJ
aiua-12307	59	29	stable	stable	ADJ
aiua-12307	59	30	disease	disease	NOUN
aiua-12307	59	31	was	be	AUX
aiua-12307	59	32	achieved	achieve	VERB
aiua-12307	59	33	.	.	PUNCT
aiua-12307	60	1	there	there	PRON
aiua-12307	60	2	was	be	VERB
aiua-12307	60	3	a	a	DET
aiua-12307	60	4	benefit	benefit	NOUN
aiua-12307	60	5	in	in	ADP
aiua-12307	60	6	progression	progression	NOUN
aiua-12307	60	7	-	-	PUNCT
aiua-12307	60	8	free	free	ADJ
aiua-12307	60	9	survival	survival	NOUN
aiua-12307	60	10	(	(	PUNCT
aiua-12307	60	11	pfs	pfs	PROPN
aiua-12307	60	12	)	)	PUNCT
aiua-12307	60	13	(	(	PUNCT
aiua-12307	60	14	5.4	5.4	NUM
aiua-12307	60	15	vs	vs	ADP
aiua-12307	60	16	3	3	NUM
aiua-12307	60	17	mo	mo	PROPN
aiua-12307	60	18	.	.	PROPN
aiua-12307	60	19	,	,	PUNCT
aiua-12307	60	20	p	p	X
aiua-12307	60	21	=	=	NOUN
aiua-12307	60	22	0.04	0.04	NUM
aiua-12307	60	23	)	)	PUNCT
aiua-12307	60	24	(	(	PUNCT
aiua-12307	60	25	15	15	NUM
aiua-12307	60	26	)	)	PUNCT
aiua-12307	60	27	.	.	PUNCT
aiua-12307	61	1	in	in	ADP
aiua-12307	61	2	another	another	DET
aiua-12307	61	3	phase	phase	NOUN
aiua-12307	61	4	iii	iii	NOUN
aiua-12307	61	5	randomized	randomize	VERB
aiua-12307	61	6	controlled	control	VERB
aiua-12307	61	7	trial	trial	NOUN
aiua-12307	61	8	(	(	PUNCT
aiua-12307	61	9	rct	rct	PROPN
aiua-12307	61	10	)	)	PUNCT
aiua-12307	61	11	,	,	PUNCT
aiua-12307	61	12	pembrolizumab	pembrolizumab	NOUN
aiua-12307	61	13	monotherapy	monotherapy	NOUN
aiua-12307	61	14	in	in	ADP
aiua-12307	61	15	second	second	ADJ
aiua-12307	61	16	-	-	PUNCT
aiua-12307	61	17	line	line	NOUN
aiua-12307	61	18	treatment	treatment	NOUN
aiua-12307	61	19	showed	show	VERB
aiua-12307	61	20	improvement	improvement	NOUN
aiua-12307	61	21	in	in	ADP
aiua-12307	61	22	overall	overall	ADJ
aiua-12307	61	23	survival	survival	NOUN
aiua-12307	61	24	(	(	PUNCT
aiua-12307	61	25	os	os	NOUN
aiua-12307	61	26	)	)	PUNCT
aiua-12307	61	27	compared	compare	VERB
aiua-12307	61	28	to	to	ADP
aiua-12307	61	29	ct	ct	PROPN
aiua-12307	61	30	(	(	PUNCT
aiua-12307	61	31	10.3	10.3	NUM
aiua-12307	61	32	vs	vs	ADP
aiua-12307	61	33	7.4	7.4	NUM
aiua-12307	61	34	mo	mo	NOUN
aiua-12307	61	35	.	.	PROPN
aiua-12307	61	36	,	,	PUNCT
aiua-12307	61	37	p	p	X
aiua-12307	61	38	=	=	NOUN
aiua-12307	61	39	0.002	0.002	NUM
aiua-12307	61	40	)	)	PUNCT
aiua-12307	61	41	(	(	PUNCT
aiua-12307	61	42	16	16	NUM
aiua-12307	61	43	)	)	PUNCT
aiua-12307	61	44	.	.	PUNCT
aiua-12307	62	1	however	however	ADV
aiua-12307	62	2	,	,	PUNCT
aiua-12307	62	3	there	there	PRON
aiua-12307	62	4	are	be	VERB
aiua-12307	62	5	also	also	ADV
aiua-12307	62	6	studies	study	NOUN
aiua-12307	62	7	reporting	report	VERB
aiua-12307	62	8	that	that	SCONJ
aiua-12307	62	9	adding	add	VERB
aiua-12307	62	10	pembrolizumab	pembrolizumab	NOUN
aiua-12307	62	11	to	to	ADP
aiua-12307	62	12	standard	standard	ADJ
aiua-12307	62	13	adjuvant	adjuvant	ADJ
aiua-12307	62	14	ct	ct	PRON
aiua-12307	62	15	in	in	ADP
aiua-12307	62	16	patients	patient	NOUN
aiua-12307	62	17	with	with	ADP
aiua-12307	62	18	advanced	advanced	ADJ
aiua-12307	62	19	urothelial	urothelial	ADJ
aiua-12307	62	20	carcinoma	carcinoma	NOUN
aiua-12307	62	21	does	do	AUX
aiua-12307	62	22	not	not	PART
aiua-12307	62	23	increase	increase	VERB
aiua-12307	62	24	treatment	treatment	NOUN
aiua-12307	62	25	effectiveness	effectiveness	NOUN
aiua-12307	62	26	(	(	PUNCT
aiua-12307	62	27	12	12	NUM
aiua-12307	62	28	)	)	PUNCT
aiua-12307	62	29	.	.	PUNCT
aiua-12307	63	1	nivolumab	nivolumab	ADV
aiua-12307	63	2	according	accord	VERB
aiua-12307	63	3	to	to	ADP
aiua-12307	63	4	a	a	DET
aiua-12307	63	5	phase	phase	NOUN
aiua-12307	63	6	ii	ii	NOUN
aiua-12307	63	7	single	single	ADJ
aiua-12307	63	8	-	-	PUNCT
aiua-12307	63	9	arm	arm	NOUN
aiua-12307	63	10	trial	trial	NOUN
aiua-12307	63	11	results	result	NOUN
aiua-12307	63	12	in	in	ADP
aiua-12307	63	13	270	270	NUM
aiua-12307	63	14	patients	patient	NOUN
aiua-12307	63	15	diagnosed	diagnose	VERB
aiua-12307	63	16	with	with	ADP
aiua-12307	63	17	surgically	surgically	ADV
aiua-12307	63	18	unresectable	unresectable	ADJ
aiua-12307	63	19	locally	locally	ADV
aiua-12307	63	20	advanced	advanced	ADJ
aiua-12307	63	21	or	or	CCONJ
aiua-12307	63	22	muc	muc	ADJ
aiua-12307	63	23	,	,	PUNCT
aiua-12307	63	24	an	an	DET
aiua-12307	63	25	objective	objective	ADJ
aiua-12307	63	26	response	response	NOUN
aiua-12307	63	27	rate	rate	NOUN
aiua-12307	63	28	(	(	PUNCT
aiua-12307	63	29	orr	orr	PROPN
aiua-12307	63	30	)	)	PUNCT
aiua-12307	63	31	of	of	ADP
aiua-12307	63	32	19.6	19.6	NUM
aiua-12307	63	33	%	%	NOUN
aiua-12307	63	34	was	be	AUX
aiua-12307	63	35	achieved	achieve	VERB
aiua-12307	63	36	in	in	ADP
aiua-12307	63	37	patients	patient	NOUN
aiua-12307	63	38	receiving	receive	VERB
aiua-12307	63	39	nivolumab	nivolumab	DET
aiua-12307	63	40	monotherapy	monotherapy	NOUN
aiua-12307	63	41	.	.	PUNCT
aiua-12307	64	1	it	it	PRON
aiua-12307	64	2	was	be	AUX
aiua-12307	64	3	shown	show	VERB
aiua-12307	64	4	to	to	PART
aiua-12307	64	5	provide	provide	VERB
aiua-12307	64	6	clinical	clinical	ADJ
aiua-12307	64	7	benefit	benefit	NOUN
aiua-12307	64	8	regardless	regardless	ADV
aiua-12307	64	9	of	of	ADP
aiua-12307	64	10	pd	pd	PROPN
aiua-12307	64	11	-	-	PROPN
aiua-12307	64	12	l1	l1	PROPN
aiua-12307	64	13	expression	expression	NOUN
aiua-12307	64	14	.	.	PUNCT
aiua-12307	65	1	based	base	VERB
aiua-12307	65	2	on	on	ADP
aiua-12307	65	3	the	the	DET
aiua-12307	65	4	results	result	NOUN
aiua-12307	65	5	of	of	ADP
aiua-12307	65	6	this	this	DET
aiua-12307	65	7	study	study	NOUN
aiua-12307	65	8	,	,	PUNCT
aiua-12307	65	9	the	the	DET
aiua-12307	65	10	pd-1	pd-1	ADJ
aiua-12307	65	11	inhibitor	inhibitor	NOUN
aiua-12307	65	12	nivolumab	nivolumab	NOUN
aiua-12307	65	13	has	have	AUX
aiua-12307	65	14	been	be	AUX
aiua-12307	65	15	approved	approve	VERB
aiua-12307	65	16	for	for	ADP
aiua-12307	65	17	second	second	ADJ
aiua-12307	65	18	-	-	PUNCT
aiua-12307	65	19	line	line	NOUN
aiua-12307	65	20	treatment	treatment	NOUN
aiua-12307	65	21	in	in	ADP
aiua-12307	65	22	patients	patient	NOUN
aiua-12307	65	23	diagnosed	diagnose	VERB
aiua-12307	65	24	with	with	ADP
aiua-12307	65	25	muc	muc	PROPN
aiua-12307	65	26	who	who	PRON
aiua-12307	65	27	have	have	AUX
aiua-12307	65	28	not	not	PART
aiua-12307	65	29	received	receive	VERB
aiua-12307	65	30	an	an	DET
aiua-12307	65	31	adequate	adequate	ADJ
aiua-12307	65	32	response	response	NOUN
aiua-12307	65	33	to	to	ADP
aiua-12307	65	34	platinum	platinum	NOUN
aiua-12307	65	35	-	-	PUNCT
aiua-12307	65	36	based	base	VERB
aiua-12307	65	37	ct	ct	PROPN
aiua-12307	65	38	(	(	PUNCT
aiua-12307	65	39	17	17	NUM
aiua-12307	65	40	)	)	PUNCT
aiua-12307	65	41	.	.	PUNCT
aiua-12307	66	1	according	accord	VERB
aiua-12307	66	2	to	to	ADP
aiua-12307	66	3	the	the	DET
aiua-12307	66	4	phase	phase	NOUN
aiua-12307	66	5	i	i	PROPN
aiua-12307	66	6	-	-	PUNCT
aiua-12307	66	7	ii	ii	PROPN
aiua-12307	66	8	trial	trial	NOUN
aiua-12307	66	9	results	result	NOUN
aiua-12307	66	10	conducted	conduct	VERB
aiua-12307	66	11	in	in	ADP
aiua-12307	66	12	patients	patient	NOUN
aiua-12307	66	13	with	with	ADP
aiua-12307	66	14	muc	muc	PROPN
aiua-12307	66	15	who	who	PRON
aiua-12307	66	16	did	do	AUX
aiua-12307	66	17	not	not	PART
aiua-12307	66	18	respond	respond	VERB
aiua-12307	66	19	adequately	adequately	ADV
aiua-12307	66	20	to	to	ADP
aiua-12307	66	21	platinum	platinum	NOUN
aiua-12307	66	22	-	-	PUNCT
aiua-12307	66	23	based	base	VERB
aiua-12307	66	24	ct	ct	PROPN
aiua-12307	66	25	,	,	PUNCT
aiua-12307	66	26	nivolumab	nivolumab	ADJ
aiua-12307	66	27	/	/	SYM
aiua-12307	66	28	ipilimumab	ipilimumab	NOUN
aiua-12307	66	29	combination	combination	NOUN
aiua-12307	66	30	therapy	therapy	NOUN
aiua-12307	66	31	had	have	VERB
aiua-12307	66	32	an	an	DET
aiua-12307	66	33	orr	orr	NOUN
aiua-12307	66	34	of	of	ADP
aiua-12307	66	35	up	up	ADP
aiua-12307	66	36	to	to	PART
aiua-12307	66	37	38	38	NUM
aiua-12307	66	38	%	%	NOUN
aiua-12307	66	39	(	(	PUNCT
aiua-12307	66	40	18	18	NUM
aiua-12307	66	41	)	)	PUNCT
aiua-12307	66	42	.	.	PUNCT
aiua-12307	67	1	according	accord	VERB
aiua-12307	67	2	to	to	ADP
aiua-12307	67	3	eau	eau	PROPN
aiua-12307	67	4	guidelines	guideline	NOUN
aiua-12307	67	5	,	,	PUNCT
aiua-12307	67	6	adjuvant	adjuvant	ADJ
aiua-12307	67	7	nivolumab	nivolumab	NOUN
aiua-12307	67	8	treatment	treatment	NOUN
aiua-12307	67	9	is	be	AUX
aiua-12307	67	10	recommended	recommend	VERB
aiua-12307	67	11	for	for	ADP
aiua-12307	67	12	patients	patient	NOUN
aiua-12307	67	13	with	with	ADP
aiua-12307	67	14	pt3	pt3	NOUN
aiua-12307	67	15	,	,	PUNCT
aiua-12307	67	16	pt4	pt4	NOUN
aiua-12307	67	17	,	,	PUNCT
aiua-12307	67	18	and	and	CCONJ
aiua-12307	67	19	pn+	pn+	NOUN
aiua-12307	67	20	utuc	utuc	NOUN
aiua-12307	67	21	who	who	PRON
aiua-12307	67	22	can	can	AUX
aiua-12307	67	23	not	not	PART
aiua-12307	67	24	receive	receive	VERB
aiua-12307	67	25	adjuvant	adjuvant	ADJ
aiua-12307	67	26	platinum	platinum	NOUN
aiua-12307	67	27	-	-	PUNCT
aiua-12307	67	28	based	base	VERB
aiua-12307	67	29	ct	ct	PROPN
aiua-12307	67	30	(	(	PUNCT
aiua-12307	67	31	19	19	NUM
aiua-12307	67	32	)	)	PUNCT
aiua-12307	67	33	.	.	PUNCT
aiua-12307	68	1	in	in	ADP
aiua-12307	68	2	the	the	DET
aiua-12307	68	3	checkmate-274	checkmate-274	ADJ
aiua-12307	68	4	trial	trial	NOUN
aiua-12307	68	5	,	,	PUNCT
aiua-12307	68	6	709	709	NUM
aiua-12307	68	7	patients	patient	NOUN
aiua-12307	68	8	with	with	ADP
aiua-12307	68	9	a	a	DET
aiua-12307	68	10	high	high	ADJ
aiua-12307	68	11	risk	risk	NOUN
aiua-12307	68	12	of	of	ADP
aiua-12307	68	13	recurrence	recurrence	NOUN
aiua-12307	68	14	and	and	CCONJ
aiua-12307	68	15	diagnosed	diagnose	VERB
aiua-12307	68	16	with	with	ADP
aiua-12307	68	17	locally	locally	ADV
aiua-12307	68	18	advanced	advance	VERB
aiua-12307	68	19	urothelial	urothelial	ADJ
aiua-12307	68	20	cancer	cancer	NOUN
aiua-12307	68	21	were	be	AUX
aiua-12307	68	22	randomized	randomize	VERB
aiua-12307	68	23	.	.	PUNCT
aiua-12307	69	1	in	in	ADP
aiua-12307	69	2	this	this	DET
aiua-12307	69	3	study	study	NOUN
aiua-12307	69	4	,	,	PUNCT
aiua-12307	69	5	adjuvant	adjuvant	ADJ
aiua-12307	69	6	nivolumab	nivolumab	NOUN
aiua-12307	69	7	was	be	AUX
aiua-12307	69	8	given	give	VERB
aiua-12307	69	9	to	to	ADP
aiua-12307	69	10	one	one	NUM
aiua-12307	69	11	group	group	NOUN
aiua-12307	69	12	and	and	CCONJ
aiua-12307	69	13	placebo	placebo	NOUN
aiua-12307	69	14	to	to	ADP
aiua-12307	69	15	the	the	DET
aiua-12307	69	16	other	other	ADJ
aiua-12307	69	17	group	group	NOUN
aiua-12307	69	18	,	,	PUNCT
aiua-12307	69	19	and	and	CCONJ
aiua-12307	69	20	a	a	DET
aiua-12307	69	21	statistically	statistically	ADV
aiua-12307	69	22	significant	significant	ADJ
aiua-12307	69	23	improvement	improvement	NOUN
aiua-12307	69	24	in	in	ADP
aiua-12307	69	25	disease	disease	NOUN
aiua-12307	69	26	-	-	PUNCT
aiua-12307	69	27	free	free	ADJ
aiua-12307	69	28	survival	survival	NOUN
aiua-12307	69	29	(	(	PUNCT
aiua-12307	69	30	dfs	dfs	PROPN
aiua-12307	69	31	)	)	PUNCT
aiua-12307	69	32	was	be	AUX
aiua-12307	69	33	detected	detect	VERB
aiua-12307	69	34	in	in	ADP
aiua-12307	69	35	the	the	DET
aiua-12307	69	36	treatment	treatment	NOUN
aiua-12307	69	37	arm	arm	NOUN
aiua-12307	69	38	(	(	PUNCT
aiua-12307	69	39	10.8	10.8	NUM
aiua-12307	69	40	vs	vs	ADP
aiua-12307	69	41	20.8	20.8	NUM
aiua-12307	69	42	mo	mo	NOUN
aiua-12307	69	43	.	.	PUNCT
aiua-12307	70	1	p	p	X
aiua-12307	70	2	<	<	X
aiua-12307	70	3	0.001	0.001	NUM
aiua-12307	70	4	)	)	PUNCT
aiua-12307	70	5	(	(	PUNCT
aiua-12307	70	6	20	20	NUM
aiua-12307	70	7	)	)	PUNCT
aiua-12307	70	8	.	.	PUNCT
aiua-12307	71	1	based	base	VERB
aiua-12307	71	2	on	on	ADP
aiua-12307	71	3	data	datum	NOUN
aiua-12307	71	4	from	from	ADP
aiua-12307	71	5	the	the	DET
aiua-12307	71	6	study	study	NOUN
aiua-12307	71	7	,	,	PUNCT
aiua-12307	71	8	nivolumab	nivolumab	ADV
aiua-12307	71	9	was	be	AUX
aiua-12307	71	10	approved	approve	VERB
aiua-12307	71	11	by	by	ADP
aiua-12307	71	12	the	the	DET
aiua-12307	71	13	fda	fda	PROPN
aiua-12307	71	14	for	for	ADP
aiua-12307	71	15	the	the	DET
aiua-12307	71	16	adjuvant	adjuvant	ADJ
aiua-12307	71	17	treatment	treatment	NOUN
aiua-12307	71	18	of	of	ADP
aiua-12307	71	19	urothelial	urothelial	ADJ
aiua-12307	71	20	carcinoma	carcinoma	NOUN
aiua-12307	71	21	.	.	PUNCT
aiua-12307	72	1	atezolizumab	atezolizumab	PROPN
aiua-12307	72	2	atezolizumab	atezolizumab	NOUN
aiua-12307	72	3	is	be	AUX
aiua-12307	72	4	a	a	DET
aiua-12307	72	5	monoclonal	monoclonal	NOUN
aiua-12307	72	6	antibody	antibody	NOUN
aiua-12307	72	7	that	that	PRON
aiua-12307	72	8	inhibits	inhibit	VERB
aiua-12307	72	9	antipd	antipd	NOUN
aiua-12307	72	10	-	-	PUNCT
aiua-12307	72	11	l1	l1	PROPN
aiua-12307	72	12	.	.	PUNCT
aiua-12307	73	1	in	in	ADP
aiua-12307	73	2	light	light	NOUN
aiua-12307	73	3	of	of	ADP
aiua-12307	73	4	the	the	DET
aiua-12307	73	5	data	datum	NOUN
aiua-12307	73	6	from	from	ADP
aiua-12307	73	7	rcts	rct	NOUN
aiua-12307	73	8	,	,	PUNCT
aiua-12307	73	9	the	the	DET
aiua-12307	73	10	use	use	NOUN
aiua-12307	73	11	of	of	ADP
aiua-12307	73	12	atezolizumab	atezolizumab	NOUN
aiua-12307	73	13	in	in	ADP
aiua-12307	73	14	the	the	DET
aiua-12307	73	15	first	first	ADJ
aiua-12307	73	16	-	-	PUNCT
aiua-12307	73	17	line	line	NOUN
aiua-12307	73	18	treatment	treatment	NOUN
aiua-12307	73	19	of	of	ADP
aiua-12307	73	20	patients	patient	NOUN
aiua-12307	73	21	diagnosed	diagnose	VERB
aiua-12307	73	22	with	with	ADP
aiua-12307	73	23	locally	locally	ADV
aiua-12307	73	24	advanced	advanced	ADJ
aiua-12307	73	25	or	or	CCONJ
aiua-12307	73	26	muc	muc	PRON
aiua-12307	73	27	who	who	PRON
aiua-12307	73	28	are	be	AUX
aiua-12307	73	29	not	not	PART
aiua-12307	73	30	suitable	suitable	ADJ
aiua-12307	73	31	for	for	ADP
aiua-12307	73	32	platinum	platinum	NOUN
aiua-12307	73	33	-	-	PUNCT
aiua-12307	73	34	based	base	VERB
aiua-12307	73	35	ct	ct	NOUN
aiua-12307	73	36	and	and	CCONJ
aiua-12307	73	37	in	in	ADP
aiua-12307	73	38	the	the	DET
aiua-12307	73	39	second	second	ADJ
aiua-12307	73	40	-	-	PUNCT
aiua-12307	73	41	line	line	NOUN
aiua-12307	73	42	treatment	treatment	NOUN
aiua-12307	73	43	of	of	ADP
aiua-12307	73	44	patients	patient	NOUN
aiua-12307	73	45	whose	whose	DET
aiua-12307	73	46	disease	disease	NOUN
aiua-12307	73	47	progresses	progress	VERB
aiua-12307	73	48	despite	despite	SCONJ
aiua-12307	73	49	platinum	platinum	NOUN
aiua-12307	73	50	-	-	PUNCT
aiua-12307	73	51	based	base	VERB
aiua-12307	73	52	ct	ct	NOUN
aiua-12307	73	53	and	and	CCONJ
aiua-12307	73	54	who	who	PRON
aiua-12307	73	55	can	can	AUX
aiua-12307	73	56	not	not	PART
aiua-12307	73	57	undergo	undergo	VERB
aiua-12307	73	58	surgical	surgical	ADJ
aiua-12307	73	59	resection	resection	NOUN
aiua-12307	73	60	has	have	AUX
aiua-12307	73	61	been	be	AUX
aiua-12307	73	62	approved	approve	VERB
aiua-12307	73	63	by	by	ADP
aiua-12307	73	64	the	the	DET
aiua-12307	73	65	fda	fda	PROPN
aiua-12307	73	66	and	and	CCONJ
aiua-12307	73	67	european	european	PROPN
aiua-12307	73	68	medicines	medicine	NOUN
aiua-12307	73	69	agency	agency	NOUN
aiua-12307	73	70	(	(	PUNCT
aiua-12307	73	71	ema	ema	PROPN
aiua-12307	73	72	)	)	PUNCT
aiua-12307	73	73	(	(	PUNCT
aiua-12307	73	74	21	21	NUM
aiua-12307	73	75	,	,	PUNCT
aiua-12307	73	76	22	22	NUM
aiua-12307	73	77	)	)	PUNCT
aiua-12307	73	78	.	.	PUNCT
aiua-12307	74	1	the	the	DET
aiua-12307	74	2	recently	recently	ADV
aiua-12307	74	3	published	publish	VERB
aiua-12307	74	4	abacus	abacus	PROPN
aiua-12307	74	5	study	study	NOUN
aiua-12307	74	6	evaluated	evaluate	VERB
aiua-12307	74	7	the	the	DET
aiua-12307	74	8	effectiveness	effectiveness	NOUN
aiua-12307	74	9	of	of	ADP
aiua-12307	74	10	neoadjuvant	neoadjuvant	ADJ
aiua-12307	74	11	atezolizumab	atezolizumab	NOUN
aiua-12307	74	12	treatment	treatment	NOUN
aiua-12307	74	13	in	in	ADP
aiua-12307	74	14	patients	patient	NOUN
aiua-12307	74	15	unsuitable	unsuitable	ADJ
aiua-12307	74	16	for	for	ADP
aiua-12307	74	17	cisplatin	cisplatin	NOUN
aiua-12307	74	18	treatment	treatment	NOUN
aiua-12307	74	19	.	.	PUNCT
aiua-12307	75	1	according	accord	VERB
aiua-12307	75	2	to	to	ADP
aiua-12307	75	3	the	the	DET
aiua-12307	75	4	results	result	NOUN
aiua-12307	75	5	of	of	ADP
aiua-12307	75	6	this	this	DET
aiua-12307	75	7	study	study	NOUN
aiua-12307	75	8	,	,	PUNCT
aiua-12307	75	9	2	2	NUM
aiua-12307	75	10	-	-	PUNCT
aiua-12307	75	11	year	year	NOUN
aiua-12307	75	12	dfs	dfs	NOUN
aiua-12307	75	13	and	and	CCONJ
aiua-12307	75	14	os	os	NOUN
aiua-12307	75	15	were	be	AUX
aiua-12307	75	16	reported	report	VERB
aiua-12307	75	17	as	as	ADP
aiua-12307	75	18	68	68	NUM
aiua-12307	75	19	%	%	NOUN
aiua-12307	75	20	and	and	CCONJ
aiua-12307	75	21	77	77	NUM
aiua-12307	75	22	%	%	NOUN
aiua-12307	75	23	,	,	PUNCT
aiua-12307	75	24	respectively	respectively	ADV
aiua-12307	75	25	.	.	PUNCT
aiua-12307	76	1	in	in	ADP
aiua-12307	76	2	another	another	DET
aiua-12307	76	3	single	single	ADJ
aiua-12307	76	4	-	-	PUNCT
aiua-12307	76	5	arm	arm	NOUN
aiua-12307	76	6	phase	phase	NOUN
aiua-12307	76	7	ii	ii	NOUN
aiua-12307	76	8	clinical	clinical	ADJ
aiua-12307	76	9	study	study	NOUN
aiua-12307	76	10	,	,	PUNCT
aiua-12307	76	11	in	in	ADP
aiua-12307	76	12	the	the	DET
aiua-12307	76	13	neoadjuvant	neoadjuvant	ADJ
aiua-12307	76	14	treatment	treatment	NOUN
aiua-12307	76	15	of	of	ADP
aiua-12307	76	16	patients	patient	NOUN
aiua-12307	76	17	with	with	ADP
aiua-12307	76	18	ct2archivio	ct2archivio	NOUN
aiua-12307	76	19	italiano	italiano	NOUN
aiua-12307	76	20	di	di	X
aiua-12307	76	21	urologia	urologia	PROPN
aiua-12307	76	22	e	e	PROPN
aiua-12307	76	23	andrologia	andrologia	NOUN
aiua-12307	76	24	2024	2024	NUM
aiua-12307	76	25	;	;	PUNCT
aiua-12307	76	26	96(2):12307	96(2):12307	NUM
aiua-12307	76	27	3	3	NUM
aiua-12307	76	28	the	the	DET
aiua-12307	76	29	role	role	NOUN
aiua-12307	76	30	of	of	ADP
aiua-12307	76	31	immunotherapy	immunotherapy	NOUN
aiua-12307	76	32	in	in	ADP
aiua-12307	76	33	urological	urological	ADJ
aiua-12307	76	34	cancers	cancer	NOUN
aiua-12307	76	35	t4an0m0	t4an0m0	PROPN
aiua-12307	76	36	stage	stage	NOUN
aiua-12307	76	37	tumours	tumour	VERB
aiua-12307	76	38	,	,	PUNCT
aiua-12307	76	39	the	the	DET
aiua-12307	76	40	addition	addition	NOUN
aiua-12307	76	41	of	of	ADP
aiua-12307	76	42	atezolizumab	atezolizumab	NOUN
aiua-12307	76	43	to	to	ADP
aiua-12307	76	44	gemcitabine	gemcitabine	NOUN
aiua-12307	76	45	-	-	PUNCT
aiua-12307	76	46	cisplatin	cisplatin	NOUN
aiua-12307	76	47	combination	combination	NOUN
aiua-12307	76	48	has	have	AUX
aiua-12307	76	49	been	be	AUX
aiua-12307	76	50	shown	show	VERB
aiua-12307	76	51	to	to	PART
aiua-12307	76	52	provide	provide	VERB
aiua-12307	76	53	a	a	DET
aiua-12307	76	54	relapse	relapse	NOUN
aiua-12307	76	55	-	-	PUNCT
aiua-12307	76	56	free	free	ADJ
aiua-12307	76	57	survival	survival	NOUN
aiua-12307	76	58	advantage	advantage	NOUN
aiua-12307	76	59	(	(	PUNCT
aiua-12307	76	60	23	23	NUM
aiua-12307	76	61	)	)	PUNCT
aiua-12307	76	62	.	.	PUNCT
aiua-12307	77	1	in	in	ADP
aiua-12307	77	2	the	the	DET
aiua-12307	77	3	multicenter	multicenter	NOUN
aiua-12307	77	4	randomized	randomize	VERB
aiua-12307	77	5	controlled	control	VERB
aiua-12307	77	6	phase	phase	NOUN
aiua-12307	77	7	iii	iii	NUM
aiua-12307	77	8	study	study	NOUN
aiua-12307	77	9	(	(	PUNCT
aiua-12307	77	10	imvigor	imvigor	PROPN
aiua-12307	77	11	130	130	NUM
aiua-12307	77	12	)	)	PUNCT
aiua-12307	77	13	,	,	PUNCT
aiua-12307	77	14	1213	1213	NUM
aiua-12307	77	15	patients	patient	NOUN
aiua-12307	77	16	with	with	ADP
aiua-12307	77	17	locally	locally	ADV
aiua-12307	77	18	advanced	advanced	ADJ
aiua-12307	77	19	or	or	CCONJ
aiua-12307	77	20	muc	muc	PROPN
aiua-12307	77	21	were	be	AUX
aiua-12307	77	22	divided	divide	VERB
aiua-12307	77	23	into	into	ADP
aiua-12307	77	24	three	three	NUM
aiua-12307	77	25	groups	group	NOUN
aiua-12307	77	26	.	.	PUNCT
aiua-12307	78	1	survival	survival	NOUN
aiua-12307	78	2	analyses	analysis	NOUN
aiua-12307	78	3	were	be	AUX
aiua-12307	78	4	compared	compare	VERB
aiua-12307	78	5	by	by	ADP
aiua-12307	78	6	giving	give	VERB
aiua-12307	78	7	platinum	platinum	NOUN
aiua-12307	78	8	-	-	PUNCT
aiua-12307	78	9	based	base	VERB
aiua-12307	78	10	ct	ct	PROPN
aiua-12307	78	11	/	/	SYM
aiua-12307	78	12	atezolizumab	atezolizumab	NOUN
aiua-12307	78	13	to	to	ADP
aiua-12307	78	14	group	group	PROPN
aiua-12307	78	15	a	a	PROPN
aiua-12307	78	16	,	,	PUNCT
aiua-12307	78	17	atezolizumab	atezolizumab	NOUN
aiua-12307	78	18	to	to	ADP
aiua-12307	78	19	group	group	PROPN
aiua-12307	78	20	b	b	PROPN
aiua-12307	78	21	,	,	PUNCT
aiua-12307	78	22	and	and	CCONJ
aiua-12307	78	23	platinumbased	platinumbase	VERB
aiua-12307	78	24	ct	ct	PROPN
aiua-12307	78	25	/	/	SYM
aiua-12307	78	26	placebo	placebo	NOUN
aiua-12307	78	27	to	to	ADP
aiua-12307	78	28	group	group	PROPN
aiua-12307	78	29	c.	c.	PROPN
aiua-12307	79	1	the	the	DET
aiua-12307	79	2	median	median	PROPN
aiua-12307	79	3	os	os	PROPN
aiua-12307	79	4	times	time	NOUN
aiua-12307	79	5	of	of	ADP
aiua-12307	79	6	patients	patient	NOUN
aiua-12307	79	7	in	in	ADP
aiua-12307	79	8	groups	group	NOUN
aiua-12307	79	9	a	a	PRON
aiua-12307	79	10	and	and	CCONJ
aiua-12307	79	11	c	c	PROPN
aiua-12307	79	12	were	be	AUX
aiua-12307	79	13	reported	report	VERB
aiua-12307	79	14	as	as	ADP
aiua-12307	79	15	16	16	NUM
aiua-12307	79	16	mo	mo	NOUN
aiua-12307	79	17	.	.	PROPN
aiua-12307	79	18	and	and	CCONJ
aiua-12307	79	19	13.4	13.4	NUM
aiua-12307	79	20	mo	mo	NOUN
aiua-12307	79	21	.	.	PROPN
aiua-12307	79	22	,	,	PUNCT
aiua-12307	79	23	respectively	respectively	ADV
aiua-12307	79	24	,	,	PUNCT
aiua-12307	79	25	and	and	CCONJ
aiua-12307	79	26	there	there	PRON
aiua-12307	79	27	was	be	VERB
aiua-12307	79	28	a	a	DET
aiua-12307	79	29	statistically	statistically	ADV
aiua-12307	79	30	significant	significant	ADJ
aiua-12307	79	31	difference	difference	NOUN
aiua-12307	79	32	between	between	ADP
aiua-12307	79	33	both	both	DET
aiua-12307	79	34	groups	group	NOUN
aiua-12307	79	35	(	(	PUNCT
aiua-12307	79	36	0.83	0.83	NUM
aiua-12307	79	37	,	,	PUNCT
aiua-12307	79	38	95	95	NUM
aiua-12307	79	39	%	%	NOUN
aiua-12307	79	40	ci	ci	NOUN
aiua-12307	79	41	0.69	0.69	NUM
aiua-12307	79	42	-	-	SYM
aiua-12307	79	43	1	1	NUM
aiua-12307	79	44	,	,	PUNCT
aiua-12307	79	45	p	p	X
aiua-12307	79	46	=	=	PROPN
aiua-12307	79	47	0.027	0.027	NUM
aiua-12307	79	48	)	)	PUNCT
aiua-12307	79	49	.	.	PUNCT
aiua-12307	80	1	the	the	DET
aiua-12307	80	2	median	median	PROPN
aiua-12307	80	3	os	os	PROPN
aiua-12307	80	4	times	time	NOUN
aiua-12307	80	5	of	of	ADP
aiua-12307	80	6	patients	patient	NOUN
aiua-12307	80	7	in	in	ADP
aiua-12307	80	8	groups	group	NOUN
aiua-12307	80	9	b	b	PROPN
aiua-12307	80	10	and	and	CCONJ
aiua-12307	80	11	c	c	PROPN
aiua-12307	80	12	were	be	AUX
aiua-12307	80	13	15.7	15.7	NUM
aiua-12307	80	14	mo	mo	NOUN
aiua-12307	80	15	.	.	PROPN
aiua-12307	80	16	,	,	PUNCT
aiua-12307	80	17	and	and	CCONJ
aiua-12307	80	18	13.1	13.1	NUM
aiua-12307	80	19	mo	mo	NOUN
aiua-12307	80	20	.	.	PROPN
aiua-12307	80	21	,	,	PUNCT
aiua-12307	80	22	respectively	respectively	ADV
aiua-12307	80	23	,	,	PUNCT
aiua-12307	80	24	and	and	CCONJ
aiua-12307	80	25	it	it	PRON
aiua-12307	80	26	was	be	AUX
aiua-12307	80	27	reported	report	VERB
aiua-12307	80	28	that	that	SCONJ
aiua-12307	80	29	there	there	PRON
aiua-12307	80	30	was	be	VERB
aiua-12307	80	31	no	no	DET
aiua-12307	80	32	statistically	statistically	ADV
aiua-12307	80	33	significant	significant	ADJ
aiua-12307	80	34	difference	difference	NOUN
aiua-12307	80	35	between	between	ADP
aiua-12307	80	36	the	the	DET
aiua-12307	80	37	two	two	NUM
aiua-12307	80	38	groups	group	NOUN
aiua-12307	80	39	.	.	PUNCT
aiua-12307	81	1	as	as	ADP
aiua-12307	81	2	a	a	DET
aiua-12307	81	3	result	result	NOUN
aiua-12307	81	4	,	,	PUNCT
aiua-12307	81	5	it	it	PRON
aiua-12307	81	6	has	have	AUX
aiua-12307	81	7	been	be	AUX
aiua-12307	81	8	reported	report	VERB
aiua-12307	81	9	that	that	SCONJ
aiua-12307	81	10	adding	add	VERB
aiua-12307	81	11	atezolizumab	atezolizumab	NOUN
aiua-12307	81	12	to	to	PART
aiua-12307	81	13	platinumbased	platinumbase	VERB
aiua-12307	81	14	ct	ct	PROPN
aiua-12307	81	15	in	in	ADP
aiua-12307	81	16	first	first	ADJ
aiua-12307	81	17	-	-	PUNCT
aiua-12307	81	18	line	line	NOUN
aiua-12307	81	19	treatment	treatment	NOUN
aiua-12307	81	20	provides	provide	VERB
aiua-12307	81	21	a	a	DET
aiua-12307	81	22	survival	survival	NOUN
aiua-12307	81	23	advantage	advantage	NOUN
aiua-12307	81	24	in	in	ADP
aiua-12307	81	25	patients	patient	NOUN
aiua-12307	81	26	diagnosed	diagnose	VERB
aiua-12307	81	27	with	with	ADP
aiua-12307	81	28	muc	muc	PROPN
aiua-12307	81	29	(	(	PUNCT
aiua-12307	81	30	24	24	NUM
aiua-12307	81	31	)	)	PUNCT
aiua-12307	81	32	.	.	PUNCT
aiua-12307	82	1	avelumab	avelumab	PROPN
aiua-12307	82	2	avelumab	avelumab	PRON
aiua-12307	82	3	is	be	AUX
aiua-12307	82	4	a	a	DET
aiua-12307	82	5	humanized	humanize	VERB
aiua-12307	82	6	monoclonal	monoclonal	NOUN
aiua-12307	82	7	antibody	antibody	NOUN
aiua-12307	82	8	that	that	PRON
aiua-12307	82	9	acts	act	VERB
aiua-12307	82	10	by	by	ADP
aiua-12307	82	11	binding	bind	VERB
aiua-12307	82	12	to	to	ADP
aiua-12307	82	13	pd	pd	PROPN
aiua-12307	82	14	-	-	PUNCT
aiua-12307	82	15	l1	l1	PROPN
aiua-12307	82	16	,	,	PUNCT
aiua-12307	82	17	similar	similar	ADJ
aiua-12307	82	18	to	to	ADP
aiua-12307	82	19	atezolizumab	atezolizumab	VERB
aiua-12307	82	20	and	and	CCONJ
aiua-12307	82	21	durvalumab	durvalumab	VERB
aiua-12307	82	22	.	.	PUNCT
aiua-12307	83	1	in	in	ADP
aiua-12307	83	2	the	the	DET
aiua-12307	83	3	javelin	javelin	NOUN
aiua-12307	83	4	bladder	bladder	NOUN
aiua-12307	83	5	100	100	NUM
aiua-12307	83	6	trial	trial	NOUN
aiua-12307	83	7	,	,	PUNCT
aiua-12307	83	8	patients	patient	NOUN
aiua-12307	83	9	with	with	ADP
aiua-12307	83	10	locally	locally	ADV
aiua-12307	83	11	advanced	advance	VERB
aiua-12307	83	12	/	/	SYM
aiua-12307	83	13	muc	muc	X
aiua-12307	83	14	whose	whose	DET
aiua-12307	83	15	disease	disease	NOUN
aiua-12307	83	16	was	be	AUX
aiua-12307	83	17	stable	stable	ADJ
aiua-12307	83	18	or	or	CCONJ
aiua-12307	83	19	had	have	VERB
aiua-12307	83	20	clinical	clinical	ADJ
aiua-12307	83	21	improvement	improvement	NOUN
aiua-12307	83	22	after	after	SCONJ
aiua-12307	83	23	4	4	NUM
aiua-12307	83	24	-	-	SYM
aiua-12307	83	25	6	6	NUM
aiua-12307	83	26	courses	course	NOUN
aiua-12307	83	27	of	of	ADP
aiua-12307	83	28	platinum	platinum	NOUN
aiua-12307	83	29	-	-	PUNCT
aiua-12307	83	30	based	base	VERB
aiua-12307	83	31	ct	ct	PROPN
aiua-12307	83	32	were	be	AUX
aiua-12307	83	33	divided	divide	VERB
aiua-12307	83	34	into	into	ADP
aiua-12307	83	35	two	two	NUM
aiua-12307	83	36	groups	group	NOUN
aiua-12307	83	37	.	.	PUNCT
aiua-12307	84	1	one	one	NUM
aiua-12307	84	2	group	group	NOUN
aiua-12307	84	3	was	be	AUX
aiua-12307	84	4	given	give	VERB
aiua-12307	84	5	supportive	supportive	ADJ
aiua-12307	84	6	treatment	treatment	NOUN
aiua-12307	84	7	,	,	PUNCT
aiua-12307	84	8	and	and	CCONJ
aiua-12307	84	9	the	the	DET
aiua-12307	84	10	other	other	ADJ
aiua-12307	84	11	group	group	NOUN
aiua-12307	84	12	was	be	AUX
aiua-12307	84	13	given	give	VERB
aiua-12307	84	14	avelumab	avelumab	ADJ
aiua-12307	84	15	treatment	treatment	NOUN
aiua-12307	84	16	.	.	PUNCT
aiua-12307	85	1	in	in	ADP
aiua-12307	85	2	the	the	DET
aiua-12307	85	3	avelumab	avelumab	ADJ
aiua-12307	85	4	arm	arm	NOUN
aiua-12307	85	5	,	,	PUNCT
aiua-12307	85	6	a	a	DET
aiua-12307	85	7	statistically	statistically	ADV
aiua-12307	85	8	significant	significant	ADJ
aiua-12307	85	9	improvement	improvement	NOUN
aiua-12307	85	10	in	in	ADP
aiua-12307	85	11	os	os	NOUN
aiua-12307	85	12	was	be	AUX
aiua-12307	85	13	detected	detect	VERB
aiua-12307	85	14	(	(	PUNCT
aiua-12307	85	15	14.3	14.3	NUM
aiua-12307	85	16	vs	vs	ADP
aiua-12307	85	17	21.4	21.4	NUM
aiua-12307	85	18	mo	mo	NOUN
aiua-12307	85	19	.	.	PROPN
aiua-12307	85	20	)	)	PUNCT
aiua-12307	86	1	(	(	PUNCT
aiua-12307	86	2	25	25	NUM
aiua-12307	86	3	)	)	PUNCT
aiua-12307	86	4	.	.	PUNCT
aiua-12307	87	1	based	base	VERB
aiua-12307	87	2	on	on	ADP
aiua-12307	87	3	the	the	DET
aiua-12307	87	4	data	datum	NOUN
aiua-12307	87	5	of	of	ADP
aiua-12307	87	6	this	this	DET
aiua-12307	87	7	study	study	NOUN
aiua-12307	87	8	,	,	PUNCT
aiua-12307	87	9	the	the	DET
aiua-12307	87	10	use	use	NOUN
aiua-12307	87	11	of	of	ADP
aiua-12307	87	12	avelumab	avelumab	NOUN
aiua-12307	87	13	in	in	ADP
aiua-12307	87	14	maintenance	maintenance	NOUN
aiua-12307	87	15	therapy	therapy	NOUN
aiua-12307	87	16	in	in	ADP
aiua-12307	87	17	patients	patient	NOUN
aiua-12307	87	18	with	with	ADP
aiua-12307	87	19	locally	locally	ADV
aiua-12307	87	20	advanced	advanced	ADJ
aiua-12307	87	21	or	or	CCONJ
aiua-12307	87	22	muc	muc	PROPN
aiua-12307	87	23	has	have	AUX
aiua-12307	87	24	been	be	AUX
aiua-12307	87	25	approved	approve	VERB
aiua-12307	87	26	by	by	ADP
aiua-12307	87	27	the	the	DET
aiua-12307	87	28	fda	fda	PROPN
aiua-12307	87	29	(	(	PUNCT
aiua-12307	87	30	26	26	NUM
aiua-12307	87	31	)	)	PUNCT
aiua-12307	87	32	.	.	PUNCT
aiua-12307	88	1	in	in	ADP
aiua-12307	88	2	the	the	DET
aiua-12307	88	3	eau	eau	PROPN
aiua-12307	88	4	2023	2023	NUM
aiua-12307	88	5	guideline	guideline	NOUN
aiua-12307	88	6	,	,	PUNCT
aiua-12307	88	7	maintenance	maintenance	NOUN
aiua-12307	88	8	avelumab	avelumab	ADJ
aiua-12307	88	9	treatment	treatment	NOUN
aiua-12307	88	10	is	be	AUX
aiua-12307	88	11	strongly	strongly	ADV
aiua-12307	88	12	recommended	recommend	VERB
aiua-12307	88	13	in	in	ADP
aiua-12307	88	14	patients	patient	NOUN
aiua-12307	88	15	diagnosed	diagnose	VERB
aiua-12307	88	16	with	with	ADP
aiua-12307	88	17	muc	muc	NOUN
aiua-12307	88	18	whose	whose	DET
aiua-12307	88	19	disease	disease	NOUN
aiua-12307	88	20	is	be	AUX
aiua-12307	88	21	stable	stable	ADJ
aiua-12307	88	22	after	after	ADP
aiua-12307	88	23	first	first	ADJ
aiua-12307	88	24	-	-	PUNCT
aiua-12307	88	25	line	line	NOUN
aiua-12307	88	26	platinum	platinum	NOUN
aiua-12307	88	27	-	-	PUNCT
aiua-12307	88	28	based	base	VERB
aiua-12307	88	29	ct	ct	PROPN
aiua-12307	88	30	(	(	PUNCT
aiua-12307	88	31	19	19	NUM
aiua-12307	88	32	)	)	PUNCT
aiua-12307	88	33	.	.	PUNCT
aiua-12307	89	1	durvalumab	durvalumab	PROPN
aiua-12307	89	2	durvalumab	durvalumab	NOUN
aiua-12307	89	3	is	be	AUX
aiua-12307	89	4	a	a	DET
aiua-12307	89	5	humanized	humanize	VERB
aiua-12307	89	6	monoclonal	monoclonal	NOUN
aiua-12307	89	7	antibody	antibody	NOUN
aiua-12307	89	8	that	that	PRON
aiua-12307	89	9	acts	act	VERB
aiua-12307	89	10	by	by	ADP
aiua-12307	89	11	binding	bind	VERB
aiua-12307	89	12	to	to	ADP
aiua-12307	89	13	pd	pd	PROPN
aiua-12307	89	14	-	-	PROPN
aiua-12307	89	15	l1	l1	PROPN
aiua-12307	89	16	and	and	CCONJ
aiua-12307	89	17	blocking	block	VERB
aiua-12307	89	18	the	the	DET
aiua-12307	89	19	pd-1	pd-1	ADJ
aiua-12307	89	20	-	-	ADJ
aiua-12307	89	21	cd80	cd80	NOUN
aiua-12307	89	22	interaction	interaction	NOUN
aiua-12307	89	23	.	.	PUNCT
aiua-12307	90	1	it	it	PRON
aiua-12307	90	2	received	receive	VERB
aiua-12307	90	3	accelerated	accelerate	VERB
aiua-12307	90	4	approval	approval	NOUN
aiua-12307	90	5	from	from	ADP
aiua-12307	90	6	the	the	DET
aiua-12307	90	7	fda	fda	PROPN
aiua-12307	90	8	in	in	ADP
aiua-12307	90	9	2017	2017	NUM
aiua-12307	90	10	for	for	ADP
aiua-12307	90	11	patients	patient	NOUN
aiua-12307	90	12	with	with	ADP
aiua-12307	90	13	urothelial	urothelial	ADJ
aiua-12307	90	14	carcinoma	carcinoma	NOUN
aiua-12307	90	15	who	who	PRON
aiua-12307	90	16	did	do	AUX
aiua-12307	90	17	not	not	PART
aiua-12307	90	18	respond	respond	VERB
aiua-12307	90	19	adequately	adequately	ADV
aiua-12307	90	20	to	to	ADP
aiua-12307	90	21	neoadjuvant	neoadjuvant	ADJ
aiua-12307	90	22	or	or	CCONJ
aiua-12307	90	23	adjuvant	adjuvant	ADJ
aiua-12307	90	24	treatment	treatment	NOUN
aiua-12307	90	25	(	(	PUNCT
aiua-12307	90	26	26	26	NUM
aiua-12307	90	27	)	)	PUNCT
aiua-12307	90	28	.	.	PUNCT
aiua-12307	91	1	the	the	DET
aiua-12307	91	2	danube	danube	PROPN
aiua-12307	91	3	phase	phase	NOUN
aiua-12307	91	4	iii	iii	NUM
aiua-12307	91	5	clinical	clinical	ADJ
aiua-12307	91	6	study	study	NOUN
aiua-12307	91	7	compared	compare	VERB
aiua-12307	91	8	durvalumab	durvalumab	NOUN
aiua-12307	91	9	monotherapy	monotherapy	NOUN
aiua-12307	91	10	with	with	ADP
aiua-12307	91	11	durvalumab	durvalumab	NOUN
aiua-12307	91	12	/	/	SYM
aiua-12307	91	13	tremelimumab	tremelimumab	NOUN
aiua-12307	91	14	and	and	CCONJ
aiua-12307	91	15	platinum	platinum	NOUN
aiua-12307	91	16	-	-	PUNCT
aiua-12307	91	17	based	base	VERB
aiua-12307	91	18	ct	ct	PROPN
aiua-12307	91	19	.	.	PUNCT
aiua-12307	92	1	the	the	DET
aiua-12307	92	2	superiority	superiority	NOUN
aiua-12307	92	3	of	of	ADP
aiua-12307	92	4	the	the	DET
aiua-12307	92	5	tried	try	VERB
aiua-12307	92	6	treatments	treatment	NOUN
aiua-12307	92	7	over	over	ADP
aiua-12307	92	8	ct	ct	PROPN
aiua-12307	92	9	has	have	AUX
aiua-12307	92	10	not	not	PART
aiua-12307	92	11	been	be	AUX
aiua-12307	92	12	determined	determine	VERB
aiua-12307	92	13	(	(	PUNCT
aiua-12307	92	14	27	27	NUM
aiua-12307	92	15	)	)	PUNCT
aiua-12307	92	16	.	.	PUNCT
aiua-12307	93	1	after	after	SCONJ
aiua-12307	93	2	the	the	DET
aiua-12307	93	3	report	report	NOUN
aiua-12307	93	4	of	of	ADP
aiua-12307	93	5	the	the	DET
aiua-12307	93	6	danube	danube	PROPN
aiua-12307	93	7	study	study	NOUN
aiua-12307	93	8	was	be	AUX
aiua-12307	93	9	published	publish	VERB
aiua-12307	93	10	,	,	PUNCT
aiua-12307	93	11	the	the	DET
aiua-12307	93	12	indication	indication	NOUN
aiua-12307	93	13	of	of	ADP
aiua-12307	93	14	durvalumab	durvalumab	NOUN
aiua-12307	93	15	in	in	ADP
aiua-12307	93	16	bc	bc	PROPN
aiua-12307	93	17	was	be	AUX
aiua-12307	93	18	withdrawn	withdraw	VERB
aiua-12307	93	19	(	(	PUNCT
aiua-12307	93	20	28	28	NUM
aiua-12307	93	21	)	)	PUNCT
aiua-12307	93	22	.	.	PUNCT
aiua-12307	94	1	clinical	clinical	ADJ
aiua-12307	94	2	trials	trial	NOUN
aiua-12307	94	3	of	of	ADP
aiua-12307	94	4	various	various	ADJ
aiua-12307	94	5	urothelial	urothelial	ADJ
aiua-12307	94	6	cancer	cancer	NOUN
aiua-12307	94	7	immune	immune	ADJ
aiua-12307	94	8	therapies	therapy	NOUN
aiua-12307	94	9	were	be	AUX
aiua-12307	94	10	summarized	summarize	VERB
aiua-12307	94	11	in	in	ADP
aiua-12307	94	12	table	table	NOUN
aiua-12307	94	13	1	1	NUM
aiua-12307	94	14	(	(	PUNCT
aiua-12307	94	15	29	29	NUM
aiua-12307	94	16	)	)	PUNCT
aiua-12307	94	17	.	.	PUNCT
aiua-12307	95	1	role	role	NOUN
aiua-12307	95	2	of	of	ADP
aiua-12307	95	3	immunotherapy	immunotherapy	NOUN
aiua-12307	95	4	in	in	ADP
aiua-12307	95	5	urothelial	urothelial	ADJ
aiua-12307	95	6	carcinoma	carcinoma	NOUN
aiua-12307	95	7	urothelial	urothelial	ADJ
aiua-12307	95	8	carcinoma	carcinoma	NOUN
aiua-12307	95	9	is	be	AUX
aiua-12307	95	10	a	a	DET
aiua-12307	95	11	common	common	ADJ
aiua-12307	95	12	type	type	NOUN
aiua-12307	95	13	of	of	ADP
aiua-12307	95	14	cancer	cancer	NOUN
aiua-12307	95	15	in	in	ADP
aiua-12307	95	16	the	the	DET
aiua-12307	95	17	genitourinary	genitourinary	ADJ
aiua-12307	95	18	system	system	NOUN
aiua-12307	95	19	,	,	PUNCT
aiua-12307	95	20	and	and	CCONJ
aiua-12307	95	21	treatment	treatment	NOUN
aiua-12307	95	22	strategies	strategy	NOUN
aiua-12307	95	23	in	in	ADP
aiua-12307	95	24	this	this	DET
aiua-12307	95	25	area	area	NOUN
aiua-12307	95	26	are	be	AUX
aiua-12307	95	27	constantly	constantly	ADV
aiua-12307	95	28	evolving	evolve	VERB
aiua-12307	95	29	.	.	PUNCT
aiua-12307	96	1	agents	agent	NOUN
aiua-12307	96	2	used	use	VERB
aiua-12307	96	3	in	in	ADP
aiua-12307	96	4	immunotherapy	immunotherapy	NOUN
aiua-12307	96	5	in	in	ADP
aiua-12307	96	6	urothelial	urothelial	ADJ
aiua-12307	96	7	carcinoma	carcinoma	NOUN
aiua-12307	96	8	include	include	VERB
aiua-12307	96	9	various	various	ADJ
aiua-12307	96	10	options	option	NOUN
aiua-12307	96	11	such	such	ADJ
aiua-12307	96	12	as	as	ADP
aiua-12307	96	13	bcg	bcg	PROPN
aiua-12307	96	14	,	,	PUNCT
aiua-12307	96	15	interferon	interferon	ADJ
aiua-12307	96	16	,	,	PUNCT
aiua-12307	96	17	anti	anti	ADJ
aiua-12307	96	18	-	-	ADJ
aiua-12307	96	19	pd-1	pd-1	ADJ
aiua-12307	96	20	(	(	PUNCT
aiua-12307	96	21	nivolumab	nivolumab	NOUN
aiua-12307	96	22	,	,	PUNCT
aiua-12307	96	23	pembrolizumab	pembrolizumab	NOUN
aiua-12307	96	24	)	)	PUNCT
aiua-12307	96	25	,	,	PUNCT
aiua-12307	96	26	anti	anti	ADJ
aiua-12307	96	27	-	-	ADJ
aiua-12307	96	28	pd	pd	ADJ
aiua-12307	96	29	-	-	PUNCT
aiua-12307	96	30	l1	l1	PROPN
aiua-12307	96	31	(	(	PUNCT
aiua-12307	96	32	atezolizumab	atezolizumab	PROPN
aiua-12307	96	33	,	,	PUNCT
aiua-12307	96	34	durvalumab	durvalumab	PROPN
aiua-12307	96	35	,	,	PUNCT
aiua-12307	96	36	avelumab	avelumab	NOUN
aiua-12307	96	37	)	)	PUNCT
aiua-12307	96	38	.	.	PUNCT
aiua-12307	97	1	these	these	DET
aiua-12307	97	2	agents	agent	NOUN
aiua-12307	97	3	increase	increase	VERB
aiua-12307	97	4	the	the	DET
aiua-12307	97	5	anti	anti	ADJ
aiua-12307	97	6	-	-	ADJ
aiua-12307	97	7	tumour	tumour	ADJ
aiua-12307	97	8	response	response	NOUN
aiua-12307	97	9	by	by	ADP
aiua-12307	97	10	affecting	affect	VERB
aiua-12307	97	11	the	the	DET
aiua-12307	97	12	body	body	NOUN
aiua-12307	97	13	's	's	PART
aiua-12307	97	14	defence	defence	NOUN
aiua-12307	97	15	mechanisms	mechanism	NOUN
aiua-12307	97	16	.	.	PUNCT
aiua-12307	98	1	they	they	PRON
aiua-12307	98	2	show	show	VERB
aiua-12307	98	3	effectiveness	effectiveness	NOUN
aiua-12307	98	4	at	at	ADP
aiua-12307	98	5	different	different	ADJ
aiua-12307	98	6	treatment	treatment	NOUN
aiua-12307	98	7	stages	stage	NOUN
aiua-12307	98	8	in	in	ADP
aiua-12307	98	9	bc	bc	PROPN
aiua-12307	98	10	and	and	CCONJ
aiua-12307	98	11	utuc	utuc	NOUN
aiua-12307	98	12	.	.	PUNCT
aiua-12307	99	1	cisplatin	cisplatin	NOUN
aiua-12307	99	2	-	-	PUNCT
aiua-12307	99	3	based	base	VERB
aiua-12307	99	4	ct	ct	PROPN
aiua-12307	99	5	has	have	AUX
aiua-12307	99	6	been	be	AUX
aiua-12307	99	7	used	use	VERB
aiua-12307	99	8	as	as	ADP
aiua-12307	99	9	standard	standard	ADJ
aiua-12307	99	10	therapy	therapy	NOUN
aiua-12307	99	11	in	in	ADP
aiua-12307	99	12	the	the	DET
aiua-12307	99	13	treatment	treatment	NOUN
aiua-12307	99	14	of	of	ADP
aiua-12307	99	15	urothelial	urothelial	ADJ
aiua-12307	99	16	carcinoma	carcinoma	NOUN
aiua-12307	99	17	for	for	ADP
aiua-12307	99	18	many	many	ADJ
aiua-12307	99	19	years	year	NOUN
aiua-12307	99	20	.	.	PUNCT
aiua-12307	100	1	the	the	DET
aiua-12307	100	2	results	result	NOUN
aiua-12307	100	3	of	of	ADP
aiua-12307	100	4	clinical	clinical	ADJ
aiua-12307	100	5	studies	study	NOUN
aiua-12307	100	6	with	with	ADP
aiua-12307	100	7	systemic	systemic	ADJ
aiua-12307	100	8	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	100	9	agents	agent	NOUN
aiua-12307	100	10	show	show	VERB
aiua-12307	100	11	that	that	SCONJ
aiua-12307	100	12	the	the	DET
aiua-12307	100	13	use	use	NOUN
aiua-12307	100	14	of	of	ADP
aiua-12307	100	15	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	100	16	agents	agent	NOUN
aiua-12307	100	17	in	in	ADP
aiua-12307	100	18	treating	treat	VERB
aiua-12307	100	19	urothelial	urothelial	ADJ
aiua-12307	100	20	carcinoma	carcinoma	NOUN
aiua-12307	100	21	is	be	AUX
aiua-12307	100	22	becoming	become	VERB
aiua-12307	100	23	increasingly	increasingly	ADV
aiua-12307	100	24	widespread	widespread	ADJ
aiua-12307	100	25	and	and	CCONJ
aiua-12307	100	26	is	be	AUX
aiua-12307	100	27	considered	consider	VERB
aiua-12307	100	28	an	an	DET
aiua-12307	100	29	effective	effective	ADJ
aiua-12307	100	30	alternative	alternative	NOUN
aiua-12307	100	31	in	in	ADP
aiua-12307	100	32	patients	patient	NOUN
aiua-12307	100	33	who	who	PRON
aiua-12307	100	34	are	be	AUX
aiua-12307	100	35	resistant	resistant	ADJ
aiua-12307	100	36	or	or	CCONJ
aiua-12307	100	37	unsuitable	unsuitable	ADJ
aiua-12307	100	38	for	for	ADP
aiua-12307	100	39	platinumbased	platinumbase	VERB
aiua-12307	100	40	ct	ct	PROPN
aiua-12307	100	41	.	.	PUNCT
aiua-12307	101	1	comparisons	comparison	NOUN
aiua-12307	101	2	between	between	ADP
aiua-12307	101	3	these	these	DET
aiua-12307	101	4	agents	agent	NOUN
aiua-12307	101	5	should	should	AUX
aiua-12307	101	6	consider	consider	VERB
aiua-12307	101	7	clinical	clinical	ADJ
aiua-12307	101	8	outcomes	outcome	NOUN
aiua-12307	101	9	such	such	ADJ
aiua-12307	101	10	as	as	ADP
aiua-12307	101	11	orr	orr	PROPN
aiua-12307	101	12	,	,	PUNCT
aiua-12307	101	13	os	os	NOUN
aiua-12307	101	14	,	,	PUNCT
aiua-12307	101	15	and	and	CCONJ
aiua-12307	101	16	dfs	dfs	INTJ
aiua-12307	101	17	.	.	PUNCT
aiua-12307	102	1	when	when	SCONJ
aiua-12307	102	2	determining	determine	VERB
aiua-12307	102	3	the	the	DET
aiua-12307	102	4	areas	area	NOUN
aiua-12307	102	5	of	of	ADP
aiua-12307	102	6	use	use	NOUN
aiua-12307	102	7	and	and	CCONJ
aiua-12307	102	8	advantages	advantage	NOUN
aiua-12307	102	9	of	of	ADP
aiua-12307	102	10	each	each	DET
aiua-12307	102	11	agent	agent	NOUN
aiua-12307	102	12	,	,	PUNCT
aiua-12307	102	13	the	the	DET
aiua-12307	102	14	characteristics	characteristic	NOUN
aiua-12307	102	15	of	of	ADP
aiua-12307	102	16	the	the	DET
aiua-12307	102	17	patients	patient	NOUN
aiua-12307	102	18	and	and	CCONJ
aiua-12307	102	19	their	their	PRON
aiua-12307	102	20	pre	pre	ADJ
aiua-12307	102	21	-	-	ADJ
aiua-12307	102	22	treatment	treatment	ADJ
aiua-12307	102	23	conditions	condition	NOUN
aiua-12307	102	24	should	should	AUX
aiua-12307	102	25	be	be	AUX
aiua-12307	102	26	considered	consider	VERB
aiua-12307	102	27	.	.	PUNCT
aiua-12307	103	1	the	the	DET
aiua-12307	103	2	usage	usage	NOUN
aiua-12307	103	3	recommendations	recommendation	NOUN
aiua-12307	103	4	regarding	regard	VERB
aiua-12307	103	5	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	103	6	agents	agent	NOUN
aiua-12307	103	7	employed	employ	VERB
aiua-12307	103	8	in	in	ADP
aiua-12307	103	9	urothelial	urothelial	ADJ
aiua-12307	103	10	carcinoma	carcinoma	NOUN
aiua-12307	103	11	in	in	ADP
aiua-12307	103	12	the	the	DET
aiua-12307	103	13	eau	eau	PROPN
aiua-12307	103	14	guidelines	guideline	NOUN
aiua-12307	103	15	are	be	AUX
aiua-12307	103	16	presented	present	VERB
aiua-12307	103	17	in	in	ADP
aiua-12307	103	18	table	table	NOUN
aiua-12307	103	19	2	2	NUM
aiua-12307	103	20	(	(	PUNCT
aiua-12307	103	21	19	19	NUM
aiua-12307	103	22	)	)	PUNCT
aiua-12307	103	23	.	.	PUNCT
aiua-12307	104	1	immunotherapy	immunotherapy	NOUN
aiua-12307	104	2	has	have	AUX
aiua-12307	104	3	become	become	VERB
aiua-12307	104	4	an	an	DET
aiua-12307	104	5	increasingly	increasingly	ADV
aiua-12307	104	6	important	important	ADJ
aiua-12307	104	7	table	table	NOUN
aiua-12307	104	8	1	1	NUM
aiua-12307	104	9	.	.	PUNCT
aiua-12307	105	1	clinical	clinical	ADJ
aiua-12307	105	2	trials	trial	NOUN
aiua-12307	105	3	of	of	ADP
aiua-12307	105	4	varying	vary	VERB
aiua-12307	105	5	treatment	treatment	NOUN
aiua-12307	105	6	plans	plan	NOUN
aiua-12307	105	7	for	for	ADP
aiua-12307	105	8	urothelial	urothelial	ADJ
aiua-12307	105	9	carcinoma	carcinoma	NOUN
aiua-12307	105	10	(	(	PUNCT
aiua-12307	105	11	29	29	NUM
aiua-12307	105	12	)	)	PUNCT
aiua-12307	105	13	.	.	PUNCT
aiua-12307	106	1	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	106	2	drug	drug	NOUN
aiua-12307	106	3	trial	trial	NOUN
aiua-12307	106	4	name	name	NOUN
aiua-12307	106	5	clinical	clinical	ADJ
aiua-12307	106	6	indication	indication	NOUN
aiua-12307	106	7	fda	fda	PROPN
aiua-12307	106	8	approval	approval	PROPN
aiua-12307	106	9	clinical	clinical	ADJ
aiua-12307	106	10	outcome	outcome	NOUN
aiua-12307	106	11	references	reference	NOUN
aiua-12307	106	12	atezolizumab	atezolizumab	VERB
aiua-12307	106	13	imvigor210	imvigor210	PROPN
aiua-12307	106	14	second	second	ADJ
aiua-12307	106	15	-	-	PUNCT
aiua-12307	106	16	line	line	NOUN
aiua-12307	106	17	muc	muc	NOUN
aiua-12307	106	18	,	,	PUNCT
aiua-12307	106	19	after	after	ADP
aiua-12307	106	20	platinum	platinum	NOUN
aiua-12307	106	21	ct	ct	PROPN
aiua-12307	106	22	may	may	PROPN
aiua-12307	106	23	2016	2016	NUM
aiua-12307	106	24	orr	orr	PROPN
aiua-12307	106	25	15	15	NUM
aiua-12307	106	26	%	%	NOUN
aiua-12307	106	27	rosenberg	rosenberg	PROPN
aiua-12307	106	28	2016	2016	NUM
aiua-12307	106	29	atezolizumab	atezolizumab	VERB
aiua-12307	106	30	imvigor210	imvigor210	PROPN
aiua-12307	106	31	first	first	ADJ
aiua-12307	106	32	-	-	PUNCT
aiua-12307	106	33	line	line	NOUN
aiua-12307	106	34	muc	muc	ADJ
aiua-12307	106	35	,	,	PUNCT
aiua-12307	106	36	platinum	platinum	NOUN
aiua-12307	106	37	-	-	PUNCT
aiua-12307	106	38	ineligible	ineligible	ADJ
aiua-12307	106	39	april	april	PROPN
aiua-12307	106	40	2017	2017	NUM
aiua-12307	106	41	orr	orr	NOUN
aiua-12307	106	42	23	23	NUM
aiua-12307	106	43	%	%	NOUN
aiua-12307	106	44	balar	balar	ADJ
aiua-12307	106	45	2017	2017	NUM
aiua-12307	106	46	nivolumab	nivolumab	ADV
aiua-12307	106	47	checkmate-275	checkmate-275	ADJ
aiua-12307	106	48	second	second	ADJ
aiua-12307	106	49	-	-	PUNCT
aiua-12307	106	50	line	line	NOUN
aiua-12307	106	51	muc	muc	ADJ
aiua-12307	106	52	february	february	PROPN
aiua-12307	106	53	2017	2017	NUM
aiua-12307	106	54	rr	rr	NOUN
aiua-12307	106	55	19.6	19.6	NUM
aiua-12307	106	56	%	%	NOUN
aiua-12307	106	57	sharma	sharma	PROPN
aiua-12307	106	58	2016	2016	NUM
aiua-12307	106	59	durvalumab	durvalumab	NOUN
aiua-12307	106	60	danube	danube	PROPN
aiua-12307	106	61	second	second	ADJ
aiua-12307	106	62	-	-	PUNCT
aiua-12307	106	63	line	line	NOUN
aiua-12307	106	64	muc	muc	VERB
aiua-12307	106	65	orr	orr	PROPN
aiua-12307	106	66	26	26	NUM
aiua-12307	106	67	%	%	NOUN
aiua-12307	106	68	powles	powle	NOUN
aiua-12307	106	69	2020	2020	NUM
aiua-12307	106	70	pembrolizumab	pembrolizumab	VERB
aiua-12307	106	71	keynote-045	keynote-045	ADJ
aiua-12307	106	72	second	second	ADJ
aiua-12307	106	73	-	-	PUNCT
aiua-12307	106	74	line	line	NOUN
aiua-12307	106	75	may	may	AUX
aiua-12307	106	76	2017	2017	NUM
aiua-12307	106	77	median	median	ADJ
aiua-12307	106	78	os	os	NOUN
aiua-12307	106	79	bellmunt	bellmunt	NOUN
aiua-12307	106	80	2017	2017	NUM
aiua-12307	106	81	advanced	advanced	ADJ
aiua-12307	106	82	uc	uc	PROPN
aiua-12307	106	83	10.3	10.3	NUM
aiua-12307	106	84	mo	mo	PROPN
aiua-12307	106	85	.	.	PROPN
aiua-12307	106	86	pembrolizumab	pembrolizumab	PROPN
aiua-12307	106	87	keynote-052	keynote-052	PROPN
aiua-12307	106	88	first	first	ADJ
aiua-12307	106	89	-	-	PUNCT
aiua-12307	106	90	line	line	NOUN
aiua-12307	106	91	muc	muc	ADJ
aiua-12307	106	92	,	,	PUNCT
aiua-12307	106	93	platinum	platinum	NOUN
aiua-12307	106	94	-	-	PUNCT
aiua-12307	106	95	ineligible	ineligible	ADJ
aiua-12307	106	96	may	may	PROPN
aiua-12307	106	97	2017	2017	NUM
aiua-12307	106	98	orr	orr	NOUN
aiua-12307	106	99	24	24	NUM
aiua-12307	106	100	%	%	NOUN
aiua-12307	106	101	balar	balar	ADJ
aiua-12307	106	102	2017	2017	NUM
aiua-12307	106	103	and	and	CCONJ
aiua-12307	106	104	vuky	vuky	NOUN
aiua-12307	106	105	2020	2020	NUM
aiua-12307	106	106	pembrolizumab	pembrolizumab	NOUN
aiua-12307	106	107	keynote-057	keynote-057	NOUN
aiua-12307	106	108	recurrent	recurrent	PROPN
aiua-12307	106	109	nmibc	nmibc	PROPN
aiua-12307	106	110	january	january	PROPN
aiua-12307	106	111	2020	2020	NUM
aiua-12307	107	1	crr	crr	PROPN
aiua-12307	107	2	41	41	NUM
aiua-12307	107	3	%	%	NOUN
aiua-12307	107	4	balar	balar	ADJ
aiua-12307	107	5	2021	2021	NUM
aiua-12307	107	6	avelumab	avelumab	NOUN
aiua-12307	107	7	javelin	javelin	NOUN
aiua-12307	107	8	bladder	bladder	NOUN
aiua-12307	107	9	100	100	NUM
aiua-12307	107	10	maintenance	maintenance	NOUN
aiua-12307	107	11	,	,	PUNCT
aiua-12307	107	12	muc	muc	X
aiua-12307	107	13	june	june	PROPN
aiua-12307	107	14	2020	2020	NUM
aiua-12307	107	15	median	median	PROPN
aiua-12307	107	16	os	os	PROPN
aiua-12307	107	17	powles	powle	NOUN
aiua-12307	107	18	2020	2020	NUM
aiua-12307	107	19	21	21	NUM
aiua-12307	107	20	vs	vs	ADP
aiua-12307	107	21	14	14	NUM
aiua-12307	107	22	mo	mo	NOUN
aiua-12307	107	23	.	.	PROPN
aiua-12307	107	24	of	of	ADP
aiua-12307	107	25	the	the	DET
aiua-12307	107	26	control	control	NOUN
aiua-12307	107	27	nivolumab	nivolumab	NOUN
aiua-12307	107	28	checkmate-274	checkmate-274	PROPN
aiua-12307	107	29	adjuvant	adjuvant	PROPN
aiua-12307	107	30	,	,	PUNCT
aiua-12307	107	31	mibc	mibc	PROPN
aiua-12307	107	32	august	august	PROPN
aiua-12307	107	33	2021	2021	NUM
aiua-12307	107	34	median	median	ADJ
aiua-12307	107	35	dfs	dfs	PROPN
aiua-12307	107	36	bajorin	bajorin	NOUN
aiua-12307	107	37	2021	2021	NUM
aiua-12307	107	38	20.8	20.8	NUM
aiua-12307	107	39	vs	vs	ADP
aiua-12307	107	40	10.8	10.8	NUM
aiua-12307	107	41	mo	mo	NOUN
aiua-12307	107	42	.	.	PROPN
aiua-12307	107	43	of	of	ADP
aiua-12307	107	44	the	the	DET
aiua-12307	107	45	control	control	NOUN
aiua-12307	107	46	table	table	NOUN
aiua-12307	107	47	2	2	NUM
aiua-12307	107	48	.	.	PUNCT
aiua-12307	107	49	summary	summary	NOUN
aiua-12307	107	50	of	of	ADP
aiua-12307	107	51	the	the	DET
aiua-12307	107	52	use	use	NOUN
aiua-12307	107	53	of	of	ADP
aiua-12307	107	54	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	107	55	agents	agent	NOUN
aiua-12307	107	56	in	in	ADP
aiua-12307	107	57	the	the	DET
aiua-12307	107	58	treatment	treatment	NOUN
aiua-12307	107	59	of	of	ADP
aiua-12307	107	60	urothelial	urothelial	ADJ
aiua-12307	107	61	carcinoma	carcinoma	NOUN
aiua-12307	107	62	according	accord	VERB
aiua-12307	107	63	to	to	ADP
aiua-12307	107	64	eau	eau	PROPN
aiua-12307	107	65	guidelines	guideline	NOUN
aiua-12307	107	66	(	(	PUNCT
aiua-12307	107	67	19	19	NUM
aiua-12307	107	68	)	)	PUNCT
aiua-12307	107	69	.	.	PUNCT
aiua-12307	108	1	the	the	DET
aiua-12307	108	2	pd	pd	PROPN
aiua-12307	108	3	-	-	PUNCT
aiua-12307	108	4	l1	l1	PROPN
aiua-12307	108	5	inhibitors	inhibitor	NOUN
aiua-12307	108	6	atezolizumab	atezolizumab	VERB
aiua-12307	108	7	and	and	CCONJ
aiua-12307	108	8	nivolumab	nivolumab	NOUN
aiua-12307	108	9	and	and	CCONJ
aiua-12307	108	10	the	the	DET
aiua-12307	108	11	pd-1	pd-1	ADJ
aiua-12307	108	12	inhibitor	inhibitor	NOUN
aiua-12307	108	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	108	14	have	have	AUX
aiua-12307	108	15	been	be	AUX
aiua-12307	108	16	approved	approve	VERB
aiua-12307	108	17	for	for	ADP
aiua-12307	108	18	patients	patient	NOUN
aiua-12307	108	19	whose	whose	DET
aiua-12307	108	20	disease	disease	NOUN
aiua-12307	108	21	has	have	AUX
aiua-12307	108	22	progressed	progress	VERB
aiua-12307	108	23	despite	despite	SCONJ
aiua-12307	108	24	platinum	platinum	NOUN
aiua-12307	108	25	-	-	PUNCT
aiua-12307	108	26	based	base	VERB
aiua-12307	108	27	ct	ct	NOUN
aiua-12307	108	28	and	and	CCONJ
aiua-12307	108	29	who	who	PRON
aiua-12307	108	30	have	have	AUX
aiua-12307	108	31	not	not	PART
aiua-12307	108	32	received	receive	VERB
aiua-12307	108	33	prior	prior	ADJ
aiua-12307	108	34	immunotherapy	immunotherapy	NOUN
aiua-12307	108	35	.	.	PUNCT
aiua-12307	109	1	the	the	DET
aiua-12307	109	2	pd	pd	PROPN
aiua-12307	109	3	-	-	PUNCT
aiua-12307	109	4	l1	l1	PROPN
aiua-12307	109	5	inhibitor	inhibitor	NOUN
aiua-12307	109	6	atezolizumab	atezolizumab	NOUN
aiua-12307	109	7	and	and	CCONJ
aiua-12307	109	8	the	the	DET
aiua-12307	109	9	pd-1	pd-1	ADJ
aiua-12307	109	10	inhibitor	inhibitor	NOUN
aiua-12307	109	11	pembrolizumab	pembrolizumab	NOUN
aiua-12307	109	12	are	be	AUX
aiua-12307	109	13	approved	approve	VERB
aiua-12307	109	14	for	for	ADP
aiua-12307	109	15	patients	patient	NOUN
aiua-12307	109	16	with	with	ADP
aiua-12307	109	17	advanced	advanced	ADJ
aiua-12307	109	18	or	or	CCONJ
aiua-12307	109	19	muc	muc	NOUN
aiua-12307	109	20	unsuitable	unsuitable	ADJ
aiua-12307	109	21	for	for	ADP
aiua-12307	109	22	first	first	ADJ
aiua-12307	109	23	-	-	PUNCT
aiua-12307	109	24	line	line	NOUN
aiua-12307	109	25	platinum	platinum	NOUN
aiua-12307	109	26	-	-	PUNCT
aiua-12307	109	27	based	base	VERB
aiua-12307	109	28	ct	ct	PROPN
aiua-12307	109	29	.	.	PUNCT
aiua-12307	109	30	offer	offer	VERB
aiua-12307	109	31	patients	patient	NOUN
aiua-12307	109	32	with	with	ADP
aiua-12307	109	33	pd	pd	PROPN
aiua-12307	109	34	-	-	PUNCT
aiua-12307	109	35	l1	l1	PROPN
aiua-12307	109	36	-	-	PUNCT
aiua-12307	109	37	positive	positive	ADJ
aiua-12307	109	38	tumours	tumour	NOUN
aiua-12307	109	39	the	the	DET
aiua-12307	109	40	checkpoint	checkpoint	NOUN
aiua-12307	109	41	inhibitors	inhibitor	NOUN
aiua-12307	109	42	pembrolizumab	pembrolizumab	NOUN
aiua-12307	109	43	or	or	CCONJ
aiua-12307	109	44	atezolizumab	atezolizumab	NOUN
aiua-12307	109	45	.	.	PUNCT
aiua-12307	110	1	offer	offer	VERB
aiua-12307	110	2	adjuvant	adjuvant	ADJ
aiua-12307	110	3	nivolumab	nivolumab	NOUN
aiua-12307	110	4	to	to	ADP
aiua-12307	110	5	selected	select	VERB
aiua-12307	110	6	patients	patient	NOUN
aiua-12307	110	7	with	with	ADP
aiua-12307	110	8	pt3/4	pt3/4	PROPN
aiua-12307	110	9	and/or	and/or	CCONJ
aiua-12307	110	10	pn+	pn+	NOUN
aiua-12307	110	11	disease	disease	NOUN
aiua-12307	110	12	who	who	PRON
aiua-12307	110	13	are	be	AUX
aiua-12307	110	14	ineligible	ineligible	ADJ
aiua-12307	110	15	for	for	ADP
aiua-12307	110	16	or	or	CCONJ
aiua-12307	110	17	refuse	refuse	VERB
aiua-12307	110	18	adjuvant	adjuvant	ADJ
aiua-12307	110	19	cisplatin	cisplatin	NOUN
aiua-12307	110	20	-	-	PUNCT
aiua-12307	110	21	based	base	VERB
aiua-12307	110	22	ct	ct	PROPN
aiua-12307	110	23	.	.	PUNCT
aiua-12307	111	1	for	for	ADP
aiua-12307	111	2	patients	patient	NOUN
aiua-12307	111	3	who	who	PRON
aiua-12307	111	4	achieve	achieve	VERB
aiua-12307	111	5	stable	stable	ADJ
aiua-12307	111	6	disease	disease	NOUN
aiua-12307	111	7	after	after	ADP
aiua-12307	111	8	first	first	ADJ
aiua-12307	111	9	-	-	PUNCT
aiua-12307	111	10	line	line	NOUN
aiua-12307	111	11	platinum	platinum	NOUN
aiua-12307	111	12	-	-	PUNCT
aiua-12307	111	13	based	base	VERB
aiua-12307	111	14	ct	ct	PROPN
aiua-12307	111	15	,	,	PUNCT
aiua-12307	111	16	use	use	VERB
aiua-12307	111	17	maintenance	maintenance	NOUN
aiua-12307	111	18	treatment	treatment	NOUN
aiua-12307	111	19	with	with	ADP
aiua-12307	111	20	the	the	DET
aiua-12307	111	21	pd	pd	PROPN
aiua-12307	111	22	-	-	PUNCT
aiua-12307	111	23	l1	l1	PROPN
aiua-12307	111	24	inhibitor	inhibitor	NOUN
aiua-12307	111	25	avelumab	avelumab	NOUN
aiua-12307	111	26	.	.	PUNCT
aiua-12307	112	1	archivio	archivio	NOUN
aiua-12307	112	2	italiano	italiano	PROPN
aiua-12307	112	3	di	di	PROPN
aiua-12307	112	4	urologia	urologia	PROPN
aiua-12307	112	5	e	e	PROPN
aiua-12307	112	6	andrologia	andrologia	NOUN
aiua-12307	112	7	2024	2024	NUM
aiua-12307	112	8	;	;	PUNCT
aiua-12307	112	9	96(2):12307	96(2):12307	NUM
aiua-12307	112	10	e.	e.	PROPN
aiua-12307	112	11	bosnali	bosnali	PROPN
aiua-12307	112	12	,	,	PUNCT
aiua-12307	112	13	e.	e.	PROPN
aiua-12307	112	14	malik	malik	PROPN
aiua-12307	112	15	akdas	akdas	PROPN
aiua-12307	112	16	,	,	PUNCT
aiua-12307	112	17	e.	e.	PROPN
aiua-12307	112	18	telli	telli	PROPN
aiua-12307	112	19	,	,	PUNCT
aiua-12307	112	20	k.	k.	PROPN
aiua-12307	112	21	teke	teke	PROPN
aiua-12307	112	22	,	,	PUNCT
aiua-12307	112	23	o.	o.	PROPN
aiua-12307	112	24	kara	kara	PROPN
aiua-12307	112	25	4	4	NUM
aiua-12307	112	26	treatment	treatment	NOUN
aiua-12307	112	27	modality	modality	NOUN
aiua-12307	112	28	in	in	ADP
aiua-12307	112	29	urothelial	urothelial	ADJ
aiua-12307	112	30	carcinoma	carcinoma	NOUN
aiua-12307	112	31	.	.	PUNCT
aiua-12307	113	1	however	however	ADV
aiua-12307	113	2	,	,	PUNCT
aiua-12307	113	3	further	further	ADJ
aiua-12307	113	4	rcts	rct	NOUN
aiua-12307	113	5	and	and	CCONJ
aiua-12307	113	6	long	long	ADJ
aiua-12307	113	7	-	-	PUNCT
aiua-12307	113	8	term	term	NOUN
aiua-12307	113	9	follow	follow	NOUN
aiua-12307	113	10	-	-	PUNCT
aiua-12307	113	11	up	up	ADP
aiua-12307	113	12	periods	period	NOUN
aiua-12307	113	13	will	will	AUX
aiua-12307	113	14	strengthen	strengthen	VERB
aiua-12307	113	15	our	our	PRON
aiua-12307	113	16	knowledge	knowledge	NOUN
aiua-12307	113	17	of	of	ADP
aiua-12307	113	18	the	the	DET
aiua-12307	113	19	effectiveness	effectiveness	NOUN
aiua-12307	113	20	and	and	CCONJ
aiua-12307	113	21	safety	safety	NOUN
aiua-12307	113	22	of	of	ADP
aiua-12307	113	23	these	these	DET
aiua-12307	113	24	agents	agent	NOUN
aiua-12307	113	25	.	.	PUNCT
aiua-12307	114	1	in	in	ADP
aiua-12307	114	2	the	the	DET
aiua-12307	114	3	future	future	NOUN
aiua-12307	114	4	,	,	PUNCT
aiua-12307	114	5	the	the	DET
aiua-12307	114	6	role	role	NOUN
aiua-12307	114	7	of	of	ADP
aiua-12307	114	8	immunotherapy	immunotherapy	NOUN
aiua-12307	114	9	will	will	AUX
aiua-12307	114	10	be	be	AUX
aiua-12307	114	11	better	well	ADV
aiua-12307	114	12	understood	understand	VERB
aiua-12307	114	13	by	by	ADP
aiua-12307	114	14	focusing	focus	VERB
aiua-12307	114	15	on	on	ADP
aiua-12307	114	16	more	more	ADV
aiua-12307	114	17	specific	specific	ADJ
aiua-12307	114	18	treatment	treatment	NOUN
aiua-12307	114	19	strategies	strategy	NOUN
aiua-12307	114	20	and	and	CCONJ
aiua-12307	114	21	personalized	personalized	ADJ
aiua-12307	114	22	treatments	treatment	NOUN
aiua-12307	114	23	for	for	ADP
aiua-12307	114	24	disease	disease	NOUN
aiua-12307	114	25	subtypes	subtype	NOUN
aiua-12307	114	26	.	.	PUNCT
aiua-12307	115	1	renal	renal	ADJ
aiua-12307	115	2	cell	cell	NOUN
aiua-12307	115	3	carcinoma	carcinoma	NOUN
aiua-12307	115	4	renal	renal	ADJ
aiua-12307	115	5	cell	cell	NOUN
aiua-12307	115	6	carcinoma	carcinoma	NOUN
aiua-12307	115	7	(	(	PUNCT
aiua-12307	115	8	rcc	rcc	PROPN
aiua-12307	115	9	)	)	PUNCT
aiua-12307	115	10	accounts	account	VERB
aiua-12307	115	11	for	for	ADP
aiua-12307	115	12	2	2	NUM
aiua-12307	115	13	-	-	SYM
aiua-12307	115	14	3	3	NUM
aiua-12307	115	15	%	%	NOUN
aiua-12307	115	16	of	of	ADP
aiua-12307	115	17	adult	adult	NOUN
aiua-12307	115	18	cancers	cancer	NOUN
aiua-12307	115	19	,	,	PUNCT
aiua-12307	115	20	although	although	SCONJ
aiua-12307	115	21	its	its	PRON
aiua-12307	115	22	incidence	incidence	NOUN
aiua-12307	115	23	is	be	AUX
aiua-12307	115	24	increasing	increase	VERB
aiua-12307	115	25	in	in	ADP
aiua-12307	115	26	western	western	ADJ
aiua-12307	115	27	countries	country	NOUN
aiua-12307	115	28	(	(	PUNCT
aiua-12307	115	29	30	30	NUM
aiua-12307	115	30	)	)	PUNCT
aiua-12307	115	31	.	.	PUNCT
aiua-12307	116	1	according	accord	VERB
aiua-12307	116	2	to	to	ADP
aiua-12307	116	3	the	the	DET
aiua-12307	116	4	american	american	PROPN
aiua-12307	116	5	cancer	cancer	PROPN
aiua-12307	116	6	society	society	PROPN
aiua-12307	116	7	data	datum	NOUN
aiua-12307	116	8	for	for	ADP
aiua-12307	116	9	2023	2023	NUM
aiua-12307	116	10	,	,	PUNCT
aiua-12307	116	11	it	it	PRON
aiua-12307	116	12	is	be	AUX
aiua-12307	116	13	predicted	predict	VERB
aiua-12307	116	14	that	that	SCONJ
aiua-12307	116	15	approximately	approximately	ADV
aiua-12307	116	16	81.800	81.800	NUM
aiua-12307	116	17	new	new	ADJ
aiua-12307	116	18	cases	case	NOUN
aiua-12307	116	19	will	will	AUX
aiua-12307	116	20	be	be	AUX
aiua-12307	116	21	diagnosed	diagnose	VERB
aiua-12307	116	22	in	in	ADP
aiua-12307	116	23	the	the	DET
aiua-12307	116	24	united	united	PROPN
aiua-12307	116	25	states	states	PROPN
aiua-12307	116	26	,	,	PUNCT
aiua-12307	116	27	and	and	CCONJ
aiua-12307	116	28	14.890	14.890	NUM
aiua-12307	116	29	of	of	ADP
aiua-12307	116	30	the	the	DET
aiua-12307	116	31	patients	patient	NOUN
aiua-12307	116	32	will	will	AUX
aiua-12307	116	33	die	die	VERB
aiua-12307	116	34	from	from	ADP
aiua-12307	116	35	kidney	kidney	NOUN
aiua-12307	116	36	cancer	cancer	NOUN
aiua-12307	116	37	(	(	PUNCT
aiua-12307	116	38	31	31	NUM
aiua-12307	116	39	)	)	PUNCT
aiua-12307	116	40	.	.	PUNCT
aiua-12307	117	1	approximately	approximately	ADV
aiua-12307	117	2	70	70	NUM
aiua-12307	117	3	%	%	NOUN
aiua-12307	117	4	of	of	ADP
aiua-12307	117	5	kidney	kidney	NOUN
aiua-12307	117	6	cancer	cancer	NOUN
aiua-12307	117	7	cases	case	NOUN
aiua-12307	117	8	are	be	AUX
aiua-12307	117	9	diagnosed	diagnose	VERB
aiua-12307	117	10	at	at	ADP
aiua-12307	117	11	a	a	DET
aiua-12307	117	12	localized	localize	VERB
aiua-12307	117	13	or	or	CCONJ
aiua-12307	117	14	locally	locally	ADV
aiua-12307	117	15	advanced	advanced	ADJ
aiua-12307	117	16	stage	stage	NOUN
aiua-12307	117	17	,	,	PUNCT
aiua-12307	117	18	and	and	CCONJ
aiua-12307	117	19	the	the	DET
aiua-12307	117	20	standard	standard	NOUN
aiua-12307	117	21	of	of	ADP
aiua-12307	117	22	care	care	NOUN
aiua-12307	117	23	for	for	ADP
aiua-12307	117	24	these	these	DET
aiua-12307	117	25	patients	patient	NOUN
aiua-12307	117	26	is	be	AUX
aiua-12307	117	27	radical	radical	ADJ
aiua-12307	117	28	or	or	CCONJ
aiua-12307	117	29	partial	partial	ADJ
aiua-12307	117	30	nephrectomy	nephrectomy	NOUN
aiua-12307	117	31	(	(	PUNCT
aiua-12307	117	32	32	32	NUM
aiua-12307	117	33	)	)	PUNCT
aiua-12307	117	34	.	.	PUNCT
aiua-12307	118	1	despite	despite	SCONJ
aiua-12307	118	2	this	this	PRON
aiua-12307	118	3	,	,	PUNCT
aiua-12307	118	4	approximately	approximately	ADV
aiua-12307	118	5	35	35	NUM
aiua-12307	118	6	%	%	NOUN
aiua-12307	118	7	of	of	ADP
aiua-12307	118	8	patients	patient	NOUN
aiua-12307	118	9	initially	initially	ADV
aiua-12307	118	10	present	present	VERB
aiua-12307	118	11	with	with	ADP
aiua-12307	118	12	advanced	advanced	ADJ
aiua-12307	118	13	or	or	CCONJ
aiua-12307	118	14	metastatic	metastatic	ADJ
aiua-12307	118	15	rcc	rcc	PROPN
aiua-12307	118	16	(	(	PUNCT
aiua-12307	118	17	mrcc	mrcc	NOUN
aiua-12307	118	18	)	)	PUNCT
aiua-12307	118	19	,	,	PUNCT
aiua-12307	118	20	and	and	CCONJ
aiua-12307	118	21	30	30	NUM
aiua-12307	118	22	%	%	NOUN
aiua-12307	118	23	of	of	ADP
aiua-12307	118	24	patients	patient	NOUN
aiua-12307	118	25	presenting	present	VERB
aiua-12307	118	26	with	with	ADP
aiua-12307	118	27	localized	localized	ADJ
aiua-12307	118	28	disease	disease	NOUN
aiua-12307	118	29	experience	experience	NOUN
aiua-12307	118	30	recurrence	recurrence	NOUN
aiua-12307	118	31	(	(	PUNCT
aiua-12307	118	32	33	33	NUM
aiua-12307	118	33	)	)	PUNCT
aiua-12307	118	34	.	.	PUNCT
aiua-12307	119	1	rcc	rcc	PROPN
aiua-12307	119	2	has	have	AUX
aiua-12307	119	3	been	be	AUX
aiua-12307	119	4	known	know	VERB
aiua-12307	119	5	for	for	ADP
aiua-12307	119	6	many	many	ADJ
aiua-12307	119	7	years	year	NOUN
aiua-12307	119	8	as	as	ADP
aiua-12307	119	9	a	a	DET
aiua-12307	119	10	tumour	tumour	NOUN
aiua-12307	119	11	with	with	ADP
aiua-12307	119	12	unique	unique	ADJ
aiua-12307	119	13	sensitivity	sensitivity	NOUN
aiua-12307	119	14	to	to	ADP
aiua-12307	119	15	immunotherapies	immunotherapy	NOUN
aiua-12307	119	16	(	(	PUNCT
aiua-12307	119	17	34	34	NUM
aiua-12307	119	18	)	)	PUNCT
aiua-12307	119	19	.	.	PUNCT
aiua-12307	120	1	systemic	systemic	ADJ
aiua-12307	120	2	first	first	ADJ
aiua-12307	120	3	-	-	PUNCT
aiua-12307	120	4	line	line	NOUN
aiua-12307	120	5	treatment	treatment	NOUN
aiua-12307	120	6	for	for	ADP
aiua-12307	120	7	mrcc	mrcc	NOUN
aiua-12307	120	8	is	be	AUX
aiua-12307	120	9	rapidly	rapidly	ADV
aiua-12307	120	10	evolving	evolve	VERB
aiua-12307	120	11	,	,	PUNCT
aiua-12307	120	12	with	with	ADP
aiua-12307	120	13	multiple	multiple	ADJ
aiua-12307	120	14	approved	approve	VERB
aiua-12307	120	15	strategies	strategy	NOUN
aiua-12307	120	16	and	and	CCONJ
aiua-12307	120	17	new	new	ADJ
aiua-12307	120	18	clinical	clinical	ADJ
aiua-12307	120	19	trials	trial	NOUN
aiua-12307	120	20	ongoing	ongoing	ADJ
aiua-12307	120	21	.	.	PUNCT
aiua-12307	121	1	the	the	DET
aiua-12307	121	2	introduction	introduction	NOUN
aiua-12307	121	3	of	of	ADP
aiua-12307	121	4	mainly	mainly	ADV
aiua-12307	121	5	new	new	ADJ
aiua-12307	121	6	icis	icis	PROPN
aiua-12307	121	7	has	have	AUX
aiua-12307	121	8	led	lead	VERB
aiua-12307	121	9	to	to	ADP
aiua-12307	121	10	a	a	DET
aiua-12307	121	11	paradigm	paradigm	NOUN
aiua-12307	121	12	shift	shift	NOUN
aiua-12307	121	13	in	in	ADP
aiua-12307	121	14	the	the	DET
aiua-12307	121	15	treatment	treatment	NOUN
aiua-12307	121	16	of	of	ADP
aiua-12307	121	17	this	this	DET
aiua-12307	121	18	disease	disease	NOUN
aiua-12307	121	19	(	(	PUNCT
aiua-12307	121	20	35	35	NUM
aiua-12307	121	21	)	)	PUNCT
aiua-12307	121	22	.	.	PUNCT
aiua-12307	122	1	rcc	rcc	PROPN
aiua-12307	122	2	immunotherapy	immunotherapy	NOUN
aiua-12307	122	3	agents	agent	NOUN
aiua-12307	122	4	inhibit	inhibit	VERB
aiua-12307	122	5	receptor	receptor	NOUN
aiua-12307	122	6	-	-	PUNCT
aiua-12307	122	7	ligand	ligand	NOUN
aiua-12307	122	8	pairs	pair	NOUN
aiua-12307	122	9	that	that	PRON
aiua-12307	122	10	modulate	modulate	VERB
aiua-12307	122	11	the	the	DET
aiua-12307	122	12	congenital	congenital	ADJ
aiua-12307	122	13	or	or	CCONJ
aiua-12307	122	14	acquired	acquire	VERB
aiua-12307	122	15	immune	immune	ADJ
aiua-12307	122	16	system	system	NOUN
aiua-12307	122	17	.	.	PUNCT
aiua-12307	123	1	these	these	DET
aiua-12307	123	2	molecular	molecular	ADJ
aiua-12307	123	3	pairs	pair	NOUN
aiua-12307	123	4	,	,	PUNCT
aiua-12307	123	5	known	know	VERB
aiua-12307	123	6	as	as	ADP
aiua-12307	123	7	immune	immune	ADJ
aiua-12307	123	8	checkpoints	checkpoint	NOUN
aiua-12307	123	9	,	,	PUNCT
aiua-12307	123	10	include	include	VERB
aiua-12307	123	11	pd-1	pd-1	ADP
aiua-12307	123	12	and	and	CCONJ
aiua-12307	123	13	pd	pd	PROPN
aiua-12307	123	14	-	-	PROPN
aiua-12307	123	15	l1	l1	PROPN
aiua-12307	123	16	and	and	CCONJ
aiua-12307	123	17	ctla4	ctla4	NOUN
aiua-12307	123	18	multiple	multiple	ADJ
aiua-12307	123	19	ligands	ligand	NOUN
aiua-12307	123	20	,	,	PUNCT
aiua-12307	123	21	including	include	VERB
aiua-12307	123	22	cytotoxic	cytotoxic	ADJ
aiua-12307	123	23	t	t	NOUN
aiua-12307	123	24	lymphocyte	lymphocyte	NOUN
aiua-12307	123	25	-	-	PUNCT
aiua-12307	123	26	associated	associate	VERB
aiua-12307	123	27	protein	protein	NOUN
aiua-12307	123	28	4	4	NUM
aiua-12307	123	29	(	(	PUNCT
aiua-12307	123	30	ctla4	ctla4	NOUN
aiua-12307	123	31	)	)	PUNCT
aiua-12307	123	32	,	,	PUNCT
aiua-12307	123	33	cd80	cd80	PROPN
aiua-12307	123	34	,	,	PUNCT
aiua-12307	123	35	and	and	CCONJ
aiua-12307	123	36	cd86	cd86	PROPN
aiua-12307	123	37	(	(	PUNCT
aiua-12307	123	38	36	36	NUM
aiua-12307	123	39	)	)	PUNCT
aiua-12307	123	40	.	.	PUNCT
aiua-12307	124	1	the	the	DET
aiua-12307	124	2	recent	recent	ADJ
aiua-12307	124	3	emergence	emergence	NOUN
aiua-12307	124	4	of	of	ADP
aiua-12307	124	5	icis	icis	NOUN
aiua-12307	124	6	that	that	PRON
aiua-12307	124	7	block	block	VERB
aiua-12307	124	8	the	the	DET
aiua-12307	124	9	pd-1	pd-1	NOUN
aiua-12307	124	10	/	/	SYM
aiua-12307	124	11	pd	pd	NOUN
aiua-12307	124	12	-	-	PROPN
aiua-12307	124	13	l1	l1	PROPN
aiua-12307	124	14	or	or	CCONJ
aiua-12307	124	15	ctla4	ctla4	NOUN
aiua-12307	124	16	signalling	signal	VERB
aiua-12307	124	17	pathways	pathway	NOUN
aiua-12307	124	18	has	have	AUX
aiua-12307	124	19	re	re	VERB
aiua-12307	124	20	-	-	VERB
aiua-12307	124	21	established	establish	VERB
aiua-12307	124	22	systemic	systemic	ADJ
aiua-12307	124	23	immunotherapy	immunotherapy	NOUN
aiua-12307	124	24	as	as	ADP
aiua-12307	124	25	central	central	ADJ
aiua-12307	124	26	to	to	ADP
aiua-12307	124	27	the	the	DET
aiua-12307	124	28	medical	medical	ADJ
aiua-12307	124	29	treatment	treatment	NOUN
aiua-12307	124	30	of	of	ADP
aiua-12307	124	31	advanced	advanced	ADJ
aiua-12307	124	32	rcc	rcc	PROPN
aiua-12307	124	33	,	,	PUNCT
aiua-12307	124	34	resulting	result	VERB
aiua-12307	124	35	in	in	ADP
aiua-12307	124	36	increasing	increase	VERB
aiua-12307	124	37	interest	interest	NOUN
aiua-12307	124	38	in	in	ADP
aiua-12307	124	39	the	the	DET
aiua-12307	124	40	application	application	NOUN
aiua-12307	124	41	of	of	ADP
aiua-12307	124	42	immunotherapies	immunotherapy	NOUN
aiua-12307	124	43	in	in	ADP
aiua-12307	124	44	the	the	DET
aiua-12307	124	45	adjuvant	adjuvant	ADJ
aiua-12307	124	46	setting	setting	NOUN
aiua-12307	124	47	.	.	PUNCT
aiua-12307	125	1	many	many	ADJ
aiua-12307	125	2	rcts	rct	NOUN
aiua-12307	125	3	are	be	AUX
aiua-12307	125	4	being	be	AUX
aiua-12307	125	5	conducted	conduct	VERB
aiua-12307	125	6	(	(	PUNCT
aiua-12307	125	7	34	34	NUM
aiua-12307	125	8	)	)	PUNCT
aiua-12307	125	9	.	.	PUNCT
aiua-12307	126	1	treatment	treatment	NOUN
aiua-12307	126	2	of	of	ADP
aiua-12307	126	3	locally	locally	ADV
aiua-12307	126	4	advanced	advanced	ADJ
aiua-12307	126	5	rcc	rcc	PROPN
aiua-12307	126	6	(	(	PUNCT
aiua-12307	126	7	neoadjuvant	neoadjuvant	ADJ
aiua-12307	126	8	/	/	SYM
aiua-12307	126	9	adjuvant	adjuvant	NOUN
aiua-12307	126	10	therapy	therapy	NOUN
aiua-12307	126	11	)	)	PUNCT
aiua-12307	126	12	given	give	VERB
aiua-12307	126	13	the	the	DET
aiua-12307	126	14	recent	recent	ADJ
aiua-12307	126	15	success	success	NOUN
aiua-12307	126	16	of	of	ADP
aiua-12307	126	17	icis	icis	NOUN
aiua-12307	126	18	in	in	ADP
aiua-12307	126	19	mrcc	mrcc	NOUN
aiua-12307	126	20	,	,	PUNCT
aiua-12307	126	21	these	these	DET
aiua-12307	126	22	therapies	therapy	NOUN
aiua-12307	126	23	are	be	AUX
aiua-12307	126	24	now	now	ADV
aiua-12307	126	25	being	be	AUX
aiua-12307	126	26	studied	study	VERB
aiua-12307	126	27	in	in	ADP
aiua-12307	126	28	the	the	DET
aiua-12307	126	29	(	(	PUNCT
aiua-12307	126	30	neo)adjuvant	neo)adjuvant	ADJ
aiua-12307	126	31	setting	set	VERB
aiua-12307	126	32	to	to	PART
aiua-12307	126	33	treat	treat	VERB
aiua-12307	126	34	localized	localized	ADJ
aiua-12307	126	35	rcc	rcc	PROPN
aiua-12307	126	36	.	.	PUNCT
aiua-12307	127	1	the	the	DET
aiua-12307	127	2	rationale	rationale	NOUN
aiua-12307	127	3	for	for	ADP
aiua-12307	127	4	using	use	VERB
aiua-12307	127	5	neoadjuvant	neoadjuvant	ADJ
aiua-12307	127	6	icis	icis	PROPN
aiua-12307	127	7	stems	stem	VERB
aiua-12307	127	8	from	from	ADP
aiua-12307	127	9	the	the	DET
aiua-12307	127	10	hypothesis	hypothesis	NOUN
aiua-12307	127	11	that	that	PRON
aiua-12307	127	12	intact	intact	ADJ
aiua-12307	127	13	kidney	kidney	NOUN
aiua-12307	127	14	tissue	tissue	NOUN
aiua-12307	127	15	may	may	AUX
aiua-12307	127	16	provide	provide	VERB
aiua-12307	127	17	a	a	DET
aiua-12307	127	18	source	source	NOUN
aiua-12307	127	19	of	of	ADP
aiua-12307	127	20	antigen	antigen	NOUN
aiua-12307	127	21	for	for	ADP
aiua-12307	127	22	the	the	DET
aiua-12307	127	23	persistent	persistent	ADJ
aiua-12307	127	24	cancerspecific	cancerspecific	ADJ
aiua-12307	127	25	immune	immune	ADJ
aiua-12307	127	26	response	response	NOUN
aiua-12307	127	27	(	(	PUNCT
aiua-12307	127	28	37	37	NUM
aiua-12307	127	29	)	)	PUNCT
aiua-12307	127	30	.	.	PUNCT
aiua-12307	128	1	the	the	DET
aiua-12307	128	2	advantage	advantage	NOUN
aiua-12307	128	3	of	of	ADP
aiua-12307	128	4	adjuvant	adjuvant	ADJ
aiua-12307	128	5	immunotherapy	immunotherapy	NOUN
aiua-12307	128	6	is	be	AUX
aiua-12307	128	7	that	that	SCONJ
aiua-12307	128	8	it	it	PRON
aiua-12307	128	9	can	can	AUX
aiua-12307	128	10	maintain	maintain	VERB
aiua-12307	128	11	efficacy	efficacy	NOUN
aiua-12307	128	12	and	and	CCONJ
aiua-12307	128	13	eliminate	eliminate	VERB
aiua-12307	128	14	micrometastases	micrometastase	NOUN
aiua-12307	128	15	even	even	ADV
aiua-12307	128	16	after	after	ADP
aiua-12307	128	17	treatment	treatment	NOUN
aiua-12307	128	18	discontinuation	discontinuation	NOUN
aiua-12307	128	19	(	(	PUNCT
aiua-12307	128	20	38	38	NUM
aiua-12307	128	21	)	)	PUNCT
aiua-12307	128	22	.	.	PUNCT
aiua-12307	129	1	this	this	DET
aiua-12307	129	2	section	section	NOUN
aiua-12307	129	3	aims	aim	VERB
aiua-12307	129	4	to	to	PART
aiua-12307	129	5	provide	provide	VERB
aiua-12307	129	6	an	an	DET
aiua-12307	129	7	overview	overview	NOUN
aiua-12307	129	8	of	of	ADP
aiua-12307	129	9	completed	complete	VERB
aiua-12307	129	10	or	or	CCONJ
aiua-12307	129	11	ongoing	ongoing	ADJ
aiua-12307	129	12	clinical	clinical	ADJ
aiua-12307	129	13	trials	trial	NOUN
aiua-12307	129	14	on	on	ADP
aiua-12307	129	15	adjuvant	adjuvant	ADJ
aiua-12307	129	16	treatment	treatment	NOUN
aiua-12307	129	17	of	of	ADP
aiua-12307	129	18	rcc	rcc	PROPN
aiua-12307	129	19	,	,	PUNCT
aiua-12307	129	20	accompanied	accompany	VERB
aiua-12307	129	21	by	by	ADP
aiua-12307	129	22	the	the	DET
aiua-12307	129	23	2023	2023	NUM
aiua-12307	129	24	eau	eau	PROPN
aiua-12307	129	25	guideline	guideline	NOUN
aiua-12307	129	26	and	and	CCONJ
aiua-12307	129	27	current	current	ADJ
aiua-12307	129	28	reviews	review	NOUN
aiua-12307	129	29	.	.	PUNCT
aiua-12307	130	1	keynote-564	keynote-564	ADJ
aiua-12307	130	2	trial	trial	NOUN
aiua-12307	130	3	(	(	PUNCT
aiua-12307	130	4	pembrolizumab	pembrolizumab	NOUN
aiua-12307	130	5	)	)	PUNCT
aiua-12307	130	6	pembrolizumab	pembrolizumab	NOUN
aiua-12307	130	7	is	be	AUX
aiua-12307	130	8	a	a	DET
aiua-12307	130	9	humanized	humanize	VERB
aiua-12307	130	10	monoclonal	monoclonal	NOUN
aiua-12307	130	11	igg4	igg4	NOUN
aiua-12307	130	12	antibody	antibody	NOUN
aiua-12307	130	13	and	and	CCONJ
aiua-12307	130	14	is	be	AUX
aiua-12307	130	15	also	also	ADV
aiua-12307	130	16	a	a	DET
aiua-12307	130	17	pd-1	pd-1	ADJ
aiua-12307	130	18	inhibitor	inhibitor	NOUN
aiua-12307	130	19	.	.	PUNCT
aiua-12307	131	1	keynote-564	keynote-564	ADJ
aiua-12307	131	2	study	study	PROPN
aiua-12307	131	3	included	include	VERB
aiua-12307	131	4	intermediate	intermediate	ADJ
aiua-12307	131	5	-	-	PUNCT
aiua-12307	131	6	high	high	ADJ
aiua-12307	131	7	risk	risk	NOUN
aiua-12307	131	8	(	(	PUNCT
aiua-12307	131	9	pt2	pt2	NOUN
aiua-12307	131	10	,	,	PUNCT
aiua-12307	131	11	grade	grade	NOUN
aiua-12307	131	12	4	4	NUM
aiua-12307	131	13	or	or	CCONJ
aiua-12307	131	14	sarcomatoid	sarcomatoid	NOUN
aiua-12307	131	15	,	,	PUNCT
aiua-12307	131	16	n0	n0	PROPN
aiua-12307	131	17	,	,	PUNCT
aiua-12307	131	18	m0	m0	NOUN
aiua-12307	131	19	or	or	CCONJ
aiua-12307	131	20	pt3	pt3	NOUN
aiua-12307	131	21	,	,	PUNCT
aiua-12307	131	22	any	any	DET
aiua-12307	131	23	grade	grade	NOUN
aiua-12307	131	24	,	,	PUNCT
aiua-12307	131	25	n0	n0	PROPN
aiua-12307	131	26	,	,	PUNCT
aiua-12307	131	27	m0	m0	NOUN
aiua-12307	131	28	)	)	PUNCT
aiua-12307	131	29	or	or	CCONJ
aiua-12307	131	30	high	high	ADJ
aiua-12307	131	31	risk	risk	NOUN
aiua-12307	131	32	of	of	ADP
aiua-12307	131	33	recurrence	recurrence	NOUN
aiua-12307	131	34	(	(	PUNCT
aiua-12307	131	35	pt4	pt4	NOUN
aiua-12307	131	36	,	,	PUNCT
aiua-12307	131	37	any	any	DET
aiua-12307	131	38	grade	grade	NOUN
aiua-12307	131	39	,	,	PUNCT
aiua-12307	131	40	n0	n0	PROPN
aiua-12307	131	41	,	,	PUNCT
aiua-12307	131	42	m0	m0	NOUN
aiua-12307	131	43	or	or	CCONJ
aiua-12307	131	44	any	any	DET
aiua-12307	131	45	pt	pt	NOUN
aiua-12307	131	46	,	,	PUNCT
aiua-12307	131	47	any	any	DET
aiua-12307	131	48	grade	grade	NOUN
aiua-12307	131	49	,	,	PUNCT
aiua-12307	131	50	pn+	pn+	NOUN
aiua-12307	131	51	,	,	PUNCT
aiua-12307	131	52	m0	m0	NOUN
aiua-12307	131	53	,	,	PUNCT
aiua-12307	131	54	or	or	CCONJ
aiua-12307	131	55	no	no	DET
aiua-12307	131	56	evidence	evidence	NOUN
aiua-12307	131	57	of	of	ADP
aiua-12307	131	58	disease	disease	NOUN
aiua-12307	131	59	after	after	ADP
aiua-12307	131	60	resection	resection	NOUN
aiua-12307	131	61	of	of	ADP
aiua-12307	131	62	oligometastatic	oligometastatic	ADJ
aiua-12307	131	63	sites	site	NOUN
aiua-12307	131	64	<	<	X
aiua-12307	131	65	1	1	NUM
aiua-12307	131	66	year	year	NOUN
aiua-12307	131	67	after	after	ADP
aiua-12307	131	68	nephrectomy	nephrectomy	NOUN
aiua-12307	131	69	or	or	CCONJ
aiua-12307	131	70	ned	ne	VERB
aiua-12307	131	71	)	)	PUNCT
aiua-12307	131	72	.	.	PUNCT
aiua-12307	132	1	it	it	PRON
aiua-12307	132	2	was	be	AUX
aiua-12307	132	3	a	a	DET
aiua-12307	132	4	phase	phase	NOUN
aiua-12307	132	5	iii	iii	NUM
aiua-12307	132	6	clinical	clinical	ADJ
aiua-12307	132	7	trial	trial	NOUN
aiua-12307	132	8	in	in	ADP
aiua-12307	132	9	which	which	DET
aiua-12307	132	10	pembrolizumab	pembrolizumab	NOUN
aiua-12307	132	11	(	(	PUNCT
aiua-12307	132	12	17	17	NUM
aiua-12307	132	13	cycles	cycle	NOUN
aiua-12307	132	14	of	of	ADP
aiua-12307	132	15	3	3	NUM
aiua-12307	132	16	weeks	week	NOUN
aiua-12307	132	17	of	of	ADP
aiua-12307	132	18	treatment	treatment	NOUN
aiua-12307	132	19	)	)	PUNCT
aiua-12307	132	20	was	be	AUX
aiua-12307	132	21	randomized	randomize	VERB
aiua-12307	132	22	vs	vs	ADP
aiua-12307	132	23	placebo	placebo	NOUN
aiua-12307	132	24	as	as	ADP
aiua-12307	132	25	adjuvant	adjuvant	ADJ
aiua-12307	132	26	therapy	therapy	NOUN
aiua-12307	132	27	in	in	ADP
aiua-12307	132	28	994	994	NUM
aiua-12307	132	29	patients	patient	NOUN
aiua-12307	132	30	(	(	PUNCT
aiua-12307	132	31	39	39	NUM
aiua-12307	132	32	)	)	PUNCT
aiua-12307	132	33	.	.	PUNCT
aiua-12307	133	1	in	in	ADP
aiua-12307	133	2	this	this	DET
aiua-12307	133	3	study	study	NOUN
aiua-12307	133	4	,	,	PUNCT
aiua-12307	133	5	m1	m1	PROPN
aiua-12307	133	6	ned	ned	PROPN
aiua-12307	133	7	was	be	AUX
aiua-12307	133	8	defined	define	VERB
aiua-12307	133	9	as	as	ADP
aiua-12307	133	10	complete	complete	ADJ
aiua-12307	133	11	resection	resection	NOUN
aiua-12307	133	12	of	of	ADP
aiua-12307	133	13	oligometastasis	oligometastasis	NOUN
aiua-12307	133	14	simultaneously	simultaneously	ADV
aiua-12307	133	15	or	or	CCONJ
aiua-12307	133	16	within	within	ADP
aiua-12307	133	17	one	one	NUM
aiua-12307	133	18	year	year	NOUN
aiua-12307	133	19	after	after	ADP
aiua-12307	133	20	nephrectomy	nephrectomy	NOUN
aiua-12307	133	21	.	.	PUNCT
aiua-12307	134	1	at	at	ADP
aiua-12307	134	2	a	a	DET
aiua-12307	134	3	median	median	ADJ
aiua-12307	134	4	follow	follow	NOUN
aiua-12307	134	5	-	-	PUNCT
aiua-12307	134	6	up	up	NOUN
aiua-12307	134	7	of	of	ADP
aiua-12307	134	8	24	24	NUM
aiua-12307	134	9	mo	mo	PROPN
aiua-12307	134	10	.	.	PROPN
aiua-12307	134	11	,	,	PUNCT
aiua-12307	134	12	dfs	dfs	PROPN
aiua-12307	134	13	was	be	AUX
aiua-12307	134	14	77.1	77.1	NUM
aiua-12307	134	15	%	%	NOUN
aiua-12307	134	16	vs	vs	ADP
aiua-12307	134	17	68.1	68.1	NUM
aiua-12307	134	18	%	%	NOUN
aiua-12307	134	19	(	(	PUNCT
aiua-12307	134	20	hr	hr	NOUN
aiua-12307	134	21	0.68	0.68	NUM
aiua-12307	134	22	,	,	PUNCT
aiua-12307	134	23	95	95	NUM
aiua-12307	134	24	%	%	NOUN
aiua-12307	134	25	ci	ci	NOUN
aiua-12307	134	26	:	:	PUNCT
aiua-12307	134	27	0.53	0.53	NUM
aiua-12307	134	28	-	-	SYM
aiua-12307	134	29	0.87	0.87	NUM
aiua-12307	134	30	;	;	PUNCT
aiua-12307	134	31	p	p	PROPN
aiua-12307	134	32	=	=	PROPN
aiua-12307	134	33	0.0010	0.0010	NUM
aiua-12307	134	34	)	)	PUNCT
aiua-12307	134	35	,	,	PUNCT
aiua-12307	134	36	and	and	CCONJ
aiua-12307	134	37	this	this	DET
aiua-12307	134	38	rate	rate	NOUN
aiua-12307	134	39	was	be	AUX
aiua-12307	134	40	maintained	maintain	VERB
aiua-12307	134	41	at	at	ADP
aiua-12307	134	42	30	30	NUM
aiua-12307	134	43	mo	mo	PROPN
aiua-12307	134	44	.	.	PROPN
aiua-12307	135	1	follow	follow	NOUN
aiua-12307	135	2	-	-	PUNCT
aiua-12307	135	3	up	up	NOUN
aiua-12307	135	4	.	.	PUNCT
aiua-12307	136	1	in	in	ADP
aiua-12307	136	2	subgroup	subgroup	NOUN
aiua-12307	136	3	analyses	analysis	NOUN
aiua-12307	136	4	of	of	ADP
aiua-12307	136	5	the	the	DET
aiua-12307	136	6	study	study	NOUN
aiua-12307	136	7	,	,	PUNCT
aiua-12307	136	8	patients	patient	NOUN
aiua-12307	136	9	with	with	ADP
aiua-12307	136	10	m0	m0	PROPN
aiua-12307	136	11	tumours	tumours	PROPN
aiua-12307	136	12	(	(	PUNCT
aiua-12307	136	13	hr	hr	NOUN
aiua-12307	136	14	0.74	0.74	NUM
aiua-12307	136	15	,	,	PUNCT
aiua-12307	136	16	95	95	NUM
aiua-12307	136	17	%	%	NOUN
aiua-12307	136	18	ci	ci	NOUN
aiua-12307	136	19	:	:	PUNCT
aiua-12307	136	20	0.57	0.57	NUM
aiua-12307	136	21	-	-	SYM
aiua-12307	136	22	0.96	0.96	NUM
aiua-12307	136	23	)	)	PUNCT
aiua-12307	136	24	and	and	CCONJ
aiua-12307	136	25	patients	patient	NOUN
aiua-12307	136	26	with	with	ADP
aiua-12307	136	27	m1	m1	PROPN
aiua-12307	136	28	tumours	tumour	NOUN
aiua-12307	136	29	with	with	ADP
aiua-12307	136	30	ned	ned	PROPN
aiua-12307	136	31	(	(	PUNCT
aiua-12307	136	32	hr	hr	NOUN
aiua-12307	136	33	0.29	0.29	NUM
aiua-12307	136	34	,	,	PUNCT
aiua-12307	136	35	95	95	NUM
aiua-12307	136	36	%	%	NOUN
aiua-12307	136	37	ci	ci	NOUN
aiua-12307	136	38	:	:	PUNCT
aiua-12307	136	39	0.120.69	0.120.69	NUM
aiua-12307	136	40	)	)	PUNCT
aiua-12307	136	41	dfs	dfs	ADJ
aiua-12307	136	42	benefit	benefit	NOUN
aiua-12307	136	43	was	be	AUX
aiua-12307	136	44	observed	observe	VERB
aiua-12307	136	45	and	and	CCONJ
aiua-12307	136	46	the	the	DET
aiua-12307	136	47	dfs	dfs	PROPN
aiua-12307	136	48	benefit	benefit	NOUN
aiua-12307	136	49	of	of	ADP
aiua-12307	136	50	pembrolizumab	pembrolizumab	NOUN
aiua-12307	136	51	was	be	AUX
aiua-12307	136	52	observed	observe	VERB
aiua-12307	136	53	in	in	ADP
aiua-12307	136	54	patients	patient	NOUN
aiua-12307	136	55	with	with	ADP
aiua-12307	136	56	pd	pd	PROPN
aiua-12307	136	57	-	-	PROPN
aiua-12307	136	58	l1	l1	PROPN
aiua-12307	136	59	combined	combine	VERB
aiua-12307	136	60	positive	positive	ADJ
aiua-12307	136	61	score	score	NOUN
aiua-12307	136	62	(	(	PUNCT
aiua-12307	136	63	cps	cps	PROPN
aiua-12307	136	64	)	)	PUNCT
aiua-12307	136	65	≥	≥	NOUN
aiua-12307	136	66	1	1	NUM
aiua-12307	136	67	(	(	PUNCT
aiua-12307	136	68	hr	hr	NOUN
aiua-12307	136	69	0.67	0.67	NUM
aiua-12307	136	70	,	,	PUNCT
aiua-12307	136	71	95	95	NUM
aiua-12307	136	72	%	%	NOUN
aiua-12307	136	73	ci	ci	NOUN
aiua-12307	136	74	0.510.88	0.510.88	PROPN
aiua-12307	136	75	)	)	PUNCT
aiua-12307	136	76	compared	compare	VERB
aiua-12307	136	77	to	to	ADP
aiua-12307	136	78	patients	patient	NOUN
aiua-12307	136	79	with	with	ADP
aiua-12307	136	80	pd	pd	PROPN
aiua-12307	136	81	-	-	PROPN
aiua-12307	136	82	l1	l1	PROPN
aiua-12307	136	83	cps	cps	PROPN
aiua-12307	136	84	<	<	X
aiua-12307	136	85	1	1	NUM
aiua-12307	136	86	(	(	PUNCT
aiua-12307	136	87	hr	hr	NOUN
aiua-12307	136	88	0.83	0.83	NUM
aiua-12307	136	89	,	,	PUNCT
aiua-12307	136	90	95	95	NUM
aiua-12307	136	91	%	%	NOUN
aiua-12307	136	92	ci	ci	NOUN
aiua-12307	136	93	0.45	0.45	NUM
aiua-12307	136	94	-	-	SYM
aiua-12307	136	95	1.51	1.51	NUM
aiua-12307	136	96	)	)	PUNCT
aiua-12307	136	97	.	.	PUNCT
aiua-12307	137	1	in	in	ADP
aiua-12307	137	2	this	this	DET
aiua-12307	137	3	context	context	NOUN
aiua-12307	137	4	,	,	PUNCT
aiua-12307	137	5	keynote-564	keynote-564	NOUN
aiua-12307	137	6	is	be	AUX
aiua-12307	137	7	the	the	DET
aiua-12307	137	8	first	first	ADJ
aiua-12307	137	9	study	study	NOUN
aiua-12307	137	10	of	of	ADP
aiua-12307	137	11	adjuvant	adjuvant	ADJ
aiua-12307	137	12	ici	ici	PROPN
aiua-12307	137	13	to	to	PART
aiua-12307	137	14	report	report	VERB
aiua-12307	137	15	a	a	DET
aiua-12307	137	16	positive	positive	ADJ
aiua-12307	137	17	primary	primary	ADJ
aiua-12307	137	18	endpoint	endpoint	NOUN
aiua-12307	137	19	of	of	ADP
aiua-12307	137	20	dfs	dfs	PROPN
aiua-12307	137	21	.	.	PUNCT
aiua-12307	138	1	median	median	PROPN
aiua-12307	138	2	os	os	PROPN
aiua-12307	138	3	was	be	AUX
aiua-12307	138	4	not	not	PART
aiua-12307	138	5	reached	reach	VERB
aiua-12307	138	6	in	in	ADP
aiua-12307	138	7	both	both	DET
aiua-12307	138	8	groups	group	NOUN
aiua-12307	138	9	.	.	PUNCT
aiua-12307	139	1	the	the	DET
aiua-12307	139	2	most	most	ADV
aiua-12307	139	3	common	common	ADJ
aiua-12307	139	4	adverse	adverse	ADJ
aiua-12307	139	5	effects	effect	NOUN
aiua-12307	139	6	(	(	PUNCT
aiua-12307	139	7	aes	aes	NOUN
aiua-12307	139	8	)	)	PUNCT
aiua-12307	139	9	in	in	ADP
aiua-12307	139	10	the	the	DET
aiua-12307	139	11	pembrolizumab	pembrolizumab	NOUN
aiua-12307	139	12	group	group	NOUN
aiua-12307	139	13	were	be	AUX
aiua-12307	139	14	fatigue	fatigue	NOUN
aiua-12307	139	15	(	(	PUNCT
aiua-12307	139	16	1	1	NUM
aiua-12307	139	17	%	%	NOUN
aiua-12307	139	18	)	)	PUNCT
aiua-12307	139	19	,	,	PUNCT
aiua-12307	139	20	diarrhoea	diarrhoea	NOUN
aiua-12307	139	21	(	(	PUNCT
aiua-12307	139	22	1.6	1.6	NUM
aiua-12307	139	23	%	%	NOUN
aiua-12307	139	24	)	)	PUNCT
aiua-12307	139	25	and	and	CCONJ
aiua-12307	139	26	skin	skin	NOUN
aiua-12307	139	27	rash	rash	NOUN
aiua-12307	139	28	(	(	PUNCT
aiua-12307	139	29	0.8	0.8	NUM
aiua-12307	139	30	%	%	NOUN
aiua-12307	139	31	)	)	PUNCT
aiua-12307	139	32	,	,	PUNCT
aiua-12307	139	33	and	and	CCONJ
aiua-12307	139	34	grade	grade	NOUN
aiua-12307	139	35	4	4	NUM
aiua-12307	139	36	-	-	SYM
aiua-12307	139	37	5	5	NUM
aiua-12307	139	38	aes	aes	NOUN
aiua-12307	139	39	were	be	AUX
aiua-12307	139	40	not	not	PART
aiua-12307	139	41	observed	observe	VERB
aiua-12307	139	42	in	in	ADP
aiua-12307	139	43	both	both	DET
aiua-12307	139	44	study	study	NOUN
aiua-12307	139	45	arms	arm	NOUN
aiua-12307	139	46	(	(	PUNCT
aiua-12307	139	47	40	40	NUM
aiua-12307	139	48	)	)	PUNCT
aiua-12307	139	49	.	.	PUNCT
aiua-12307	140	1	the	the	DET
aiua-12307	140	2	study	study	NOUN
aiua-12307	140	3	's	's	PART
aiua-12307	140	4	results	result	NOUN
aiua-12307	140	5	led	lead	VERB
aiua-12307	140	6	to	to	ADP
aiua-12307	140	7	fda	fda	PROPN
aiua-12307	140	8	approval	approval	NOUN
aiua-12307	140	9	of	of	ADP
aiua-12307	140	10	single	single	ADJ
aiua-12307	140	11	-	-	PUNCT
aiua-12307	140	12	agent	agent	NOUN
aiua-12307	140	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	140	14	for	for	ADP
aiua-12307	140	15	the	the	DET
aiua-12307	140	16	adjuvant	adjuvant	ADJ
aiua-12307	140	17	treatment	treatment	NOUN
aiua-12307	140	18	of	of	ADP
aiua-12307	140	19	patients	patient	NOUN
aiua-12307	140	20	with	with	ADP
aiua-12307	140	21	resected	resect	VERB
aiua-12307	140	22	ccrcc	ccrcc	NOUN
aiua-12307	140	23	,	,	PUNCT
aiua-12307	140	24	intermediate	intermediate	ADJ
aiua-12307	140	25	-	-	PUNCT
aiua-12307	140	26	high	high	ADJ
aiua-12307	140	27	risk	risk	NOUN
aiua-12307	140	28	,	,	PUNCT
aiua-12307	140	29	or	or	CCONJ
aiua-12307	140	30	high	high	ADJ
aiua-12307	140	31	risk	risk	NOUN
aiua-12307	140	32	of	of	ADP
aiua-12307	140	33	recurrence	recurrence	NOUN
aiua-12307	140	34	.	.	PUNCT
aiua-12307	141	1	in	in	ADP
aiua-12307	141	2	2021	2021	NUM
aiua-12307	141	3	,	,	PUNCT
aiua-12307	141	4	the	the	DET
aiua-12307	141	5	eau	eau	PROPN
aiua-12307	141	6	rcc	rcc	PROPN
aiua-12307	141	7	guideline	guideline	PROPN
aiua-12307	141	8	issued	issue	VERB
aiua-12307	141	9	a	a	DET
aiua-12307	141	10	weak	weak	ADJ
aiua-12307	141	11	recommendation	recommendation	NOUN
aiua-12307	141	12	for	for	ADP
aiua-12307	141	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	141	14	as	as	ADP
aiua-12307	141	15	adjuvant	adjuvant	ADJ
aiua-12307	141	16	therapy	therapy	NOUN
aiua-12307	141	17	for	for	ADP
aiua-12307	141	18	ccrcc	ccrcc	NOUN
aiua-12307	141	19	with	with	ADP
aiua-12307	141	20	intermediate	intermediate	ADJ
aiua-12307	141	21	to	to	PART
aiua-12307	141	22	high	high	ADJ
aiua-12307	141	23	risk	risk	NOUN
aiua-12307	141	24	of	of	ADP
aiua-12307	141	25	recurrence	recurrence	NOUN
aiua-12307	141	26	,	,	PUNCT
aiua-12307	141	27	as	as	SCONJ
aiua-12307	141	28	defined	define	VERB
aiua-12307	141	29	by	by	ADP
aiua-12307	141	30	the	the	DET
aiua-12307	141	31	study	study	NOUN
aiua-12307	141	32	,	,	PUNCT
aiua-12307	141	33	until	until	SCONJ
aiua-12307	141	34	final	final	ADJ
aiua-12307	141	35	os	os	NOUN
aiua-12307	141	36	data	datum	NOUN
aiua-12307	141	37	and	and	CCONJ
aiua-12307	141	38	results	result	NOUN
aiua-12307	141	39	from	from	ADP
aiua-12307	141	40	other	other	ADJ
aiua-12307	141	41	studies	study	NOUN
aiua-12307	141	42	are	be	AUX
aiua-12307	141	43	available	available	ADJ
aiua-12307	141	44	.	.	PUNCT
aiua-12307	142	1	keynote-564	keynote-564	ADJ
aiua-12307	142	2	data	datum	NOUN
aiua-12307	142	3	should	should	AUX
aiua-12307	142	4	also	also	ADV
aiua-12307	142	5	be	be	AUX
aiua-12307	142	6	interpreted	interpret	VERB
aiua-12307	142	7	in	in	ADP
aiua-12307	142	8	the	the	DET
aiua-12307	142	9	context	context	NOUN
aiua-12307	142	10	of	of	ADP
aiua-12307	142	11	several	several	ADJ
aiua-12307	142	12	significant	significant	ADJ
aiua-12307	142	13	randomized	randomize	VERB
aiua-12307	142	14	phase	phase	NOUN
aiua-12307	142	15	iii	iii	NUM
aiua-12307	142	16	clinical	clinical	ADJ
aiua-12307	142	17	trials	trial	NOUN
aiua-12307	142	18	investigating	investigate	VERB
aiua-12307	142	19	rcc	rcc	PROPN
aiua-12307	142	20	treatment	treatment	NOUN
aiua-12307	142	21	with	with	ADP
aiua-12307	142	22	immunotherapy	immunotherapy	NOUN
aiua-12307	142	23	in	in	ADP
aiua-12307	142	24	the	the	DET
aiua-12307	142	25	adjuvant	adjuvant	ADJ
aiua-12307	142	26	setting	setting	NOUN
aiua-12307	142	27	,	,	PUNCT
aiua-12307	142	28	pending	pende	VERB
aiua-12307	142	29	or	or	CCONJ
aiua-12307	142	30	ongoing	ongoing	ADJ
aiua-12307	142	31	for	for	SCONJ
aiua-12307	142	32	data	datum	NOUN
aiua-12307	142	33	to	to	PART
aiua-12307	142	34	be	be	AUX
aiua-12307	142	35	published	publish	VERB
aiua-12307	142	36	.	.	PUNCT
aiua-12307	143	1	these	these	PRON
aiua-12307	143	2	include	include	VERB
aiua-12307	143	3	clinical	clinical	ADJ
aiua-12307	143	4	studies	study	NOUN
aiua-12307	143	5	immotion010	immotion010	PROPN
aiua-12307	143	6	(	(	PUNCT
aiua-12307	143	7	nct03024996	nct03024996	NOUN
aiua-12307	143	8	)	)	PUNCT
aiua-12307	143	9	,	,	PUNCT
aiua-12307	143	10	checkmate	checkmate	VERB
aiua-12307	143	11	914	914	NUM
aiua-12307	143	12	(	(	PUNCT
aiua-12307	143	13	nct03138512	nct03138512	NOUN
aiua-12307	143	14	)	)	PUNCT
aiua-12307	143	15	,	,	PUNCT
aiua-12307	143	16	and	and	CCONJ
aiua-12307	143	17	prosper	prosper	VERB
aiua-12307	143	18	(	(	PUNCT
aiua-12307	143	19	nct03055013	nct03055013	NOUN
aiua-12307	143	20	)	)	PUNCT
aiua-12307	143	21	(	(	PUNCT
aiua-12307	143	22	table	table	NOUN
aiua-12307	143	23	3	3	NUM
aiua-12307	143	24	)	)	PUNCT
aiua-12307	143	25	(	(	PUNCT
aiua-12307	143	26	41	41	NUM
aiua-12307	143	27	)	)	PUNCT
aiua-12307	143	28	.	.	PUNCT
aiua-12307	144	1	not	not	PART
aiua-12307	144	2	all	all	DET
aiua-12307	144	3	data	datum	NOUN
aiua-12307	144	4	published	publish	VERB
aiua-12307	144	5	in	in	ADP
aiua-12307	144	6	peer	peer	NOUN
aiua-12307	144	7	-	-	PUNCT
aiua-12307	144	8	reviewed	review	VERB
aiua-12307	144	9	journals	journal	NOUN
aiua-12307	144	10	are	be	AUX
aiua-12307	144	11	available	available	ADJ
aiua-12307	144	12	for	for	ADP
aiua-12307	144	13	these	these	DET
aiua-12307	144	14	clinical	clinical	ADJ
aiua-12307	144	15	studies	study	NOUN
aiua-12307	144	16	,	,	PUNCT
aiua-12307	144	17	but	but	CCONJ
aiua-12307	144	18	limited	limited	ADJ
aiua-12307	144	19	data	datum	NOUN
aiua-12307	144	20	were	be	AUX
aiua-12307	144	21	presented	present	VERB
aiua-12307	144	22	for	for	ADP
aiua-12307	144	23	immotion010	immotion010	PROPN
aiua-12307	144	24	,	,	PUNCT
aiua-12307	144	25	checkmate	checkmate	VERB
aiua-12307	144	26	914	914	NUM
aiua-12307	144	27	,	,	PUNCT
aiua-12307	144	28	and	and	CCONJ
aiua-12307	144	29	prosper	prosper	VERB
aiua-12307	144	30	at	at	ADP
aiua-12307	144	31	the	the	DET
aiua-12307	144	32	european	european	PROPN
aiua-12307	144	33	society	society	PROPN
aiua-12307	144	34	of	of	ADP
aiua-12307	144	35	medical	medical	ADJ
aiua-12307	144	36	oncology	oncology	NOUN
aiua-12307	144	37	(	(	PUNCT
aiua-12307	144	38	esmo	esmo	NOUN
aiua-12307	144	39	)	)	PUNCT
aiua-12307	144	40	congress	congress	PROPN
aiua-12307	144	41	in	in	ADP
aiua-12307	144	42	september	september	PROPN
aiua-12307	144	43	2022	2022	NUM
aiua-12307	144	44	.	.	PUNCT
aiua-12307	145	1	immotion010	immotion010	PROPN
aiua-12307	145	2	trial	trial	NOUN
aiua-12307	145	3	(	(	PUNCT
aiua-12307	145	4	atezolizumab	atezolizumab	PROPN
aiua-12307	145	5	)	)	PUNCT
aiua-12307	145	6	immotion010	immotion010	PROPN
aiua-12307	145	7	is	be	AUX
aiua-12307	145	8	a	a	DET
aiua-12307	145	9	randomized	randomized	ADJ
aiua-12307	145	10	placebo	placebo	NOUN
aiua-12307	145	11	-	-	PUNCT
aiua-12307	145	12	controlled	control	VERB
aiua-12307	145	13	phase	phase	NOUN
aiua-12307	145	14	iii	iii	NOUN
aiua-12307	145	15	trial	trial	NOUN
aiua-12307	145	16	evaluating	evaluate	VERB
aiua-12307	145	17	the	the	DET
aiua-12307	145	18	pd	pd	PROPN
aiua-12307	145	19	-	-	PUNCT
aiua-12307	145	20	l1	l1	PROPN
aiua-12307	145	21	inhibitor	inhibitor	NOUN
aiua-12307	145	22	atezolizumab	atezolizumab	NOUN
aiua-12307	145	23	as	as	ADP
aiua-12307	145	24	an	an	DET
aiua-12307	145	25	adjuvant	adjuvant	ADJ
aiua-12307	145	26	treatment	treatment	NOUN
aiua-12307	145	27	option	option	NOUN
aiua-12307	145	28	in	in	ADP
aiua-12307	145	29	778	778	NUM
aiua-12307	145	30	rcc	rcc	PROPN
aiua-12307	145	31	patients	patient	NOUN
aiua-12307	145	32	with	with	ADP
aiua-12307	145	33	a	a	DET
aiua-12307	145	34	clear	clear	ADJ
aiua-12307	145	35	cell	cell	NOUN
aiua-12307	145	36	or	or	CCONJ
aiua-12307	145	37	sarcomatoid	sarcomatoid	NOUN
aiua-12307	145	38	component	component	NOUN
aiua-12307	145	39	and	and	CCONJ
aiua-12307	145	40	a	a	DET
aiua-12307	145	41	high	high	ADJ
aiua-12307	145	42	risk	risk	NOUN
aiua-12307	145	43	of	of	ADP
aiua-12307	145	44	recurrence	recurrence	NOUN
aiua-12307	145	45	.	.	PUNCT
aiua-12307	146	1	immotion010	immotion010	PROPN
aiua-12307	146	2	is	be	AUX
aiua-12307	146	3	the	the	DET
aiua-12307	146	4	first	first	ADJ
aiua-12307	146	5	adjuvant	adjuvant	ADJ
aiua-12307	146	6	ici	ici	PROPN
aiua-12307	146	7	study	study	NOUN
aiua-12307	146	8	to	to	PART
aiua-12307	146	9	investigate	investigate	VERB
aiua-12307	146	10	the	the	DET
aiua-12307	146	11	efficacy	efficacy	NOUN
aiua-12307	146	12	of	of	ADP
aiua-12307	146	13	a	a	DET
aiua-12307	146	14	pd	pd	PROPN
aiua-12307	146	15	-	-	PUNCT
aiua-12307	146	16	l1	l1	PROPN
aiua-12307	146	17	inhibitor	inhibitor	NOUN
aiua-12307	146	18	in	in	ADP
aiua-12307	146	19	terms	term	NOUN
aiua-12307	146	20	of	of	ADP
aiua-12307	146	21	dfs	dfs	NOUN
aiua-12307	146	22	and	and	CCONJ
aiua-12307	146	23	os	os	NOUN
aiua-12307	146	24	in	in	ADP
aiua-12307	146	25	rcc	rcc	PROPN
aiua-12307	146	26	.	.	PUNCT
aiua-12307	147	1	however	however	ADV
aiua-12307	147	2	,	,	PUNCT
aiua-12307	147	3	the	the	DET
aiua-12307	147	4	study	study	NOUN
aiua-12307	147	5	did	do	AUX
aiua-12307	147	6	not	not	PART
aiua-12307	147	7	reach	reach	VERB
aiua-12307	147	8	its	its	PRON
aiua-12307	147	9	primary	primary	ADJ
aiua-12307	147	10	endpoint	endpoint	NOUN
aiua-12307	147	11	,	,	PUNCT
aiua-12307	147	12	with	with	ADP
aiua-12307	147	13	a	a	DET
aiua-12307	147	14	mean	mean	ADJ
aiua-12307	147	15	dfs	dfs	NOUN
aiua-12307	147	16	of	of	ADP
aiua-12307	147	17	57.2	57.2	NUM
aiua-12307	147	18	mo	mo	NOUN
aiua-12307	147	19	.	.	PROPN
aiua-12307	147	20	in	in	ADP
aiua-12307	147	21	the	the	DET
aiua-12307	147	22	atezolizumab	atezolizumab	NOUN
aiua-12307	147	23	arm	arm	NOUN
aiua-12307	147	24	vs	vs	ADP
aiua-12307	147	25	49.5	49.5	NUM
aiua-12307	147	26	mo	mo	NOUN
aiua-12307	147	27	.	.	PROPN
aiua-12307	148	1	in	in	ADP
aiua-12307	148	2	the	the	DET
aiua-12307	148	3	placebo	placebo	NOUN
aiua-12307	148	4	arm	arm	NOUN
aiua-12307	149	1	[	[	X
aiua-12307	149	2	hr	hr	NOUN
aiua-12307	149	3	0.93	0.93	NUM
aiua-12307	149	4	95	95	NUM
aiua-12307	149	5	%	%	NOUN
aiua-12307	149	6	ci	ci	NOUN
aiua-12307	149	7	0.751.15	0.751.15	NOUN
aiua-12307	149	8	;	;	PUNCT
aiua-12307	149	9	p	p	X
aiua-12307	149	10	=	=	NOUN
aiua-12307	149	11	0.495	0.495	NUM
aiua-12307	149	12	]	]	PUNCT
aiua-12307	149	13	(	(	PUNCT
aiua-12307	149	14	42	42	NUM
aiua-12307	149	15	)	)	PUNCT
aiua-12307	149	16	.	.	PUNCT
aiua-12307	150	1	no	no	DET
aiua-12307	150	2	dfs	dfs	PROPN
aiua-12307	150	3	improvement	improvement	NOUN
aiua-12307	150	4	was	be	AUX
aiua-12307	150	5	detected	detect	VERB
aiua-12307	150	6	with	with	ADP
aiua-12307	150	7	atezolizumab	atezolizumab	NOUN
aiua-12307	150	8	in	in	ADP
aiua-12307	150	9	any	any	DET
aiua-12307	150	10	investigational	investigational	ADJ
aiua-12307	150	11	subgroups	subgroup	NOUN
aiua-12307	150	12	.	.	PUNCT
aiua-12307	151	1	grade	grade	NOUN
aiua-12307	151	2	≥	≥	PROPN
aiua-12307	151	3	3	3	NUM
aiua-12307	151	4	aes	aes	NOUN
aiua-12307	151	5	were	be	AUX
aiua-12307	151	6	reported	report	VERB
aiua-12307	151	7	in	in	ADP
aiua-12307	151	8	27	27	NUM
aiua-12307	151	9	%	%	NOUN
aiua-12307	151	10	and	and	CCONJ
aiua-12307	151	11	21	21	NUM
aiua-12307	151	12	%	%	NOUN
aiua-12307	151	13	of	of	ADP
aiua-12307	151	14	patients	patient	NOUN
aiua-12307	151	15	in	in	ADP
aiua-12307	151	16	the	the	DET
aiua-12307	151	17	atezolizumab	atezolizumab	NOUN
aiua-12307	151	18	and	and	CCONJ
aiua-12307	151	19	placebo	placebo	NOUN
aiua-12307	151	20	groups	group	NOUN
aiua-12307	151	21	,	,	PUNCT
aiua-12307	151	22	respectively	respectively	ADV
aiua-12307	151	23	.	.	PUNCT
aiua-12307	152	1	the	the	DET
aiua-12307	152	2	most	most	ADV
aiua-12307	152	3	common	common	ADJ
aiua-12307	152	4	grade	grade	NOUN
aiua-12307	152	5	3	3	NUM
aiua-12307	152	6	-	-	SYM
aiua-12307	152	7	4	4	NUM
aiua-12307	152	8	aes	aes	NOUN
aiua-12307	152	9	were	be	AUX
aiua-12307	152	10	hypertension	hypertension	NOUN
aiua-12307	152	11	,	,	PUNCT
aiua-12307	152	12	hyperglycemia	hyperglycemia	NOUN
aiua-12307	152	13	(	(	PUNCT
aiua-12307	152	14	3	3	NUM
aiua-12307	152	15	%	%	NOUN
aiua-12307	152	16	vs	vs	ADP
aiua-12307	152	17	2	2	NUM
aiua-12307	152	18	%	%	NOUN
aiua-12307	152	19	)	)	PUNCT
aiua-12307	152	20	,	,	PUNCT
aiua-12307	152	21	and	and	CCONJ
aiua-12307	152	22	diarrhoea	diarrhoea	NOUN
aiua-12307	152	23	(	(	PUNCT
aiua-12307	152	24	1	1	NUM
aiua-12307	152	25	%	%	NOUN
aiua-12307	152	26	vs	vs	ADP
aiua-12307	152	27	2	2	NUM
aiua-12307	152	28	%	%	NOUN
aiua-12307	152	29	)	)	PUNCT
aiua-12307	152	30	,	,	PUNCT
aiua-12307	152	31	observed	observe	VERB
aiua-12307	152	32	in	in	ADP
aiua-12307	152	33	2	2	NUM
aiua-12307	152	34	%	%	NOUN
aiua-12307	152	35	vs	vs	ADP
aiua-12307	152	36	archivio	archivio	NOUN
aiua-12307	152	37	italiano	italiano	X
aiua-12307	152	38	di	di	X
aiua-12307	152	39	urologia	urologia	PROPN
aiua-12307	152	40	e	e	PROPN
aiua-12307	152	41	andrologia	andrologia	NOUN
aiua-12307	152	42	2024	2024	NUM
aiua-12307	152	43	;	;	PUNCT
aiua-12307	152	44	96(2):12307	96(2):12307	NUM
aiua-12307	152	45	5	5	NUM
aiua-12307	152	46	the	the	DET
aiua-12307	152	47	role	role	NOUN
aiua-12307	152	48	of	of	ADP
aiua-12307	152	49	immunotherapy	immunotherapy	NOUN
aiua-12307	152	50	in	in	ADP
aiua-12307	152	51	urological	urological	ADJ
aiua-12307	152	52	cancers	cancer	NOUN
aiua-12307	152	53	15	15	NUM
aiua-12307	152	54	%	%	NOUN
aiua-12307	152	55	of	of	ADP
aiua-12307	152	56	patients	patient	NOUN
aiua-12307	152	57	in	in	ADP
aiua-12307	152	58	the	the	DET
aiua-12307	152	59	atezolizumab	atezolizumab	NOUN
aiua-12307	152	60	vs	vs	ADP
aiua-12307	152	61	the	the	DET
aiua-12307	152	62	placebo	placebo	NOUN
aiua-12307	152	63	group	group	NOUN
aiua-12307	152	64	,	,	PUNCT
aiua-12307	152	65	respectively	respectively	ADV
aiua-12307	152	66	(	(	PUNCT
aiua-12307	152	67	43	43	NUM
aiua-12307	152	68	)	)	PUNCT
aiua-12307	152	69	.	.	PUNCT
aiua-12307	153	1	checkmate	checkmate	VERB
aiua-12307	153	2	914	914	NUM
aiua-12307	153	3	trial	trial	NOUN
aiua-12307	153	4	(	(	PUNCT
aiua-12307	153	5	nivolumab	nivolumab	NOUN
aiua-12307	153	6	/	/	SYM
aiua-12307	153	7	ipilimumab	ipilimumab	NOUN
aiua-12307	153	8	)	)	PUNCT
aiua-12307	153	9	checkmate	checkmate	VERB
aiua-12307	153	10	914	914	NUM
aiua-12307	153	11	is	be	AUX
aiua-12307	153	12	a	a	DET
aiua-12307	153	13	phase	phase	NOUN
aiua-12307	153	14	iii	iii	NOUN
aiua-12307	153	15	randomized	randomized	ADJ
aiua-12307	153	16	placebo	placebo	NOUN
aiua-12307	153	17	-	-	PUNCT
aiua-12307	153	18	controlled	control	VERB
aiua-12307	153	19	two	two	NUM
aiua-12307	153	20	-	-	PUNCT
aiua-12307	153	21	part	part	NOUN
aiua-12307	153	22	study	study	NOUN
aiua-12307	153	23	examining	examine	VERB
aiua-12307	153	24	the	the	DET
aiua-12307	153	25	effectiveness	effectiveness	NOUN
aiua-12307	153	26	of	of	ADP
aiua-12307	153	27	adjuvant	adjuvant	ADJ
aiua-12307	153	28	nivolumab	nivolumab	NOUN
aiua-12307	153	29	and	and	CCONJ
aiua-12307	153	30	nivolumab	nivolumab	ADV
aiua-12307	153	31	/	/	SYM
aiua-12307	153	32	ipilimumab	ipilimumab	NOUN
aiua-12307	153	33	in	in	ADP
aiua-12307	153	34	patients	patient	NOUN
aiua-12307	153	35	with	with	ADP
aiua-12307	153	36	clear	clear	ADJ
aiua-12307	153	37	cell	cell	NOUN
aiua-12307	153	38	rcc	rcc	NOUN
aiua-12307	153	39	at	at	ADP
aiua-12307	153	40	high	high	ADJ
aiua-12307	153	41	risk	risk	NOUN
aiua-12307	153	42	of	of	ADP
aiua-12307	153	43	recurrence	recurrence	NOUN
aiua-12307	153	44	after	after	ADP
aiua-12307	153	45	nephrectomy	nephrectomy	NOUN
aiua-12307	153	46	(	(	PUNCT
aiua-12307	153	47	44	44	NUM
aiua-12307	153	48	)	)	PUNCT
aiua-12307	153	49	.	.	PUNCT
aiua-12307	154	1	results	result	NOUN
aiua-12307	154	2	of	of	ADP
aiua-12307	154	3	the	the	DET
aiua-12307	154	4	part	part	NOUN
aiua-12307	154	5	a	a	DET
aiua-12307	154	6	study	study	NOUN
aiua-12307	154	7	were	be	AUX
aiua-12307	154	8	reported	report	VERB
aiua-12307	154	9	at	at	ADP
aiua-12307	154	10	esmo	esmo	NOUN
aiua-12307	154	11	congress	congress	PROPN
aiua-12307	154	12	2022	2022	NUM
aiua-12307	154	13	;	;	PUNCT
aiua-12307	154	14	816	816	NUM
aiua-12307	154	15	patients	patient	NOUN
aiua-12307	154	16	were	be	AUX
aiua-12307	154	17	randomized	randomize	VERB
aiua-12307	154	18	to	to	ADP
aiua-12307	154	19	nivolumab	nivolumab	NOUN
aiua-12307	154	20	/	/	SYM
aiua-12307	154	21	ipilimumab	ipilimumab	NOUN
aiua-12307	154	22	or	or	CCONJ
aiua-12307	154	23	placebo	placebo	NOUN
aiua-12307	154	24	.	.	PUNCT
aiua-12307	155	1	the	the	DET
aiua-12307	155	2	study	study	NOUN
aiua-12307	155	3	evaluated	evaluate	VERB
aiua-12307	155	4	12	12	NUM
aiua-12307	155	5	cycles	cycle	NOUN
aiua-12307	155	6	of	of	ADP
aiua-12307	155	7	nivolumab	nivolumab	NOUN
aiua-12307	155	8	at	at	ADP
aiua-12307	155	9	240	240	NUM
aiua-12307	155	10	mg	mg	NOUN
aiua-12307	155	11	every	every	DET
aiua-12307	155	12	two	two	NUM
aiua-12307	155	13	weeks	week	NOUN
aiua-12307	155	14	for	for	ADP
aiua-12307	155	15	six	six	NUM
aiua-12307	155	16	mo	mo	PROPN
aiua-12307	155	17	.	.	PROPN
aiua-12307	155	18	plus	plus	CCONJ
aiua-12307	155	19	ipilimumab	ipilimumab	VERB
aiua-12307	155	20	at	at	ADP
aiua-12307	155	21	1	1	NUM
aiua-12307	155	22	mg	mg	PROPN
aiua-12307	155	23	/	/	SYM
aiua-12307	155	24	kg	kg	NOUN
aiua-12307	155	25	every	every	DET
aiua-12307	155	26	six	six	NUM
aiua-12307	155	27	weeks	week	NOUN
aiua-12307	155	28	for	for	ADP
aiua-12307	155	29	four	four	NUM
aiua-12307	155	30	cycles	cycle	NOUN
aiua-12307	155	31	vs	vs	ADP
aiua-12307	155	32	placebo	placebo	NOUN
aiua-12307	155	33	as	as	ADP
aiua-12307	155	34	adjuvant	adjuvant	ADJ
aiua-12307	155	35	therapy	therapy	NOUN
aiua-12307	155	36	for	for	ADP
aiua-12307	155	37	816	816	NUM
aiua-12307	155	38	patients	patient	NOUN
aiua-12307	155	39	.	.	PUNCT
aiua-12307	156	1	at	at	ADP
aiua-12307	156	2	a	a	DET
aiua-12307	156	3	median	median	ADJ
aiua-12307	156	4	follow	follow	NOUN
aiua-12307	156	5	-	-	PUNCT
aiua-12307	156	6	up	up	NOUN
aiua-12307	156	7	of	of	ADP
aiua-12307	156	8	37	37	NUM
aiua-12307	156	9	mo	mo	PROPN
aiua-12307	156	10	.	.	PROPN
aiua-12307	156	11	,	,	PUNCT
aiua-12307	156	12	dfs	dfs	PROPN
aiua-12307	156	13	was	be	AUX
aiua-12307	156	14	similar	similar	ADJ
aiua-12307	156	15	between	between	ADP
aiua-12307	156	16	patients	patient	NOUN
aiua-12307	156	17	in	in	ADP
aiua-12307	156	18	both	both	DET
aiua-12307	156	19	arms	arm	NOUN
aiua-12307	156	20	,	,	PUNCT
aiua-12307	156	21	and	and	CCONJ
aiua-12307	156	22	the	the	DET
aiua-12307	156	23	study	study	NOUN
aiua-12307	156	24	did	do	AUX
aiua-12307	156	25	not	not	PART
aiua-12307	156	26	meet	meet	VERB
aiua-12307	156	27	its	its	PRON
aiua-12307	156	28	primary	primary	ADJ
aiua-12307	156	29	endpoint	endpoint	NOUN
aiua-12307	156	30	(	(	PUNCT
aiua-12307	156	31	hr	hr	NOUN
aiua-12307	156	32	0.92	0.92	NUM
aiua-12307	156	33	,	,	PUNCT
aiua-12307	156	34	95	95	NUM
aiua-12307	156	35	%	%	NOUN
aiua-12307	156	36	ci	ci	NOUN
aiua-12307	156	37	0.71	0.71	NUM
aiua-12307	156	38	-	-	SYM
aiua-12307	156	39	1.91	1.91	NUM
aiua-12307	156	40	;	;	PUNCT
aiua-12307	156	41	p	p	X
aiua-12307	156	42	=	=	NOUN
aiua-12307	156	43	0.5347	0.5347	NUM
aiua-12307	156	44	)	)	PUNCT
aiua-12307	156	45	.	.	PUNCT
aiua-12307	157	1	os	os	NOUN
aiua-12307	157	2	analysis	analysis	NOUN
aiua-12307	157	3	could	could	AUX
aiua-12307	157	4	not	not	PART
aiua-12307	157	5	be	be	AUX
aiua-12307	157	6	performed	perform	VERB
aiua-12307	157	7	due	due	ADP
aiua-12307	157	8	to	to	ADP
aiua-12307	157	9	a	a	DET
aiua-12307	157	10	hierarchical	hierarchical	ADJ
aiua-12307	157	11	study	study	NOUN
aiua-12307	157	12	design	design	NOUN
aiua-12307	157	13	.	.	PUNCT
aiua-12307	158	1	the	the	DET
aiua-12307	158	2	incidence	incidence	NOUN
aiua-12307	158	3	of	of	ADP
aiua-12307	158	4	treatment	treatment	NOUN
aiua-12307	158	5	-	-	PUNCT
aiua-12307	158	6	related	relate	VERB
aiua-12307	158	7	grade	grade	NOUN
aiua-12307	158	8	3	3	NUM
aiua-12307	158	9	aes	aes	NOUN
aiua-12307	158	10	was	be	AUX
aiua-12307	158	11	29	29	NUM
aiua-12307	158	12	%	%	NOUN
aiua-12307	158	13	in	in	ADP
aiua-12307	158	14	the	the	DET
aiua-12307	158	15	nivolumab	nivolumab	NOUN
aiua-12307	158	16	/	/	SYM
aiua-12307	158	17	ipilimumab	ipilimumab	NOUN
aiua-12307	158	18	group	group	NOUN
aiua-12307	158	19	and	and	CCONJ
aiua-12307	158	20	2	2	NUM
aiua-12307	158	21	%	%	NOUN
aiua-12307	158	22	in	in	ADP
aiua-12307	158	23	the	the	DET
aiua-12307	158	24	placebo	placebo	NOUN
aiua-12307	158	25	group	group	NOUN
aiua-12307	158	26	,	,	PUNCT
aiua-12307	158	27	with	with	ADP
aiua-12307	158	28	4	4	NUM
aiua-12307	158	29	(	(	PUNCT
aiua-12307	158	30	1	1	NUM
aiua-12307	158	31	%	%	NOUN
aiua-12307	158	32	)	)	PUNCT
aiua-12307	158	33	deaths	death	NOUN
aiua-12307	158	34	considered	consider	VERB
aiua-12307	158	35	to	to	PART
aiua-12307	158	36	be	be	AUX
aiua-12307	158	37	related	relate	VERB
aiua-12307	158	38	to	to	ADP
aiua-12307	158	39	combination	combination	NOUN
aiua-12307	158	40	therapy	therapy	NOUN
aiua-12307	158	41	.	.	PUNCT
aiua-12307	159	1	the	the	DET
aiua-12307	159	2	high	high	ADJ
aiua-12307	159	3	discontinuation	discontinuation	NOUN
aiua-12307	159	4	rate	rate	NOUN
aiua-12307	159	5	of	of	ADP
aiua-12307	159	6	33	33	NUM
aiua-12307	159	7	%	%	NOUN
aiua-12307	159	8	in	in	ADP
aiua-12307	159	9	checkmate	checkmate	NOUN
aiua-12307	159	10	914	914	NUM
aiua-12307	159	11	is	be	AUX
aiua-12307	159	12	concerning	concern	VERB
aiua-12307	159	13	and	and	CCONJ
aiua-12307	159	14	may	may	AUX
aiua-12307	159	15	negatively	negatively	ADV
aiua-12307	159	16	impact	impact	VERB
aiua-12307	159	17	the	the	DET
aiua-12307	159	18	study	study	NOUN
aiua-12307	159	19	's	's	PART
aiua-12307	159	20	effectiveness	effectiveness	NOUN
aiua-12307	159	21	(	(	PUNCT
aiua-12307	159	22	45	45	NUM
aiua-12307	159	23	,	,	PUNCT
aiua-12307	159	24	46	46	NUM
aiua-12307	159	25	)	)	PUNCT
aiua-12307	159	26	.	.	PUNCT
aiua-12307	160	1	based	base	VERB
aiua-12307	160	2	on	on	ADP
aiua-12307	160	3	these	these	DET
aiua-12307	160	4	data	datum	NOUN
aiua-12307	160	5	,	,	PUNCT
aiua-12307	160	6	ici	ici	PROPN
aiua-12307	160	7	/	/	SYM
aiua-12307	160	8	ici	ici	NOUN
aiua-12307	160	9	combination	combination	NOUN
aiua-12307	160	10	therapy	therapy	NOUN
aiua-12307	160	11	appears	appear	VERB
aiua-12307	160	12	to	to	PART
aiua-12307	160	13	increase	increase	VERB
aiua-12307	160	14	risk	risk	NOUN
aiua-12307	160	15	rather	rather	ADV
aiua-12307	160	16	than	than	ADP
aiua-12307	160	17	benefit	benefit	VERB
aiua-12307	160	18	and	and	CCONJ
aiua-12307	160	19	is	be	AUX
aiua-12307	160	20	unlikely	unlikely	ADJ
aiua-12307	160	21	to	to	PART
aiua-12307	160	22	be	be	AUX
aiua-12307	160	23	introduced	introduce	VERB
aiua-12307	160	24	into	into	ADP
aiua-12307	160	25	clinical	clinical	ADJ
aiua-12307	160	26	practice	practice	NOUN
aiua-12307	160	27	.	.	PUNCT
aiua-12307	161	1	prosper	prosper	NOUN
aiua-12307	161	2	trial	trial	NOUN
aiua-12307	161	3	(	(	PUNCT
aiua-12307	161	4	peroperative	peroperative	ADJ
aiua-12307	161	5	nivolumab	nivolumab	NOUN
aiua-12307	161	6	)	)	PUNCT
aiua-12307	161	7	prosper	prosper	NOUN
aiua-12307	161	8	is	be	AUX
aiua-12307	161	9	a	a	DET
aiua-12307	161	10	perioperative	perioperative	ADJ
aiua-12307	161	11	phase	phase	NOUN
aiua-12307	161	12	iii	iii	NUM
aiua-12307	161	13	randomized	randomized	ADJ
aiua-12307	161	14	study	study	NOUN
aiua-12307	161	15	comparing	compare	VERB
aiua-12307	161	16	neoadjuvant	neoadjuvant	ADJ
aiua-12307	161	17	nivolumab	nivolumab	NOUN
aiua-12307	161	18	(	(	PUNCT
aiua-12307	161	19	1	1	NUM
aiua-12307	161	20	cycle	cycle	NOUN
aiua-12307	161	21	)	)	PUNCT
aiua-12307	161	22	followed	follow	VERB
aiua-12307	161	23	by	by	ADP
aiua-12307	161	24	radical	radical	ADJ
aiua-12307	161	25	/	/	SYM
aiua-12307	161	26	partial	partial	ADJ
aiua-12307	161	27	nephrectomy	nephrectomy	ADJ
aiua-12307	161	28	and	and	CCONJ
aiua-12307	161	29	postsurgical	postsurgical	ADJ
aiua-12307	161	30	follow	follow	NOUN
aiua-12307	161	31	-	-	PUNCT
aiua-12307	161	32	up	up	NOUN
aiua-12307	161	33	with	with	ADP
aiua-12307	161	34	the	the	DET
aiua-12307	161	35	group	group	NOUN
aiua-12307	161	36	receiving	receive	VERB
aiua-12307	161	37	nine	nine	NUM
aiua-12307	161	38	doses	dose	NOUN
aiua-12307	161	39	of	of	ADP
aiua-12307	161	40	adjuvant	adjuvant	ADJ
aiua-12307	161	41	nivolumab	nivolumab	NOUN
aiua-12307	161	42	(	(	PUNCT
aiua-12307	161	43	480	480	NUM
aiua-12307	161	44	mg	mg	NUM
aiua-12307	161	45	iv	iv	NUM
aiua-12307	161	46	every	every	DET
aiua-12307	161	47	four	four	NUM
aiua-12307	161	48	weeks	week	NOUN
aiua-12307	161	49	)	)	PUNCT
aiua-12307	161	50	.	.	PUNCT
aiua-12307	162	1	the	the	DET
aiua-12307	162	2	study	study	NOUN
aiua-12307	162	3	included	include	VERB
aiua-12307	162	4	819	819	NUM
aiua-12307	162	5	high	high	ADJ
aiua-12307	162	6	-	-	PUNCT
aiua-12307	162	7	risk	risk	NOUN
aiua-12307	162	8	patients	patient	NOUN
aiua-12307	162	9	,	,	PUNCT
aiua-12307	162	10	defined	define	VERB
aiua-12307	162	11	as	as	ADP
aiua-12307	162	12	≥t2	≥t2	NUM
aiua-12307	162	13	or	or	CCONJ
aiua-12307	162	14	t	t	X
aiua-12307	162	15	any	any	DET
aiua-12307	162	16	pn+	pn+	NOUN
aiua-12307	162	17	rcc	rcc	NOUN
aiua-12307	162	18	of	of	ADP
aiua-12307	162	19	any	any	DET
aiua-12307	162	20	histology	histology	NOUN
aiua-12307	162	21	,	,	PUNCT
aiua-12307	162	22	for	for	ADP
aiua-12307	162	23	whom	whom	PRON
aiua-12307	162	24	radical	radical	ADJ
aiua-12307	162	25	/	/	SYM
aiua-12307	162	26	partial	partial	ADJ
aiua-12307	162	27	nephrectomy	nephrectomy	NOUN
aiua-12307	162	28	was	be	AUX
aiua-12307	162	29	planned	plan	VERB
aiua-12307	162	30	.	.	PUNCT
aiua-12307	163	1	most	most	ADJ
aiua-12307	163	2	patients	patient	NOUN
aiua-12307	163	3	had	have	VERB
aiua-12307	163	4	clear	clear	ADJ
aiua-12307	163	5	cell	cell	NOUN
aiua-12307	163	6	histology	histology	NOUN
aiua-12307	163	7	(	(	PUNCT
aiua-12307	163	8	78	78	NUM
aiua-12307	163	9	%	%	NOUN
aiua-12307	163	10	)	)	PUNCT
aiua-12307	163	11	,	,	PUNCT
aiua-12307	163	12	8	8	NUM
aiua-12307	163	13	%	%	NOUN
aiua-12307	163	14	had	have	VERB
aiua-12307	163	15	papillary	papillary	NOUN
aiua-12307	163	16	,	,	PUNCT
aiua-12307	163	17	and	and	CCONJ
aiua-12307	163	18	7	7	NUM
aiua-12307	163	19	%	%	NOUN
aiua-12307	163	20	had	have	VERB
aiua-12307	163	21	chromophobe	chromophobe	NOUN
aiua-12307	163	22	histology	histology	NOUN
aiua-12307	163	23	.	.	PUNCT
aiua-12307	164	1	the	the	DET
aiua-12307	164	2	primary	primary	ADJ
aiua-12307	164	3	endpoint	endpoint	NOUN
aiua-12307	164	4	of	of	ADP
aiua-12307	164	5	the	the	DET
aiua-12307	164	6	study	study	NOUN
aiua-12307	164	7	was	be	AUX
aiua-12307	164	8	relapse	relapse	NOUN
aiua-12307	164	9	-	-	PUNCT
aiua-12307	164	10	free	free	ADJ
aiua-12307	164	11	survival	survival	NOUN
aiua-12307	164	12	.	.	PUNCT
aiua-12307	165	1	an	an	DET
aiua-12307	165	2	interim	interim	ADJ
aiua-12307	165	3	analysis	analysis	NOUN
aiua-12307	165	4	at	at	ADP
aiua-12307	165	5	16	16	NUM
aiua-12307	165	6	mo	mo	PROPN
aiua-12307	165	7	.	.	PROPN
aiua-12307	165	8	of	of	ADP
aiua-12307	165	9	follow	follow	VERB
aiua-12307	165	10	-	-	PUNCT
aiua-12307	165	11	up	up	NOUN
aiua-12307	165	12	showed	show	VERB
aiua-12307	165	13	that	that	SCONJ
aiua-12307	165	14	the	the	DET
aiua-12307	165	15	addition	addition	NOUN
aiua-12307	165	16	of	of	ADP
aiua-12307	165	17	perioperative	perioperative	ADJ
aiua-12307	165	18	nivolumab	nivolumab	NOUN
aiua-12307	165	19	did	do	AUX
aiua-12307	165	20	not	not	PART
aiua-12307	165	21	improve	improve	VERB
aiua-12307	165	22	relapse	relapse	NOUN
aiua-12307	165	23	-	-	PUNCT
aiua-12307	165	24	free	free	ADJ
aiua-12307	165	25	survival	survival	NOUN
aiua-12307	165	26	compared	compare	VERB
aiua-12307	165	27	with	with	ADP
aiua-12307	165	28	standard	standard	NOUN
aiua-12307	165	29	of	of	ADP
aiua-12307	165	30	care	care	NOUN
aiua-12307	165	31	surgery	surgery	NOUN
aiua-12307	165	32	,	,	PUNCT
aiua-12307	165	33	and	and	CCONJ
aiua-12307	165	34	the	the	DET
aiua-12307	165	35	study	study	NOUN
aiua-12307	165	36	was	be	AUX
aiua-12307	165	37	stopped	stop	VERB
aiua-12307	165	38	early	early	ADV
aiua-12307	165	39	due	due	ADJ
aiua-12307	165	40	to	to	ADP
aiua-12307	165	41	lack	lack	NOUN
aiua-12307	165	42	of	of	ADP
aiua-12307	165	43	efficacy	efficacy	NOUN
aiua-12307	165	44	(	(	PUNCT
aiua-12307	165	45	hr	hr	NOUN
aiua-12307	165	46	0.97	0.97	NUM
aiua-12307	165	47	[	[	SYM
aiua-12307	165	48	95	95	NUM
aiua-12307	165	49	%	%	NOUN
aiua-12307	165	50	ci	ci	NOUN
aiua-12307	165	51	:	:	PUNCT
aiua-12307	165	52	0.74	0.74	NUM
aiua-12307	165	53	-	-	SYM
aiua-12307	165	54	1.28	1.28	NUM
aiua-12307	165	55	]	]	PUNCT
aiua-12307	165	56	,	,	PUNCT
aiua-12307	165	57	p	p	X
aiua-12307	165	58	=	=	NOUN
aiua-12307	165	59	0.43	0.43	NUM
aiua-12307	165	60	)	)	PUNCT
aiua-12307	165	61	(	(	PUNCT
aiua-12307	165	62	37	37	NUM
aiua-12307	165	63	)	)	PUNCT
aiua-12307	165	64	.	.	PUNCT
aiua-12307	166	1	as	as	ADP
aiua-12307	166	2	a	a	DET
aiua-12307	166	3	result	result	NOUN
aiua-12307	166	4	,	,	PUNCT
aiua-12307	166	5	single	single	ADJ
aiua-12307	166	6	-	-	PUNCT
aiua-12307	166	7	agent	agent	NOUN
aiua-12307	166	8	neoadjuvant	neoadjuvant	ADJ
aiua-12307	166	9	immunotherapy	immunotherapy	NOUN
aiua-12307	166	10	does	do	AUX
aiua-12307	166	11	not	not	PART
aiua-12307	166	12	currently	currently	ADV
aiua-12307	166	13	have	have	VERB
aiua-12307	166	14	any	any	DET
aiua-12307	166	15	role	role	NOUN
aiua-12307	166	16	in	in	ADP
aiua-12307	166	17	the	the	DET
aiua-12307	166	18	treatment	treatment	NOUN
aiua-12307	166	19	of	of	ADP
aiua-12307	166	20	ccrcc	ccrcc	NOUN
aiua-12307	166	21	.	.	PUNCT
aiua-12307	167	1	treatment	treatment	NOUN
aiua-12307	167	2	of	of	ADP
aiua-12307	167	3	mrcc	mrcc	NOUN
aiua-12307	167	4	(	(	PUNCT
aiua-12307	167	5	ici	ici	NOUN
aiua-12307	167	6	monotherapy	monotherapy	NOUN
aiua-12307	167	7	/	/	SYM
aiua-12307	167	8	combination	combination	NOUN
aiua-12307	167	9	therapy	therapy	NOUN
aiua-12307	167	10	)	)	PUNCT
aiua-12307	167	11	several	several	ADJ
aiua-12307	167	12	positive	positive	ADJ
aiua-12307	167	13	phase	phase	NOUN
aiua-12307	167	14	iii	iii	NUM
aiua-12307	167	15	trials	trial	NOUN
aiua-12307	167	16	of	of	ADP
aiua-12307	167	17	ici	ici	PROPN
aiua-12307	167	18	/	/	SYM
aiua-12307	167	19	ici	ici	PROPN
aiua-12307	167	20	or	or	CCONJ
aiua-12307	167	21	ici	ici	PROPN
aiua-12307	167	22	/	/	SYM
aiua-12307	167	23	tyrosine	tyrosine	PROPN
aiua-12307	167	24	kinase	kinase	PROPN
aiua-12307	167	25	inhibitor	inhibitor	PROPN
aiua-12307	167	26	(	(	PUNCT
aiua-12307	167	27	tki	tki	NOUN
aiua-12307	167	28	)	)	PUNCT
aiua-12307	167	29	dual	dual	ADJ
aiua-12307	167	30	combinations	combination	NOUN
aiua-12307	167	31	have	have	AUX
aiua-12307	167	32	established	establish	VERB
aiua-12307	167	33	the	the	DET
aiua-12307	167	34	current	current	ADJ
aiua-12307	167	35	treatment	treatment	NOUN
aiua-12307	167	36	paradigm	paradigm	NOUN
aiua-12307	167	37	for	for	ADP
aiua-12307	167	38	mrcc	mrcc	NOUN
aiua-12307	167	39	,	,	PUNCT
aiua-12307	167	40	all	all	PRON
aiua-12307	167	41	demonstrating	demonstrate	VERB
aiua-12307	167	42	superior	superior	ADJ
aiua-12307	167	43	clinical	clinical	ADJ
aiua-12307	167	44	benefits	benefit	NOUN
aiua-12307	167	45	,	,	PUNCT
aiua-12307	167	46	including	include	VERB
aiua-12307	167	47	os	os	NOUN
aiua-12307	167	48	,	,	PUNCT
aiua-12307	167	49	compared	compare	VERB
aiua-12307	167	50	to	to	ADP
aiua-12307	167	51	sunitinib	sunitinib	NOUN
aiua-12307	167	52	monotherapy	monotherapy	NOUN
aiua-12307	167	53	(	(	PUNCT
aiua-12307	167	54	47	47	NUM
aiua-12307	167	55	)	)	PUNCT
aiua-12307	167	56	.	.	PUNCT
aiua-12307	168	1	ici	ici	NOUN
aiua-12307	168	2	combination	combination	NOUN
aiua-12307	168	3	therapies	therapy	NOUN
aiua-12307	168	4	have	have	AUX
aiua-12307	168	5	become	become	VERB
aiua-12307	168	6	the	the	DET
aiua-12307	168	7	standard	standard	ADJ
aiua-12307	168	8	first	first	ADJ
aiua-12307	168	9	-	-	PUNCT
aiua-12307	168	10	line	line	NOUN
aiua-12307	168	11	treatment	treatment	NOUN
aiua-12307	168	12	of	of	ADP
aiua-12307	168	13	mrcc	mrcc	NOUN
aiua-12307	168	14	.	.	PUNCT
aiua-12307	169	1	these	these	DET
aiua-12307	169	2	combinations	combination	NOUN
aiua-12307	169	3	include	include	VERB
aiua-12307	169	4	a	a	DET
aiua-12307	169	5	dual	dual	ADJ
aiua-12307	169	6	ici	ici	NOUN
aiua-12307	169	7	blockade	blockade	NOUN
aiua-12307	169	8	or	or	CCONJ
aiua-12307	169	9	a	a	DET
aiua-12307	169	10	single	single	ADJ
aiua-12307	169	11	ici	ici	NOUN
aiua-12307	169	12	combined	combine	VERB
aiua-12307	169	13	with	with	ADP
aiua-12307	169	14	a	a	DET
aiua-12307	169	15	tki	tki	X
aiua-12307	169	16	(	(	PUNCT
aiua-12307	169	17	48	48	NUM
aiua-12307	169	18	)	)	PUNCT
aiua-12307	169	19	.	.	PUNCT
aiua-12307	170	1	a	a	DET
aiua-12307	170	2	direct	direct	ADJ
aiua-12307	170	3	comparison	comparison	NOUN
aiua-12307	170	4	between	between	ADP
aiua-12307	170	5	combination	combination	NOUN
aiua-12307	170	6	regimes	regime	NOUN
aiua-12307	170	7	is	be	AUX
aiua-12307	170	8	not	not	PART
aiua-12307	170	9	currently	currently	ADV
aiua-12307	170	10	available	available	ADJ
aiua-12307	170	11	;	;	PUNCT
aiua-12307	170	12	therefore	therefore	ADV
aiua-12307	170	13	,	,	PUNCT
aiua-12307	170	14	the	the	DET
aiua-12307	170	15	choice	choice	NOUN
aiua-12307	170	16	of	of	ADP
aiua-12307	170	17	first	first	ADJ
aiua-12307	170	18	-	-	PUNCT
aiua-12307	170	19	line	line	NOUN
aiua-12307	170	20	treatment	treatment	NOUN
aiua-12307	170	21	for	for	ADP
aiua-12307	170	22	each	each	DET
aiua-12307	170	23	patient	patient	NOUN
aiua-12307	170	24	is	be	AUX
aiua-12307	170	25	based	base	VERB
aiua-12307	170	26	on	on	ADP
aiua-12307	170	27	numerous	numerous	ADJ
aiua-12307	170	28	individualized	individualized	ADJ
aiua-12307	170	29	variables	variable	NOUN
aiua-12307	170	30	,	,	PUNCT
aiua-12307	170	31	including	include	VERB
aiua-12307	170	32	comorbidities	comorbiditie	NOUN
aiua-12307	170	33	,	,	PUNCT
aiua-12307	170	34	disease	disease	NOUN
aiua-12307	170	35	location	location	NOUN
aiua-12307	170	36	and	and	CCONJ
aiua-12307	170	37	burden	burden	NOUN
aiua-12307	170	38	,	,	PUNCT
aiua-12307	170	39	and	and	CCONJ
aiua-12307	170	40	psychosocial	psychosocial	ADJ
aiua-12307	170	41	and	and	CCONJ
aiua-12307	170	42	economic	economic	ADJ
aiua-12307	170	43	factors	factor	NOUN
aiua-12307	170	44	(	(	PUNCT
aiua-12307	170	45	49	49	NUM
aiua-12307	170	46	)	)	PUNCT
aiua-12307	170	47	.	.	PUNCT
aiua-12307	171	1	in	in	ADP
aiua-12307	171	2	recent	recent	ADJ
aiua-12307	171	3	years	year	NOUN
aiua-12307	171	4	,	,	PUNCT
aiua-12307	171	5	advances	advance	NOUN
aiua-12307	171	6	have	have	AUX
aiua-12307	171	7	been	be	AUX
aiua-12307	171	8	seen	see	VERB
aiua-12307	171	9	in	in	ADP
aiua-12307	171	10	the	the	DET
aiua-12307	171	11	diagnosis	diagnosis	NOUN
aiua-12307	171	12	,	,	PUNCT
aiua-12307	171	13	management	management	NOUN
aiua-12307	171	14	,	,	PUNCT
aiua-12307	171	15	and	and	CCONJ
aiua-12307	171	16	treatment	treatment	NOUN
aiua-12307	171	17	of	of	ADP
aiua-12307	171	18	the	the	DET
aiua-12307	171	19	ccrcc	ccrcc	NOUN
aiua-12307	171	20	subtype	subtype	NOUN
aiua-12307	171	21	resulting	result	VERB
aiua-12307	171	22	from	from	ADP
aiua-12307	171	23	various	various	ADJ
aiua-12307	171	24	randomized	randomized	ADJ
aiua-12307	171	25	and	and	CCONJ
aiua-12307	171	26	prospective	prospective	ADJ
aiua-12307	171	27	phase	phase	NOUN
aiua-12307	171	28	iii	iii	NUM
aiua-12307	171	29	clinical	clinical	ADJ
aiua-12307	171	30	studies	study	NOUN
aiua-12307	171	31	,	,	PUNCT
aiua-12307	171	32	including	include	VERB
aiua-12307	171	33	combined	combine	VERB
aiua-12307	171	34	therapy	therapy	NOUN
aiua-12307	171	35	effective	effective	ADJ
aiua-12307	171	36	on	on	ADP
aiua-12307	171	37	immune	immune	ADJ
aiua-12307	171	38	checkpoints	checkpoint	NOUN
aiua-12307	171	39	such	such	ADJ
aiua-12307	171	40	as	as	ADP
aiua-12307	171	41	pd-1	pd-1	ADV
aiua-12307	171	42	,	,	PUNCT
aiua-12307	171	43	ctla-4	ctla-4	PROPN
aiua-12307	171	44	,	,	PUNCT
aiua-12307	171	45	and	and	CCONJ
aiua-12307	171	46	pdl-1	pdl-1	X
aiua-12307	171	47	(	(	PUNCT
aiua-12307	171	48	checkmate-9er	checkmate-9er	PROPN
aiua-12307	171	49	,	,	PUNCT
aiua-12307	171	50	keynote-426	keynote-426	NOUN
aiua-12307	171	51	,	,	PUNCT
aiua-12307	171	52	clear	clear	ADJ
aiua-12307	171	53	and	and	CCONJ
aiua-12307	171	54	checkmate-214	checkmate-214	ADJ
aiua-12307	171	55	)	)	PUNCT
aiua-12307	171	56	.	.	PUNCT
aiua-12307	172	1	ici	ici	PROPN
aiua-12307	172	2	monotherapy	monotherapy	NOUN
aiua-12307	172	3	in	in	ADP
aiua-12307	172	4	the	the	DET
aiua-12307	172	5	treatment	treatment	NOUN
aiua-12307	172	6	of	of	ADP
aiua-12307	172	7	mrcc	mrcc	NOUN
aiua-12307	172	8	nivolumab	nivolumab	ADV
aiua-12307	172	9	is	be	AUX
aiua-12307	172	10	a	a	DET
aiua-12307	172	11	humanized	humanize	VERB
aiua-12307	172	12	monoclonal	monoclonal	NOUN
aiua-12307	172	13	pd-1	pd-1	ADP
aiua-12307	172	14	antibody	antibody	NOUN
aiua-12307	172	15	approved	approve	VERB
aiua-12307	172	16	for	for	ADP
aiua-12307	172	17	various	various	ADJ
aiua-12307	172	18	metastatic	metastatic	ADJ
aiua-12307	172	19	tumours	tumour	NOUN
aiua-12307	172	20	.	.	PUNCT
aiua-12307	173	1	the	the	DET
aiua-12307	173	2	use	use	NOUN
aiua-12307	173	3	of	of	ADP
aiua-12307	173	4	the	the	DET
aiua-12307	173	5	drug	drug	NOUN
aiua-12307	173	6	in	in	ADP
aiua-12307	173	7	treating	treat	VERB
aiua-12307	173	8	mrcc	mrcc	NOUN
aiua-12307	173	9	was	be	AUX
aiua-12307	173	10	based	base	VERB
aiua-12307	173	11	on	on	ADP
aiua-12307	173	12	data	datum	NOUN
aiua-12307	173	13	from	from	ADP
aiua-12307	173	14	checkmate-025	checkmate-025	NOUN
aiua-12307	173	15	(	(	PUNCT
aiua-12307	173	16	nct01668784	nct01668784	NOUN
aiua-12307	173	17	)	)	PUNCT
aiua-12307	173	18	.	.	PUNCT
aiua-12307	174	1	in	in	ADP
aiua-12307	174	2	this	this	DET
aiua-12307	174	3	phase	phase	NOUN
aiua-12307	174	4	iii	iii	NUM
aiua-12307	174	5	clinical	clinical	ADJ
aiua-12307	174	6	trial	trial	NOUN
aiua-12307	174	7	comparing	compare	VERB
aiua-12307	174	8	nivolumab	nivolumab	NOUN
aiua-12307	174	9	with	with	ADP
aiua-12307	174	10	everolimus	everolimus	NOUN
aiua-12307	174	11	in	in	ADP
aiua-12307	174	12	the	the	DET
aiua-12307	174	13	table	table	NOUN
aiua-12307	174	14	3	3	NUM
aiua-12307	174	15	.	.	PUNCT
aiua-12307	174	16	clinical	clinical	ADJ
aiua-12307	174	17	trials	trial	NOUN
aiua-12307	174	18	investigating	investigate	VERB
aiua-12307	174	19	immunotherapy	immunotherapy	NOUN
aiua-12307	174	20	in	in	ADP
aiua-12307	174	21	the	the	DET
aiua-12307	174	22	adjuvant	adjuvant	ADJ
aiua-12307	174	23	setting	set	VERB
aiua-12307	174	24	in	in	ADP
aiua-12307	174	25	rcc	rcc	PROPN
aiua-12307	174	26	(	(	PUNCT
aiua-12307	174	27	41	41	NUM
aiua-12307	174	28	)	)	PUNCT
aiua-12307	174	29	.	.	PUNCT
aiua-12307	175	1	trial	trial	NOUN
aiua-12307	175	2	identifier	identifier	NOUN
aiua-12307	175	3	therapeutic	therapeutic	ADJ
aiua-12307	175	4	agent	agent	NOUN
aiua-12307	175	5	inclusion	inclusion	NOUN
aiua-12307	175	6	criteria	criterion	NOUN
aiua-12307	175	7	histology	histology	VERB
aiua-12307	175	8	the	the	DET
aiua-12307	175	9	primary	primary	ADJ
aiua-12307	175	10	endpoint(s	endpoint(s	PROPN
aiua-12307	175	11	)	)	PUNCT
aiua-12307	175	12	estimated	estimate	VERB
aiua-12307	175	13	primary	primary	NOUN
aiua-12307	175	14	(	(	PUNCT
aiua-12307	175	15	tumour	tumour	NOUN
aiua-12307	175	16	stage	stage	NOUN
aiua-12307	175	17	and	and	CCONJ
aiua-12307	175	18	grade	grade	NOUN
aiua-12307	175	19	)	)	PUNCT
aiua-12307	175	20	and	and	CCONJ
aiua-12307	175	21	results	result	VERB
aiua-12307	175	22	completion	completion	NOUN
aiua-12307	175	23	date	date	NOUN
aiua-12307	175	24	bicr	bicr	ADV
aiua-12307	175	25	:	:	PUNCT
aiua-12307	175	26	blinded	blind	VERB
aiua-12307	175	27	independent	independent	ADJ
aiua-12307	175	28	central	central	ADJ
aiua-12307	175	29	review	review	NOUN
aiua-12307	175	30	;	;	PUNCT
aiua-12307	175	31	ccrcc	ccrcc	NOUN
aiua-12307	175	32	:	:	PUNCT
aiua-12307	175	33	clear	clear	ADJ
aiua-12307	175	34	cell	cell	NOUN
aiua-12307	175	35	renal	renal	ADJ
aiua-12307	175	36	cell	cell	NOUN
aiua-12307	175	37	carcinoma	carcinoma	NOUN
aiua-12307	175	38	;	;	PUNCT
aiua-12307	175	39	dfs	dfs	ADJ
aiua-12307	175	40	:	:	PUNCT
aiua-12307	175	41	disease	disease	NOUN
aiua-12307	175	42	-	-	PUNCT
aiua-12307	175	43	free	free	ADJ
aiua-12307	175	44	survival	survival	NOUN
aiua-12307	175	45	;	;	PUNCT
aiua-12307	175	46	efs	ef	NOUN
aiua-12307	175	47	:	:	PUNCT
aiua-12307	175	48	event	event	NOUN
aiua-12307	175	49	-	-	PUNCT
aiua-12307	175	50	free	free	ADJ
aiua-12307	175	51	survival	survival	NOUN
aiua-12307	175	52	;	;	PUNCT
aiua-12307	175	53	g	g	NOUN
aiua-12307	175	54	:	:	PUNCT
aiua-12307	175	55	tumour	tumour	NOUN
aiua-12307	175	56	grade	grade	NOUN
aiua-12307	175	57	;	;	PUNCT
aiua-12307	175	58	irf	irf	PROPN
aiua-12307	175	59	:	:	PUNCT
aiua-12307	175	60	independent	independent	ADJ
aiua-12307	175	61	review	review	NOUN
aiua-12307	175	62	facility	facility	NOUN
aiua-12307	175	63	;	;	PUNCT
aiua-12307	175	64	iv	iv	NUM
aiua-12307	175	65	:	:	PUNCT
aiua-12307	175	66	intravenously	intravenously	ADV
aiua-12307	175	67	;	;	PUNCT
aiua-12307	175	68	n	n	CCONJ
aiua-12307	175	69	:	:	PUNCT
aiua-12307	175	70	nodal	nodal	NOUN
aiua-12307	175	71	stage	stage	NOUN
aiua-12307	175	72	;	;	PUNCT
aiua-12307	175	73	ned	ne	VERB
aiua-12307	175	74	:	:	PUNCT
aiua-12307	175	75	no	no	DET
aiua-12307	175	76	evidence	evidence	NOUN
aiua-12307	175	77	of	of	ADP
aiua-12307	175	78	disease	disease	NOUN
aiua-12307	175	79	;	;	PUNCT
aiua-12307	175	80	os	os	ADJ
aiua-12307	175	81	:	:	PUNCT
aiua-12307	175	82	overall	overall	ADJ
aiua-12307	175	83	survival	survival	NOUN
aiua-12307	175	84	;	;	PUNCT
aiua-12307	175	85	p	p	X
aiua-12307	175	86	:	:	PUNCT
aiua-12307	175	87	pathological	pathological	ADJ
aiua-12307	175	88	;	;	PUNCT
aiua-12307	175	89	t	t	X
aiua-12307	175	90	:	:	PUNCT
aiua-12307	175	91	tumour	tumour	NOUN
aiua-12307	175	92	stage	stage	NOUN
aiua-12307	175	93	.	.	PUNCT
aiua-12307	176	1	keynote-564	keynote-564	NOUN
aiua-12307	176	2	nct03142334	nct03142334	NOUN
aiua-12307	176	3	immotion010	immotion010	PROPN
aiua-12307	176	4	nct03024996	nct03024996	NOUN
aiua-12307	176	5	checkmate	checkmate	VERB
aiua-12307	176	6	914	914	NUM
aiua-12307	176	7	nct03138512	nct03138512	NOUN
aiua-12307	176	8	prosper	prosper	VERB
aiua-12307	176	9	nct03055013	nct03055013	ADJ
aiua-12307	176	10	rampart	rampart	PROPN
aiua-12307	176	11	nct03288532	nct03288532	PROPN
aiua-12307	176	12	pembrolizumab	pembrolizumab	VERB
aiua-12307	176	13	200	200	NUM
aiua-12307	176	14	mg	mg	NUM
aiua-12307	176	15	iv	iv	NUM
aiua-12307	176	16	every	every	DET
aiua-12307	176	17	3	3	NUM
aiua-12307	176	18	weeks	week	NOUN
aiua-12307	176	19	for	for	ADP
aiua-12307	176	20	up	up	ADP
aiua-12307	176	21	to	to	PART
aiua-12307	176	22	17	17	NUM
aiua-12307	176	23	cycles	cycle	NOUN
aiua-12307	176	24	atezolizumab	atezolizumab	VERB
aiua-12307	176	25	1.200	1.200	NUM
aiua-12307	176	26	mg	mg	NOUN
aiua-12307	176	27	every	every	DET
aiua-12307	176	28	21	21	NUM
aiua-12307	176	29	days	day	NOUN
aiua-12307	176	30	for	for	ADP
aiua-12307	176	31	1	1	NUM
aiua-12307	176	32	year	year	NOUN
aiua-12307	176	33	part	part	NOUN
aiua-12307	176	34	a	a	DET
aiua-12307	176	35	:	:	PUNCT
aiua-12307	176	36	nivolumab	nivolumab	NOUN
aiua-12307	176	37	240	240	NUM
aiua-12307	176	38	mg	mg	NUM
aiua-12307	176	39	iv	iv	NUM
aiua-12307	176	40	every	every	DET
aiua-12307	176	41	2	2	NUM
aiua-12307	176	42	weeks	week	NOUN
aiua-12307	176	43	,	,	PUNCT
aiua-12307	176	44	up	up	ADP
aiua-12307	176	45	to	to	PART
aiua-12307	176	46	12	12	NUM
aiua-12307	176	47	doses	dose	NOUN
aiua-12307	176	48	,	,	PUNCT
aiua-12307	176	49	ipilimumab	ipilimumab	VERB
aiua-12307	176	50	1	1	NUM
aiua-12307	176	51	mg	mg	PROPN
aiua-12307	176	52	/	/	SYM
aiua-12307	176	53	kg	kg	NOUN
aiua-12307	176	54	iv	iv	NOUN
aiua-12307	176	55	,	,	PUNCT
aiua-12307	176	56	up	up	ADP
aiua-12307	176	57	to	to	PART
aiua-12307	176	58	four	four	NUM
aiua-12307	176	59	doses	dose	NOUN
aiua-12307	176	60	given	give	VERB
aiua-12307	176	61	in	in	ADP
aiua-12307	176	62	cycles	cycle	NOUN
aiua-12307	176	63	1	1	NUM
aiua-12307	176	64	,	,	PUNCT
aiua-12307	176	65	4	4	NUM
aiua-12307	176	66	,	,	PUNCT
aiua-12307	176	67	7	7	NUM
aiua-12307	176	68	and	and	CCONJ
aiua-12307	176	69	10	10	NUM
aiua-12307	176	70	part	part	NOUN
aiua-12307	176	71	b	b	NOUN
aiua-12307	176	72	:	:	PUNCT
aiua-12307	176	73	nivolumab	nivolumab	NOUN
aiua-12307	176	74	240	240	NUM
aiua-12307	176	75	mg	mg	NOUN
aiua-12307	176	76	intravenously	intravenously	ADV
aiua-12307	176	77	every	every	DET
aiua-12307	176	78	2	2	NUM
aiua-12307	176	79	weeks	week	NOUN
aiua-12307	176	80	,	,	PUNCT
aiua-12307	176	81	up	up	ADP
aiua-12307	176	82	to	to	PART
aiua-12307	176	83	12	12	NUM
aiua-12307	176	84	doses	dose	NOUN
aiua-12307	176	85	nivolumab	nivolumab	ADV
aiua-12307	176	86	480	480	NUM
aiua-12307	176	87	mg	mg	NUM
aiua-12307	176	88	iv	iv	NUM
aiua-12307	176	89	,	,	PUNCT
aiua-12307	176	90	one	one	NUM
aiua-12307	176	91	dose	dose	NOUN
aiua-12307	176	92	given	give	VERB
aiua-12307	176	93	before	before	ADP
aiua-12307	176	94	surgery	surgery	NOUN
aiua-12307	176	95	,	,	PUNCT
aiua-12307	176	96	up	up	ADP
aiua-12307	176	97	to	to	PART
aiua-12307	176	98	nine	nine	NUM
aiua-12307	176	99	doses	dose	NOUN
aiua-12307	176	100	given	give	VERB
aiua-12307	176	101	every	every	DET
aiua-12307	176	102	28	28	NUM
aiua-12307	176	103	days	day	NOUN
aiua-12307	176	104	following	follow	VERB
aiua-12307	176	105	surgery	surgery	NOUN
aiua-12307	176	106	part	part	NOUN
aiua-12307	176	107	a	a	DET
aiua-12307	176	108	:	:	PUNCT
aiua-12307	176	109	durvalumab	durvalumab	NOUN
aiua-12307	176	110	1.500	1.500	NUM
aiua-12307	176	111	mg	mg	NOUN
aiua-12307	176	112	every	every	DET
aiua-12307	176	113	28	28	NUM
aiua-12307	176	114	days	day	NOUN
aiua-12307	176	115	for	for	ADP
aiua-12307	176	116	1	1	NUM
aiua-12307	176	117	year	year	NOUN
aiua-12307	176	118	part	part	NOUN
aiua-12307	176	119	b	b	NOUN
aiua-12307	176	120	:	:	PUNCT
aiua-12307	176	121	durvalumab	durvalumab	NOUN
aiua-12307	176	122	1.500	1.500	NUM
aiua-12307	176	123	mg	mg	NOUN
aiua-12307	176	124	every	every	DET
aiua-12307	176	125	28	28	NUM
aiua-12307	176	126	days	day	NOUN
aiua-12307	176	127	for	for	ADP
aiua-12307	176	128	1	1	NUM
aiua-12307	176	129	year	year	NOUN
aiua-12307	176	130	+	+	NOUN
aiua-12307	176	131	tremelimumab	tremelimumab	NOUN
aiua-12307	176	132	75	75	NUM
aiua-12307	176	133	mg	mg	NOUN
aiua-12307	176	134	on	on	ADP
aiua-12307	176	135	weeks	week	NOUN
aiua-12307	176	136	1	1	NUM
aiua-12307	176	137	and	and	CCONJ
aiua-12307	176	138	4	4	NUM
aiua-12307	176	139	pt2	pt2	PROPN
aiua-12307	176	140	n0	n0	X
aiua-12307	176	141	(	(	PUNCT
aiua-12307	176	142	g4	g4	NOUN
aiua-12307	176	143	only	only	ADV
aiua-12307	176	144	)	)	PUNCT
aiua-12307	176	145	,	,	PUNCT
aiua-12307	176	146	pt3a	pt3a	PROPN
aiua-12307	176	147	n0	n0	X
aiua-12307	176	148	(	(	PUNCT
aiua-12307	176	149	g3–4	g3–4	PROPN
aiua-12307	176	150	)	)	PUNCT
aiua-12307	176	151	,	,	PUNCT
aiua-12307	176	152	pt3b	pt3b	PROPN
aiua-12307	176	153	–	–	PUNCT
aiua-12307	176	154	t4	t4	PROPN
aiua-12307	176	155	n0	n0	PROPN
aiua-12307	176	156	,	,	PUNCT
aiua-12307	176	157	ptx	ptx	NOUN
aiua-12307	176	158	n1	n1	NOUN
aiua-12307	176	159	,	,	PUNCT
aiua-12307	176	160	m1	m1	PROPN
aiua-12307	176	161	ned	ned	PROPN
aiua-12307	176	162	pt2	pt2	PROPN
aiua-12307	176	163	n0	n0	X
aiua-12307	176	164	(	(	PUNCT
aiua-12307	176	165	g4	g4	NOUN
aiua-12307	176	166	only	only	ADV
aiua-12307	176	167	)	)	PUNCT
aiua-12307	176	168	,	,	PUNCT
aiua-12307	176	169	pt3a	pt3a	PROPN
aiua-12307	176	170	n0	n0	X
aiua-12307	176	171	(	(	PUNCT
aiua-12307	176	172	g3–4	g3–4	PROPN
aiua-12307	176	173	)	)	PUNCT
aiua-12307	176	174	,	,	PUNCT
aiua-12307	176	175	pt3b	pt3b	PROPN
aiua-12307	176	176	–	–	PUNCT
aiua-12307	176	177	t4	t4	PROPN
aiua-12307	176	178	n0	n0	PROPN
aiua-12307	176	179	,	,	PUNCT
aiua-12307	176	180	ptx	ptx	VERB
aiua-12307	176	181	n1	n1	ADJ
aiua-12307	176	182	pt2a	pt2a	PROPN
aiua-12307	176	183	n0	n0	X
aiua-12307	176	184	(	(	PUNCT
aiua-12307	176	185	g3–4	g3–4	PROPN
aiua-12307	176	186	)	)	PUNCT
aiua-12307	176	187	,	,	PUNCT
aiua-12307	176	188	pt2b–4	pt2b–4	NOUN
aiua-12307	176	189	n0	n0	PROPN
aiua-12307	176	190	,	,	PUNCT
aiua-12307	176	191	pt(any	pt(any	NOUN
aiua-12307	176	192	)	)	PUNCT
aiua-12307	176	193	n1	n1	PROPN
aiua-12307	176	194	pt2–4	pt2–4	PROPN
aiua-12307	176	195	n0	n0	PROPN
aiua-12307	176	196	,	,	PUNCT
aiua-12307	176	197	pt(any	pt(any	NOUN
aiua-12307	176	198	)	)	PUNCT
aiua-12307	176	199	n1	n1	NOUN
aiua-12307	176	200	leibovich	leibovich	NOUN
aiua-12307	176	201	score	score	VERB
aiua-12307	176	202	3	3	NUM
aiua-12307	176	203	-	-	SYM
aiua-12307	176	204	11	11	NUM
aiua-12307	176	205	ccrcc	ccrcc	NOUN
aiua-12307	176	206	might	might	AUX
aiua-12307	176	207	include	include	VERB
aiua-12307	176	208	sarcomatoid	sarcomatoid	NOUN
aiua-12307	176	209	features	feature	VERB
aiua-12307	176	210	rcc	rcc	PROPN
aiua-12307	176	211	including	include	VERB
aiua-12307	176	212	clear	clear	ADJ
aiua-12307	176	213	cell	cell	NOUN
aiua-12307	176	214	or	or	CCONJ
aiua-12307	176	215	sarcomatoid	sarcomatoid	NOUN
aiua-12307	176	216	component	component	NOUN
aiua-12307	176	217	ccrcc	ccrcc	NOUN
aiua-12307	176	218	might	might	AUX
aiua-12307	176	219	include	include	VERB
aiua-12307	176	220	sarcomatoid	sarcomatoid	NOUN
aiua-12307	176	221	features	feature	NOUN
aiua-12307	176	222	ccrcc	ccrcc	NOUN
aiua-12307	176	223	might	might	AUX
aiua-12307	176	224	include	include	VERB
aiua-12307	176	225	sarcomatoid	sarcomatoid	NOUN
aiua-12307	176	226	features	feature	VERB
aiua-12307	176	227	all	all	DET
aiua-12307	176	228	histological	histological	ADJ
aiua-12307	176	229	subtypes	subtype	NOUN
aiua-12307	176	230	included	include	VERB
aiua-12307	176	231	dfs	dfs	NOUN
aiua-12307	176	232	for	for	ADP
aiua-12307	176	233	treatment	treatment	NOUN
aiua-12307	176	234	vs	vs	ADP
aiua-12307	176	235	placebo	placebo	NOUN
aiua-12307	176	236	:	:	PUNCT
aiua-12307	176	237	(	(	PUNCT
aiua-12307	176	238	hr	hr	NOUN
aiua-12307	176	239	0.68	0.68	NUM
aiua-12307	176	240	,	,	PUNCT
aiua-12307	176	241	95	95	NUM
aiua-12307	176	242	%	%	NOUN
aiua-12307	176	243	ci	ci	NOUN
aiua-12307	176	244	0.53–0.87	0.53–0.87	PROPN
aiua-12307	176	245	;	;	PUNCT
aiua-12307	176	246	p	p	PROPN
aiua-12307	176	247	=	=	PROPN
aiua-12307	176	248	0.0010	0.0010	NUM
aiua-12307	176	249	)	)	PUNCT
aiua-12307	176	250	dfs	dfs	NOUN
aiua-12307	176	251	(	(	PUNCT
aiua-12307	176	252	assessed	assess	VERB
aiua-12307	176	253	through	through	ADP
aiua-12307	176	254	irf	irf	PROPN
aiua-12307	176	255	)	)	PUNCT
aiua-12307	176	256	for	for	ADP
aiua-12307	176	257	atezolizumab	atezolizumab	NOUN
aiua-12307	176	258	vs	vs	ADP
aiua-12307	176	259	surgery	surgery	NOUN
aiua-12307	176	260	alone	alone	ADV
aiua-12307	176	261	:	:	PUNCT
aiua-12307	176	262	(	(	PUNCT
aiua-12307	176	263	hr	hr	NOUN
aiua-12307	176	264	0.97	0.97	NUM
aiua-12307	176	265	,	,	PUNCT
aiua-12307	176	266	95	95	NUM
aiua-12307	176	267	%	%	NOUN
aiua-12307	176	268	ci	ci	NOUN
aiua-12307	176	269	0.74–1.28	0.74–1.28	NOUN
aiua-12307	176	270	;	;	PUNCT
aiua-12307	176	271	p=	p=	NOUN
aiua-12307	176	272	0.43	0.43	NUM
aiua-12307	176	273	)	)	PUNCT
aiua-12307	176	274	dfs	dfs	NOUN
aiua-12307	176	275	(	(	PUNCT
aiua-12307	176	276	assessed	assess	VERB
aiua-12307	176	277	through	through	ADP
aiua-12307	176	278	bicr	bicr	NOUN
aiua-12307	176	279	)	)	PUNCT
aiua-12307	176	280	for	for	ADP
aiua-12307	176	281	nivolumab	nivolumab	NOUN
aiua-12307	176	282	or	or	CCONJ
aiua-12307	176	283	ipilimumab	ipilimumab	VERB
aiua-12307	176	284	vs	vs	ADP
aiua-12307	176	285	placebo	placebo	NOUN
aiua-12307	176	286	part	part	NOUN
aiua-12307	176	287	a	a	NOUN
aiua-12307	176	288	:	:	PUNCT
aiua-12307	176	289	(	(	PUNCT
aiua-12307	176	290	hr	hr	NOUN
aiua-12307	176	291	0.92	0.92	NUM
aiua-12307	176	292	,	,	PUNCT
aiua-12307	176	293	95	95	NUM
aiua-12307	176	294	%	%	NOUN
aiua-12307	176	295	ci	ci	NOUN
aiua-12307	176	296	0.71–1.19	0.71–1.19	NOUN
aiua-12307	176	297	;	;	PUNCT
aiua-12307	176	298	p	p	X
aiua-12307	176	299	=	=	NOUN
aiua-12307	176	300	0.5347	0.5347	NUM
aiua-12307	176	301	)	)	PUNCT
aiua-12307	176	302	part	part	NOUN
aiua-12307	176	303	b	b	NOUN
aiua-12307	176	304	:	:	PUNCT
aiua-12307	176	305	results	result	VERB
aiua-12307	176	306	pending	pende	VERB
aiua-12307	176	307	efs	ef	NOUN
aiua-12307	176	308	for	for	ADP
aiua-12307	176	309	nivolumab	nivolumab	NOUN
aiua-12307	176	310	(	(	PUNCT
aiua-12307	176	311	hr	hr	NOUN
aiua-12307	176	312	0.97	0.97	NUM
aiua-12307	176	313	,	,	PUNCT
aiua-12307	176	314	95	95	NUM
aiua-12307	176	315	%	%	NOUN
aiua-12307	176	316	ci	ci	NOUN
aiua-12307	176	317	0.74–1.28	0.74–1.28	NOUN
aiua-12307	176	318	;	;	PUNCT
aiua-12307	177	1	p	p	X
aiua-12307	177	2	=	=	NOUN
aiua-12307	177	3	0.43	0.43	NUM
aiua-12307	177	4	)	)	PUNCT
aiua-12307	177	5	dfs	dfs	NOUN
aiua-12307	177	6	,	,	PUNCT
aiua-12307	177	7	os	os	X
aiua-12307	177	8	(	(	PUNCT
aiua-12307	177	9	results	result	NOUN
aiua-12307	177	10	pending	pende	VERB
aiua-12307	177	11	)	)	PUNCT
aiua-12307	177	12	dec	dec	PROPN
aiua-12307	177	13	2020	2020	NUM
aiua-12307	177	14	may	may	AUX
aiua-12307	177	15	2022	2022	NUM
aiua-12307	177	16	july	july	PROPN
aiua-12307	177	17	2024	2024	NUM
aiua-12307	177	18	nov	nov	PROPN
aiua-12307	177	19	2023	2023	NUM
aiua-12307	177	20	july	july	PROPN
aiua-12307	177	21	2024	2024	NUM
aiua-12307	177	22	archivio	archivio	NOUN
aiua-12307	177	23	italiano	italiano	NOUN
aiua-12307	177	24	di	di	X
aiua-12307	177	25	urologia	urologia	PROPN
aiua-12307	177	26	e	e	PROPN
aiua-12307	177	27	andrologia	andrologia	NOUN
aiua-12307	177	28	2024	2024	NUM
aiua-12307	177	29	;	;	PUNCT
aiua-12307	177	30	96(2):12307	96(2):12307	NUM
aiua-12307	177	31	e.	e.	PROPN
aiua-12307	177	32	bosnali	bosnali	PROPN
aiua-12307	177	33	,	,	PUNCT
aiua-12307	177	34	e.	e.	PROPN
aiua-12307	177	35	malik	malik	PROPN
aiua-12307	177	36	akdas	akdas	PROPN
aiua-12307	177	37	,	,	PUNCT
aiua-12307	177	38	e.	e.	PROPN
aiua-12307	177	39	telli	telli	PROPN
aiua-12307	177	40	,	,	PUNCT
aiua-12307	177	41	k.	k.	PROPN
aiua-12307	177	42	teke	teke	PROPN
aiua-12307	177	43	,	,	PUNCT
aiua-12307	178	1	o.	o.	PROPN
aiua-12307	178	2	kara	kara	PROPN
aiua-12307	178	3	6	6	NUM
aiua-12307	178	4	treatment	treatment	NOUN
aiua-12307	178	5	of	of	ADP
aiua-12307	178	6	mrcc	mrcc	NOUN
aiua-12307	178	7	with	with	ADP
aiua-12307	178	8	clear	clear	ADJ
aiua-12307	178	9	cell	cell	NOUN
aiua-12307	178	10	subtype	subtype	NOUN
aiua-12307	178	11	refractory	refractory	NOUN
aiua-12307	178	12	to	to	PART
aiua-12307	178	13	vascular	vascular	VERB
aiua-12307	178	14	endothelial	endothelial	ADJ
aiua-12307	178	15	growth	growth	NOUN
aiua-12307	178	16	factor	factor	NOUN
aiua-12307	178	17	(	(	PUNCT
aiua-12307	178	18	vegfr)-targeted	vegfr)-targete	VERB
aiua-12307	178	19	therapy	therapy	NOUN
aiua-12307	178	20	,	,	PUNCT
aiua-12307	178	21	nivolumab	nivolumab	NOUN
aiua-12307	178	22	had	have	AUX
aiua-12307	178	23	longer	long	ADV
aiua-12307	178	24	os	os	VERB
aiua-12307	178	25	,	,	PUNCT
aiua-12307	178	26	better	well	ADJ
aiua-12307	178	27	quality	quality	NOUN
aiua-12307	178	28	of	of	ADP
aiua-12307	178	29	life	life	NOUN
aiua-12307	178	30	and	and	CCONJ
aiua-12307	178	31	lesser	less	ADJ
aiua-12307	178	32	grade	grade	NOUN
aiua-12307	178	33	3	3	NUM
aiua-12307	178	34	-	-	SYM
aiua-12307	178	35	4	4	NUM
aiua-12307	178	36	aes	aes	NOUN
aiua-12307	178	37	than	than	ADP
aiua-12307	178	38	everolimus	everolimus	NOUN
aiua-12307	178	39	.	.	PUNCT
aiua-12307	179	1	despite	despite	SCONJ
aiua-12307	179	2	the	the	DET
aiua-12307	179	3	os	os	NOUN
aiua-12307	179	4	advantage	advantage	NOUN
aiua-12307	179	5	of	of	ADP
aiua-12307	179	6	nivolumab	nivolumab	NOUN
aiua-12307	179	7	,	,	PUNCT
aiua-12307	179	8	no	no	DET
aiua-12307	179	9	pfs	pfs	PROPN
aiua-12307	179	10	advantage	advantage	NOUN
aiua-12307	179	11	was	be	AUX
aiua-12307	179	12	detected	detect	VERB
aiua-12307	179	13	in	in	ADP
aiua-12307	179	14	this	this	DET
aiua-12307	179	15	study	study	NOUN
aiua-12307	179	16	(	(	PUNCT
aiua-12307	179	17	50	50	NUM
aiua-12307	179	18	)	)	PUNCT
aiua-12307	179	19	.	.	PUNCT
aiua-12307	180	1	pfs	pfs	PROPN
aiua-12307	180	2	does	do	AUX
aiua-12307	180	3	not	not	PART
aiua-12307	180	4	appear	appear	VERB
aiua-12307	180	5	to	to	PART
aiua-12307	180	6	be	be	AUX
aiua-12307	180	7	a	a	DET
aiua-12307	180	8	reliable	reliable	ADJ
aiua-12307	180	9	outcome	outcome	NOUN
aiua-12307	180	10	indicator	indicator	NOUN
aiua-12307	180	11	for	for	ADP
aiua-12307	180	12	pd-1	pd-1	VERB
aiua-12307	180	13	therapy	therapy	NOUN
aiua-12307	180	14	in	in	ADP
aiua-12307	180	15	rcc	rcc	PROPN
aiua-12307	180	16	.	.	PUNCT
aiua-12307	181	1	no	no	DET
aiua-12307	181	2	rcts	rct	NOUN
aiua-12307	181	3	supporting	support	VERB
aiua-12307	181	4	single	single	ADJ
aiua-12307	181	5	-	-	PUNCT
aiua-12307	181	6	agent	agent	NOUN
aiua-12307	181	7	icis	icis	NOUN
aiua-12307	181	8	in	in	ADP
aiua-12307	181	9	treatment	treatment	NOUN
aiua-12307	181	10	-	-	PUNCT
aiua-12307	181	11	naïve	naïve	ADJ
aiua-12307	181	12	patients	patient	NOUN
aiua-12307	181	13	have	have	AUX
aiua-12307	181	14	been	be	AUX
aiua-12307	181	15	reported	report	VERB
aiua-12307	181	16	.	.	PUNCT
aiua-12307	182	1	keynote-427	keynote-427	PROPN
aiua-12307	182	2	(	(	PUNCT
aiua-12307	182	3	nct02853344	nct02853344	PROPN
aiua-12307	182	4	)	)	PUNCT
aiua-12307	182	5	,	,	PUNCT
aiua-12307	182	6	published	publish	VERB
aiua-12307	182	7	in	in	ADP
aiua-12307	182	8	2021	2021	NUM
aiua-12307	182	9	,	,	PUNCT
aiua-12307	182	10	is	be	AUX
aiua-12307	182	11	a	a	DET
aiua-12307	182	12	prospective	prospective	ADJ
aiua-12307	182	13	phase	phase	NOUN
aiua-12307	182	14	ii	ii	NOUN
aiua-12307	182	15	single	single	ADJ
aiua-12307	182	16	-	-	PUNCT
aiua-12307	182	17	arm	arm	NOUN
aiua-12307	182	18	clinical	clinical	ADJ
aiua-12307	182	19	study	study	NOUN
aiua-12307	182	20	using	use	VERB
aiua-12307	182	21	pembrolizumab	pembrolizumab	NOUN
aiua-12307	182	22	in	in	ADP
aiua-12307	182	23	mrcc	mrcc	NOUN
aiua-12307	182	24	patients	patient	NOUN
aiua-12307	182	25	consisting	consist	VERB
aiua-12307	182	26	of	of	ADP
aiua-12307	182	27	two	two	NUM
aiua-12307	182	28	cohorts	cohort	NOUN
aiua-12307	182	29	(	(	PUNCT
aiua-12307	182	30	ccrcc	ccrcc	NOUN
aiua-12307	182	31	and	and	CCONJ
aiua-12307	182	32	nccrcc	nccrcc	NOUN
aiua-12307	182	33	)	)	PUNCT
aiua-12307	182	34	(	(	PUNCT
aiua-12307	182	35	51	51	NUM
aiua-12307	182	36	)	)	PUNCT
aiua-12307	182	37	.	.	PUNCT
aiua-12307	183	1	the	the	DET
aiua-12307	183	2	nivolumab	nivolumab	NOUN
aiua-12307	183	3	study	study	NOUN
aiua-12307	183	4	included	include	VERB
aiua-12307	183	5	patients	patient	NOUN
aiua-12307	183	6	who	who	PRON
aiua-12307	183	7	had	have	AUX
aiua-12307	183	8	received	receive	VERB
aiua-12307	183	9	prior	prior	ADJ
aiua-12307	183	10	treatment	treatment	NOUN
aiua-12307	183	11	,	,	PUNCT
aiua-12307	183	12	while	while	SCONJ
aiua-12307	183	13	the	the	DET
aiua-12307	183	14	pembrolizumab	pembrolizumab	NOUN
aiua-12307	183	15	study	study	NOUN
aiua-12307	183	16	included	include	VERB
aiua-12307	183	17	patients	patient	NOUN
aiua-12307	183	18	who	who	PRON
aiua-12307	183	19	had	have	AUX
aiua-12307	183	20	not	not	PART
aiua-12307	183	21	received	receive	VERB
aiua-12307	183	22	prior	prior	ADJ
aiua-12307	183	23	treatment	treatment	NOUN
aiua-12307	183	24	.	.	PUNCT
aiua-12307	184	1	moreover	moreover	ADV
aiua-12307	184	2	,	,	PUNCT
aiua-12307	184	3	the	the	DET
aiua-12307	184	4	subtypes	subtype	NOUN
aiua-12307	184	5	included	include	VERB
aiua-12307	184	6	in	in	ADP
aiua-12307	184	7	these	these	DET
aiua-12307	184	8	clinical	clinical	ADJ
aiua-12307	184	9	studies	study	NOUN
aiua-12307	184	10	and	and	CCONJ
aiua-12307	184	11	their	their	PRON
aiua-12307	184	12	representation	representation	NOUN
aiua-12307	184	13	percentages	percentage	NOUN
aiua-12307	184	14	differed	differ	VERB
aiua-12307	184	15	.	.	PUNCT
aiua-12307	185	1	therefore	therefore	ADV
aiua-12307	185	2	,	,	PUNCT
aiua-12307	185	3	each	each	DET
aiua-12307	185	4	study	study	NOUN
aiua-12307	185	5	's	's	PART
aiua-12307	185	6	subtype	subtype	NOUN
aiua-12307	185	7	that	that	PRON
aiua-12307	185	8	responds	respond	VERB
aiua-12307	185	9	better	well	ADV
aiua-12307	185	10	to	to	ADP
aiua-12307	185	11	immunotherapy	immunotherapy	NOUN
aiua-12307	185	12	differs	differ	NOUN
aiua-12307	185	13	because	because	SCONJ
aiua-12307	185	14	the	the	DET
aiua-12307	185	15	populations	population	NOUN
aiua-12307	185	16	studied	study	VERB
aiua-12307	185	17	are	be	AUX
aiua-12307	185	18	heterogeneous	heterogeneous	ADJ
aiua-12307	185	19	(	(	PUNCT
aiua-12307	185	20	52	52	NUM
aiua-12307	185	21	)	)	PUNCT
aiua-12307	185	22	.	.	PUNCT
aiua-12307	186	1	given	give	VERB
aiua-12307	186	2	these	these	DET
aiua-12307	186	3	results	result	NOUN
aiua-12307	186	4	and	and	CCONJ
aiua-12307	186	5	without	without	ADP
aiua-12307	186	6	randomized	randomized	ADJ
aiua-12307	186	7	phase	phase	NOUN
aiua-12307	186	8	iii	iii	NUM
aiua-12307	186	9	data	data	PROPN
aiua-12307	186	10	,	,	PUNCT
aiua-12307	186	11	singleagent	singleagent	ADJ
aiua-12307	186	12	ici	ici	NOUN
aiua-12307	186	13	therapy	therapy	NOUN
aiua-12307	186	14	is	be	AUX
aiua-12307	186	15	not	not	PART
aiua-12307	186	16	recommended	recommend	VERB
aiua-12307	186	17	as	as	ADP
aiua-12307	186	18	an	an	DET
aiua-12307	186	19	alternative	alternative	NOUN
aiua-12307	186	20	in	in	ADP
aiua-12307	186	21	the	the	DET
aiua-12307	186	22	first	first	ADJ
aiua-12307	186	23	-	-	PUNCT
aiua-12307	186	24	line	line	NOUN
aiua-12307	186	25	treatment	treatment	NOUN
aiua-12307	186	26	setting	setting	NOUN
aiua-12307	186	27	(	(	PUNCT
aiua-12307	186	28	48	48	NUM
aiua-12307	186	29	)	)	PUNCT
aiua-12307	186	30	.	.	PUNCT
aiua-12307	187	1	combination	combination	NOUN
aiua-12307	187	2	therapy	therapy	NOUN
aiua-12307	187	3	in	in	ADP
aiua-12307	187	4	the	the	DET
aiua-12307	187	5	treatment	treatment	NOUN
aiua-12307	187	6	of	of	ADP
aiua-12307	187	7	mrcc	mrcc	NOUN
aiua-12307	187	8	(	(	PUNCT
aiua-12307	187	9	ici	ici	NOUN
aiua-12307	187	10	/	/	SYM
aiua-12307	187	11	ici	ici	PROPN
aiua-12307	187	12	-	-	PUNCT
aiua-12307	187	13	ici	ici	PROPN
aiua-12307	187	14	/	/	SYM
aiua-12307	187	15	tki	tki	PROPN
aiua-12307	187	16	)	)	PUNCT
aiua-12307	187	17	the	the	DET
aiua-12307	187	18	beneficial	beneficial	ADJ
aiua-12307	187	19	results	result	NOUN
aiua-12307	187	20	obtained	obtain	VERB
aiua-12307	187	21	in	in	ADP
aiua-12307	187	22	clinical	clinical	ADJ
aiua-12307	187	23	trials	trial	NOUN
aiua-12307	187	24	with	with	ADP
aiua-12307	187	25	immunotherapy	immunotherapy	NOUN
aiua-12307	187	26	treatment	treatment	NOUN
aiua-12307	187	27	have	have	AUX
aiua-12307	187	28	allowed	allow	VERB
aiua-12307	187	29	combining	combine	VERB
aiua-12307	187	30	such	such	ADJ
aiua-12307	187	31	treatments	treatment	NOUN
aiua-12307	187	32	with	with	ADP
aiua-12307	187	33	others	other	NOUN
aiua-12307	187	34	using	use	VERB
aiua-12307	187	35	different	different	ADJ
aiua-12307	187	36	mechanisms	mechanism	NOUN
aiua-12307	187	37	to	to	PART
aiua-12307	187	38	enhance	enhance	VERB
aiua-12307	187	39	immunomodulatory	immunomodulatory	ADJ
aiua-12307	187	40	effects	effect	NOUN
aiua-12307	187	41	(	(	PUNCT
aiua-12307	187	42	53	53	NUM
aiua-12307	187	43	)	)	PUNCT
aiua-12307	187	44	.	.	PUNCT
aiua-12307	188	1	the	the	DET
aiua-12307	188	2	contemporary	contemporary	ADJ
aiua-12307	188	3	standard	standard	NOUN
aiua-12307	188	4	of	of	ADP
aiua-12307	188	5	care	care	NOUN
aiua-12307	188	6	for	for	ADP
aiua-12307	188	7	metastatic	metastatic	ADJ
aiua-12307	188	8	clear	clear	ADJ
aiua-12307	188	9	cell	cell	NOUN
aiua-12307	188	10	rcc	rcc	PROPN
aiua-12307	188	11	(	(	PUNCT
aiua-12307	188	12	ccmrcc	ccmrcc	PROPN
aiua-12307	188	13	)	)	PUNCT
aiua-12307	188	14	is	be	AUX
aiua-12307	188	15	the	the	DET
aiua-12307	188	16	use	use	NOUN
aiua-12307	188	17	of	of	ADP
aiua-12307	188	18	tkis	tkis	PROPN
aiua-12307	188	19	dually	dually	NOUN
aiua-12307	188	20	(	(	PUNCT
aiua-12307	188	21	ici	ici	NOUN
aiua-12307	188	22	/	/	SYM
aiua-12307	188	23	ici	ici	PROPN
aiua-12307	188	24	)	)	PUNCT
aiua-12307	188	25	or	or	CCONJ
aiua-12307	188	26	in	in	ADP
aiua-12307	188	27	combination	combination	NOUN
aiua-12307	188	28	with	with	ADP
aiua-12307	188	29	ici	ici	PROPN
aiua-12307	188	30	(	(	PUNCT
aiua-12307	188	31	54	54	NUM
aiua-12307	188	32	)	)	PUNCT
aiua-12307	188	33	.	.	PUNCT
aiua-12307	189	1	in	in	ADP
aiua-12307	189	2	the	the	DET
aiua-12307	189	3	first	first	ADJ
aiua-12307	189	4	-	-	PUNCT
aiua-12307	189	5	line	line	NOUN
aiua-12307	189	6	treatment	treatment	NOUN
aiua-12307	189	7	of	of	ADP
aiua-12307	189	8	cc	cc	NOUN
aiua-12307	189	9	-	-	NOUN
aiua-12307	189	10	mrcc	mrcc	NOUN
aiua-12307	189	11	,	,	PUNCT
aiua-12307	189	12	ici	ici	NOUN
aiua-12307	189	13	and	and	CCONJ
aiua-12307	189	14	vegfr	vegfr	ADV
aiua-12307	189	15	-	-	PUNCT
aiua-12307	189	16	targeted	target	VERB
aiua-12307	189	17	tkis	tkis	NOUN
aiua-12307	189	18	have	have	AUX
aiua-12307	189	19	been	be	AUX
aiua-12307	189	20	shown	show	VERB
aiua-12307	189	21	to	to	PART
aiua-12307	189	22	improve	improve	VERB
aiua-12307	189	23	os	os	NOUN
aiua-12307	189	24	compared	compare	VERB
aiua-12307	189	25	to	to	ADP
aiua-12307	189	26	tki	tki	PROPN
aiua-12307	189	27	monotherapy	monotherapy	NOUN
aiua-12307	189	28	in	in	ADP
aiua-12307	189	29	randomized	randomized	ADJ
aiua-12307	189	30	studies	study	NOUN
aiua-12307	189	31	.	.	PUNCT
aiua-12307	190	1	however	however	ADV
aiua-12307	190	2	,	,	PUNCT
aiua-12307	190	3	each	each	DET
aiua-12307	190	4	combination	combination	NOUN
aiua-12307	190	5	regimen	regimen	NOUN
aiua-12307	190	6	is	be	AUX
aiua-12307	190	7	thought	think	VERB
aiua-12307	190	8	to	to	PART
aiua-12307	190	9	be	be	AUX
aiua-12307	190	10	highly	highly	ADV
aiua-12307	190	11	effective	effective	ADJ
aiua-12307	190	12	,	,	PUNCT
aiua-12307	190	13	with	with	ADP
aiua-12307	190	14	orr	orr	NOUN
aiua-12307	190	15	ranging	range	VERB
aiua-12307	190	16	from	from	ADP
aiua-12307	190	17	42	42	NUM
aiua-12307	190	18	%	%	NOUN
aiua-12307	190	19	to	to	ADP
aiua-12307	190	20	71	71	NUM
aiua-12307	190	21	%	%	NOUN
aiua-12307	190	22	(	(	PUNCT
aiua-12307	190	23	55	55	NUM
aiua-12307	190	24	-	-	SYM
aiua-12307	190	25	58	58	NUM
aiua-12307	190	26	)	)	PUNCT
aiua-12307	190	27	.	.	PUNCT
aiua-12307	191	1	several	several	ADJ
aiua-12307	191	2	studies	study	NOUN
aiua-12307	191	3	have	have	AUX
aiua-12307	191	4	evaluated	evaluate	VERB
aiua-12307	191	5	combination	combination	NOUN
aiua-12307	191	6	therapies	therapy	NOUN
aiua-12307	191	7	in	in	ADP
aiua-12307	191	8	cc	cc	NOUN
aiua-12307	191	9	-	-	NOUN
aiua-12307	191	10	mrcc	mrcc	NOUN
aiua-12307	191	11	and	and	CCONJ
aiua-12307	191	12	demonstrated	demonstrate	VERB
aiua-12307	191	13	improvement	improvement	NOUN
aiua-12307	191	14	in	in	ADP
aiua-12307	191	15	overall	overall	ADJ
aiua-12307	191	16	response	response	NOUN
aiua-12307	191	17	rate	rate	NOUN
aiua-12307	191	18	,	,	PUNCT
aiua-12307	191	19	pfs	pfs	PROPN
aiua-12307	191	20	,	,	PUNCT
aiua-12307	191	21	and	and	CCONJ
aiua-12307	191	22	os	os	NOUN
aiua-12307	191	23	compared	compare	VERB
aiua-12307	191	24	to	to	ADP
aiua-12307	191	25	standard	standard	ADJ
aiua-12307	191	26	treatment	treatment	NOUN
aiua-12307	191	27	(	(	PUNCT
aiua-12307	191	28	sunitinib	sunitinib	NOUN
aiua-12307	191	29	)	)	PUNCT
aiua-12307	191	30	.	.	PUNCT
aiua-12307	192	1	these	these	DET
aiua-12307	192	2	studies	study	NOUN
aiua-12307	192	3	were	be	AUX
aiua-12307	192	4	checkmate-9er	checkmate-9er	ADP
aiua-12307	192	5	(	(	PUNCT
aiua-12307	192	6	58	58	NUM
aiua-12307	192	7	)	)	PUNCT
aiua-12307	192	8	(	(	PUNCT
aiua-12307	192	9	nivolumab	nivolumab	NOUN
aiua-12307	192	10	/	/	SYM
aiua-12307	192	11	cabozantinib	cabozantinib	ADV
aiua-12307	192	12	)	)	PUNCT
aiua-12307	192	13	,	,	PUNCT
aiua-12307	192	14	keynote426	keynote426	PROPN
aiua-12307	192	15	(	(	PUNCT
aiua-12307	192	16	57	57	NUM
aiua-12307	192	17	)	)	PUNCT
aiua-12307	192	18	(	(	PUNCT
aiua-12307	192	19	pembrolizumab	pembrolizumab	NOUN
aiua-12307	192	20	/	/	SYM
aiua-12307	192	21	axitinib	axitinib	NOUN
aiua-12307	192	22	)	)	PUNCT
aiua-12307	192	23	,	,	PUNCT
aiua-12307	192	24	and	and	CCONJ
aiua-12307	192	25	clear	clear	ADJ
aiua-12307	192	26	(	(	PUNCT
aiua-12307	192	27	55	55	NUM
aiua-12307	192	28	)	)	PUNCT
aiua-12307	192	29	(	(	PUNCT
aiua-12307	192	30	pembrolizumab	pembrolizumab	NOUN
aiua-12307	192	31	/	/	SYM
aiua-12307	192	32	lenvatinib	lenvatinib	PROPN
aiua-12307	192	33	)	)	PUNCT
aiua-12307	192	34	,	,	PUNCT
aiua-12307	192	35	all	all	PRON
aiua-12307	192	36	of	of	ADP
aiua-12307	192	37	which	which	PRON
aiua-12307	192	38	focused	focus	VERB
aiua-12307	192	39	on	on	ADP
aiua-12307	192	40	ccrcc	ccrcc	NOUN
aiua-12307	192	41	and	and	CCONJ
aiua-12307	192	42	did	do	AUX
aiua-12307	192	43	not	not	PART
aiua-12307	192	44	include	include	VERB
aiua-12307	192	45	less	less	ADJ
aiua-12307	192	46	common	common	ADJ
aiua-12307	192	47	subtypes	subtype	NOUN
aiua-12307	192	48	of	of	ADP
aiua-12307	192	49	kidney	kidney	NOUN
aiua-12307	192	50	cancer	cancer	NOUN
aiua-12307	192	51	.	.	PUNCT
aiua-12307	193	1	in	in	ADP
aiua-12307	193	2	recent	recent	ADJ
aiua-12307	193	3	years	year	NOUN
aiua-12307	193	4	,	,	PUNCT
aiua-12307	193	5	new	new	ADJ
aiua-12307	193	6	prospective	prospective	ADJ
aiua-12307	193	7	trials	trial	NOUN
aiua-12307	193	8	have	have	AUX
aiua-12307	193	9	been	be	AUX
aiua-12307	193	10	conducted	conduct	VERB
aiua-12307	193	11	to	to	PART
aiua-12307	193	12	evaluate	evaluate	VERB
aiua-12307	193	13	the	the	DET
aiua-12307	193	14	effectiveness	effectiveness	NOUN
aiua-12307	193	15	of	of	ADP
aiua-12307	193	16	ici	ici	PROPN
aiua-12307	193	17	/	/	SYM
aiua-12307	193	18	tki	tki	PROPN
aiua-12307	193	19	combinations	combination	NOUN
aiua-12307	193	20	in	in	ADP
aiua-12307	193	21	less	less	ADV
aiua-12307	193	22	common	common	ADJ
aiua-12307	193	23	subtypes	subtype	NOUN
aiua-12307	193	24	(	(	PUNCT
aiua-12307	193	25	table	table	NOUN
aiua-12307	193	26	4	4	NUM
aiua-12307	193	27	)	)	PUNCT
aiua-12307	193	28	(	(	PUNCT
aiua-12307	193	29	59	59	NUM
aiua-12307	193	30	)	)	PUNCT
aiua-12307	193	31	.	.	PUNCT
aiua-12307	194	1	checkmate-9er	checkmate-9er	PROPN
aiua-12307	194	2	trial	trial	NOUN
aiua-12307	194	3	(	(	PUNCT
aiua-12307	194	4	nivolumab	nivolumab	NOUN
aiua-12307	194	5	/	/	SYM
aiua-12307	194	6	cabozantinib	cabozantinib	PROPN
aiua-12307	194	7	)	)	PUNCT
aiua-12307	194	8	checkmate-9er	checkmate-9er	ADP
aiua-12307	194	9	is	be	AUX
aiua-12307	194	10	a	a	DET
aiua-12307	194	11	phase	phase	NOUN
aiua-12307	194	12	iii	iii	NUM
aiua-12307	194	13	rct	rct	PROPN
aiua-12307	194	14	comparing	compare	VERB
aiua-12307	194	15	nivolumab	nivolumab	NOUN
aiua-12307	194	16	/	/	SYM
aiua-12307	194	17	cabozantinib	cabozantinib	ADV
aiua-12307	194	18	(	(	PUNCT
aiua-12307	194	19	n	n	NOUN
aiua-12307	194	20	=	=	SYM
aiua-12307	194	21	323	323	NUM
aiua-12307	194	22	)	)	PUNCT
aiua-12307	194	23	combination	combination	NOUN
aiua-12307	194	24	therapy	therapy	NOUN
aiua-12307	194	25	with	with	ADP
aiua-12307	194	26	sunitinib	sunitinib	NOUN
aiua-12307	194	27	(	(	PUNCT
aiua-12307	194	28	n	n	NOUN
aiua-12307	194	29	=	=	SYM
aiua-12307	194	30	328	328	NUM
aiua-12307	194	31	)	)	PUNCT
aiua-12307	194	32	in	in	ADP
aiua-12307	194	33	651	651	NUM
aiua-12307	194	34	treatment	treatment	NOUN
aiua-12307	194	35	-	-	PUNCT
aiua-12307	194	36	naive	naive	ADJ
aiua-12307	194	37	patients	patient	NOUN
aiua-12307	194	38	diagnosed	diagnose	VERB
aiua-12307	194	39	with	with	ADP
aiua-12307	194	40	cc	cc	NOUN
aiua-12307	194	41	-	-	NOUN
aiua-12307	194	42	mrcc	mrcc	NOUN
aiua-12307	194	43	.	.	PUNCT
aiua-12307	195	1	during	during	ADP
aiua-12307	195	2	a	a	DET
aiua-12307	195	3	mean	mean	ADJ
aiua-12307	195	4	follow	follow	NOUN
aiua-12307	195	5	-	-	PUNCT
aiua-12307	195	6	up	up	NOUN
aiua-12307	195	7	period	period	NOUN
aiua-12307	195	8	of	of	ADP
aiua-12307	195	9	32.9	32.9	NUM
aiua-12307	195	10	mo	mo	NOUN
aiua-12307	195	11	.	.	PROPN
aiua-12307	195	12	,	,	PUNCT
aiua-12307	195	13	the	the	DET
aiua-12307	195	14	median	median	ADJ
aiua-12307	195	15	os	os	NOUN
aiua-12307	195	16	was	be	AUX
aiua-12307	195	17	37.7	37.7	NUM
aiua-12307	195	18	mo	mo	NOUN
aiua-12307	195	19	.	.	PROPN
aiua-12307	196	1	in	in	ADP
aiua-12307	196	2	the	the	DET
aiua-12307	196	3	group	group	NOUN
aiua-12307	196	4	treated	treat	VERB
aiua-12307	196	5	with	with	ADP
aiua-12307	196	6	nivolumab	nivolumab	NOUN
aiua-12307	196	7	/	/	SYM
aiua-12307	196	8	cabozantinib	cabozantinib	NOUN
aiua-12307	196	9	and	and	CCONJ
aiua-12307	196	10	34.3	34.3	NUM
aiua-12307	196	11	mo	mo	NOUN
aiua-12307	196	12	.	.	PROPN
aiua-12307	196	13	in	in	ADP
aiua-12307	196	14	the	the	DET
aiua-12307	196	15	patients	patient	NOUN
aiua-12307	196	16	treated	treat	VERB
aiua-12307	196	17	with	with	ADP
aiua-12307	196	18	sunitinib	sunitinib	NOUN
aiua-12307	196	19	,	,	PUNCT
aiua-12307	196	20	and	and	CCONJ
aiua-12307	196	21	as	as	ADP
aiua-12307	196	22	a	a	DET
aiua-12307	196	23	result	result	NOUN
aiua-12307	196	24	,	,	PUNCT
aiua-12307	196	25	no	no	DET
aiua-12307	196	26	statistically	statistically	ADV
aiua-12307	196	27	significant	significant	ADJ
aiua-12307	196	28	difference	difference	NOUN
aiua-12307	196	29	was	be	AUX
aiua-12307	196	30	observed	observe	VERB
aiua-12307	196	31	.	.	PUNCT
aiua-12307	197	1	while	while	SCONJ
aiua-12307	197	2	the	the	DET
aiua-12307	197	3	median	median	PROPN
aiua-12307	197	4	pfs	pfs	PROPN
aiua-12307	197	5	was	be	AUX
aiua-12307	197	6	16.6	16.6	NUM
aiua-12307	197	7	mo	mo	NOUN
aiua-12307	197	8	.	.	PROPN
aiua-12307	198	1	in	in	ADP
aiua-12307	198	2	the	the	DET
aiua-12307	198	3	group	group	NOUN
aiua-12307	198	4	receiving	receive	VERB
aiua-12307	198	5	nivolumab	nivolumab	NOUN
aiua-12307	198	6	/	/	SYM
aiua-12307	198	7	cabozantinib	cabozantinib	NOUN
aiua-12307	198	8	treatment	treatment	NOUN
aiua-12307	198	9	,	,	PUNCT
aiua-12307	198	10	pfs	pfs	PROPN
aiua-12307	198	11	was	be	AUX
aiua-12307	198	12	8.3	8.3	NUM
aiua-12307	198	13	mo	mo	NOUN
aiua-12307	198	14	.	.	PROPN
aiua-12307	199	1	in	in	ADP
aiua-12307	199	2	sunitinib	sunitinib	NOUN
aiua-12307	199	3	treatment	treatment	NOUN
aiua-12307	199	4	alone	alone	ADV
aiua-12307	199	5	.	.	PUNCT
aiua-12307	200	1	as	as	ADP
aiua-12307	200	2	a	a	DET
aiua-12307	200	3	result	result	NOUN
aiua-12307	200	4	,	,	PUNCT
aiua-12307	200	5	a	a	DET
aiua-12307	200	6	statistically	statistically	ADV
aiua-12307	200	7	significant	significant	ADJ
aiua-12307	200	8	survival	survival	NOUN
aiua-12307	200	9	increase	increase	NOUN
aiua-12307	200	10	in	in	ADP
aiua-12307	200	11	pfs	pfs	PROPN
aiua-12307	200	12	was	be	AUX
aiua-12307	200	13	observed	observe	VERB
aiua-12307	200	14	in	in	ADP
aiua-12307	200	15	favour	favour	NOUN
aiua-12307	200	16	of	of	ADP
aiua-12307	200	17	combination	combination	NOUN
aiua-12307	200	18	treatment	treatment	NOUN
aiua-12307	200	19	.	.	PUNCT
aiua-12307	201	1	treatment	treatment	NOUN
aiua-12307	201	2	-	-	PUNCT
aiua-12307	201	3	related	relate	VERB
aiua-12307	201	4	aes	aes	NOUN
aiua-12307	201	5	(	(	PUNCT
aiua-12307	201	6	>	>	X
aiua-12307	201	7	grade	grade	NOUN
aiua-12307	201	8	3	3	NUM
aiua-12307	201	9	)	)	PUNCT
aiua-12307	201	10	occurred	occur	VERB
aiua-12307	201	11	in	in	ADP
aiua-12307	201	12	61	61	NUM
aiua-12307	201	13	%	%	NOUN
aiua-12307	201	14	of	of	ADP
aiua-12307	201	15	patients	patient	NOUN
aiua-12307	201	16	receiving	receive	VERB
aiua-12307	201	17	nivolumab	nivolumab	NOUN
aiua-12307	201	18	/	/	SYM
aiua-12307	201	19	cabozantinib	cabozantinib	NOUN
aiua-12307	201	20	and	and	CCONJ
aiua-12307	201	21	51	51	NUM
aiua-12307	201	22	%	%	NOUN
aiua-12307	201	23	receiving	receive	VERB
aiua-12307	201	24	sunitinib	sunitinib	NOUN
aiua-12307	201	25	alone	alone	ADV
aiua-12307	201	26	.	.	PUNCT
aiua-12307	202	1	treatment	treatment	NOUN
aiua-12307	202	2	-	-	PUNCT
aiua-12307	202	3	related	relate	VERB
aiua-12307	202	4	death	death	NOUN
aiua-12307	202	5	was	be	AUX
aiua-12307	202	6	reported	report	VERB
aiua-12307	202	7	in	in	ADP
aiua-12307	202	8	one	one	NUM
aiua-12307	202	9	patient	patient	NOUN
aiua-12307	202	10	in	in	ADP
aiua-12307	202	11	the	the	DET
aiua-12307	202	12	nivolumab	nivolumab	NOUN
aiua-12307	202	13	/	/	SYM
aiua-12307	202	14	cabozantinib	cabozantinib	NOUN
aiua-12307	202	15	arm	arm	VERB
aiua-12307	202	16	and	and	CCONJ
aiua-12307	202	17	two	two	NUM
aiua-12307	202	18	patients	patient	NOUN
aiua-12307	202	19	in	in	ADP
aiua-12307	202	20	the	the	DET
aiua-12307	202	21	sunitinib	sunitinib	NOUN
aiua-12307	202	22	arm	arm	NOUN
aiua-12307	202	23	(	(	PUNCT
aiua-12307	202	24	58	58	NUM
aiua-12307	202	25	)	)	PUNCT
aiua-12307	202	26	.	.	PUNCT
aiua-12307	203	1	keynote-426	keynote-426	PROPN
aiua-12307	203	2	trial	trial	NOUN
aiua-12307	203	3	(	(	PUNCT
aiua-12307	203	4	pembrolizumab	pembrolizumab	NOUN
aiua-12307	203	5	/	/	SYM
aiua-12307	203	6	axitinib	axitinib	NOUN
aiua-12307	203	7	)	)	PUNCT
aiua-12307	203	8	the	the	DET
aiua-12307	203	9	keynote-426	keynote-426	NOUN
aiua-12307	203	10	trial	trial	NOUN
aiua-12307	203	11	compared	compare	VERB
aiua-12307	203	12	the	the	DET
aiua-12307	203	13	outcomes	outcome	NOUN
aiua-12307	203	14	of	of	ADP
aiua-12307	203	15	pembrolizumab	pembrolizumab	NOUN
aiua-12307	203	16	/	/	SYM
aiua-12307	203	17	axitinib	axitinib	NOUN
aiua-12307	203	18	combination	combination	NOUN
aiua-12307	203	19	therapy	therapy	NOUN
aiua-12307	203	20	with	with	ADP
aiua-12307	203	21	sunitinib	sunitinib	NOUN
aiua-12307	203	22	monotherapy	monotherapy	NOUN
aiua-12307	203	23	in	in	ADP
aiua-12307	203	24	861	861	NUM
aiua-12307	203	25	treatment	treatment	NOUN
aiua-12307	203	26	-	-	PUNCT
aiua-12307	203	27	naïve	naïve	ADJ
aiua-12307	203	28	cc	cc	NOUN
aiua-12307	203	29	-	-	PUNCT
aiua-12307	203	30	mrcc	mrcc	NOUN
aiua-12307	203	31	patients	patient	NOUN
aiua-12307	203	32	.	.	PUNCT
aiua-12307	204	1	during	during	ADP
aiua-12307	204	2	a	a	DET
aiua-12307	204	3	median	median	ADJ
aiua-12307	204	4	follow	follow	NOUN
aiua-12307	204	5	-	-	PUNCT
aiua-12307	204	6	up	up	NOUN
aiua-12307	204	7	of	of	ADP
aiua-12307	204	8	42.8	42.8	NUM
aiua-12307	204	9	mo	mo	PROPN
aiua-12307	204	10	.	.	PROPN
aiua-12307	204	11	,	,	PUNCT
aiua-12307	204	12	pembrolizumab	pembrolizumab	NOUN
aiua-12307	204	13	/	/	SYM
aiua-12307	204	14	axitinib	axitinib	NOUN
aiua-12307	204	15	combination	combination	NOUN
aiua-12307	204	16	therapy	therapy	NOUN
aiua-12307	204	17	showed	show	VERB
aiua-12307	204	18	an	an	DET
aiua-12307	204	19	os	os	NOUN
aiua-12307	204	20	advantage	advantage	NOUN
aiua-12307	204	21	for	for	ADP
aiua-12307	204	22	the	the	DET
aiua-12307	204	23	intention	intention	NOUN
aiua-12307	204	24	to	to	PART
aiua-12307	204	25	treat	treat	VERB
aiua-12307	204	26	group	group	NOUN
aiua-12307	204	27	(	(	PUNCT
aiua-12307	204	28	hr	hr	NOUN
aiua-12307	204	29	:	:	PUNCT
aiua-12307	204	30	0.73	0.73	NUM
aiua-12307	204	31	,	,	PUNCT
aiua-12307	204	32	95	95	NUM
aiua-12307	204	33	%	%	NOUN
aiua-12307	204	34	ci	ci	NOUN
aiua-12307	204	35	:	:	PUNCT
aiua-12307	204	36	0.600.88	0.600.88	NUM
aiua-12307	204	37	,	,	PUNCT
aiua-12307	204	38	p	p	X
aiua-12307	204	39	<	<	X
aiua-12307	204	40	0.001	0.001	NUM
aiua-12307	204	41	)	)	PUNCT
aiua-12307	204	42	.	.	PUNCT
aiua-12307	205	1	median	median	PROPN
aiua-12307	205	2	os	os	PROPN
aiua-12307	205	3	was	be	AUX
aiua-12307	205	4	45.7	45.7	NUM
aiua-12307	205	5	months	month	NOUN
aiua-12307	205	6	in	in	ADP
aiua-12307	205	7	the	the	DET
aiua-12307	205	8	pembrolizumab	pembrolizumab	NOUN
aiua-12307	205	9	/	/	SYM
aiua-12307	205	10	axitinib	axitinib	NOUN
aiua-12307	205	11	arm	arm	NOUN
aiua-12307	205	12	and	and	CCONJ
aiua-12307	205	13	40.1	40.1	NUM
aiua-12307	205	14	months	month	NOUN
aiua-12307	205	15	in	in	ADP
aiua-12307	205	16	the	the	DET
aiua-12307	205	17	sunitinib	sunitinib	NOUN
aiua-12307	205	18	arm	arm	NOUN
aiua-12307	205	19	,	,	PUNCT
aiua-12307	205	20	and	and	CCONJ
aiua-12307	205	21	a	a	DET
aiua-12307	205	22	pfs	pfs	PROPN
aiua-12307	205	23	advantage	advantage	NOUN
aiua-12307	205	24	was	be	AUX
aiua-12307	205	25	also	also	ADV
aiua-12307	205	26	demonstrated	demonstrate	VERB
aiua-12307	205	27	in	in	ADP
aiua-12307	205	28	the	the	DET
aiua-12307	205	29	combination	combination	NOUN
aiua-12307	205	30	arm	arm	NOUN
aiua-12307	205	31	in	in	ADP
aiua-12307	205	32	imdc	imdc	NOUN
aiua-12307	205	33	subgroups	subgroup	NOUN
aiua-12307	205	34	.	.	PUNCT
aiua-12307	206	1	treatment	treatment	NOUN
aiua-12307	206	2	-	-	PUNCT
aiua-12307	206	3	related	relate	VERB
aiua-12307	206	4	aes	aes	NOUN
aiua-12307	206	5	(	(	PUNCT
aiua-12307	206	6	>	>	X
aiua-12307	206	7	grade	grade	NOUN
aiua-12307	206	8	3	3	NUM
aiua-12307	206	9	)	)	PUNCT
aiua-12307	206	10	occurred	occur	VERB
aiua-12307	206	11	in	in	ADP
aiua-12307	206	12	63	63	NUM
aiua-12307	206	13	%	%	NOUN
aiua-12307	206	14	of	of	ADP
aiua-12307	206	15	patients	patient	NOUN
aiua-12307	206	16	receiving	receive	VERB
aiua-12307	206	17	combination	combination	NOUN
aiua-12307	206	18	therapy	therapy	NOUN
aiua-12307	206	19	and	and	CCONJ
aiua-12307	206	20	58	58	NUM
aiua-12307	206	21	%	%	NOUN
aiua-12307	206	22	of	of	ADP
aiua-12307	206	23	patients	patient	NOUN
aiua-12307	206	24	receiving	receive	VERB
aiua-12307	206	25	sunitinib	sunitinib	NOUN
aiua-12307	206	26	.	.	PUNCT
aiua-12307	207	1	treatment	treatment	NOUN
aiua-12307	207	2	-	-	PUNCT
aiua-12307	207	3	related	relate	VERB
aiua-12307	207	4	deaths	death	NOUN
aiua-12307	207	5	were	be	AUX
aiua-12307	207	6	reported	report	VERB
aiua-12307	207	7	at	at	ADP
aiua-12307	207	8	a	a	DET
aiua-12307	207	9	rate	rate	NOUN
aiua-12307	207	10	of	of	ADP
aiua-12307	207	11	approximately	approximately	ADV
aiua-12307	207	12	1	1	NUM
aiua-12307	207	13	%	%	NOUN
aiua-12307	207	14	in	in	ADP
aiua-12307	207	15	both	both	DET
aiua-12307	207	16	arms	arm	NOUN
aiua-12307	207	17	(	(	PUNCT
aiua-12307	207	18	57	57	NUM
aiua-12307	207	19	)	)	PUNCT
aiua-12307	207	20	.	.	PUNCT
aiua-12307	208	1	clear	clear	ADJ
aiua-12307	208	2	trial	trial	NOUN
aiua-12307	208	3	(	(	PUNCT
aiua-12307	208	4	everolimus	everolimus	NOUN
aiua-12307	208	5	/	/	SYM
aiua-12307	208	6	lenvantinib	lenvantinib	NOUN
aiua-12307	208	7	-	-	PUNCT
aiua-12307	208	8	pembrolizumab	pembrolizumab	NOUN
aiua-12307	208	9	/	/	SYM
aiua-12307	208	10	lenvantinib	lenvantinib	NOUN
aiua-12307	208	11	)	)	PUNCT
aiua-12307	208	12	the	the	DET
aiua-12307	208	13	clear	clear	ADJ
aiua-12307	208	14	randomized	randomized	ADJ
aiua-12307	208	15	phase	phase	NOUN
aiua-12307	208	16	iii	iii	NUM
aiua-12307	208	17	clinical	clinical	ADJ
aiua-12307	208	18	trial	trial	NOUN
aiua-12307	208	19	compared	compare	VERB
aiua-12307	208	20	everolimus	everolimus	NOUN
aiua-12307	208	21	/	/	SYM
aiua-12307	208	22	lenvantinib	lenvantinib	NOUN
aiua-12307	208	23	or	or	CCONJ
aiua-12307	208	24	pembrolizumab	pembrolizumab	NOUN
aiua-12307	208	25	/	/	SYM
aiua-12307	208	26	lenvantinib	lenvantinib	NOUN
aiua-12307	208	27	combination	combination	NOUN
aiua-12307	208	28	therapy	therapy	NOUN
aiua-12307	208	29	with	with	ADP
aiua-12307	208	30	sunitinib	sunitinib	NOUN
aiua-12307	208	31	alone	alone	ADJ
aiua-12307	208	32	in	in	ADP
aiua-12307	208	33	treating	treat	VERB
aiua-12307	208	34	advanced	advanced	ADJ
aiua-12307	208	35	rcc	rcc	PROPN
aiua-12307	208	36	.	.	PUNCT
aiua-12307	209	1	clear	clear	PROPN
aiua-12307	209	2	randomized	randomize	VERB
aiua-12307	209	3	a	a	DET
aiua-12307	209	4	total	total	NOUN
aiua-12307	209	5	of	of	ADP
aiua-12307	209	6	1,069	1,069	NUM
aiua-12307	209	7	patients	patient	NOUN
aiua-12307	209	8	(	(	PUNCT
aiua-12307	209	9	in	in	ADP
aiua-12307	209	10	a	a	DET
aiua-12307	209	11	1:1:1	1:1:1	NUM
aiua-12307	209	12	ratio	ratio	NOUN
aiua-12307	209	13	)	)	PUNCT
aiua-12307	209	14	to	to	PART
aiua-12307	209	15	pembrolizumab	pembrolizumab	VERB
aiua-12307	209	16	/	/	SYM
aiua-12307	209	17	lenvatinib	lenvatinib	PROPN
aiua-12307	209	18	(	(	PUNCT
aiua-12307	209	19	n	n	NOUN
aiua-12307	209	20	=	=	NUM
aiua-12307	209	21	355	355	NUM
aiua-12307	209	22	)	)	PUNCT
aiua-12307	209	23	,	,	PUNCT
aiua-12307	209	24	everolimus	everolimus	NOUN
aiua-12307	209	25	/	/	SYM
aiua-12307	209	26	lenvatinib	lenvatinib	PROPN
aiua-12307	209	27	(	(	PUNCT
aiua-12307	209	28	n	n	NOUN
aiua-12307	209	29	=	=	NUM
aiua-12307	209	30	357	357	NUM
aiua-12307	209	31	)	)	PUNCT
aiua-12307	209	32	,	,	PUNCT
aiua-12307	209	33	and	and	CCONJ
aiua-12307	209	34	sunitinib	sunitinib	NOUN
aiua-12307	209	35	(	(	PUNCT
aiua-12307	209	36	n	n	NOUN
aiua-12307	209	37	=	=	NUM
aiua-12307	209	38	357	357	NUM
aiua-12307	209	39	)	)	PUNCT
aiua-12307	209	40	.	.	PUNCT
aiua-12307	210	1	in	in	ADP
aiua-12307	210	2	the	the	DET
aiua-12307	210	3	study	study	NOUN
aiua-12307	210	4	,	,	PUNCT
aiua-12307	210	5	the	the	DET
aiua-12307	210	6	pembrolizumab	pembrolizumab	NOUN
aiua-12307	210	7	/	/	SYM
aiua-12307	210	8	lenvatinib	lenvatinib	PROPN
aiua-12307	210	9	arm	arm	NOUN
aiua-12307	210	10	reached	reach	VERB
aiua-12307	210	11	its	its	PRON
aiua-12307	210	12	primary	primary	ADJ
aiua-12307	210	13	endpoint	endpoint	NOUN
aiua-12307	210	14	compared	compare	VERB
aiua-12307	210	15	to	to	ADP
aiua-12307	210	16	sunitinib	sunitinib	NOUN
aiua-12307	210	17	,	,	PUNCT
aiua-12307	210	18	with	with	ADP
aiua-12307	210	19	a	a	DET
aiua-12307	210	20	median	median	ADJ
aiua-12307	210	21	pfs	pf	NOUN
aiua-12307	210	22	of	of	ADP
aiua-12307	210	23	9.2	9.2	NUM
aiua-12307	210	24	mo	mo	PROPN
aiua-12307	210	25	.	.	PROPN
aiua-12307	211	1	vs	vs	ADP
aiua-12307	211	2	23.9	23.9	NUM
aiua-12307	211	3	mo	mo	NOUN
aiua-12307	211	4	.	.	PUNCT
aiua-12307	212	1	(	(	PUNCT
aiua-12307	212	2	hr	hr	NOUN
aiua-12307	212	3	:	:	PUNCT
aiua-12307	212	4	0.39	0.39	NUM
aiua-12307	212	5	,	,	PUNCT
aiua-12307	212	6	95	95	NUM
aiua-12307	212	7	%	%	NOUN
aiua-12307	212	8	ci	ci	NOUN
aiua-12307	212	9	:	:	PUNCT
aiua-12307	212	10	0.32	0.32	NUM
aiua-12307	212	11	-	-	SYM
aiua-12307	212	12	0.49	0.49	NUM
aiua-12307	212	13	,	,	PUNCT
aiua-12307	212	14	p	p	X
aiua-12307	212	15	<	<	X
aiua-12307	212	16	0.001	0.001	NUM
aiua-12307	212	17	)	)	PUNCT
aiua-12307	212	18	.	.	PUNCT
aiua-12307	213	1	compared	compare	VERB
aiua-12307	213	2	to	to	ADP
aiua-12307	213	3	sunitinib	sunitinib	NOUN
aiua-12307	213	4	,	,	PUNCT
aiua-12307	213	5	os	os	PROPN
aiua-12307	213	6	was	be	AUX
aiua-12307	213	7	significantly	significantly	ADV
aiua-12307	213	8	improved	improve	VERB
aiua-12307	213	9	with	with	ADP
aiua-12307	213	10	pembrolizumab	pembrolizumab	NOUN
aiua-12307	213	11	/	/	SYM
aiua-12307	213	12	lenvatinib	lenvatinib	PROPN
aiua-12307	213	13	(	(	PUNCT
aiua-12307	213	14	hr	hr	NOUN
aiua-12307	213	15	:	:	PUNCT
aiua-12307	213	16	0.66	0.66	NUM
aiua-12307	213	17	,	,	PUNCT
aiua-12307	213	18	95	95	NUM
aiua-12307	213	19	%	%	NOUN
aiua-12307	213	20	ci	ci	NOUN
aiua-12307	213	21	:	:	PUNCT
aiua-12307	213	22	0.49	0.49	NUM
aiua-12307	213	23	-	-	SYM
aiua-12307	213	24	0.88	0.88	NUM
aiua-12307	213	25	,	,	PUNCT
aiua-12307	213	26	p	p	NOUN
aiua-12307	213	27	=	=	NOUN
aiua-12307	213	28	0.005	0.005	NUM
aiua-12307	213	29	)	)	PUNCT
aiua-12307	213	30	.	.	PUNCT
aiua-12307	214	1	efficacy	efficacy	NOUN
aiua-12307	214	2	was	be	AUX
aiua-12307	214	3	observed	observe	VERB
aiua-12307	214	4	in	in	ADP
aiua-12307	214	5	all	all	DET
aiua-12307	214	6	imdc	imdc	ADJ
aiua-12307	214	7	risk	risk	NOUN
aiua-12307	214	8	groups	group	NOUN
aiua-12307	214	9	,	,	PUNCT
aiua-12307	214	10	regardless	regardless	ADV
aiua-12307	214	11	of	of	ADP
aiua-12307	214	12	pd	pd	PROPN
aiua-12307	214	13	-	-	PUNCT
aiua-12307	214	14	l1	l1	PROPN
aiua-12307	214	15	status	status	NOUN
aiua-12307	214	16	.	.	PUNCT
aiua-12307	215	1	grade	grade	NOUN
aiua-12307	215	2	3	3	NUM
aiua-12307	215	3	or	or	CCONJ
aiua-12307	215	4	higher	high	ADJ
aiua-12307	215	5	aes	aes	NOUN
aiua-12307	215	6	associated	associate	VERB
aiua-12307	215	7	with	with	ADP
aiua-12307	215	8	treatment	treatment	NOUN
aiua-12307	215	9	with	with	ADP
aiua-12307	215	10	pembrolizumab	pembrolizumab	NOUN
aiua-12307	215	11	/	/	SYM
aiua-12307	215	12	lenvatinib	lenvatinib	NOUN
aiua-12307	215	13	were	be	AUX
aiua-12307	215	14	72	72	NUM
aiua-12307	215	15	%	%	NOUN
aiua-12307	215	16	.	.	PUNCT
aiua-12307	216	1	treatmentrelated	treatmentrelate	VERB
aiua-12307	216	2	deaths	death	NOUN
aiua-12307	216	3	occurred	occur	VERB
aiua-12307	216	4	in	in	ADP
aiua-12307	216	5	four	four	NUM
aiua-12307	216	6	patients	patient	NOUN
aiua-12307	216	7	in	in	ADP
aiua-12307	216	8	the	the	DET
aiua-12307	216	9	pembrolizumab	pembrolizumab	NOUN
aiua-12307	216	10	/	/	SYM
aiua-12307	216	11	lenvatinib	lenvatinib	NOUN
aiua-12307	216	12	arm	arm	NOUN
aiua-12307	216	13	and	and	CCONJ
aiua-12307	216	14	one	one	NUM
aiua-12307	216	15	patient	patient	NOUN
aiua-12307	216	16	in	in	ADP
aiua-12307	216	17	the	the	DET
aiua-12307	216	18	sunitinib	sunitinib	NOUN
aiua-12307	216	19	arm	arm	NOUN
aiua-12307	216	20	(	(	PUNCT
aiua-12307	216	21	55	55	NUM
aiua-12307	216	22	)	)	PUNCT
aiua-12307	216	23	.	.	PUNCT
aiua-12307	217	1	checkmate-214	checkmate-214	ADJ
aiua-12307	217	2	trial	trial	NOUN
aiua-12307	217	3	(	(	PUNCT
aiua-12307	217	4	ipilimumab	ipilimumab	NOUN
aiua-12307	217	5	/	/	SYM
aiua-12307	217	6	nivolumab	nivolumab	NOUN
aiua-12307	217	7	)	)	PUNCT
aiua-12307	217	8	the	the	DET
aiua-12307	217	9	combination	combination	NOUN
aiua-12307	217	10	of	of	ADP
aiua-12307	217	11	ipilimumab	ipilimumab	NOUN
aiua-12307	217	12	/	/	SYM
aiua-12307	217	13	nivolumab	nivolumab	NOUN
aiua-12307	217	14	,	,	PUNCT
aiua-12307	217	15	targeting	target	VERB
aiua-12307	217	16	anti	anti	ADJ
aiua-12307	217	17	-	-	ADJ
aiua-12307	217	18	ctla4	ctla4	ADJ
aiua-12307	217	19	and	and	CCONJ
aiua-12307	217	20	anti	anti	ADJ
aiua-12307	217	21	-	-	ADJ
aiua-12307	217	22	pd-1	pd-1	ADV
aiua-12307	217	23	,	,	PUNCT
aiua-12307	217	24	showed	show	VERB
aiua-12307	217	25	improvements	improvement	NOUN
aiua-12307	217	26	in	in	ADP
aiua-12307	217	27	pfs	pfs	PROPN
aiua-12307	217	28	and	and	CCONJ
aiua-12307	217	29	os	os	NOUN
aiua-12307	217	30	compared	compare	VERB
aiua-12307	217	31	to	to	ADP
aiua-12307	217	32	sunitinib	sunitinib	NOUN
aiua-12307	217	33	based	base	VERB
aiua-12307	217	34	on	on	ADP
aiua-12307	217	35	data	datum	NOUN
aiua-12307	217	36	from	from	ADP
aiua-12307	217	37	the	the	DET
aiua-12307	217	38	phase	phase	NOUN
aiua-12307	217	39	iii	iii	NUM
aiua-12307	217	40	checkmate-214	checkmate-214	ADJ
aiua-12307	217	41	trial	trial	NOUN
aiua-12307	217	42	,	,	PUNCT
aiua-12307	217	43	which	which	PRON
aiua-12307	217	44	led	lead	VERB
aiua-12307	217	45	to	to	ADP
aiua-12307	217	46	its	its	PRON
aiua-12307	217	47	approval	approval	NOUN
aiua-12307	217	48	by	by	ADP
aiua-12307	217	49	the	the	DET
aiua-12307	217	50	international	international	ADJ
aiua-12307	217	51	metastatic	metastatic	PROPN
aiua-12307	217	52	rcc	rcc	PROPN
aiua-12307	217	53	database	database	PROPN
aiua-12307	217	54	consortium	consortium	PROPN
aiua-12307	217	55	(	(	PUNCT
aiua-12307	217	56	imdc	imdc	PROPN
aiua-12307	217	57	)	)	PUNCT
aiua-12307	217	58	for	for	ADP
aiua-12307	217	59	the	the	DET
aiua-12307	217	60	treatment	treatment	NOUN
aiua-12307	217	61	of	of	ADP
aiua-12307	217	62	low	low	ADJ
aiua-12307	217	63	and	and	CCONJ
aiua-12307	217	64	intermediate	intermediate	ADJ
aiua-12307	217	65	risk	risk	NOUN
aiua-12307	217	66	ccmrcc	ccmrcc	NOUN
aiua-12307	217	67	.	.	PUNCT
aiua-12307	218	1	at	at	ADP
aiua-12307	218	2	60	60	NUM
aiua-12307	218	3	mo	mo	PROPN
aiua-12307	218	4	.	.	PROPN
aiua-12307	218	5	of	of	ADP
aiua-12307	218	6	follow	follow	VERB
aiua-12307	218	7	-	-	PUNCT
aiua-12307	218	8	up	up	NOUN
aiua-12307	218	9	in	in	ADP
aiua-12307	218	10	the	the	DET
aiua-12307	218	11	checkmate-214	checkmate-214	ADJ
aiua-12307	218	12	trial	trial	NOUN
aiua-12307	218	13	,	,	PUNCT
aiua-12307	218	14	os	os	NOUN
aiua-12307	218	15	rates	rate	NOUN
aiua-12307	218	16	were	be	AUX
aiua-12307	218	17	43	43	NUM
aiua-12307	218	18	%	%	NOUN
aiua-12307	218	19	in	in	ADP
aiua-12307	218	20	the	the	DET
aiua-12307	218	21	ipilimumab	ipilimumab	ADJ
aiua-12307	218	22	/	/	SYM
aiua-12307	218	23	nivolumab	nivolumab	NOUN
aiua-12307	218	24	arm	arm	NOUN
aiua-12307	218	25	and	and	CCONJ
aiua-12307	218	26	31	31	NUM
aiua-12307	218	27	%	%	NOUN
aiua-12307	218	28	in	in	ADP
aiua-12307	218	29	the	the	DET
aiua-12307	218	30	sunitinib	sunitinib	NOUN
aiua-12307	218	31	arm	arm	NOUN
aiua-12307	218	32	,	,	PUNCT
aiua-12307	218	33	respectively	respectively	ADV
aiua-12307	218	34	.	.	PUNCT
aiua-12307	219	1	grade	grade	NOUN
aiua-12307	219	2	34	34	NUM
aiua-12307	219	3	toxicity	toxicity	NOUN
aiua-12307	219	4	was	be	AUX
aiua-12307	219	5	reported	report	VERB
aiua-12307	219	6	in	in	ADP
aiua-12307	219	7	46	46	NUM
aiua-12307	219	8	%	%	NOUN
aiua-12307	219	9	and	and	CCONJ
aiua-12307	219	10	treatment	treatment	NOUN
aiua-12307	219	11	-	-	PUNCT
aiua-12307	219	12	secondary	secondary	ADJ
aiua-12307	219	13	death	death	NOUN
aiua-12307	219	14	in	in	ADP
aiua-12307	219	15	1.5	1.5	NUM
aiua-12307	219	16	%	%	NOUN
aiua-12307	219	17	in	in	ADP
aiua-12307	219	18	the	the	DET
aiua-12307	219	19	ipilimumab	ipilimumab	ADJ
aiua-12307	219	20	/	/	SYM
aiua-12307	219	21	nivolumab	nivolumab	NOUN
aiua-12307	219	22	arm	arm	NOUN
aiua-12307	219	23	(	(	PUNCT
aiua-12307	219	24	56	56	NUM
aiua-12307	219	25	)	)	PUNCT
aiua-12307	219	26	.	.	PUNCT
aiua-12307	220	1	therefore	therefore	ADV
aiua-12307	220	2	,	,	PUNCT
aiua-12307	220	3	immune	immune	ADJ
aiua-12307	220	4	combination	combination	NOUN
aiua-12307	220	5	therapy	therapy	NOUN
aiua-12307	220	6	should	should	AUX
aiua-12307	220	7	be	be	AUX
aiua-12307	220	8	applied	apply	VERB
aiua-12307	220	9	within	within	ADP
aiua-12307	220	10	the	the	DET
aiua-12307	220	11	scope	scope	NOUN
aiua-12307	220	12	of	of	ADP
aiua-12307	220	13	a	a	DET
aiua-12307	220	14	multidisciplinary	multidisciplinary	ADJ
aiua-12307	220	15	team	team	NOUN
aiua-12307	220	16	in	in	ADP
aiua-12307	220	17	centres	centre	NOUN
aiua-12307	220	18	with	with	ADP
aiua-12307	220	19	appropriate	appropriate	ADJ
aiua-12307	220	20	supportive	supportive	ADJ
aiua-12307	220	21	care	care	NOUN
aiua-12307	220	22	experience	experience	NOUN
aiua-12307	220	23	(	(	PUNCT
aiua-12307	220	24	table	table	NOUN
aiua-12307	220	25	5	5	NUM
aiua-12307	220	26	)	)	PUNCT
aiua-12307	220	27	(	(	PUNCT
aiua-12307	220	28	48	48	NUM
aiua-12307	220	29	)	)	PUNCT
aiua-12307	220	30	.	.	PUNCT
aiua-12307	221	1	archivio	archivio	NOUN
aiua-12307	221	2	italiano	italiano	PROPN
aiua-12307	221	3	di	di	X
aiua-12307	221	4	urologia	urologia	PROPN
aiua-12307	221	5	e	e	PROPN
aiua-12307	221	6	andrologia	andrologia	NOUN
aiua-12307	221	7	2024	2024	NUM
aiua-12307	221	8	;	;	PUNCT
aiua-12307	221	9	96(2):12307	96(2):12307	NUM
aiua-12307	221	10	7	7	NUM
aiua-12307	221	11	the	the	DET
aiua-12307	221	12	role	role	NOUN
aiua-12307	221	13	of	of	ADP
aiua-12307	221	14	immunotherapy	immunotherapy	NOUN
aiua-12307	221	15	in	in	ADP
aiua-12307	221	16	urological	urological	ADJ
aiua-12307	221	17	cancers	cancer	NOUN
aiua-12307	221	18	table	table	NOUN
aiua-12307	221	19	4	4	NUM
aiua-12307	221	20	.	.	PUNCT
aiua-12307	222	1	first	first	ADJ
aiua-12307	222	2	-	-	PUNCT
aiua-12307	222	3	line	line	NOUN
aiua-12307	222	4	immune	immune	ADJ
aiua-12307	222	5	checkpoint	checkpoint	NOUN
aiua-12307	222	6	inhibitor	inhibitor	NOUN
aiua-12307	222	7	combination	combination	NOUN
aiua-12307	222	8	trials	trial	NOUN
aiua-12307	222	9	for	for	ADP
aiua-12307	222	10	clear	clear	ADJ
aiua-12307	222	11	-	-	PUNCT
aiua-12307	222	12	cell	cell	NOUN
aiua-12307	222	13	rcc	rcc	NOUN
aiua-12307	222	14	(	(	PUNCT
aiua-12307	222	15	59	59	NUM
aiua-12307	222	16	)	)	PUNCT
aiua-12307	222	17	.	.	PUNCT
aiua-12307	223	1	study	study	VERB
aiua-12307	223	2	n	n	CCONJ
aiua-12307	223	3	experimental	experimental	ADJ
aiua-12307	223	4	arm	arm	NOUN
aiua-12307	223	5	primary	primary	ADJ
aiua-12307	223	6	endpoint	endpoint	NOUN
aiua-12307	223	7	risk	risk	NOUN
aiua-12307	223	8	groups	group	NOUN
aiua-12307	223	9	pfs	pfs	PROPN
aiua-12307	223	10	(	(	PUNCT
aiua-12307	223	11	mo	mo	PROPN
aiua-12307	223	12	)	)	PUNCT
aiua-12307	223	13	median	median	NOUN
aiua-12307	223	14	os	os	PROPN
aiua-12307	223	15	(	(	PUNCT
aiua-12307	223	16	mo	mo	PROPN
aiua-12307	223	17	)	)	PUNCT
aiua-12307	223	18	median	median	NOUN
aiua-12307	223	19	(	(	PUNCT
aiua-12307	223	20	95	95	NUM
aiua-12307	223	21	%	%	NOUN
aiua-12307	223	22	ci	ci	NOUN
aiua-12307	223	23	)	)	PUNCT
aiua-12307	223	24	hr	hr	NOUN
aiua-12307	223	25	(	(	PUNCT
aiua-12307	223	26	95	95	NUM
aiua-12307	223	27	%	%	NOUN
aiua-12307	223	28	ci	ci	NOUN
aiua-12307	223	29	)	)	PUNCT
aiua-12307	223	30	hr	hr	NOUN
aiua-12307	223	31	batezo	batezo	X
aiua-12307	223	32	=	=	SYM
aiua-12307	223	33	atezolizumab	atezolizumab	PROPN
aiua-12307	223	34	;	;	PUNCT
aiua-12307	223	35	ave	ave	NOUN
aiua-12307	223	36	=	=	SYM
aiua-12307	223	37	avelumab	avelumab	NOUN
aiua-12307	223	38	;	;	PUNCT
aiua-12307	223	39	axi	axi	NOUN
aiua-12307	223	40	=	=	SYM
aiua-12307	223	41	axitinib	axitinib	NOUN
aiua-12307	223	42	;	;	PUNCT
aiua-12307	223	43	bev	bev	PROPN
aiua-12307	223	44	=	=	SYM
aiua-12307	223	45	bevacizumab	bevacizumab	PROPN
aiua-12307	223	46	;	;	PUNCT
aiua-12307	223	47	bicr	bicr	NOUN
aiua-12307	223	48	=	=	SYM
aiua-12307	223	49	blinded	blind	VERB
aiua-12307	223	50	independent	independent	ADJ
aiua-12307	223	51	central	central	ADJ
aiua-12307	223	52	review	review	NOUN
aiua-12307	223	53	;	;	PUNCT
aiua-12307	223	54	bid	bid	NOUN
aiua-12307	223	55	=	=	PUNCT
aiua-12307	223	56	twice	twice	DET
aiua-12307	223	57	a	a	DET
aiua-12307	223	58	day	day	NOUN
aiua-12307	223	59	;	;	PUNCT
aiua-12307	223	60	cabo	cabo	NOUN
aiua-12307	223	61	=	=	PUNCT
aiua-12307	223	62	cabozantinib	cabozantinib	ADV
aiua-12307	223	63	;	;	PUNCT
aiua-12307	223	64	ci	ci	NOUN
aiua-12307	223	65	=	=	NOUN
aiua-12307	223	66	confidence	confidence	NOUN
aiua-12307	223	67	interval	interval	NOUN
aiua-12307	223	68	;	;	PUNCT
aiua-12307	223	69	fav	fav	ADJ
aiua-12307	223	70	=	=	SYM
aiua-12307	223	71	favourable	favourable	ADJ
aiua-12307	223	72	;	;	PUNCT
aiua-12307	223	73	hr	hr	NOUN
aiua-12307	223	74	=	=	PUNCT
aiua-12307	223	75	hazard	hazard	NOUN
aiua-12307	223	76	ratio	ratio	NOUN
aiua-12307	223	77	;	;	PUNCT
aiua-12307	223	78	ipi	ipi	PROPN
aiua-12307	223	79	=	=	PUNCT
aiua-12307	223	80	ipilimumab	ipilimumab	PROPN
aiua-12307	223	81	;	;	PUNCT
aiua-12307	223	82	imd	imd	PROPN
aiua-12307	223	83	=	=	SYM
aiua-12307	223	84	intermediate	intermediate	ADJ
aiua-12307	223	85	;	;	PUNCT
aiua-12307	223	86	imdc	imdc	NOUN
aiua-12307	223	87	=	=	SYM
aiua-12307	223	88	metastatic	metastatic	ADJ
aiua-12307	223	89	renal	renal	ADJ
aiua-12307	223	90	cancer	cancer	NOUN
aiua-12307	223	91	database	database	NOUN
aiua-12307	223	92	consortium	consortium	NOUN
aiua-12307	223	93	;	;	PUNCT
aiua-12307	223	94	ir	ir	PROPN
aiua-12307	223	95	=	=	NOUN
aiua-12307	223	96	investigator	investigator	NOUN
aiua-12307	223	97	review	review	NOUN
aiua-12307	223	98	;	;	PUNCT
aiua-12307	223	99	itt	itt	ADJ
aiua-12307	223	100	=	=	PUNCT
aiua-12307	223	101	intention	intention	NOUN
aiua-12307	223	102	-	-	PUNCT
aiua-12307	223	103	to	to	ADP
aiua-12307	223	104	-	-	PUNCT
aiua-12307	223	105	treat	treat	NOUN
aiua-12307	223	106	;	;	PUNCT
aiua-12307	223	107	iv	iv	X
aiua-12307	223	108	=	=	SYM
aiua-12307	223	109	intravenous	intravenous	ADJ
aiua-12307	223	110	;	;	PUNCT
aiua-12307	223	111	len	len	NOUN
aiua-12307	223	112	=	=	PUNCT
aiua-12307	223	113	lenvatinib	lenvatinib	NOUN
aiua-12307	223	114	;	;	PUNCT
aiua-12307	223	115	mo	mo	PROPN
aiua-12307	223	116	=	=	PROPN
aiua-12307	223	117	months	month	NOUN
aiua-12307	223	118	;	;	PUNCT
aiua-12307	223	119	mskcc	mskcc	X
aiua-12307	223	120	=	=	SYM
aiua-12307	223	121	memorial	memorial	ADJ
aiua-12307	223	122	sloan	sloan	PROPN
aiua-12307	223	123	kettering	kettering	PROPN
aiua-12307	223	124	cancer	cancer	NOUN
aiua-12307	223	125	center	center	NOUN
aiua-12307	223	126	;	;	PUNCT
aiua-12307	223	127	ne	ne	X
aiua-12307	223	128	=	=	SYM
aiua-12307	223	129	non	non	ADJ
aiua-12307	223	130	-	-	ADJ
aiua-12307	223	131	estimable	estimable	ADJ
aiua-12307	223	132	;	;	PUNCT
aiua-12307	223	133	nr	nr	PRON
aiua-12307	223	134	=	=	PUNCT
aiua-12307	223	135	not	not	PART
aiua-12307	223	136	reached	reach	VERB
aiua-12307	223	137	;	;	PUNCT
aiua-12307	223	138	nivo	nivo	PROPN
aiua-12307	223	139	=	=	SYM
aiua-12307	223	140	nivolumab	nivolumab	NOUN
aiua-12307	223	141	;	;	PUNCT
aiua-12307	223	142	os	os	NOUN
aiua-12307	223	143	=	=	VERB
aiua-12307	223	144	overall	overall	ADJ
aiua-12307	223	145	survival	survival	NOUN
aiua-12307	223	146	;	;	PUNCT
aiua-12307	223	147	pembro	pembro	NOUN
aiua-12307	223	148	=	=	NOUN
aiua-12307	223	149	pembrolizumab	pembrolizumab	NOUN
aiua-12307	223	150	;	;	PUNCT
aiua-12307	223	151	pfs	pfs	PROPN
aiua-12307	223	152	=	=	SYM
aiua-12307	223	153	profession	profession	NOUN
aiua-12307	223	154	-	-	PUNCT
aiua-12307	223	155	free	free	ADJ
aiua-12307	223	156	survival	survival	NOUN
aiua-12307	223	157	;	;	PUNCT
aiua-12307	223	158	pitt	pitt	PROPN
aiua-12307	223	159	=	=	SYM
aiua-12307	223	160	pfs	pfs	PROPN
aiua-12307	223	161	intention	intention	NOUN
aiua-12307	223	162	-	-	PUNCT
aiua-12307	223	163	to	to	ADP
aiua-12307	223	164	-	-	PUNCT
aiua-12307	223	165	treat	treat	NOUN
aiua-12307	223	166	;	;	PUNCT
aiua-12307	223	167	po	po	X
aiua-12307	223	168	=	=	PUNCT
aiua-12307	223	169	by	by	ADP
aiua-12307	223	170	mouth	mouth	NOUN
aiua-12307	223	171	;	;	PUNCT
aiua-12307	223	172	pts	pt	NOUN
aiua-12307	223	173	=	=	NOUN
aiua-12307	223	174	patients	patient	NOUN
aiua-12307	223	175	;	;	PUNCT
aiua-12307	223	176	qd	qd	NOUN
aiua-12307	223	177	=	=	PUNCT
aiua-12307	223	178	once	once	ADV
aiua-12307	223	179	a	a	DET
aiua-12307	223	180	day	day	NOUN
aiua-12307	223	181	;	;	PUNCT
aiua-12307	223	182	q2w	q2w	X
aiua-12307	223	183	=	=	SYM
aiua-12307	223	184	every	every	DET
aiua-12307	223	185	2	2	NUM
aiua-12307	223	186	weeks	week	NOUN
aiua-12307	223	187	;	;	PUNCT
aiua-12307	223	188	q3w	q3w	NOUN
aiua-12307	223	189	=	=	PUNCT
aiua-12307	223	190	every	every	DET
aiua-12307	223	191	3	3	NUM
aiua-12307	223	192	weeks	week	NOUN
aiua-12307	223	193	;	;	PUNCT
aiua-12307	223	194	sun	sun	NOUN
aiua-12307	223	195	=	=	SYM
aiua-12307	223	196	sunitinib	sunitinib	NOUN
aiua-12307	223	197	;	;	PUNCT
aiua-12307	223	198	wk	wk	NOUN
aiua-12307	223	199	=	=	SYM
aiua-12307	223	200	weeks	week	NOUN
aiua-12307	223	201	.	.	PUNCT
aiua-12307	223	202	checkmate	checkmate	VERB
aiua-12307	223	203	9er	9er	ADJ
aiua-12307	223	204	nct03141177	nct03141177	ADJ
aiua-12307	223	205	median	median	ADJ
aiua-12307	223	206	follow	follow	NOUN
aiua-12307	223	207	-	-	PUNCT
aiua-12307	223	208	up	up	NOUN
aiua-12307	223	209	of	of	ADP
aiua-12307	223	210	23.5	23.5	NUM
aiua-12307	223	211	mo	mo	PROPN
aiua-12307	223	212	.	.	PROPN
aiua-12307	223	213	keynote-426	keynote-426	PROPN
aiua-12307	223	214	nct02853331	nct02853331	PROPN
aiua-12307	224	1	median	median	PROPN
aiua-12307	224	2	follow	follow	NOUN
aiua-12307	224	3	-	-	PUNCT
aiua-12307	224	4	up	up	NOUN
aiua-12307	224	5	of	of	ADP
aiua-12307	224	6	42.8	42.8	NUM
aiua-12307	224	7	mo	mo	PROPN
aiua-12307	224	8	.	.	PROPN
aiua-12307	224	9	clear	clear	PROPN
aiua-12307	224	10	nct02811861	nct02811861	NOUN
aiua-12307	224	11	median	median	ADJ
aiua-12307	224	12	follow	follow	NOUN
aiua-12307	224	13	-	-	PUNCT
aiua-12307	224	14	up	up	NOUN
aiua-12307	224	15	of	of	ADP
aiua-12307	224	16	33.4	33.4	NUM
aiua-12307	224	17	mo	mo	PROPN
aiua-12307	224	18	.	.	PROPN
aiua-12307	224	19	checkmate	checkmate	VERB
aiua-12307	224	20	214	214	NUM
aiua-12307	224	21	nct02231749	nct02231749	NOUN
aiua-12307	224	22	median	median	ADJ
aiua-12307	224	23	follow	follow	NOUN
aiua-12307	224	24	-	-	PUNCT
aiua-12307	224	25	up	up	NOUN
aiua-12307	224	26	of	of	ADP
aiua-12307	224	27	60	60	NUM
aiua-12307	224	28	mo	mo	PROPN
aiua-12307	224	29	.	.	PROPN
aiua-12307	224	30	javelin	javelin	PROPN
aiua-12307	224	31	101	101	NUM
aiua-12307	224	32	nct02684006	nct02684006	ADJ
aiua-12307	224	33	median	median	ADJ
aiua-12307	224	34	follow	follow	NOUN
aiua-12307	224	35	-	-	PUNCT
aiua-12307	224	36	up	up	NOUN
aiua-12307	224	37	19	19	NUM
aiua-12307	224	38	mo	mo	NOUN
aiua-12307	224	39	.	.	PROPN
aiua-12307	225	1	immotion151	immotion151	PROPN
aiua-12307	225	2	nct02420821	nct02420821	VERB
aiua-12307	225	3	median	median	ADJ
aiua-12307	225	4	follow	follow	VERB
aiua-12307	225	5	-	-	PUNCT
aiua-12307	225	6	up	up	NOUN
aiua-12307	225	7	24	24	NUM
aiua-12307	225	8	mo	mo	PROPN
aiua-12307	225	9	.	.	PROPN
aiua-12307	225	10	nivo	nivo	PROPN
aiua-12307	225	11	240	240	NUM
aiua-12307	225	12	mg	mg	PROPN
aiua-12307	225	13	fixed	fix	VERB
aiua-12307	225	14	dose	dose	NOUN
aiua-12307	225	15	iv	iv	NUM
aiua-12307	225	16	every	every	DET
aiua-12307	225	17	2	2	NUM
aiua-12307	225	18	wk	wk	NOUN
aiua-12307	225	19	plus	plus	CCONJ
aiua-12307	225	20	cabo	cabo	NOUN
aiua-12307	225	21	40	40	NUM
aiua-12307	225	22	mg	mg	PROPN
aiua-12307	225	23	po	po	PROPN
aiua-12307	225	24	daily	daily	PROPN
aiua-12307	225	25	vs	vs	ADP
aiua-12307	225	26	sun	sun	PROPN
aiua-12307	225	27	50	50	NUM
aiua-12307	225	28	mg	mg	PROPN
aiua-12307	225	29	po	po	PROPN
aiua-12307	225	30	qd	qd	ADP
aiua-12307	225	31	4/2	4/2	NUM
aiua-12307	225	32	wk	wk	NOUN
aiua-12307	225	33	pembro	pembro	NOUN
aiua-12307	225	34	200	200	NUM
aiua-12307	225	35	mg	mg	NOUN
aiua-12307	225	36	.	.	PUNCT
aiua-12307	226	1	iv	iv	NUM
aiua-12307	226	2	q3w	q3w	NOUN
aiua-12307	226	3	plus	plus	CCONJ
aiua-12307	226	4	axi	axi	PROPN
aiua-12307	226	5	5	5	NUM
aiua-12307	226	6	mg	mg	PROPN
aiua-12307	226	7	.	.	PUNCT
aiua-12307	227	1	po	po	PROPN
aiua-12307	227	2	bid	bid	VERB
aiua-12307	227	3	vs	vs	ADP
aiua-12307	227	4	sun	sun	NOUN
aiua-12307	227	5	50	50	NUM
aiua-12307	227	6	mg	mg	PROPN
aiua-12307	227	7	po	po	PROPN
aiua-12307	227	8	qd	qd	ADP
aiua-12307	227	9	4/2	4/2	NUM
aiua-12307	227	10	wk	wk	NOUN
aiua-12307	227	11	pembro	pembro	NOUN
aiua-12307	227	12	200	200	NUM
aiua-12307	227	13	mg	mg	NOUN
aiua-12307	227	14	iv	iv	ADP
aiua-12307	227	15	q3w	q3w	NOUN
aiua-12307	227	16	plus	plus	CCONJ
aiua-12307	227	17	len	len	VERB
aiua-12307	227	18	20	20	NUM
aiua-12307	227	19	mg	mg	PROPN
aiua-12307	227	20	po	po	PROPN
aiua-12307	227	21	qd	qd	PROPN
aiua-12307	227	22	vs	vs	ADP
aiua-12307	227	23	sun	sun	NOUN
aiua-12307	227	24	50	50	NUM
aiua-12307	227	25	mg	mg	PROPN
aiua-12307	227	26	po	po	PROPN
aiua-12307	227	27	qd	qd	ADP
aiua-12307	227	28	4/2	4/2	NUM
aiua-12307	227	29	wk	wk	NOUN
aiua-12307	227	30	nivo	nivo	PROPN
aiua-12307	227	31	3	3	NUM
aiua-12307	227	32	mg	mg	PROPN
aiua-12307	227	33	/	/	SYM
aiua-12307	227	34	kg	kg	PROPN
aiua-12307	227	35	plus	plus	CCONJ
aiua-12307	227	36	ipi	ipi	PROPN
aiua-12307	227	37	1	1	NUM
aiua-12307	227	38	mg	mg	PROPN
aiua-12307	227	39	/	/	SYM
aiua-12307	227	40	kg	kg	NOUN
aiua-12307	227	41	iv	iv	NUM
aiua-12307	227	42	q3w	q3w	NOUN
aiua-12307	227	43	for	for	ADP
aiua-12307	227	44	4	4	NUM
aiua-12307	227	45	doses	dose	NOUN
aiua-12307	227	46	then	then	ADV
aiua-12307	227	47	nivo	nivo	PROPN
aiua-12307	227	48	3	3	NUM
aiua-12307	227	49	mg	mg	PROPN
aiua-12307	227	50	/	/	SYM
aiua-12307	227	51	kg	kg	NOUN
aiua-12307	228	1	iv	iv	NUM
aiua-12307	228	2	q2w	q2w	NOUN
aiua-12307	228	3	vs	vs	ADP
aiua-12307	228	4	sun	sun	NOUN
aiua-12307	228	5	50	50	NUM
aiua-12307	228	6	mg	mg	PROPN
aiua-12307	228	7	po	po	PROPN
aiua-12307	228	8	qd	qd	ADP
aiua-12307	228	9	4/2	4/2	NUM
aiua-12307	228	10	wk	wk	NOUN
aiua-12307	228	11	ave	ave	PROPN
aiua-12307	228	12	10	10	NUM
aiua-12307	228	13	mg	mg	PROPN
aiua-12307	228	14	/	/	SYM
aiua-12307	228	15	kg	kg	NOUN
aiua-12307	228	16	iv	iv	NUM
aiua-12307	228	17	q2w	q2w	NOUN
aiua-12307	228	18	plus	plus	CCONJ
aiua-12307	228	19	axi	axi	NOUN
aiua-12307	228	20	,	,	PUNCT
aiua-12307	228	21	5	5	NUM
aiua-12307	228	22	mg	mg	PROPN
aiua-12307	228	23	po	po	NOUN
aiua-12307	228	24	bid	bid	VERB
aiua-12307	228	25	vs	vs	ADP
aiua-12307	228	26	sun	sun	NOUN
aiua-12307	228	27	50	50	NUM
aiua-12307	228	28	mg	mg	PROPN
aiua-12307	228	29	po	po	PROPN
aiua-12307	228	30	qd	qd	ADP
aiua-12307	228	31	4/2	4/2	NUM
aiua-12307	228	32	wk	wk	X
aiua-12307	228	33	atezo	atezo	PROPN
aiua-12307	228	34	1200	1200	NUM
aiua-12307	228	35	mg	mg	PROPN
aiua-12307	228	36	fixed	fix	VERB
aiua-12307	228	37	dose	dose	PROPN
aiua-12307	228	38	iv	iv	PROPN
aiua-12307	228	39	plus	plus	CCONJ
aiua-12307	228	40	bev	bev	PROPN
aiua-12307	228	41	15	15	NUM
aiua-12307	228	42	mg	mg	PROPN
aiua-12307	228	43	/	/	SYM
aiua-12307	228	44	kg	kg	NOUN
aiua-12307	228	45	iv	iv	ADP
aiua-12307	228	46	on	on	ADP
aiua-12307	228	47	days	day	NOUN
aiua-12307	228	48	1	1	NUM
aiua-12307	228	49	and	and	CCONJ
aiua-12307	228	50	22	22	NUM
aiua-12307	228	51	of	of	ADP
aiua-12307	228	52	each	each	DET
aiua-12307	228	53	42	42	NUM
aiua-12307	228	54	-	-	PUNCT
aiua-12307	228	55	day	day	NOUN
aiua-12307	228	56	cycle	cycle	NOUN
aiua-12307	228	57	vs	vs	ADP
aiua-12307	228	58	sun	sun	NOUN
aiua-12307	228	59	50	50	NUM
aiua-12307	228	60	mg	mg	PROPN
aiua-12307	228	61	po	po	PROPN
aiua-12307	228	62	qd	qd	ADP
aiua-12307	228	63	4/2	4/2	NUM
aiua-12307	228	64	wk	wk	NOUN
aiua-12307	229	1	651	651	NUM
aiua-12307	229	2	861	861	NUM
aiua-12307	229	3	712	712	NUM
aiua-12307	229	4	1096	1096	NUM
aiua-12307	229	5	886	886	NUM
aiua-12307	229	6	915	915	NUM
aiua-12307	229	7	pfs	pfs	PROPN
aiua-12307	229	8	in	in	ADP
aiua-12307	229	9	the	the	DET
aiua-12307	229	10	itt	itt	NOUN
aiua-12307	229	11	by	by	ADP
aiua-12307	229	12	bicr	bicr	PROPN
aiua-12307	229	13	pfs	pfs	PROPN
aiua-12307	229	14	and	and	CCONJ
aiua-12307	229	15	os	os	NOUN
aiua-12307	229	16	in	in	ADP
aiua-12307	229	17	the	the	DET
aiua-12307	229	18	itt	itt	NOUN
aiua-12307	229	19	by	by	ADP
aiua-12307	229	20	bicr	bicr	PROPN
aiua-12307	229	21	pfs	pfs	PROPN
aiua-12307	229	22	in	in	ADP
aiua-12307	229	23	the	the	DET
aiua-12307	229	24	itt	itt	NOUN
aiua-12307	229	25	by	by	ADP
aiua-12307	229	26	birc	birc	PROPN
aiua-12307	229	27	pfs	pfs	PROPN
aiua-12307	229	28	and	and	CCONJ
aiua-12307	229	29	os	os	NOUN
aiua-12307	229	30	in	in	ADP
aiua-12307	229	31	the	the	DET
aiua-12307	229	32	imdc	imdc	NOUN
aiua-12307	229	33	intermediate	intermediate	ADJ
aiua-12307	229	34	and	and	CCONJ
aiua-12307	229	35	poor	poor	ADJ
aiua-12307	229	36	risk	risk	NOUN
aiua-12307	229	37	population	population	NOUN
aiua-12307	229	38	by	by	ADP
aiua-12307	229	39	bicr	bicr	PROPN
aiua-12307	229	40	pfs	pfs	PROPN
aiua-12307	229	41	in	in	ADP
aiua-12307	229	42	the	the	DET
aiua-12307	229	43	pd	pd	PROPN
aiua-12307	229	44	-	-	PUNCT
aiua-12307	229	45	l1	l1	NOUN
aiua-12307	229	46	+	+	CCONJ
aiua-12307	229	47	population	population	NOUN
aiua-12307	229	48	and	and	CCONJ
aiua-12307	229	49	os	os	NOUN
aiua-12307	229	50	in	in	ADP
aiua-12307	229	51	the	the	DET
aiua-12307	229	52	itt	itt	NOUN
aiua-12307	229	53	by	by	ADP
aiua-12307	229	54	bicr	bicr	PROPN
aiua-12307	229	55	pfs	pfs	PROPN
aiua-12307	229	56	in	in	ADP
aiua-12307	229	57	the	the	DET
aiua-12307	229	58	pd	pd	PROPN
aiua-12307	229	59	-	-	PUNCT
aiua-12307	229	60	l1	l1	NOUN
aiua-12307	229	61	+	+	CCONJ
aiua-12307	229	62	population	population	NOUN
aiua-12307	229	63	and	and	CCONJ
aiua-12307	229	64	os	os	NOUN
aiua-12307	229	65	in	in	ADP
aiua-12307	229	66	the	the	DET
aiua-12307	229	67	itt	itt	NOUN
aiua-12307	229	68	by	by	ADP
aiua-12307	229	69	ir	ir	PROPN
aiua-12307	229	70	imdc	imdc	PROPN
aiua-12307	229	71	fav	fav	NOUN
aiua-12307	229	72	22	22	NUM
aiua-12307	229	73	%	%	NOUN
aiua-12307	229	74	imd	imd	PROPN
aiua-12307	229	75	58	58	NUM
aiua-12307	229	76	%	%	NOUN
aiua-12307	229	77	poor	poor	ADJ
aiua-12307	229	78	20	20	NUM
aiua-12307	229	79	%	%	NOUN
aiua-12307	229	80	mskcc	mskcc	NOUN
aiua-12307	229	81	not	not	PART
aiua-12307	229	82	determined	determine	VERB
aiua-12307	229	83	imdc	imdc	NOUN
aiua-12307	229	84	fav	fav	NOUN
aiua-12307	229	85	31	31	NUM
aiua-12307	229	86	%	%	NOUN
aiua-12307	229	87	imd	imd	PROPN
aiua-12307	229	88	56	56	NUM
aiua-12307	229	89	%	%	NOUN
aiua-12307	229	90	poor	poor	ADJ
aiua-12307	229	91	13	13	NUM
aiua-12307	229	92	%	%	NOUN
aiua-12307	229	93	mskcc	mskcc	NOUN
aiua-12307	229	94	not	not	PART
aiua-12307	229	95	determined	determine	VERB
aiua-12307	229	96	imdc	imdc	NOUN
aiua-12307	229	97	fav	fav	NOUN
aiua-12307	229	98	31	31	NUM
aiua-12307	229	99	%	%	NOUN
aiua-12307	229	100	imd	imd	PROPN
aiua-12307	229	101	59	59	NUM
aiua-12307	229	102	%	%	NOUN
aiua-12307	229	103	poor	poor	ADJ
aiua-12307	229	104	9	9	NUM
aiua-12307	229	105	%	%	NOUN
aiua-12307	229	106	ne	ne	NOUN
aiua-12307	229	107	1	1	NUM
aiua-12307	229	108	%	%	NOUN
aiua-12307	229	109	mskcc	mskcc	NOUN
aiua-12307	229	110	fav	fav	NOUN
aiua-12307	229	111	27	27	NUM
aiua-12307	229	112	%	%	NOUN
aiua-12307	229	113	imd	imd	PROPN
aiua-12307	229	114	64	64	NUM
aiua-12307	229	115	%	%	NOUN
aiua-12307	229	116	poor	poor	ADJ
aiua-12307	229	117	9	9	NUM
aiua-12307	229	118	%	%	NOUN
aiua-12307	229	119	imdc	imdc	NOUN
aiua-12307	229	120	fav	fav	NOUN
aiua-12307	229	121	23	23	NUM
aiua-12307	229	122	%	%	NOUN
aiua-12307	229	123	imd	imd	PROPN
aiua-12307	229	124	61	61	NUM
aiua-12307	229	125	%	%	NOUN
aiua-12307	229	126	poor	poor	ADJ
aiua-12307	229	127	17	17	NUM
aiua-12307	229	128	%	%	NOUN
aiua-12307	229	129	mskcc	mskcc	NOUN
aiua-12307	229	130	not	not	PART
aiua-12307	229	131	determined	determine	VERB
aiua-12307	229	132	imdc	imdc	NOUN
aiua-12307	229	133	fav	fav	NOUN
aiua-12307	229	134	22	22	NUM
aiua-12307	229	135	%	%	NOUN
aiua-12307	229	136	imd	imd	PROPN
aiua-12307	229	137	62	62	NUM
aiua-12307	229	138	%	%	NOUN
aiua-12307	229	139	poor	poor	ADJ
aiua-12307	229	140	16	16	NUM
aiua-12307	229	141	%	%	NOUN
aiua-12307	230	1	mskcc	mskcc	NOUN
aiua-12307	230	2	fav	fav	NOUN
aiua-12307	230	3	23	23	NUM
aiua-12307	230	4	%	%	NOUN
aiua-12307	230	5	imd	imd	PROPN
aiua-12307	230	6	66	66	NUM
aiua-12307	230	7	%	%	NOUN
aiua-12307	230	8	poor	poor	ADJ
aiua-12307	230	9	12	12	NUM
aiua-12307	230	10	%	%	NOUN
aiua-12307	230	11	imdc	imdc	NOUN
aiua-12307	230	12	not	not	PART
aiua-12307	230	13	determined	determine	VERB
aiua-12307	230	14	mskcc	mskcc	PROPN
aiua-12307	230	15	fav	fav	NOUN
aiua-12307	230	16	20	20	NUM
aiua-12307	230	17	%	%	NOUN
aiua-12307	230	18	imd	imd	PROPN
aiua-12307	230	19	69	69	NUM
aiua-12307	230	20	%	%	NOUN
aiua-12307	230	21	poor	poor	ADJ
aiua-12307	230	22	12	12	NUM
aiua-12307	230	23	%	%	NOUN
aiua-12307	230	24	(	(	PUNCT
aiua-12307	230	25	itt	itt	ADJ
aiua-12307	230	26	)	)	PUNCT
aiua-12307	230	27	nivo	nivo	NOUN
aiua-12307	230	28	+	+	NUM
aiua-12307	230	29	cabo	cabo	NOUN
aiua-12307	230	30	:	:	PUNCT
aiua-12307	230	31	17.0	17.0	NUM
aiua-12307	230	32	(	(	PUNCT
aiua-12307	230	33	12.6–19.4	12.6–19.4	NUM
aiua-12307	230	34	)	)	PUNCT
aiua-12307	230	35	sun	sun	NOUN
aiua-12307	230	36	:	:	PUNCT
aiua-12307	230	37	8.3	8.3	NUM
aiua-12307	230	38	(	(	PUNCT
aiua-12307	230	39	6.9–9.7	6.9–9.7	NOUN
aiua-12307	230	40	)	)	PUNCT
aiua-12307	230	41	hr	hr	NOUN
aiua-12307	230	42	:	:	PUNCT
aiua-12307	230	43	0.52	0.52	NUM
aiua-12307	230	44	(	(	PUNCT
aiua-12307	230	45	95	95	NUM
aiua-12307	230	46	%	%	NOUN
aiua-12307	230	47	ci	ci	NOUN
aiua-12307	230	48	:	:	PUNCT
aiua-12307	230	49	0.43–0.64	0.43–0.64	NOUN
aiua-12307	230	50	)	)	PUNCT
aiua-12307	231	1	p	p	X
aiua-12307	231	2	<	<	X
aiua-12307	231	3	0.0001	0.0001	NUM
aiua-12307	231	4	(	(	PUNCT
aiua-12307	231	5	itt	itt	ADJ
aiua-12307	231	6	)	)	PUNCT
aiua-12307	231	7	pembro	pembro	NOUN
aiua-12307	231	8	+	+	CCONJ
aiua-12307	231	9	axi	axi	NOUN
aiua-12307	231	10	:	:	PUNCT
aiua-12307	231	11	15.7	15.7	NUM
aiua-12307	231	12	(	(	PUNCT
aiua-12307	231	13	13.6–20.2	13.6–20.2	NUM
aiua-12307	231	14	)	)	PUNCT
aiua-12307	231	15	sun	sun	NOUN
aiua-12307	231	16	:	:	PUNCT
aiua-12307	231	17	11.1	11.1	NUM
aiua-12307	231	18	(	(	PUNCT
aiua-12307	231	19	8.9–12.5	8.9–12.5	NUM
aiua-12307	231	20	)	)	PUNCT
aiua-12307	231	21	hr	hr	NOUN
aiua-12307	231	22	:	:	PUNCT
aiua-12307	231	23	0.68	0.68	NUM
aiua-12307	231	24	(	(	PUNCT
aiua-12307	231	25	95	95	NUM
aiua-12307	231	26	%	%	NOUN
aiua-12307	231	27	ci	ci	NOUN
aiua-12307	231	28	:	:	PUNCT
aiua-12307	231	29	0.58–0.80	0.58–0.80	NUM
aiua-12307	231	30	)	)	PUNCT
aiua-12307	232	1	p	p	X
aiua-12307	232	2	<	<	X
aiua-12307	232	3	0.0001	0.0001	NUM
aiua-12307	232	4	(	(	PUNCT
aiua-12307	232	5	itt	itt	ADJ
aiua-12307	232	6	)	)	PUNCT
aiua-12307	232	7	pembro	pembro	NOUN
aiua-12307	232	8	+	+	CCONJ
aiua-12307	232	9	len	len	ADJ
aiua-12307	232	10	:	:	PUNCT
aiua-12307	232	11	23.9	23.9	NUM
aiua-12307	232	12	(	(	PUNCT
aiua-12307	232	13	20.8–27.7	20.8–27.7	NUM
aiua-12307	232	14	)	)	PUNCT
aiua-12307	232	15	sun	sun	NOUN
aiua-12307	232	16	:	:	PUNCT
aiua-12307	232	17	9.2	9.2	NUM
aiua-12307	232	18	(	(	PUNCT
aiua-12307	232	19	6.0–11.0	6.0–11.0	NOUN
aiua-12307	232	20	)	)	PUNCT
aiua-12307	232	21	hr	hr	NOUN
aiua-12307	232	22	:	:	PUNCT
aiua-12307	232	23	0.39	0.39	NUM
aiua-12307	232	24	(	(	PUNCT
aiua-12307	232	25	95	95	NUM
aiua-12307	232	26	%	%	NOUN
aiua-12307	232	27	ci	ci	NOUN
aiua-12307	232	28	:	:	PUNCT
aiua-12307	232	29	0.32–0.49	0.32–0.49	NUM
aiua-12307	232	30	)	)	PUNCT
aiua-12307	233	1	p	p	X
aiua-12307	233	2	>	>	X
aiua-12307	233	3	0.001	0.001	NUM
aiua-12307	233	4	(	(	PUNCT
aiua-12307	233	5	imdc	imdc	PROPN
aiua-12307	233	6	imd	imd	PROPN
aiua-12307	233	7	/	/	SYM
aiua-12307	233	8	poor	poor	ADJ
aiua-12307	233	9	)	)	PUNCT
aiua-12307	233	10	nivo	nivo	PROPN
aiua-12307	233	11	+	+	CCONJ
aiua-12307	233	12	ipi	ipi	PROPN
aiua-12307	233	13	:	:	PUNCT
aiua-12307	233	14	11.6	11.6	NUM
aiua-12307	233	15	(	(	PUNCT
aiua-12307	233	16	8.4–16.5	8.4–16.5	NUM
aiua-12307	233	17	)	)	PUNCT
aiua-12307	233	18	sun	sun	NOUN
aiua-12307	233	19	:	:	PUNCT
aiua-12307	233	20	8.3	8.3	NUM
aiua-12307	233	21	(	(	PUNCT
aiua-12307	233	22	7.0–10.4	7.0–10.4	NUM
aiua-12307	233	23	)	)	PUNCT
aiua-12307	233	24	hr	hr	NOUN
aiua-12307	233	25	:	:	PUNCT
aiua-12307	233	26	0.73	0.73	NUM
aiua-12307	233	27	(	(	PUNCT
aiua-12307	233	28	95	95	NUM
aiua-12307	233	29	%	%	NOUN
aiua-12307	233	30	ci	ci	NOUN
aiua-12307	233	31	:	:	PUNCT
aiua-12307	233	32	0.61–0.87	0.61–0.87	NUM
aiua-12307	233	33	)	)	PUNCT
aiua-12307	233	34	(	(	PUNCT
aiua-12307	233	35	pd	pd	NOUN
aiua-12307	233	36	-	-	PROPN
aiua-12307	233	37	l1	l1	NOUN
aiua-12307	233	38	+	+	NOUN
aiua-12307	233	39	)	)	PUNCT
aiua-12307	233	40	ave	ave	NOUN
aiua-12307	233	41	+	+	CCONJ
aiua-12307	233	42	axi	axi	NOUN
aiua-12307	233	43	:	:	PUNCT
aiua-12307	233	44	13.8	13.8	NUM
aiua-12307	233	45	(	(	PUNCT
aiua-12307	233	46	10.1–20.7	10.1–20.7	NUM
aiua-12307	233	47	)	)	PUNCT
aiua-12307	233	48	sun	sun	NOUN
aiua-12307	233	49	:	:	PUNCT
aiua-12307	233	50	7.0	7.0	NUM
aiua-12307	233	51	(	(	PUNCT
aiua-12307	233	52	5.7–9.6	5.7–9.6	NUM
aiua-12307	233	53	)	)	PUNCT
aiua-12307	233	54	hr	hr	NOUN
aiua-12307	233	55	:	:	PUNCT
aiua-12307	233	56	0.62	0.62	NUM
aiua-12307	233	57	(	(	PUNCT
aiua-12307	233	58	95	95	NUM
aiua-12307	233	59	%	%	NOUN
aiua-12307	233	60	ci	ci	NOUN
aiua-12307	233	61	:	:	PUNCT
aiua-12307	233	62	0.49–0.78	0.49–0.78	NUM
aiua-12307	233	63	)	)	PUNCT
aiua-12307	234	1	p	p	X
aiua-12307	234	2	<	<	X
aiua-12307	234	3	0.0001	0.0001	NUM
aiua-12307	234	4	(	(	PUNCT
aiua-12307	234	5	pd	pd	NOUN
aiua-12307	234	6	-	-	NOUN
aiua-12307	234	7	l1	l1	NOUN
aiua-12307	234	8	+	+	NOUN
aiua-12307	234	9	)	)	PUNCT
aiua-12307	234	10	atezo	atezo	PROPN
aiua-12307	234	11	+	+	X
aiua-12307	234	12	bev	bev	PROPN
aiua-12307	234	13	:	:	PUNCT
aiua-12307	234	14	11.2	11.2	NUM
aiua-12307	234	15	(	(	PUNCT
aiua-12307	234	16	8.9–15.0	8.9–15.0	NOUN
aiua-12307	234	17	)	)	PUNCT
aiua-12307	234	18	sun	sun	NOUN
aiua-12307	234	19	:	:	PUNCT
aiua-12307	234	20	7.7	7.7	NUM
aiua-12307	234	21	(	(	PUNCT
aiua-12307	234	22	6.8–9.7	6.8–9.7	NOUN
aiua-12307	234	23	)	)	PUNCT
aiua-12307	234	24	hr	hr	NOUN
aiua-12307	234	25	:	:	PUNCT
aiua-12307	234	26	0.74	0.74	NUM
aiua-12307	234	27	(	(	PUNCT
aiua-12307	234	28	95	95	NUM
aiua-12307	234	29	%	%	NOUN
aiua-12307	234	30	ci	ci	NOUN
aiua-12307	234	31	:	:	PUNCT
aiua-12307	234	32	0.57–0.96	0.57–0.96	NUM
aiua-12307	234	33	)	)	PUNCT
aiua-12307	235	1	p	p	X
aiua-12307	235	2	=	=	SYM
aiua-12307	235	3	0.0217	0.0217	NUM
aiua-12307	235	4	(	(	PUNCT
aiua-12307	235	5	itt	itt	ADJ
aiua-12307	235	6	)	)	PUNCT
aiua-12307	235	7	nivo	nivo	NOUN
aiua-12307	236	1	+	+	NUM
aiua-12307	236	2	cabo	cabo	NOUN
aiua-12307	236	3	:	:	PUNCT
aiua-12307	236	4	nr	nr	PROPN
aiua-12307	236	5	(	(	PUNCT
aiua-12307	236	6	ne	ne	PROPN
aiua-12307	236	7	)	)	PUNCT
aiua-12307	236	8	sun	sun	NOUN
aiua-12307	236	9	:	:	PUNCT
aiua-12307	236	10	29.5	29.5	NUM
aiua-12307	236	11	(	(	PUNCT
aiua-12307	236	12	28.4	28.4	NUM
aiua-12307	236	13	–	–	SYM
aiua-12307	236	14	ne	ne	NOUN
aiua-12307	236	15	)	)	PUNCT
aiua-12307	236	16	hr	hr	NOUN
aiua-12307	236	17	:	:	PUNCT
aiua-12307	236	18	0.66	0.66	NUM
aiua-12307	236	19	(	(	PUNCT
aiua-12307	236	20	98.9	98.9	NUM
aiua-12307	236	21	%	%	NOUN
aiua-12307	236	22	ci	ci	NOUN
aiua-12307	236	23	:	:	PUNCT
aiua-12307	236	24	0.50	0.50	NUM
aiua-12307	236	25	–	–	PUNCT
aiua-12307	236	26	0.87	0.87	NUM
aiua-12307	236	27	)	)	PUNCT
aiua-12307	236	28	p	p	X
aiua-12307	236	29	=	=	SYM
aiua-12307	236	30	0.0034	0.0034	NUM
aiua-12307	236	31	(	(	PUNCT
aiua-12307	236	32	itt	itt	ADJ
aiua-12307	236	33	)	)	PUNCT
aiua-12307	236	34	pembro	pembro	NOUN
aiua-12307	236	35	+	+	CCONJ
aiua-12307	236	36	axi	axi	NOUN
aiua-12307	236	37	:	:	PUNCT
aiua-12307	236	38	45.7	45.7	NUM
aiua-12307	236	39	(	(	PUNCT
aiua-12307	236	40	43.6	43.6	NUM
aiua-12307	236	41	–	–	PUNCT
aiua-12307	236	42	nr	nr	NOUN
aiua-12307	236	43	)	)	PUNCT
aiua-12307	236	44	sun	sun	NOUN
aiua-12307	236	45	:	:	PUNCT
aiua-12307	236	46	40.1	40.1	NUM
aiua-12307	236	47	(	(	PUNCT
aiua-12307	236	48	34.3–44.2	34.3–44.2	NUM
aiua-12307	236	49	)	)	PUNCT
aiua-12307	236	50	hr	hr	NOUN
aiua-12307	236	51	:	:	PUNCT
aiua-12307	236	52	0.73	0.73	NUM
aiua-12307	236	53	(	(	PUNCT
aiua-12307	236	54	95	95	NUM
aiua-12307	236	55	%	%	NOUN
aiua-12307	236	56	ci	ci	NOUN
aiua-12307	236	57	:	:	PUNCT
aiua-12307	236	58	0.60–0.88	0.60–0.88	NUM
aiua-12307	236	59	)	)	PUNCT
aiua-12307	237	1	p	p	X
aiua-12307	237	2	=	=	NOUN
aiua-12307	237	3	0.001	0.001	NUM
aiua-12307	237	4	(	(	PUNCT
aiua-12307	237	5	itt	itt	ADJ
aiua-12307	237	6	)	)	PUNCT
aiua-12307	237	7	pembro	pembro	NOUN
aiua-12307	237	8	+	+	CCONJ
aiua-12307	237	9	len	len	ADJ
aiua-12307	237	10	:	:	PUNCT
aiua-12307	237	11	nr	nr	PROPN
aiua-12307	237	12	(	(	PUNCT
aiua-12307	237	13	41.5	41.5	NUM
aiua-12307	237	14	–	–	PUNCT
aiua-12307	237	15	ne	ne	NOUN
aiua-12307	237	16	)	)	PUNCT
aiua-12307	237	17	sun	sun	NOUN
aiua-12307	237	18	:	:	PUNCT
aiua-12307	237	19	nr	nr	PROPN
aiua-12307	237	20	(	(	PUNCT
aiua-12307	237	21	38.4	38.4	NUM
aiua-12307	237	22	–	–	PUNCT
aiua-12307	237	23	e	e	NOUN
aiua-12307	237	24	)	)	PUNCT
aiua-12307	237	25	hr	hr	NOUN
aiua-12307	237	26	:	:	PUNCT
aiua-12307	237	27	0.72	0.72	NUM
aiua-12307	237	28	(	(	PUNCT
aiua-12307	237	29	95	95	NUM
aiua-12307	237	30	%	%	NOUN
aiua-12307	237	31	ci	ci	NOUN
aiua-12307	237	32	:	:	PUNCT
aiua-12307	237	33	0.55–0.93	0.55–0.93	NUM
aiua-12307	237	34	)	)	PUNCT
aiua-12307	238	1	p	p	X
aiua-12307	238	2	=	=	NOUN
aiua-12307	238	3	0.005	0.005	NUM
aiua-12307	238	4	(	(	PUNCT
aiua-12307	238	5	imdc	imdc	PROPN
aiua-12307	238	6	imd	imd	PROPN
aiua-12307	238	7	/	/	SYM
aiua-12307	238	8	poor	poor	ADJ
aiua-12307	238	9	)	)	PUNCT
aiua-12307	238	10	nivo	nivo	PROPN
aiua-12307	239	1	+	+	CCONJ
aiua-12307	239	2	ipi	ipi	PROPN
aiua-12307	239	3	:	:	PUNCT
aiua-12307	239	4	47.0	47.0	NUM
aiua-12307	239	5	(	(	PUNCT
aiua-12307	239	6	35.4–57.4	35.4–57.4	NUM
aiua-12307	239	7	)	)	PUNCT
aiua-12307	239	8	sun	sun	NOUN
aiua-12307	239	9	:	:	PUNCT
aiua-12307	239	10	26.6	26.6	NUM
aiua-12307	239	11	(	(	PUNCT
aiua-12307	239	12	22.1–33.5	22.1–33.5	NUM
aiua-12307	239	13	)	)	PUNCT
aiua-12307	239	14	hr	hr	NOUN
aiua-12307	239	15	:	:	PUNCT
aiua-12307	239	16	0.68	0.68	NUM
aiua-12307	239	17	(	(	PUNCT
aiua-12307	239	18	0.58–0.81	0.58–0.81	NUM
aiua-12307	239	19	)	)	PUNCT
aiua-12307	240	1	p	p	X
aiua-12307	240	2	<	<	X
aiua-12307	240	3	0.0001	0.0001	NUM
aiua-12307	240	4	(	(	PUNCT
aiua-12307	240	5	pd	pd	NOUN
aiua-12307	240	6	-	-	NOUN
aiua-12307	240	7	l1	l1	NOUN
aiua-12307	240	8	+	+	NOUN
aiua-12307	240	9	)	)	PUNCT
aiua-12307	240	10	ave	ave	NOUN
aiua-12307	240	11	+	+	CCONJ
aiua-12307	240	12	axi	axi	PROPN
aiua-12307	240	13	:	:	PUNCT
aiua-12307	240	14	nr	nr	PROPN
aiua-12307	240	15	sun	sun	NOUN
aiua-12307	240	16	:	:	PUNCT
aiua-12307	240	17	28.6	28.6	NUM
aiua-12307	240	18	(	(	PUNCT
aiua-12307	240	19	27.4	27.4	NUM
aiua-12307	240	20	–	–	SYM
aiua-12307	240	21	ne	ne	NOUN
aiua-12307	240	22	)	)	PUNCT
aiua-12307	240	23	hr	hr	NOUN
aiua-12307	240	24	:	:	PUNCT
aiua-12307	240	25	0.83	0.83	NUM
aiua-12307	240	26	(	(	PUNCT
aiua-12307	240	27	95	95	NUM
aiua-12307	240	28	%	%	NOUN
aiua-12307	240	29	ci	ci	NOUN
aiua-12307	240	30	:	:	PUNCT
aiua-12307	240	31	0.60–1.15	0.60–1.15	NUM
aiua-12307	240	32	)	)	PUNCT
aiua-12307	240	33	p	p	NOUN
aiua-12307	241	1	=	=	PUNCT
aiua-12307	241	2	0.1301	0.1301	NUM
aiua-12307	241	3	(	(	PUNCT
aiua-12307	241	4	itt	itt	ADJ
aiua-12307	241	5	)	)	PUNCT
aiua-12307	241	6	atezo	atezo	PROPN
aiua-12307	241	7	+	+	CCONJ
aiua-12307	241	8	bev	bev	PROPN
aiua-12307	241	9	:	:	PUNCT
aiua-12307	241	10	36.1	36.1	NUM
aiua-12307	241	11	(	(	PUNCT
aiua-12307	241	12	31.5–42.3	31.5–42.3	NUM
aiua-12307	241	13	)	)	PUNCT
aiua-12307	241	14	sun	sun	NOUN
aiua-12307	241	15	:	:	PUNCT
aiua-12307	241	16	35.3	35.3	NUM
aiua-12307	241	17	(	(	PUNCT
aiua-12307	241	18	28.6–42.1ne	28.6–42.1ne	NUM
aiua-12307	241	19	)	)	PUNCT
aiua-12307	241	20	hr	hr	NOUN
aiua-12307	241	21	:	:	PUNCT
aiua-12307	241	22	0.91	0.91	NUM
aiua-12307	241	23	(	(	PUNCT
aiua-12307	241	24	95	95	NUM
aiua-12307	241	25	%	%	NOUN
aiua-12307	241	26	ci	ci	NOUN
aiua-12307	241	27	:	:	PUNCT
aiua-12307	241	28	0.76–1.08	0.76–1.08	NUM
aiua-12307	241	29	)	)	PUNCT
aiua-12307	242	1	p	p	X
aiua-12307	242	2	=	=	SYM
aiua-12307	242	3	0.27	0.27	NUM
aiua-12307	242	4	table	table	NOUN
aiua-12307	242	5	5	5	NUM
aiua-12307	242	6	.	.	PUNCT
aiua-12307	242	7	updated	update	VERB
aiua-12307	242	8	eau	eau	PROPN
aiua-12307	242	9	guidelines	guideline	NOUN
aiua-12307	242	10	recommendations	recommendation	NOUN
aiua-12307	242	11	for	for	ADP
aiua-12307	242	12	the	the	DET
aiua-12307	242	13	first	first	ADJ
aiua-12307	242	14	-	-	PUNCT
aiua-12307	242	15	line	line	NOUN
aiua-12307	242	16	treatment	treatment	NOUN
aiua-12307	242	17	of	of	ADP
aiua-12307	242	18	cc	cc	NOUN
aiua-12307	242	19	-	-	NOUN
aiua-12307	242	20	mrcc	mrcc	NOUN
aiua-12307	242	21	(	(	PUNCT
aiua-12307	242	22	48	48	NUM
aiua-12307	242	23	)	)	PUNCT
aiua-12307	242	24	.	.	PUNCT
aiua-12307	243	1	standard	standard	NOUN
aiua-12307	243	2	of	of	ADP
aiua-12307	243	3	care	care	NOUN
aiua-12307	243	4	alternative	alternative	NOUN
aiua-12307	243	5	in	in	ADP
aiua-12307	243	6	patients	patient	NOUN
aiua-12307	243	7	who	who	PRON
aiua-12307	243	8	can	can	AUX
aiua-12307	243	9	not	not	PART
aiua-12307	243	10	receive	receive	VERB
aiua-12307	243	11	or	or	CCONJ
aiua-12307	243	12	tolerate	tolerate	VERB
aiua-12307	243	13	immune	immune	ADJ
aiua-12307	243	14	checkpoint	checkpoint	NOUN
aiua-12307	243	15	inhibitors	inhibitor	NOUN
aiua-12307	243	16	imdc	imdc	VERB
aiua-12307	243	17	favourable	favourable	ADJ
aiua-12307	243	18	risk	risk	NOUN
aiua-12307	243	19	nivolumab	nivolumab	NOUN
aiua-12307	243	20	/	/	SYM
aiua-12307	243	21	cabozantinib	cabozantinib	PROPN
aiua-12307	243	22	[	[	X
aiua-12307	243	23	1b	1b	X
aiua-12307	243	24	]	]	X
aiua-12307	243	25	sunitinib	sunitinib	NOUN
aiua-12307	243	26	*	*	PUNCT
aiua-12307	244	1	[	[	X
aiua-12307	244	2	1b	1b	X
aiua-12307	244	3	]	]	PUNCT
aiua-12307	244	4	pembrolizumab	pembrolizumab	NOUN
aiua-12307	244	5	/	/	SYM
aiua-12307	244	6	axitinib	axitinib	NOUN
aiua-12307	244	7	[	[	X
aiua-12307	244	8	1b	1b	X
aiua-12307	244	9	]	]	PUNCT
aiua-12307	244	10	pazopanib	pazopanib	PROPN
aiua-12307	244	11	*	*	PUNCT
aiua-12307	245	1	[	[	X
aiua-12307	245	2	1b	1b	X
aiua-12307	245	3	]	]	PUNCT
aiua-12307	245	4	pembrolizumab	pembrolizumab	NOUN
aiua-12307	245	5	/	/	SYM
aiua-12307	245	6	lenvatinib	lenvatinib	PROPN
aiua-12307	245	7	[	[	X
aiua-12307	245	8	1b	1b	NUM
aiua-12307	245	9	]	]	X
aiua-12307	245	10	imdc	imdc	NOUN
aiua-12307	245	11	intermediate	intermediate	ADJ
aiua-12307	245	12	and	and	CCONJ
aiua-12307	245	13	poor	poor	ADJ
aiua-12307	245	14	risk	risk	NOUN
aiua-12307	245	15	nivolumab	nivolumab	NOUN
aiua-12307	245	16	/	/	SYM
aiua-12307	245	17	cabozantinib	cabozantinib	PROPN
aiua-12307	246	1	[	[	X
aiua-12307	246	2	1b	1b	X
aiua-12307	246	3	]	]	X
aiua-12307	246	4	cabozantinib	cabozantinib	NOUN
aiua-12307	246	5	*	*	PUNCT
aiua-12307	247	1	[	[	X
aiua-12307	247	2	2a	2a	NUM
aiua-12307	247	3	]	]	PUNCT
aiua-12307	247	4	pembrolizumab	pembrolizumab	NOUN
aiua-12307	247	5	/	/	SYM
aiua-12307	247	6	axitinib	axitinib	NOUN
aiua-12307	247	7	[	[	X
aiua-12307	247	8	1b	1b	NUM
aiua-12307	247	9	]	]	X
aiua-12307	247	10	sunitinib*[1b	sunitinib*[1b	PROPN
aiua-12307	247	11	]	]	PUNCT
aiua-12307	247	12	pembrolizumab	pembrolizumab	NOUN
aiua-12307	247	13	/	/	SYM
aiua-12307	247	14	lenvatinib	lenvatinib	PROPN
aiua-12307	247	15	[	[	X
aiua-12307	247	16	1b	1b	NUM
aiua-12307	247	17	]	]	PUNCT
aiua-12307	247	18	pazopanib	pazopanib	PROPN
aiua-12307	247	19	*	*	PUNCT
aiua-12307	248	1	[	[	X
aiua-12307	248	2	1b	1b	X
aiua-12307	248	3	]	]	X
aiua-12307	248	4	nivolumab	nivolumab	ADJ
aiua-12307	248	5	/	/	SYM
aiua-12307	248	6	ipilimumab	ipilimumab	NOUN
aiua-12307	248	7	[	[	X
aiua-12307	248	8	1b	1b	X
aiua-12307	248	9	]	]	X
aiua-12307	248	10	imdc	imdc	NOUN
aiua-12307	248	11	=	=	PUNCT
aiua-12307	248	12	the	the	DET
aiua-12307	248	13	international	international	ADJ
aiua-12307	248	14	metastatic	metastatic	ADJ
aiua-12307	248	15	renal	renal	ADJ
aiua-12307	248	16	cell	cell	NOUN
aiua-12307	248	17	carcinoma	carcinoma	NOUN
aiua-12307	248	18	database	database	NOUN
aiua-12307	248	19	consortium	consortium	NOUN
aiua-12307	248	20	.	.	PUNCT
aiua-12307	249	1	*	*	PUNCT
aiua-12307	249	2	pazopanib	pazopanib	PROPN
aiua-12307	249	3	for	for	ADP
aiua-12307	249	4	intermediate	intermediate	ADJ
aiua-12307	249	5	-	-	PUNCT
aiua-12307	249	6	risk	risk	NOUN
aiua-12307	249	7	disease	disease	NOUN
aiua-12307	249	8	only	only	ADV
aiua-12307	249	9	.	.	PUNCT
aiua-12307	250	1	[	[	X
aiua-12307	250	2	1b	1b	X
aiua-12307	250	3	]	]	X
aiua-12307	250	4	=	=	PUNCT
aiua-12307	250	5	based	base	VERB
aiua-12307	250	6	on	on	ADP
aiua-12307	250	7	one	one	NUM
aiua-12307	250	8	randomised	randomise	VERB
aiua-12307	250	9	controlled	control	VERB
aiua-12307	250	10	phase	phase	NOUN
aiua-12307	250	11	iii	iii	NOUN
aiua-12307	250	12	trial	trial	NOUN
aiua-12307	250	13	.	.	PUNCT
aiua-12307	251	1	[	[	X
aiua-12307	251	2	2a	2a	X
aiua-12307	251	3	]	]	PUNCT
aiua-12307	251	4	=	=	VERB
aiua-12307	251	5	based	base	VERB
aiua-12307	251	6	on	on	ADP
aiua-12307	251	7	a	a	DET
aiua-12307	251	8	well	well	ADV
aiua-12307	251	9	-	-	PUNCT
aiua-12307	251	10	designed	design	VERB
aiua-12307	251	11	study	study	NOUN
aiua-12307	251	12	without	without	ADP
aiua-12307	251	13	randomisation	randomisation	NOUN
aiua-12307	251	14	or	or	CCONJ
aiua-12307	251	15	subgroup	subgroup	NOUN
aiua-12307	251	16	analysis	analysis	NOUN
aiua-12307	251	17	of	of	ADP
aiua-12307	251	18	a	a	DET
aiua-12307	251	19	randomised	randomised	ADJ
aiua-12307	251	20	controlled	control	VERB
aiua-12307	251	21	trial	trial	NOUN
aiua-12307	251	22	.	.	PUNCT
aiua-12307	252	1	archivio	archivio	NOUN
aiua-12307	252	2	italiano	italiano	PROPN
aiua-12307	252	3	di	di	PROPN
aiua-12307	252	4	urologia	urologia	PROPN
aiua-12307	252	5	e	e	PROPN
aiua-12307	252	6	andrologia	andrologia	NOUN
aiua-12307	252	7	2024	2024	NUM
aiua-12307	252	8	;	;	PUNCT
aiua-12307	252	9	96(2):12307	96(2):12307	NUM
aiua-12307	252	10	e.	e.	PROPN
aiua-12307	252	11	bosnali	bosnali	PROPN
aiua-12307	252	12	,	,	PUNCT
aiua-12307	252	13	e.	e.	PROPN
aiua-12307	252	14	malik	malik	PROPN
aiua-12307	252	15	akdas	akdas	PROPN
aiua-12307	252	16	,	,	PUNCT
aiua-12307	252	17	e.	e.	PROPN
aiua-12307	252	18	telli	telli	PROPN
aiua-12307	252	19	,	,	PUNCT
aiua-12307	252	20	k.	k.	PROPN
aiua-12307	252	21	teke	teke	PROPN
aiua-12307	252	22	,	,	PUNCT
aiua-12307	252	23	o.	o.	PROPN
aiua-12307	252	24	kara	kara	PROPN
aiua-12307	252	25	8	8	NUM
aiua-12307	252	26	immunotherapy	immunotherapy	NOUN
aiua-12307	252	27	in	in	ADP
aiua-12307	252	28	metastatic	metastatic	ADJ
aiua-12307	252	29	non	non	ADJ
aiua-12307	252	30	-	-	ADJ
aiua-12307	252	31	clear	clear	ADJ
aiua-12307	252	32	cell	cell	NOUN
aiua-12307	252	33	rcc	rcc	NOUN
aiua-12307	252	34	among	among	ADP
aiua-12307	252	35	diagnosed	diagnose	VERB
aiua-12307	252	36	renal	renal	ADJ
aiua-12307	252	37	tumours	tumour	NOUN
aiua-12307	252	38	,	,	PUNCT
aiua-12307	252	39	clear	clear	ADJ
aiua-12307	252	40	cell	cell	NOUN
aiua-12307	252	41	rcc	rcc	PROPN
aiua-12307	252	42	is	be	AUX
aiua-12307	252	43	the	the	DET
aiua-12307	252	44	most	most	ADV
aiua-12307	252	45	common	common	ADJ
aiua-12307	252	46	type	type	NOUN
aiua-12307	252	47	(	(	PUNCT
aiua-12307	252	48	80	80	NUM
aiua-12307	252	49	%	%	NOUN
aiua-12307	252	50	)	)	PUNCT
aiua-12307	252	51	;	;	PUNCT
aiua-12307	252	52	the	the	DET
aiua-12307	252	53	remaining	remain	VERB
aiua-12307	252	54	20	20	NUM
aiua-12307	252	55	%	%	NOUN
aiua-12307	252	56	is	be	AUX
aiua-12307	252	57	nonclear	nonclear	NOUN
aiua-12307	252	58	cell	cell	NOUN
aiua-12307	252	59	renal	renal	ADJ
aiua-12307	252	60	cell	cell	NOUN
aiua-12307	252	61	carcinoma	carcinoma	NOUN
aiua-12307	252	62	(	(	PUNCT
aiua-12307	252	63	nccrcc	nccrcc	NOUN
aiua-12307	252	64	)	)	PUNCT
aiua-12307	252	65	,	,	PUNCT
aiua-12307	252	66	a	a	DET
aiua-12307	252	67	rare	rare	ADJ
aiua-12307	252	68	and	and	CCONJ
aiua-12307	252	69	histopathologically	histopathologically	ADV
aiua-12307	252	70	heterogeneous	heterogeneous	ADJ
aiua-12307	252	71	group	group	NOUN
aiua-12307	252	72	of	of	ADP
aiua-12307	252	73	tumours	tumour	NOUN
aiua-12307	252	74	(	(	PUNCT
aiua-12307	252	75	31	31	NUM
aiua-12307	252	76	)	)	PUNCT
aiua-12307	252	77	.	.	PUNCT
aiua-12307	253	1	in	in	ADP
aiua-12307	253	2	most	most	ADJ
aiua-12307	253	3	kidney	kidney	NOUN
aiua-12307	253	4	cancer	cancer	NOUN
aiua-12307	253	5	trials	trial	NOUN
aiua-12307	253	6	,	,	PUNCT
aiua-12307	253	7	nccrcc	nccrcc	NOUN
aiua-12307	253	8	tumours	tumour	NOUN
aiua-12307	253	9	are	be	AUX
aiua-12307	253	10	not	not	PART
aiua-12307	253	11	included	include	VERB
aiua-12307	253	12	or	or	CCONJ
aiua-12307	253	13	only	only	ADV
aiua-12307	253	14	marginally	marginally	ADV
aiua-12307	253	15	represented	represent	VERB
aiua-12307	253	16	.	.	PUNCT
aiua-12307	254	1	therefore	therefore	ADV
aiua-12307	254	2	,	,	PUNCT
aiua-12307	254	3	little	little	ADJ
aiua-12307	254	4	is	be	AUX
aiua-12307	254	5	known	know	VERB
aiua-12307	254	6	about	about	ADP
aiua-12307	254	7	the	the	DET
aiua-12307	254	8	best	good	ADJ
aiua-12307	254	9	management	management	NOUN
aiua-12307	254	10	of	of	ADP
aiua-12307	254	11	nccrcc	nccrcc	NOUN
aiua-12307	254	12	types	type	NOUN
aiua-12307	254	13	.	.	PUNCT
aiua-12307	255	1	treatment	treatment	NOUN
aiua-12307	255	2	options	option	NOUN
aiua-12307	255	3	for	for	ADP
aiua-12307	255	4	nccrcc	nccrcc	NOUN
aiua-12307	255	5	are	be	AUX
aiua-12307	255	6	limited	limit	VERB
aiua-12307	255	7	as	as	SCONJ
aiua-12307	255	8	few	few	ADJ
aiua-12307	255	9	specific	specific	ADJ
aiua-12307	255	10	studies	study	NOUN
aiua-12307	255	11	are	be	AUX
aiua-12307	255	12	available	available	ADJ
aiua-12307	255	13	.	.	PUNCT
aiua-12307	256	1	although	although	SCONJ
aiua-12307	256	2	nccrcc	nccrcc	NOUN
aiua-12307	256	3	subtypes	subtype	NOUN
aiua-12307	256	4	have	have	AUX
aiua-12307	256	5	not	not	PART
aiua-12307	256	6	been	be	AUX
aiua-12307	256	7	included	include	VERB
aiua-12307	256	8	in	in	ADP
aiua-12307	256	9	pivotal	pivotal	ADJ
aiua-12307	256	10	ccrcc	ccrcc	NOUN
aiua-12307	256	11	clinical	clinical	ADJ
aiua-12307	256	12	trials	trial	NOUN
aiua-12307	256	13	,	,	PUNCT
aiua-12307	256	14	their	their	PRON
aiua-12307	256	15	treatments	treatment	NOUN
aiua-12307	256	16	are	be	AUX
aiua-12307	256	17	based	base	VERB
aiua-12307	256	18	on	on	ADP
aiua-12307	256	19	data	datum	NOUN
aiua-12307	256	20	from	from	ADP
aiua-12307	256	21	ccrcc	ccrcc	NOUN
aiua-12307	256	22	clinical	clinical	ADJ
aiua-12307	256	23	trials	trial	NOUN
aiua-12307	256	24	.	.	PUNCT
aiua-12307	257	1	no	no	DET
aiua-12307	257	2	phase	phase	NOUN
aiua-12307	257	3	iii	iii	NUM
aiua-12307	257	4	clinical	clinical	ADJ
aiua-12307	257	5	trials	trial	NOUN
aiua-12307	257	6	have	have	AUX
aiua-12307	257	7	been	be	AUX
aiua-12307	257	8	reported	report	VERB
aiua-12307	257	9	for	for	ADP
aiua-12307	257	10	patients	patient	NOUN
aiua-12307	257	11	diagnosed	diagnose	VERB
aiua-12307	257	12	with	with	ADP
aiua-12307	257	13	metastatic	metastatic	ADJ
aiua-12307	257	14	nccrcc	nccrcc	NOUN
aiua-12307	257	15	(	(	PUNCT
aiua-12307	257	16	60	60	NUM
aiua-12307	257	17	)	)	PUNCT
aiua-12307	257	18	.	.	PUNCT
aiua-12307	258	1	the	the	DET
aiua-12307	258	2	eau	eau	PROPN
aiua-12307	258	3	2023	2023	NUM
aiua-12307	258	4	guideline	guideline	NOUN
aiua-12307	258	5	made	make	VERB
aiua-12307	258	6	a	a	DET
aiua-12307	258	7	weak	weak	ADJ
aiua-12307	258	8	recommendation	recommendation	NOUN
aiua-12307	258	9	for	for	ADP
aiua-12307	258	10	pembrolizumab	pembrolizumab	NOUN
aiua-12307	258	11	alone	alone	ADV
aiua-12307	258	12	or	or	CCONJ
aiua-12307	258	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	258	14	/	/	SYM
aiua-12307	258	15	lenvantinib	lenvantinib	NOUN
aiua-12307	258	16	or	or	CCONJ
aiua-12307	258	17	nivolumab	nivolumab	NOUN
aiua-12307	258	18	/	/	SYM
aiua-12307	258	19	cabozantinib	cabozantinib	ADJ
aiua-12307	258	20	treatment	treatment	NOUN
aiua-12307	258	21	for	for	ADP
aiua-12307	258	22	papillary	papillary	ADJ
aiua-12307	258	23	rcc	rcc	PROPN
aiua-12307	258	24	patients	patient	NOUN
aiua-12307	258	25	based	base	VERB
aiua-12307	258	26	on	on	ADP
aiua-12307	258	27	small	small	ADJ
aiua-12307	258	28	single	single	ADJ
aiua-12307	258	29	-	-	PUNCT
aiua-12307	258	30	arm	arm	NOUN
aiua-12307	258	31	studies	study	NOUN
aiua-12307	258	32	.	.	PUNCT
aiua-12307	259	1	conducting	conduct	VERB
aiua-12307	259	2	clinical	clinical	ADJ
aiua-12307	259	3	trials	trial	NOUN
aiua-12307	259	4	on	on	ADP
aiua-12307	259	5	more	more	ADJ
aiua-12307	259	6	patients	patient	NOUN
aiua-12307	259	7	with	with	ADP
aiua-12307	259	8	different	different	ADJ
aiua-12307	259	9	histologies	histology	NOUN
aiua-12307	259	10	and	and	CCONJ
aiua-12307	259	11	investigating	investigate	VERB
aiua-12307	259	12	new	new	ADJ
aiua-12307	259	13	biomarkers	biomarker	NOUN
aiua-12307	259	14	that	that	PRON
aiua-12307	259	15	will	will	AUX
aiua-12307	259	16	help	help	VERB
aiua-12307	259	17	predict	predict	VERB
aiua-12307	259	18	response	response	NOUN
aiua-12307	259	19	to	to	ADP
aiua-12307	259	20	treatment	treatment	NOUN
aiua-12307	259	21	remain	remain	VERB
aiua-12307	259	22	questions	question	NOUN
aiua-12307	259	23	that	that	PRON
aiua-12307	259	24	researchers	researcher	NOUN
aiua-12307	259	25	need	need	VERB
aiua-12307	259	26	to	to	PART
aiua-12307	259	27	answer	answer	VERB
aiua-12307	259	28	in	in	ADP
aiua-12307	259	29	the	the	DET
aiua-12307	259	30	treatment	treatment	NOUN
aiua-12307	259	31	of	of	ADP
aiua-12307	259	32	nccrcc	nccrcc	NOUN
aiua-12307	259	33	.	.	PUNCT
aiua-12307	260	1	undoubtedly	undoubtedly	ADV
aiua-12307	260	2	,	,	PUNCT
aiua-12307	260	3	future	future	ADJ
aiua-12307	260	4	clinical	clinical	ADJ
aiua-12307	260	5	trials	trial	NOUN
aiua-12307	260	6	will	will	AUX
aiua-12307	260	7	play	play	VERB
aiua-12307	260	8	a	a	DET
aiua-12307	260	9	key	key	ADJ
aiua-12307	260	10	role	role	NOUN
aiua-12307	260	11	in	in	ADP
aiua-12307	260	12	treating	treat	VERB
aiua-12307	260	13	these	these	DET
aiua-12307	260	14	patients	patient	NOUN
aiua-12307	260	15	(	(	PUNCT
aiua-12307	260	16	61	61	NUM
aiua-12307	260	17	)	)	PUNCT
aiua-12307	260	18	.	.	PUNCT
aiua-12307	261	1	role	role	NOUN
aiua-12307	261	2	of	of	ADP
aiua-12307	261	3	immunotherapy	immunotherapy	NOUN
aiua-12307	261	4	in	in	ADP
aiua-12307	261	5	rcc	rcc	PROPN
aiua-12307	261	6	immunotherapy	immunotherapy	NOUN
aiua-12307	261	7	is	be	AUX
aiua-12307	261	8	the	the	DET
aiua-12307	261	9	cornerstone	cornerstone	NOUN
aiua-12307	261	10	of	of	ADP
aiua-12307	261	11	mrcc	mrcc	NOUN
aiua-12307	261	12	treatment	treatment	NOUN
aiua-12307	261	13	.	.	PUNCT
aiua-12307	262	1	these	these	DET
aiua-12307	262	2	agents	agent	NOUN
aiua-12307	262	3	are	be	AUX
aiua-12307	262	4	currently	currently	ADV
aiua-12307	262	5	used	use	VERB
aiua-12307	262	6	in	in	ADP
aiua-12307	262	7	clinical	clinical	ADJ
aiua-12307	262	8	trials	trial	NOUN
aiua-12307	262	9	in	in	ADP
aiua-12307	262	10	the	the	DET
aiua-12307	262	11	(	(	PUNCT
aiua-12307	262	12	neo)adjuvant	neo)adjuvant	ADJ
aiua-12307	262	13	setting	setting	NOUN
aiua-12307	262	14	for	for	ADP
aiua-12307	262	15	high	high	ADJ
aiua-12307	262	16	-	-	PUNCT
aiua-12307	262	17	risk	risk	NOUN
aiua-12307	262	18	localized	localize	VERB
aiua-12307	262	19	rcc	rcc	NOUN
aiua-12307	262	20	to	to	PART
aiua-12307	262	21	achieve	achieve	VERB
aiua-12307	262	22	primary	primary	ADJ
aiua-12307	262	23	tumour	tumour	NOUN
aiua-12307	262	24	response	response	NOUN
aiua-12307	262	25	,	,	PUNCT
aiua-12307	262	26	reduce	reduce	VERB
aiua-12307	262	27	the	the	DET
aiua-12307	262	28	risk	risk	NOUN
aiua-12307	262	29	of	of	ADP
aiua-12307	262	30	recurrence	recurrence	NOUN
aiua-12307	262	31	,	,	PUNCT
aiua-12307	262	32	and	and	CCONJ
aiua-12307	262	33	improve	improve	VERB
aiua-12307	262	34	long	long	ADJ
aiua-12307	262	35	-	-	PUNCT
aiua-12307	262	36	term	term	NOUN
aiua-12307	262	37	oncological	oncological	ADJ
aiua-12307	262	38	outcomes	outcome	NOUN
aiua-12307	262	39	.	.	PUNCT
aiua-12307	263	1	in	in	ADP
aiua-12307	263	2	addition	addition	NOUN
aiua-12307	263	3	to	to	ADP
aiua-12307	263	4	shrinking	shrink	VERB
aiua-12307	263	5	the	the	DET
aiua-12307	263	6	primary	primary	ADJ
aiua-12307	263	7	tumour	tumour	NOUN
aiua-12307	263	8	and	and	CCONJ
aiua-12307	263	9	enabling	enable	VERB
aiua-12307	263	10	nephron	nephron	NOUN
aiua-12307	263	11	-	-	PUNCT
aiua-12307	263	12	sparing	spare	VERB
aiua-12307	263	13	surgeries	surgery	NOUN
aiua-12307	263	14	,	,	PUNCT
aiua-12307	263	15	neoadjuvant	neoadjuvant	ADJ
aiua-12307	263	16	icis	icis	NOUN
aiua-12307	263	17	could	could	AUX
aiua-12307	263	18	theoretically	theoretically	ADV
aiua-12307	263	19	generate	generate	VERB
aiua-12307	263	20	a	a	DET
aiua-12307	263	21	durable	durable	ADJ
aiua-12307	263	22	immune	immune	ADJ
aiua-12307	263	23	response	response	NOUN
aiua-12307	263	24	given	give	VERB
aiua-12307	263	25	the	the	DET
aiua-12307	263	26	presence	presence	NOUN
aiua-12307	263	27	of	of	ADP
aiua-12307	263	28	antigens	antigen	NOUN
aiua-12307	263	29	in	in	ADP
aiua-12307	263	30	intact	intact	ADJ
aiua-12307	263	31	kidney	kidney	NOUN
aiua-12307	263	32	tissue	tissue	NOUN
aiua-12307	263	33	(	(	PUNCT
aiua-12307	263	34	32	32	NUM
aiua-12307	263	35	)	)	PUNCT
aiua-12307	263	36	.	.	PUNCT
aiua-12307	264	1	however	however	ADV
aiua-12307	264	2	,	,	PUNCT
aiua-12307	264	3	whether	whether	SCONJ
aiua-12307	264	4	neoadjuvant	neoadjuvant	ADJ
aiua-12307	264	5	ici	ici	NOUN
aiua-12307	264	6	/	/	SYM
aiua-12307	264	7	tki	tki	PROPN
aiua-12307	264	8	use	use	NOUN
aiua-12307	264	9	is	be	AUX
aiua-12307	264	10	associated	associate	VERB
aiua-12307	264	11	with	with	ADP
aiua-12307	264	12	longterm	longterm	PROPN
aiua-12307	264	13	dfs	dfs	NOUN
aiua-12307	264	14	or	or	CCONJ
aiua-12307	264	15	os	os	ADJ
aiua-12307	264	16	benefit	benefit	NOUN
aiua-12307	264	17	is	be	AUX
aiua-12307	264	18	not	not	PART
aiua-12307	264	19	yet	yet	ADV
aiua-12307	264	20	known	know	VERB
aiua-12307	264	21	.	.	PUNCT
aiua-12307	265	1	immunotherapy	immunotherapy	NOUN
aiua-12307	265	2	treatment	treatment	NOUN
aiua-12307	265	3	in	in	ADP
aiua-12307	265	4	the	the	DET
aiua-12307	265	5	adjuvant	adjuvant	ADJ
aiua-12307	265	6	setting	setting	NOUN
aiua-12307	265	7	is	be	AUX
aiua-12307	265	8	promising	promise	VERB
aiua-12307	265	9	,	,	PUNCT
aiua-12307	265	10	but	but	CCONJ
aiua-12307	265	11	the	the	DET
aiua-12307	265	12	risk	risk	NOUN
aiua-12307	265	13	of	of	ADP
aiua-12307	265	14	disease	disease	NOUN
aiua-12307	265	15	recurrence	recurrence	NOUN
aiua-12307	265	16	remains	remain	VERB
aiua-12307	265	17	high	high	ADJ
aiua-12307	265	18	.	.	PUNCT
aiua-12307	266	1	in	in	ADP
aiua-12307	266	2	the	the	DET
aiua-12307	266	3	keynote-564	keynote-564	NOUN
aiua-12307	266	4	(	(	PUNCT
aiua-12307	266	5	39	39	NUM
aiua-12307	266	6	)	)	PUNCT
aiua-12307	266	7	trial	trial	NOUN
aiua-12307	266	8	,	,	PUNCT
aiua-12307	266	9	relapse	relapse	NOUN
aiua-12307	266	10	was	be	AUX
aiua-12307	266	11	observed	observe	VERB
aiua-12307	266	12	in	in	ADP
aiua-12307	266	13	22.7	22.7	NUM
aiua-12307	266	14	%	%	NOUN
aiua-12307	266	15	of	of	ADP
aiua-12307	266	16	patients	patient	NOUN
aiua-12307	266	17	in	in	ADP
aiua-12307	266	18	the	the	DET
aiua-12307	266	19	pembrolizumab	pembrolizumab	NOUN
aiua-12307	266	20	group	group	NOUN
aiua-12307	266	21	.	.	PUNCT
aiua-12307	267	1	the	the	DET
aiua-12307	267	2	heterogeneity	heterogeneity	NOUN
aiua-12307	267	3	observed	observe	VERB
aiua-12307	267	4	between	between	ADP
aiua-12307	267	5	adjuvant	adjuvant	ADJ
aiua-12307	267	6	ici	ici	PROPN
aiua-12307	267	7	studies	study	NOUN
aiua-12307	267	8	may	may	AUX
aiua-12307	267	9	include	include	VERB
aiua-12307	267	10	differences	difference	NOUN
aiua-12307	267	11	in	in	ADP
aiua-12307	267	12	study	study	NOUN
aiua-12307	267	13	groups	group	NOUN
aiua-12307	267	14	(	(	PUNCT
aiua-12307	267	15	e.g.	e.g.	ADV
aiua-12307	267	16	,	,	PUNCT
aiua-12307	267	17	the	the	DET
aiua-12307	267	18	inclusion	inclusion	NOUN
aiua-12307	267	19	of	of	ADP
aiua-12307	267	20	m1	m1	PROPN
aiua-12307	267	21	ned	ne	VERB
aiua-12307	267	22	in	in	ADP
aiua-12307	267	23	keynote-564	keynote-564	NOUN
aiua-12307	267	24	and	and	CCONJ
aiua-12307	267	25	immotion010	immotion010	PROPN
aiua-12307	267	26	and	and	CCONJ
aiua-12307	267	27	no	no	DET
aiua-12307	267	28	inclusion	inclusion	NOUN
aiua-12307	267	29	in	in	ADP
aiua-12307	267	30	checkmate	checkmate	NOUN
aiua-12307	267	31	914	914	NUM
aiua-12307	267	32	)	)	PUNCT
aiua-12307	267	33	,	,	PUNCT
aiua-12307	267	34	drug	drug	NOUN
aiua-12307	267	35	tolerability	tolerability	NOUN
aiua-12307	267	36	,	,	PUNCT
aiua-12307	267	37	and	and	CCONJ
aiua-12307	267	38	factors	factor	NOUN
aiua-12307	267	39	that	that	PRON
aiua-12307	267	40	may	may	AUX
aiua-12307	267	41	affect	affect	VERB
aiua-12307	267	42	adequate	adequate	ADJ
aiua-12307	267	43	drug	drug	NOUN
aiua-12307	267	44	distribution	distribution	NOUN
aiua-12307	267	45	(	(	PUNCT
aiua-12307	267	46	e.g.	e.g.	ADV
aiua-12307	267	47	,	,	PUNCT
aiua-12307	267	48	checkmate	checkmate	VERB
aiua-12307	267	49	914	914	NUM
aiua-12307	267	50	)	)	PUNCT
aiua-12307	267	51	.	.	PUNCT
aiua-12307	268	1	(	(	PUNCT
aiua-12307	268	2	43	43	NUM
aiua-12307	268	3	%	%	NOUN
aiua-12307	268	4	medication	medication	NOUN
aiua-12307	268	5	discontinuation	discontinuation	NOUN
aiua-12307	268	6	rate	rate	NOUN
aiua-12307	268	7	)	)	PUNCT
aiua-12307	268	8	may	may	AUX
aiua-12307	268	9	contribute	contribute	VERB
aiua-12307	268	10	to	to	ADP
aiua-12307	268	11	this	this	DET
aiua-12307	268	12	heterogeneity	heterogeneity	NOUN
aiua-12307	268	13	.	.	PUNCT
aiua-12307	269	1	additionally	additionally	ADV
aiua-12307	269	2	,	,	PUNCT
aiua-12307	269	3	including	include	VERB
aiua-12307	269	4	t2a	t2a	ADP
aiua-12307	269	5	/	/	SYM
aiua-12307	269	6	grade	grade	NOUN
aiua-12307	269	7	3	3	NUM
aiua-12307	269	8	patients	patient	NOUN
aiua-12307	269	9	in	in	ADP
aiua-12307	269	10	the	the	DET
aiua-12307	269	11	checkmate	checkmate	NOUN
aiua-12307	269	12	914	914	NUM
aiua-12307	269	13	study	study	NOUN
aiua-12307	269	14	,	,	PUNCT
aiua-12307	269	15	who	who	PRON
aiua-12307	269	16	were	be	AUX
aiua-12307	269	17	assumed	assume	VERB
aiua-12307	269	18	to	to	PART
aiua-12307	269	19	have	have	VERB
aiua-12307	269	20	lower	low	ADJ
aiua-12307	269	21	malignancy	malignancy	NOUN
aiua-12307	269	22	than	than	ADP
aiua-12307	269	23	the	the	DET
aiua-12307	269	24	other	other	ADJ
aiua-12307	269	25	two	two	NUM
aiua-12307	269	26	,	,	PUNCT
aiua-12307	269	27	may	may	AUX
aiua-12307	269	28	have	have	AUX
aiua-12307	269	29	significantly	significantly	ADV
aiua-12307	269	30	affected	affect	VERB
aiua-12307	269	31	the	the	DET
aiua-12307	269	32	study	study	NOUN
aiua-12307	269	33	results	result	NOUN
aiua-12307	269	34	.	.	PUNCT
aiua-12307	270	1	these	these	DET
aiua-12307	270	2	differences	difference	NOUN
aiua-12307	270	3	in	in	ADP
aiua-12307	270	4	inclusion	inclusion	NOUN
aiua-12307	270	5	criteria	criterion	NOUN
aiua-12307	270	6	between	between	ADP
aiua-12307	270	7	ongoing	ongoing	ADJ
aiua-12307	270	8	clinical	clinical	ADJ
aiua-12307	270	9	trials	trial	NOUN
aiua-12307	270	10	may	may	AUX
aiua-12307	270	11	affect	affect	VERB
aiua-12307	270	12	the	the	DET
aiua-12307	270	13	risk	risk	NOUN
aiua-12307	270	14	of	of	ADP
aiua-12307	270	15	disease	disease	NOUN
aiua-12307	270	16	recurrence	recurrence	NOUN
aiua-12307	270	17	and	and	CCONJ
aiua-12307	270	18	,	,	PUNCT
aiua-12307	270	19	ultimately	ultimately	ADV
aiua-12307	270	20	,	,	PUNCT
aiua-12307	270	21	negatively	negatively	ADV
aiua-12307	270	22	contribute	contribute	VERB
aiua-12307	270	23	to	to	ADP
aiua-12307	270	24	disease	disease	NOUN
aiua-12307	270	25	progression	progression	NOUN
aiua-12307	270	26	.	.	PUNCT
aiua-12307	271	1	additionally	additionally	ADV
aiua-12307	271	2	,	,	PUNCT
aiua-12307	271	3	differences	difference	NOUN
aiua-12307	271	4	in	in	ADP
aiua-12307	271	5	treatment	treatment	NOUN
aiua-12307	271	6	-	-	PUNCT
aiua-12307	271	7	limiting	limit	VERB
aiua-12307	271	8	toxicity	toxicity	NOUN
aiua-12307	271	9	rates	rate	NOUN
aiua-12307	271	10	across	across	ADP
aiua-12307	271	11	studies	study	NOUN
aiua-12307	271	12	may	may	AUX
aiua-12307	271	13	alter	alter	VERB
aiua-12307	271	14	the	the	DET
aiua-12307	271	15	treatment	treatment	NOUN
aiua-12307	271	16	received	receive	VERB
aiua-12307	271	17	and	and	CCONJ
aiua-12307	271	18	impact	impact	VERB
aiua-12307	271	19	dfs	dfs	NOUN
aiua-12307	271	20	results	result	NOUN
aiua-12307	271	21	.	.	PUNCT
aiua-12307	272	1	one	one	NUM
aiua-12307	272	2	of	of	ADP
aiua-12307	272	3	the	the	DET
aiua-12307	272	4	reasons	reason	NOUN
aiua-12307	272	5	why	why	SCONJ
aiua-12307	272	6	the	the	DET
aiua-12307	272	7	immotion010	immotion010	PROPN
aiua-12307	272	8	(	(	PUNCT
aiua-12307	272	9	43	43	NUM
aiua-12307	272	10	)	)	PUNCT
aiua-12307	272	11	trial	trial	NOUN
aiua-12307	272	12	failed	fail	VERB
aiua-12307	272	13	to	to	PART
aiua-12307	272	14	meet	meet	VERB
aiua-12307	272	15	the	the	DET
aiua-12307	272	16	primary	primary	ADJ
aiua-12307	272	17	endpoint	endpoint	NOUN
aiua-12307	272	18	compared	compare	VERB
aiua-12307	272	19	to	to	ADP
aiua-12307	272	20	the	the	DET
aiua-12307	272	21	keynote-564	keynote-564	ADJ
aiua-12307	272	22	study	study	NOUN
aiua-12307	272	23	may	may	AUX
aiua-12307	272	24	be	be	AUX
aiua-12307	272	25	that	that	SCONJ
aiua-12307	272	26	the	the	DET
aiua-12307	272	27	anti	anti	ADJ
aiua-12307	272	28	-	-	ADJ
aiua-12307	272	29	pd-1	pd-1	ADJ
aiua-12307	272	30	and	and	CCONJ
aiua-12307	272	31	pd	pd	PROPN
aiua-12307	272	32	-	-	PUNCT
aiua-12307	272	33	l1	l1	PROPN
aiua-12307	272	34	antibodies	antibody	NOUN
aiua-12307	272	35	used	use	VERB
aiua-12307	272	36	in	in	ADP
aiua-12307	272	37	the	the	DET
aiua-12307	272	38	studies	study	NOUN
aiua-12307	272	39	showed	show	VERB
aiua-12307	272	40	a	a	DET
aiua-12307	272	41	difference	difference	NOUN
aiua-12307	272	42	in	in	ADP
aiua-12307	272	43	efficacy	efficacy	NOUN
aiua-12307	272	44	.	.	PUNCT
aiua-12307	273	1	liu	liu	PROPN
aiua-12307	273	2	et	et	PROPN
aiua-12307	273	3	al	al	PROPN
aiua-12307	273	4	.	.	PROPN
aiua-12307	274	1	discuss	discuss	VERB
aiua-12307	274	2	the	the	DET
aiua-12307	274	3	incidence	incidence	NOUN
aiua-12307	274	4	of	of	ADP
aiua-12307	274	5	renal	renal	ADJ
aiua-12307	274	6	adverse	adverse	ADJ
aiua-12307	274	7	events	event	NOUN
aiua-12307	274	8	(	(	PUNCT
aiua-12307	274	9	raes	raes	PROPN
aiua-12307	274	10	)	)	PUNCT
aiua-12307	274	11	for	for	ADP
aiua-12307	274	12	ici	ici	NOUN
aiua-12307	274	13	-	-	PUNCT
aiua-12307	274	14	based	base	VERB
aiua-12307	274	15	regimens	regimen	NOUN
aiua-12307	274	16	vs	vs	ADP
aiua-12307	274	17	targeted	target	VERB
aiua-12307	274	18	or	or	CCONJ
aiua-12307	274	19	chemotherapies	chemotherapy	NOUN
aiua-12307	274	20	,	,	PUNCT
aiua-12307	274	21	including	include	VERB
aiua-12307	274	22	95	95	NUM
aiua-12307	274	23	rcts	rct	NOUN
aiua-12307	274	24	totalling	total	VERB
aiua-12307	274	25	more	more	ADJ
aiua-12307	274	26	than	than	ADP
aiua-12307	274	27	40,000	40,000	NUM
aiua-12307	274	28	patients	patient	NOUN
aiua-12307	274	29	(	(	PUNCT
aiua-12307	274	30	62	62	NUM
aiua-12307	274	31	)	)	PUNCT
aiua-12307	274	32	.	.	PUNCT
aiua-12307	275	1	grade	grade	NOUN
aiua-12307	275	2	3	3	NUM
aiua-12307	275	3	or	or	CCONJ
aiua-12307	275	4	higher	high	ADJ
aiua-12307	275	5	raes	raes	PROPN
aiua-12307	275	6	incidence	incidence	NOUN
aiua-12307	275	7	was	be	AUX
aiua-12307	275	8	4.3	4.3	NUM
aiua-12307	275	9	%	%	NOUN
aiua-12307	275	10	.	.	PUNCT
aiua-12307	276	1	among	among	ADP
aiua-12307	276	2	ici	ici	PROPN
aiua-12307	276	3	monotherapies	monotherapie	NOUN
aiua-12307	276	4	,	,	PUNCT
aiua-12307	276	5	anti	anti	ADJ
aiua-12307	276	6	-	-	ADJ
aiua-12307	276	7	ctla4	ctla4	NOUN
aiua-12307	276	8	was	be	AUX
aiua-12307	276	9	found	find	VERB
aiua-12307	276	10	to	to	PART
aiua-12307	276	11	have	have	VERB
aiua-12307	276	12	a	a	DET
aiua-12307	276	13	higher	high	ADJ
aiua-12307	276	14	risk	risk	NOUN
aiua-12307	276	15	of	of	ADP
aiua-12307	276	16	≥	≥	NOUN
aiua-12307	276	17	grade	grade	NOUN
aiua-12307	276	18	3	3	NUM
aiua-12307	276	19	raes	raes	PROPN
aiua-12307	276	20	compared	compare	VERB
aiua-12307	276	21	to	to	ADP
aiua-12307	276	22	anti	anti	ADJ
aiua-12307	276	23	-	-	ADJ
aiua-12307	276	24	pd-1	pd-1	ADJ
aiua-12307	276	25	/	/	SYM
aiua-12307	276	26	pd	pd	NOUN
aiua-12307	276	27	-	-	PUNCT
aiua-12307	276	28	l1	l1	PROPN
aiua-12307	276	29	.	.	PUNCT
aiua-12307	277	1	diagnostic	diagnostic	ADJ
aiua-12307	277	2	and	and	CCONJ
aiua-12307	277	3	management	management	NOUN
aiua-12307	277	4	challenges	challenge	NOUN
aiua-12307	277	5	for	for	ADP
aiua-12307	277	6	ici	ici	NOUN
aiua-12307	277	7	-	-	PUNCT
aiua-12307	277	8	associated	associate	VERB
aiua-12307	277	9	toxicities	toxicity	NOUN
aiua-12307	277	10	highlight	highlight	VERB
aiua-12307	277	11	the	the	DET
aiua-12307	277	12	value	value	NOUN
aiua-12307	277	13	of	of	ADP
aiua-12307	277	14	a	a	DET
aiua-12307	277	15	multidisciplinary	multidisciplinary	ADJ
aiua-12307	277	16	approach	approach	NOUN
aiua-12307	277	17	to	to	ADP
aiua-12307	277	18	the	the	DET
aiua-12307	277	19	management	management	NOUN
aiua-12307	277	20	of	of	ADP
aiua-12307	277	21	high	high	ADJ
aiua-12307	277	22	-	-	PUNCT
aiua-12307	277	23	grade	grade	NOUN
aiua-12307	277	24	raes	raes	PROPN
aiua-12307	277	25	.	.	PUNCT
aiua-12307	278	1	currently	currently	ADV
aiua-12307	278	2	,	,	PUNCT
aiua-12307	278	3	there	there	PRON
aiua-12307	278	4	are	be	VERB
aiua-12307	278	5	no	no	DET
aiua-12307	278	6	standard	standard	ADJ
aiua-12307	278	7	or	or	CCONJ
aiua-12307	278	8	validated	validated	ADJ
aiua-12307	278	9	biomarkers	biomarker	NOUN
aiua-12307	278	10	to	to	PART
aiua-12307	278	11	help	help	VERB
aiua-12307	278	12	treat	treat	VERB
aiua-12307	278	13	rcc	rcc	PROPN
aiua-12307	278	14	.	.	PUNCT
aiua-12307	278	15	discovering	discover	VERB
aiua-12307	278	16	one	one	NUM
aiua-12307	278	17	or	or	CCONJ
aiua-12307	278	18	more	more	ADJ
aiua-12307	278	19	of	of	ADP
aiua-12307	278	20	these	these	DET
aiua-12307	278	21	biomarkers	biomarker	NOUN
aiua-12307	278	22	is	be	AUX
aiua-12307	278	23	probably	probably	ADV
aiua-12307	278	24	at	at	ADP
aiua-12307	278	25	the	the	DET
aiua-12307	278	26	top	top	NOUN
aiua-12307	278	27	of	of	ADP
aiua-12307	278	28	every	every	DET
aiua-12307	278	29	researcher	researcher	NOUN
aiua-12307	278	30	's	's	PART
aiua-12307	278	31	wish	wish	NOUN
aiua-12307	278	32	list	list	NOUN
aiua-12307	278	33	.	.	PUNCT
aiua-12307	279	1	if	if	SCONJ
aiua-12307	279	2	biomarkers	biomarker	NOUN
aiua-12307	279	3	can	can	AUX
aiua-12307	279	4	be	be	AUX
aiua-12307	279	5	identified	identify	VERB
aiua-12307	279	6	in	in	ADP
aiua-12307	279	7	patients	patient	NOUN
aiua-12307	279	8	who	who	PRON
aiua-12307	279	9	have	have	AUX
aiua-12307	279	10	not	not	PART
aiua-12307	279	11	received	receive	VERB
aiua-12307	279	12	ct	ct	PRON
aiua-12307	279	13	or	or	CCONJ
aiua-12307	279	14	at	at	ADP
aiua-12307	279	15	an	an	DET
aiua-12307	279	16	earlier	early	ADJ
aiua-12307	279	17	time	time	NOUN
aiua-12307	279	18	when	when	SCONJ
aiua-12307	279	19	cancer	cancer	NOUN
aiua-12307	279	20	is	be	AUX
aiua-12307	279	21	diagnosed	diagnose	VERB
aiua-12307	279	22	,	,	PUNCT
aiua-12307	279	23	opportunities	opportunity	NOUN
aiua-12307	279	24	for	for	ADP
aiua-12307	279	25	the	the	DET
aiua-12307	279	26	use	use	NOUN
aiua-12307	279	27	of	of	ADP
aiua-12307	279	28	neoadjuvant	neoadjuvant	ADJ
aiua-12307	279	29	or	or	CCONJ
aiua-12307	279	30	early	early	ADJ
aiua-12307	279	31	adjuvant	adjuvant	ADJ
aiua-12307	279	32	immunotherapy	immunotherapy	NOUN
aiua-12307	279	33	will	will	AUX
aiua-12307	279	34	increase	increase	VERB
aiua-12307	279	35	.	.	PUNCT
aiua-12307	280	1	although	although	SCONJ
aiua-12307	280	2	dfs	dfs	PROPN
aiua-12307	280	3	benefit	benefit	NOUN
aiua-12307	280	4	in	in	ADP
aiua-12307	280	5	the	the	DET
aiua-12307	280	6	adjuvant	adjuvant	ADJ
aiua-12307	280	7	setting	setting	NOUN
aiua-12307	280	8	is	be	AUX
aiua-12307	280	9	a	a	DET
aiua-12307	280	10	meaningful	meaningful	ADJ
aiua-12307	280	11	primary	primary	ADJ
aiua-12307	280	12	endpoint	endpoint	NOUN
aiua-12307	280	13	supported	support	VERB
aiua-12307	280	14	by	by	ADP
aiua-12307	280	15	the	the	DET
aiua-12307	280	16	fda	fda	PROPN
aiua-12307	280	17	and	and	CCONJ
aiua-12307	280	18	the	the	DET
aiua-12307	280	19	european	european	PROPN
aiua-12307	280	20	medical	medical	PROPN
aiua-12307	280	21	association	association	PROPN
aiua-12307	280	22	,	,	PUNCT
aiua-12307	280	23	treatment	treatment	NOUN
aiua-12307	280	24	-	-	PUNCT
aiua-12307	280	25	related	relate	VERB
aiua-12307	280	26	toxicities	toxicity	NOUN
aiua-12307	280	27	should	should	AUX
aiua-12307	280	28	not	not	PART
aiua-12307	280	29	be	be	AUX
aiua-12307	280	30	ignored	ignore	VERB
aiua-12307	280	31	by	by	ADP
aiua-12307	280	32	patients	patient	NOUN
aiua-12307	280	33	and	and	CCONJ
aiua-12307	280	34	clinicians	clinician	NOUN
aiua-12307	280	35	.	.	PUNCT
aiua-12307	281	1	while	while	SCONJ
aiua-12307	281	2	the	the	DET
aiua-12307	281	3	dfs	dfs	PROPN
aiua-12307	281	4	benefit	benefit	NOUN
aiua-12307	281	5	of	of	ADP
aiua-12307	281	6	pembrolizumab	pembrolizumab	NOUN
aiua-12307	281	7	was	be	AUX
aiua-12307	281	8	maintained	maintain	VERB
aiua-12307	281	9	in	in	ADP
aiua-12307	281	10	long	long	ADJ
aiua-12307	281	11	-	-	PUNCT
aiua-12307	281	12	term	term	NOUN
aiua-12307	281	13	follow	follow	NOUN
aiua-12307	281	14	-	-	PUNCT
aiua-12307	281	15	up	up	NOUN
aiua-12307	281	16	,	,	PUNCT
aiua-12307	281	17	against	against	ADP
aiua-12307	281	18	the	the	DET
aiua-12307	281	19	background	background	NOUN
aiua-12307	281	20	of	of	ADP
aiua-12307	281	21	many	many	ADJ
aiua-12307	281	22	negative	negative	ADJ
aiua-12307	281	23	adjuvant	adjuvant	ADJ
aiua-12307	281	24	clinical	clinical	ADJ
aiua-12307	281	25	trials	trial	NOUN
aiua-12307	281	26	,	,	PUNCT
aiua-12307	281	27	clinicians	clinician	NOUN
aiua-12307	281	28	await	await	VERB
aiua-12307	281	29	the	the	DET
aiua-12307	281	30	study	study	NOUN
aiua-12307	281	31	's	's	PART
aiua-12307	281	32	long	long	ADJ
aiua-12307	281	33	-	-	PUNCT
aiua-12307	281	34	term	term	NOUN
aiua-12307	281	35	os	os	NOUN
aiua-12307	281	36	data	datum	NOUN
aiua-12307	281	37	before	before	ADP
aiua-12307	281	38	recommending	recommend	VERB
aiua-12307	281	39	adjuvant	adjuvant	ADJ
aiua-12307	281	40	pembrolizumab	pembrolizumab	NOUN
aiua-12307	281	41	to	to	ADP
aiua-12307	281	42	patients	patient	NOUN
aiua-12307	281	43	.	.	PUNCT
aiua-12307	282	1	in	in	ADP
aiua-12307	282	2	the	the	DET
aiua-12307	282	3	meantime	meantime	NOUN
aiua-12307	282	4	,	,	PUNCT
aiua-12307	282	5	adjuvant	adjuvant	ADJ
aiua-12307	282	6	pembrolizumab	pembrolizumab	NOUN
aiua-12307	282	7	remains	remain	VERB
aiua-12307	282	8	a	a	DET
aiua-12307	282	9	reasonable	reasonable	ADJ
aiua-12307	282	10	option	option	NOUN
aiua-12307	282	11	for	for	ADP
aiua-12307	282	12	patients	patient	NOUN
aiua-12307	282	13	with	with	ADP
aiua-12307	282	14	high	high	ADJ
aiua-12307	282	15	-	-	PUNCT
aiua-12307	282	16	risk	risk	NOUN
aiua-12307	282	17	rcc	rcc	NOUN
aiua-12307	282	18	in	in	ADP
aiua-12307	282	19	light	light	NOUN
aiua-12307	282	20	of	of	ADP
aiua-12307	282	21	the	the	DET
aiua-12307	282	22	eau	eau	PROPN
aiua-12307	282	23	2023	2023	NUM
aiua-12307	282	24	guideline	guideline	NOUN
aiua-12307	282	25	.	.	PUNCT
aiua-12307	283	1	when	when	SCONJ
aiua-12307	283	2	discussing	discuss	VERB
aiua-12307	283	3	adjuvant	adjuvant	ADJ
aiua-12307	283	4	treatment	treatment	NOUN
aiua-12307	283	5	options	option	NOUN
aiua-12307	283	6	with	with	ADP
aiua-12307	283	7	a	a	DET
aiua-12307	283	8	patient	patient	NOUN
aiua-12307	283	9	with	with	ADP
aiua-12307	283	10	high	high	ADJ
aiua-12307	283	11	-	-	PUNCT
aiua-12307	283	12	risk	risk	NOUN
aiua-12307	283	13	rcc	rcc	NOUN
aiua-12307	283	14	,	,	PUNCT
aiua-12307	283	15	clinicians	clinician	NOUN
aiua-12307	283	16	should	should	AUX
aiua-12307	283	17	discuss	discuss	VERB
aiua-12307	283	18	available	available	ADJ
aiua-12307	283	19	data	datum	NOUN
aiua-12307	283	20	supporting	support	VERB
aiua-12307	283	21	the	the	DET
aiua-12307	283	22	use	use	NOUN
aiua-12307	283	23	of	of	ADP
aiua-12307	283	24	adjuvant	adjuvant	ADJ
aiua-12307	283	25	icis	icis	PROPN
aiua-12307	283	26	and	and	CCONJ
aiua-12307	283	27	outline	outline	VERB
aiua-12307	283	28	questions	question	NOUN
aiua-12307	283	29	that	that	PRON
aiua-12307	283	30	will	will	AUX
aiua-12307	283	31	be	be	AUX
aiua-12307	283	32	answered	answer	VERB
aiua-12307	283	33	over	over	ADP
aiua-12307	283	34	time	time	NOUN
aiua-12307	283	35	.	.	PUNCT
aiua-12307	284	1	until	until	SCONJ
aiua-12307	284	2	we	we	PRON
aiua-12307	284	3	get	get	VERB
aiua-12307	284	4	answers	answer	NOUN
aiua-12307	284	5	to	to	ADP
aiua-12307	284	6	these	these	DET
aiua-12307	284	7	crucial	crucial	ADJ
aiua-12307	284	8	questions	question	NOUN
aiua-12307	284	9	,	,	PUNCT
aiua-12307	284	10	adjuvant	adjuvant	ADJ
aiua-12307	284	11	immunotherapy	immunotherapy	NOUN
aiua-12307	284	12	application	application	NOUN
aiua-12307	284	13	appears	appear	VERB
aiua-12307	284	14	to	to	PART
aiua-12307	284	15	be	be	AUX
aiua-12307	284	16	a	a	DET
aiua-12307	284	17	personalized	personalized	ADJ
aiua-12307	284	18	decision	decision	NOUN
aiua-12307	284	19	.	.	PUNCT
aiua-12307	285	1	prostate	prostate	NOUN
aiua-12307	285	2	cancer	cancer	NOUN
aiua-12307	285	3	prostate	prostate	NOUN
aiua-12307	285	4	cancer	cancer	NOUN
aiua-12307	285	5	is	be	AUX
aiua-12307	285	6	the	the	DET
aiua-12307	285	7	2nd	2nd	ADJ
aiua-12307	285	8	most	most	ADV
aiua-12307	285	9	common	common	ADJ
aiua-12307	285	10	type	type	NOUN
aiua-12307	285	11	of	of	ADP
aiua-12307	285	12	cancer	cancer	NOUN
aiua-12307	285	13	in	in	ADP
aiua-12307	285	14	men	man	NOUN
aiua-12307	285	15	and	and	CCONJ
aiua-12307	285	16	ranks	rank	VERB
aiua-12307	285	17	5th	5th	ADJ
aiua-12307	285	18	among	among	ADP
aiua-12307	285	19	cancer	cancer	NOUN
aiua-12307	285	20	-	-	PUNCT
aiua-12307	285	21	related	relate	VERB
aiua-12307	285	22	deaths	death	NOUN
aiua-12307	285	23	.	.	PUNCT
aiua-12307	286	1	prostate	prostate	NOUN
aiua-12307	286	2	cancer	cancer	NOUN
aiua-12307	286	3	is	be	AUX
aiua-12307	286	4	the	the	DET
aiua-12307	286	5	most	most	ADV
aiua-12307	286	6	frequently	frequently	ADV
aiua-12307	286	7	diagnosed	diagnose	VERB
aiua-12307	286	8	cancer	cancer	NOUN
aiua-12307	286	9	in	in	ADP
aiua-12307	286	10	112	112	NUM
aiua-12307	286	11	countries	country	NOUN
aiua-12307	286	12	in	in	ADP
aiua-12307	286	13	the	the	DET
aiua-12307	286	14	world	world	NOUN
aiua-12307	286	15	,	,	PUNCT
aiua-12307	286	16	followed	follow	VERB
aiua-12307	286	17	by	by	ADP
aiua-12307	286	18	lung	lung	NOUN
aiua-12307	286	19	cancer	cancer	NOUN
aiua-12307	286	20	in	in	ADP
aiua-12307	286	21	36	36	NUM
aiua-12307	286	22	countries	country	NOUN
aiua-12307	286	23	and	and	CCONJ
aiua-12307	286	24	colorectal	colorectal	ADJ
aiua-12307	286	25	cancer	cancer	NOUN
aiua-12307	286	26	in	in	ADP
aiua-12307	286	27	11	11	NUM
aiua-12307	286	28	countries	country	NOUN
aiua-12307	286	29	(	(	PUNCT
aiua-12307	286	30	63	63	NUM
aiua-12307	286	31	)	)	PUNCT
aiua-12307	286	32	.	.	PUNCT
aiua-12307	287	1	the	the	DET
aiua-12307	287	2	widespread	widespread	ADJ
aiua-12307	287	3	use	use	NOUN
aiua-12307	287	4	of	of	ADP
aiua-12307	287	5	prostate	prostate	NOUN
aiua-12307	287	6	-	-	PUNCT
aiua-12307	287	7	specific	specific	ADJ
aiua-12307	287	8	antigen	antigen	NOUN
aiua-12307	287	9	(	(	PUNCT
aiua-12307	287	10	psa	psa	NOUN
aiua-12307	287	11	)	)	PUNCT
aiua-12307	287	12	has	have	AUX
aiua-12307	287	13	led	lead	VERB
aiua-12307	287	14	to	to	ADP
aiua-12307	287	15	a	a	DET
aiua-12307	287	16	significant	significant	ADJ
aiua-12307	287	17	increase	increase	NOUN
aiua-12307	287	18	in	in	ADP
aiua-12307	287	19	the	the	DET
aiua-12307	287	20	incidence	incidence	NOUN
aiua-12307	287	21	of	of	ADP
aiua-12307	287	22	prostate	prostate	NOUN
aiua-12307	287	23	cancer	cancer	NOUN
aiua-12307	287	24	.	.	PUNCT
aiua-12307	288	1	this	this	PRON
aiua-12307	288	2	has	have	AUX
aiua-12307	288	3	resulted	result	VERB
aiua-12307	288	4	in	in	ADP
aiua-12307	288	5	increased	increase	VERB
aiua-12307	288	6	detection	detection	NOUN
aiua-12307	288	7	of	of	ADP
aiua-12307	288	8	indolent	indolent	ADJ
aiua-12307	288	9	disease	disease	NOUN
aiua-12307	288	10	and	and	CCONJ
aiua-12307	288	11	decreased	decrease	VERB
aiua-12307	288	12	detection	detection	NOUN
aiua-12307	288	13	of	of	ADP
aiua-12307	288	14	metastatic	metastatic	ADJ
aiua-12307	288	15	prostate	prostate	NOUN
aiua-12307	288	16	cancer	cancer	NOUN
aiua-12307	288	17	(	(	PUNCT
aiua-12307	288	18	64	64	NUM
aiua-12307	288	19	)	)	PUNCT
aiua-12307	288	20	.	.	PUNCT
aiua-12307	289	1	the	the	DET
aiua-12307	289	2	most	most	ADV
aiua-12307	289	3	important	important	ADJ
aiua-12307	289	4	risk	risk	NOUN
aiua-12307	289	5	factors	factor	NOUN
aiua-12307	289	6	in	in	ADP
aiua-12307	289	7	the	the	DET
aiua-12307	289	8	aetiology	aetiology	NOUN
aiua-12307	289	9	of	of	ADP
aiua-12307	289	10	prostate	prostate	NOUN
aiua-12307	289	11	cancer	cancer	NOUN
aiua-12307	289	12	are	be	AUX
aiua-12307	289	13	,	,	PUNCT
aiua-12307	289	14	as	as	SCONJ
aiua-12307	289	15	many	many	ADJ
aiua-12307	289	16	studies	study	NOUN
aiua-12307	289	17	have	have	AUX
aiua-12307	289	18	shown	show	VERB
aiua-12307	289	19	,	,	PUNCT
aiua-12307	289	20	advanced	advanced	ADJ
aiua-12307	289	21	age	age	NOUN
aiua-12307	289	22	,	,	PUNCT
aiua-12307	289	23	geography	geography	NOUN
aiua-12307	289	24	,	,	PUNCT
aiua-12307	289	25	ethnicity	ethnicity	NOUN
aiua-12307	289	26	,	,	PUNCT
aiua-12307	289	27	family	family	NOUN
aiua-12307	289	28	history	history	NOUN
aiua-12307	289	29	and	and	CCONJ
aiua-12307	289	30	genetic	genetic	ADJ
aiua-12307	289	31	predisposition	predisposition	NOUN
aiua-12307	289	32	(	(	PUNCT
aiua-12307	289	33	65	65	NUM
aiua-12307	289	34	-	-	SYM
aiua-12307	289	35	67	67	NUM
aiua-12307	289	36	)	)	PUNCT
aiua-12307	289	37	.	.	PUNCT
aiua-12307	290	1	in	in	ADP
aiua-12307	290	2	recent	recent	ADJ
aiua-12307	290	3	years	year	NOUN
aiua-12307	290	4	,	,	PUNCT
aiua-12307	290	5	immunotherapy	immunotherapy	NOUN
aiua-12307	290	6	has	have	AUX
aiua-12307	290	7	emerged	emerge	VERB
aiua-12307	290	8	as	as	ADP
aiua-12307	290	9	an	an	DET
aiua-12307	290	10	essential	essential	ADJ
aiua-12307	290	11	field	field	NOUN
aiua-12307	290	12	in	in	ADP
aiua-12307	290	13	the	the	DET
aiua-12307	290	14	treatment	treatment	NOUN
aiua-12307	290	15	of	of	ADP
aiua-12307	290	16	prostate	prostate	NOUN
aiua-12307	290	17	cancer	cancer	NOUN
aiua-12307	290	18	.	.	PUNCT
aiua-12307	291	1	prostate	prostate	NOUN
aiua-12307	291	2	cancer	cancer	NOUN
aiua-12307	291	3	is	be	AUX
aiua-12307	291	4	an	an	DET
aiua-12307	291	5	immunological	immunological	ADJ
aiua-12307	291	6	tumour	tumour	NOUN
aiua-12307	291	7	to	to	ADP
aiua-12307	291	8	a	a	DET
aiua-12307	291	9	lesser	less	ADJ
aiua-12307	291	10	extent	extent	NOUN
aiua-12307	291	11	compared	compare	VERB
aiua-12307	291	12	to	to	ADP
aiua-12307	291	13	other	other	ADJ
aiua-12307	291	14	types	type	NOUN
aiua-12307	291	15	of	of	ADP
aiua-12307	291	16	urological	urological	ADJ
aiua-12307	291	17	cancer	cancer	NOUN
aiua-12307	291	18	.	.	PUNCT
aiua-12307	292	1	the	the	DET
aiua-12307	292	2	reasons	reason	NOUN
aiua-12307	292	3	for	for	ADP
aiua-12307	292	4	this	this	PRON
aiua-12307	292	5	are	be	AUX
aiua-12307	292	6	that	that	SCONJ
aiua-12307	292	7	prostate	prostate	NOUN
aiua-12307	292	8	cancer	cancer	NOUN
aiua-12307	292	9	has	have	VERB
aiua-12307	292	10	a	a	DET
aiua-12307	292	11	low	low	ADJ
aiua-12307	292	12	rate	rate	NOUN
aiua-12307	292	13	of	of	ADP
aiua-12307	292	14	tumour	tumour	NOUN
aiua-12307	292	15	mutation	mutation	NOUN
aiua-12307	292	16	,	,	PUNCT
aiua-12307	292	17	pdl1	pdl1	NOUN
aiua-12307	292	18	expression	expression	NOUN
aiua-12307	292	19	and	and	CCONJ
aiua-12307	292	20	t	t	NOUN
aiua-12307	292	21	-	-	PUNCT
aiua-12307	292	22	cell	cell	NOUN
aiua-12307	292	23	infiltration	infiltration	NOUN
aiua-12307	292	24	(	(	PUNCT
aiua-12307	292	25	68	68	NUM
aiua-12307	292	26	)	)	PUNCT
aiua-12307	292	27	.	.	PUNCT
aiua-12307	293	1	therefore	therefore	ADV
aiua-12307	293	2	,	,	PUNCT
aiua-12307	293	3	although	although	SCONJ
aiua-12307	293	4	immunotherapy	immunotherapy	NOUN
aiua-12307	293	5	has	have	VERB
aiua-12307	293	6	a	a	DET
aiua-12307	293	7	limited	limited	ADJ
aiua-12307	293	8	place	place	NOUN
aiua-12307	293	9	in	in	ADP
aiua-12307	293	10	prostate	prostate	NOUN
aiua-12307	293	11	cancer	cancer	NOUN
aiua-12307	293	12	,	,	PUNCT
aiua-12307	293	13	some	some	DET
aiua-12307	293	14	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	293	15	agents	agent	NOUN
aiua-12307	293	16	have	have	AUX
aiua-12307	293	17	become	become	VERB
aiua-12307	293	18	part	part	NOUN
aiua-12307	293	19	of	of	ADP
aiua-12307	293	20	standard	standard	ADJ
aiua-12307	293	21	treatment	treatment	NOUN
aiua-12307	293	22	in	in	ADP
aiua-12307	293	23	the	the	DET
aiua-12307	293	24	past	past	ADJ
aiua-12307	293	25	few	few	ADJ
aiua-12307	293	26	years	year	NOUN
aiua-12307	293	27	.	.	PUNCT
aiua-12307	294	1	it	it	PRON
aiua-12307	294	2	provides	provide	VERB
aiua-12307	294	3	an	an	DET
aiua-12307	294	4	alternative	alternative	ADJ
aiua-12307	294	5	treatment	treatment	NOUN
aiua-12307	294	6	method	method	NOUN
aiua-12307	294	7	,	,	PUNCT
aiua-12307	294	8	especially	especially	ADV
aiua-12307	294	9	for	for	ADP
aiua-12307	294	10	castrationresistant	castrationresistant	ADJ
aiua-12307	294	11	prostate	prostate	NOUN
aiua-12307	294	12	cancer	cancer	NOUN
aiua-12307	294	13	(	(	PUNCT
aiua-12307	294	14	crpc	crpc	ADJ
aiua-12307	294	15	)	)	PUNCT
aiua-12307	294	16	,	,	PUNCT
aiua-12307	294	17	in	in	ADP
aiua-12307	294	18	addition	addition	NOUN
aiua-12307	294	19	to	to	ADP
aiua-12307	294	20	standard	standard	ADJ
aiua-12307	294	21	methods	method	NOUN
aiua-12307	294	22	such	such	ADJ
aiua-12307	294	23	as	as	ADP
aiua-12307	294	24	androgen	androgen	NOUN
aiua-12307	294	25	deprivation	deprivation	NOUN
aiua-12307	294	26	therapy	therapy	NOUN
aiua-12307	294	27	and	and	CCONJ
aiua-12307	294	28	ct	ct	PROPN
aiua-12307	294	29	(	(	PUNCT
aiua-12307	294	30	69	69	NUM
aiua-12307	294	31	,	,	PUNCT
aiua-12307	294	32	70	70	NUM
aiua-12307	294	33	)	)	PUNCT
aiua-12307	294	34	.	.	PUNCT
aiua-12307	295	1	a	a	DET
aiua-12307	295	2	particular	particular	ADJ
aiua-12307	295	3	subgroup	subgroup	NOUN
aiua-12307	295	4	of	of	ADP
aiua-12307	295	5	patients	patient	NOUN
aiua-12307	295	6	,	,	PUNCT
aiua-12307	295	7	including	include	VERB
aiua-12307	295	8	mismatch	mismatch	NOUN
aiua-12307	295	9	repair	repair	NOUN
aiua-12307	295	10	(	(	PUNCT
aiua-12307	295	11	dmmr	dmmr	NOUN
aiua-12307	295	12	)	)	PUNCT
aiua-12307	295	13	deficient	deficient	ADJ
aiua-12307	295	14	,	,	PUNCT
aiua-12307	295	15	cdk12	cdk12	ADJ
aiua-12307	295	16	-	-	PUNCT
aiua-12307	295	17	mutated	mutate	VERB
aiua-12307	295	18	tumours	tumour	NOUN
aiua-12307	295	19	in	in	ADP
aiua-12307	295	20	addition	addition	NOUN
aiua-12307	295	21	to	to	ADP
aiua-12307	295	22	high	high	ADJ
aiua-12307	295	23	pd	pd	PROPN
aiua-12307	295	24	-	-	PROPN
aiua-12307	295	25	l1	l1	PROPN
aiua-12307	295	26	tumour	tumour	NOUN
aiua-12307	295	27	expression	expression	NOUN
aiua-12307	295	28	,	,	PUNCT
aiua-12307	295	29	tumour	tumour	NOUN
aiua-12307	295	30	mutaarchivio	mutaarchivio	NOUN
aiua-12307	295	31	italiano	italiano	NOUN
aiua-12307	295	32	di	di	X
aiua-12307	295	33	urologia	urologia	PROPN
aiua-12307	295	34	e	e	PROPN
aiua-12307	295	35	andrologia	andrologia	NOUN
aiua-12307	295	36	2024	2024	NUM
aiua-12307	295	37	;	;	PUNCT
aiua-12307	295	38	96(2):12307	96(2):12307	NUM
aiua-12307	295	39	9	9	NUM
aiua-12307	295	40	the	the	DET
aiua-12307	295	41	role	role	NOUN
aiua-12307	295	42	of	of	ADP
aiua-12307	295	43	immunotherapy	immunotherapy	NOUN
aiua-12307	295	44	in	in	ADP
aiua-12307	295	45	urological	urological	ADJ
aiua-12307	295	46	cancers	cancer	NOUN
aiua-12307	295	47	tional	tional	ADJ
aiua-12307	295	48	burden	burden	NOUN
aiua-12307	295	49	,	,	PUNCT
aiua-12307	295	50	and	and	CCONJ
aiua-12307	295	51	microsatellite	microsatellite	ADJ
aiua-12307	295	52	instability	instability	NOUN
aiua-12307	295	53	(	(	PUNCT
aiua-12307	295	54	msi	msi	PROPN
aiua-12307	295	55	)	)	PUNCT
aiua-12307	295	56	,	,	PUNCT
aiua-12307	295	57	have	have	AUX
aiua-12307	295	58	recently	recently	ADV
aiua-12307	295	59	shown	show	VERB
aiua-12307	295	60	good	good	ADJ
aiua-12307	295	61	responses	response	NOUN
aiua-12307	295	62	to	to	ADP
aiua-12307	295	63	ici	ici	NOUN
aiua-12307	295	64	therapy	therapy	NOUN
aiua-12307	295	65	(	(	PUNCT
aiua-12307	295	66	68	68	NUM
aiua-12307	295	67	,	,	PUNCT
aiua-12307	295	68	71	71	NUM
aiua-12307	295	69	)	)	PUNCT
aiua-12307	295	70	.	.	PUNCT
aiua-12307	296	1	the	the	DET
aiua-12307	296	2	main	main	ADJ
aiua-12307	296	3	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	296	4	agents	agent	NOUN
aiua-12307	296	5	used	use	VERB
aiua-12307	296	6	in	in	ADP
aiua-12307	296	7	prostate	prostate	NOUN
aiua-12307	296	8	cancer	cancer	NOUN
aiua-12307	296	9	are	be	AUX
aiua-12307	296	10	:	:	PUNCT
aiua-12307	296	11	•	•	ADJ
aiua-12307	296	12	ipilimumab	ipilimumab	VERB
aiua-12307	296	13	•	•	ADP
aiua-12307	296	14	nivolumab	nivolumab	NOUN
aiua-12307	296	15	•	•	NOUN
aiua-12307	296	16	pembrolizumab	pembrolizumab	NOUN
aiua-12307	296	17	•	•	NUM
aiua-12307	296	18	atezolizumab	atezolizumab	ADJ
aiua-12307	296	19	•	•	NOUN
aiua-12307	296	20	sipuleucel	sipuleucel	NOUN
aiua-12307	296	21	-	-	PUNCT
aiua-12307	296	22	t	t	NOUN
aiua-12307	296	23	(	(	PUNCT
aiua-12307	296	24	vaccine	vaccine	NOUN
aiua-12307	296	25	based	base	VERB
aiua-12307	296	26	)	)	PUNCT
aiua-12307	296	27	ipilimumab	ipilimumab	PROPN
aiua-12307	296	28	ipilimumab	ipilimumab	NOUN
aiua-12307	296	29	is	be	AUX
aiua-12307	296	30	a	a	DET
aiua-12307	296	31	monoclonal	monoclonal	NOUN
aiua-12307	296	32	antibody	antibody	NOUN
aiua-12307	296	33	that	that	PRON
aiua-12307	296	34	increases	increase	VERB
aiua-12307	296	35	the	the	DET
aiua-12307	296	36	immune	immune	ADJ
aiua-12307	296	37	system	system	NOUN
aiua-12307	296	38	's	's	PART
aiua-12307	296	39	response	response	NOUN
aiua-12307	296	40	to	to	ADP
aiua-12307	296	41	tumour	tumour	NOUN
aiua-12307	296	42	cells	cell	NOUN
aiua-12307	296	43	by	by	ADP
aiua-12307	296	44	targeting	target	VERB
aiua-12307	296	45	the	the	DET
aiua-12307	296	46	ctla-4	ctla-4	NOUN
aiua-12307	296	47	receptor	receptor	NOUN
aiua-12307	296	48	.	.	PUNCT
aiua-12307	297	1	it	it	PRON
aiua-12307	297	2	is	be	AUX
aiua-12307	297	3	the	the	DET
aiua-12307	297	4	first	first	ADJ
aiua-12307	297	5	fda	fda	PROPN
aiua-12307	297	6	-	-	PUNCT
aiua-12307	297	7	approved	approve	VERB
aiua-12307	297	8	ici	ici	NOUN
aiua-12307	297	9	for	for	ADP
aiua-12307	297	10	prostate	prostate	NOUN
aiua-12307	297	11	cancer	cancer	NOUN
aiua-12307	297	12	.	.	PUNCT
aiua-12307	298	1	when	when	SCONJ
aiua-12307	298	2	administered	administer	VERB
aiua-12307	298	3	as	as	ADP
aiua-12307	298	4	monotherapy	monotherapy	NOUN
aiua-12307	298	5	,	,	PUNCT
aiua-12307	298	6	ipilimumab	ipilimumab	NOUN
aiua-12307	298	7	has	have	AUX
aiua-12307	298	8	been	be	AUX
aiua-12307	298	9	shown	show	VERB
aiua-12307	298	10	to	to	PART
aiua-12307	298	11	significantly	significantly	ADV
aiua-12307	298	12	increase	increase	VERB
aiua-12307	298	13	the	the	DET
aiua-12307	298	14	proportion	proportion	NOUN
aiua-12307	298	15	of	of	ADP
aiua-12307	298	16	regulatory	regulatory	ADJ
aiua-12307	298	17	effector	effector	NOUN
aiua-12307	298	18	t	t	PROPN
aiua-12307	298	19	lymphocytes	lymphocyte	VERB
aiua-12307	298	20	present	present	ADJ
aiua-12307	298	21	in	in	ADP
aiua-12307	298	22	the	the	DET
aiua-12307	298	23	tumour	tumour	NOUN
aiua-12307	298	24	microenvironment	microenvironment	NOUN
aiua-12307	298	25	(	(	PUNCT
aiua-12307	298	26	tme	tme	NOUN
aiua-12307	298	27	)	)	PUNCT
aiua-12307	298	28	(	(	PUNCT
aiua-12307	298	29	72	72	NUM
aiua-12307	298	30	)	)	PUNCT
aiua-12307	298	31	.	.	PUNCT
aiua-12307	299	1	in	in	ADP
aiua-12307	299	2	the	the	DET
aiua-12307	299	3	literature	literature	NOUN
aiua-12307	299	4	,	,	PUNCT
aiua-12307	299	5	phase	phase	NOUN
aiua-12307	299	6	i	i	PRON
aiua-12307	299	7	trials	trial	NOUN
aiua-12307	299	8	have	have	AUX
aiua-12307	299	9	shown	show	VERB
aiua-12307	299	10	that	that	DET
aiua-12307	299	11	ipilimumab	ipilimumab	NOUN
aiua-12307	299	12	and	and	CCONJ
aiua-12307	299	13	its	its	PRON
aiua-12307	299	14	combinations	combination	NOUN
aiua-12307	299	15	provide	provide	VERB
aiua-12307	299	16	psa	psa	NOUN
aiua-12307	299	17	reduction	reduction	NOUN
aiua-12307	299	18	in	in	ADP
aiua-12307	299	19	patients	patient	NOUN
aiua-12307	299	20	and	and	CCONJ
aiua-12307	299	21	prolong	prolong	VERB
aiua-12307	299	22	the	the	DET
aiua-12307	299	23	psa	psa	NOUN
aiua-12307	299	24	doubling	doubling	NOUN
aiua-12307	299	25	time	time	NOUN
aiua-12307	299	26	(	(	PUNCT
aiua-12307	299	27	73	73	NUM
aiua-12307	299	28	-	-	SYM
aiua-12307	299	29	76	76	NUM
aiua-12307	299	30	)	)	PUNCT
aiua-12307	299	31	.	.	PUNCT
aiua-12307	300	1	slovin	slovin	PROPN
aiua-12307	300	2	et	et	PROPN
aiua-12307	300	3	al	al	PROPN
aiua-12307	300	4	.	.	PROPN
aiua-12307	300	5	shared	share	VERB
aiua-12307	300	6	the	the	DET
aiua-12307	300	7	results	result	NOUN
aiua-12307	300	8	of	of	ADP
aiua-12307	300	9	50	50	NUM
aiua-12307	300	10	patients	patient	NOUN
aiua-12307	300	11	diagnosed	diagnose	VERB
aiua-12307	300	12	with	with	ADP
aiua-12307	300	13	metastatic	metastatic	ADJ
aiua-12307	300	14	crpc	crpc	PROPN
aiua-12307	300	15	(	(	PUNCT
aiua-12307	300	16	mcrpc	mcrpc	PROPN
aiua-12307	300	17	)	)	PUNCT
aiua-12307	300	18	who	who	PRON
aiua-12307	300	19	received	receive	VERB
aiua-12307	300	20	ipilimumab	ipilimumab	NOUN
aiua-12307	300	21	alone	alone	ADV
aiua-12307	300	22	or	or	CCONJ
aiua-12307	300	23	ipilimumab	ipilimumab	NOUN
aiua-12307	300	24	/	/	SYM
aiua-12307	300	25	radiotherapy	radiotherapy	NOUN
aiua-12307	300	26	(	(	PUNCT
aiua-12307	300	27	rt	rt	NOUN
aiua-12307	300	28	)	)	PUNCT
aiua-12307	300	29	combination	combination	NOUN
aiua-12307	300	30	therapy	therapy	NOUN
aiua-12307	300	31	.	.	PUNCT
aiua-12307	301	1	a	a	DET
aiua-12307	301	2	more	more	ADJ
aiua-12307	301	3	than	than	ADP
aiua-12307	301	4	50	50	NUM
aiua-12307	301	5	%	%	NOUN
aiua-12307	301	6	decrease	decrease	NOUN
aiua-12307	301	7	in	in	ADP
aiua-12307	301	8	psa	psa	NOUN
aiua-12307	301	9	was	be	AUX
aiua-12307	301	10	observed	observe	VERB
aiua-12307	301	11	in	in	ADP
aiua-12307	301	12	eight	eight	NUM
aiua-12307	301	13	patients	patient	NOUN
aiua-12307	301	14	,	,	PUNCT
aiua-12307	301	15	a	a	DET
aiua-12307	301	16	complete	complete	ADJ
aiua-12307	301	17	response	response	NOUN
aiua-12307	301	18	was	be	AUX
aiua-12307	301	19	achieved	achieve	VERB
aiua-12307	301	20	in	in	ADP
aiua-12307	301	21	1	1	NUM
aiua-12307	301	22	patient	patient	NOUN
aiua-12307	301	23	,	,	PUNCT
aiua-12307	301	24	and	and	CCONJ
aiua-12307	301	25	no	no	DET
aiua-12307	301	26	progression	progression	NOUN
aiua-12307	301	27	was	be	AUX
aiua-12307	301	28	observed	observe	VERB
aiua-12307	301	29	in	in	ADP
aiua-12307	301	30	6	6	NUM
aiua-12307	301	31	patients	patient	NOUN
aiua-12307	301	32	(	(	PUNCT
aiua-12307	301	33	77	77	NUM
aiua-12307	301	34	)	)	PUNCT
aiua-12307	301	35	.	.	PUNCT
aiua-12307	302	1	kwon	kwon	PROPN
aiua-12307	302	2	et	et	PROPN
aiua-12307	302	3	al	al	PROPN
aiua-12307	302	4	.	.	PROPN
aiua-12307	302	5	,	,	PUNCT
aiua-12307	302	6	in	in	ADP
aiua-12307	302	7	a	a	DET
aiua-12307	302	8	randomized	randomized	ADJ
aiua-12307	302	9	controlled	control	VERB
aiua-12307	302	10	phase	phase	NOUN
aiua-12307	302	11	iii	iii	NUM
aiua-12307	302	12	study	study	NOUN
aiua-12307	302	13	,	,	PUNCT
aiua-12307	302	14	799	799	NUM
aiua-12307	302	15	mcrpc	mcrpc	NOUN
aiua-12307	302	16	patients	patient	NOUN
aiua-12307	302	17	received	receive	VERB
aiua-12307	302	18	palliative	palliative	ADJ
aiua-12307	302	19	rt	rt	PROPN
aiua-12307	302	20	therapy	therapy	NOUN
aiua-12307	302	21	.	.	PUNCT
aiua-12307	303	1	then	then	ADV
aiua-12307	303	2	,	,	PUNCT
aiua-12307	303	3	the	the	DET
aiua-12307	303	4	patients	patient	NOUN
aiua-12307	303	5	were	be	AUX
aiua-12307	303	6	divided	divide	VERB
aiua-12307	303	7	into	into	ADP
aiua-12307	303	8	two	two	NUM
aiua-12307	303	9	groups	group	NOUN
aiua-12307	303	10	,	,	PUNCT
aiua-12307	303	11	one	one	NUM
aiua-12307	303	12	receiving	receive	VERB
aiua-12307	303	13	ipilimumab	ipilimumab	NOUN
aiua-12307	303	14	and	and	CCONJ
aiua-12307	303	15	the	the	DET
aiua-12307	303	16	other	other	ADJ
aiua-12307	303	17	receiving	receive	VERB
aiua-12307	303	18	placebo	placebo	NOUN
aiua-12307	303	19	.	.	PUNCT
aiua-12307	304	1	although	although	SCONJ
aiua-12307	304	2	a	a	DET
aiua-12307	304	3	significant	significant	ADJ
aiua-12307	304	4	improvement	improvement	NOUN
aiua-12307	304	5	in	in	ADP
aiua-12307	304	6	pfs	pfs	PROPN
aiua-12307	304	7	was	be	AUX
aiua-12307	304	8	detected	detect	VERB
aiua-12307	304	9	in	in	ADP
aiua-12307	304	10	the	the	DET
aiua-12307	304	11	ipilimumab	ipilimumab	NOUN
aiua-12307	304	12	arm	arm	NOUN
aiua-12307	304	13	between	between	ADP
aiua-12307	304	14	the	the	DET
aiua-12307	304	15	two	two	NUM
aiua-12307	304	16	groups	group	NOUN
aiua-12307	304	17	,	,	PUNCT
aiua-12307	304	18	no	no	DET
aiua-12307	304	19	significant	significant	ADJ
aiua-12307	304	20	difference	difference	NOUN
aiua-12307	304	21	was	be	AUX
aiua-12307	304	22	detected	detect	VERB
aiua-12307	304	23	in	in	ADP
aiua-12307	304	24	os	os	PROPN
aiua-12307	304	25	data	datum	NOUN
aiua-12307	304	26	(	(	PUNCT
aiua-12307	304	27	70	70	NUM
aiua-12307	304	28	)	)	PUNCT
aiua-12307	304	29	.	.	PUNCT
aiua-12307	305	1	after	after	ADP
aiua-12307	305	2	three	three	NUM
aiua-12307	305	3	years	year	NOUN
aiua-12307	305	4	,	,	PUNCT
aiua-12307	305	5	an	an	DET
aiua-12307	305	6	approximately	approximately	ADV
aiua-12307	305	7	twoto	twoto	ADJ
aiua-12307	305	8	three	three	NUM
aiua-12307	305	9	-	-	ADJ
aiua-12307	305	10	fold	fold	VERB
aiua-12307	305	11	higher	high	ADJ
aiua-12307	305	12	os	os	NOUN
aiua-12307	305	13	benefit	benefit	NOUN
aiua-12307	305	14	was	be	AUX
aiua-12307	305	15	detected	detect	VERB
aiua-12307	305	16	in	in	ADP
aiua-12307	305	17	the	the	DET
aiua-12307	305	18	ipilimumab	ipilimumab	NOUN
aiua-12307	305	19	arm	arm	NOUN
aiua-12307	305	20	(	(	PUNCT
aiua-12307	305	21	78	78	NUM
aiua-12307	305	22	)	)	PUNCT
aiua-12307	305	23	.	.	PUNCT
aiua-12307	306	1	beer	beer	NOUN
aiua-12307	306	2	et	et	PROPN
aiua-12307	306	3	al	al	PROPN
aiua-12307	306	4	.	.	PROPN
aiua-12307	306	5	reported	report	VERB
aiua-12307	306	6	increased	increase	VERB
aiua-12307	306	7	pfs	pfs	PROPN
aiua-12307	306	8	and	and	CCONJ
aiua-12307	306	9	a	a	DET
aiua-12307	306	10	higher	high	ADJ
aiua-12307	306	11	psa	psa	NOUN
aiua-12307	306	12	response	response	NOUN
aiua-12307	306	13	rate	rate	NOUN
aiua-12307	306	14	(	(	PUNCT
aiua-12307	306	15	23	23	NUM
aiua-12307	306	16	%	%	NOUN
aiua-12307	306	17	vs	vs	ADP
aiua-12307	306	18	8	8	NUM
aiua-12307	306	19	%	%	NOUN
aiua-12307	306	20	)	)	PUNCT
aiua-12307	306	21	in	in	ADP
aiua-12307	306	22	the	the	DET
aiua-12307	306	23	ipilimumab	ipilimumab	NOUN
aiua-12307	306	24	arm	arm	NOUN
aiua-12307	306	25	(	(	PUNCT
aiua-12307	306	26	5.6	5.6	NUM
aiua-12307	306	27	mo	mo	NOUN
aiua-12307	306	28	.	.	PROPN
aiua-12307	306	29	)	)	PUNCT
aiua-12307	307	1	compared	compare	VERB
aiua-12307	307	2	to	to	ADP
aiua-12307	307	3	the	the	DET
aiua-12307	307	4	placebo	placebo	NOUN
aiua-12307	307	5	arm	arm	NOUN
aiua-12307	307	6	(	(	PUNCT
aiua-12307	307	7	3.8	3.8	NUM
aiua-12307	307	8	mo	mo	NOUN
aiua-12307	307	9	.	.	PROPN
aiua-12307	307	10	)	)	PUNCT
aiua-12307	307	11	in	in	ADP
aiua-12307	307	12	mcrpc	mcrpc	PROPN
aiua-12307	307	13	(	(	PUNCT
aiua-12307	307	14	79	79	NUM
aiua-12307	307	15	)	)	PUNCT
aiua-12307	307	16	.	.	PUNCT
aiua-12307	308	1	nivolumab	nivolumab	ADP
aiua-12307	308	2	the	the	DET
aiua-12307	308	3	interaction	interaction	NOUN
aiua-12307	308	4	of	of	ADP
aiua-12307	308	5	pd-1	pd-1	ADJ
aiua-12307	308	6	with	with	SCONJ
aiua-12307	308	7	its	its	PRON
aiua-12307	308	8	ligand	ligand	NOUN
aiua-12307	308	9	prevents	prevent	VERB
aiua-12307	308	10	the	the	DET
aiua-12307	308	11	activation	activation	NOUN
aiua-12307	308	12	of	of	ADP
aiua-12307	308	13	t	t	NOUN
aiua-12307	308	14	cells	cell	NOUN
aiua-12307	308	15	,	,	PUNCT
aiua-12307	308	16	and	and	CCONJ
aiua-12307	308	17	,	,	PUNCT
aiua-12307	308	18	as	as	ADP
aiua-12307	308	19	a	a	DET
aiua-12307	308	20	result	result	NOUN
aiua-12307	308	21	,	,	PUNCT
aiua-12307	308	22	the	the	DET
aiua-12307	308	23	destruction	destruction	NOUN
aiua-12307	308	24	of	of	ADP
aiua-12307	308	25	cancer	cancer	NOUN
aiua-12307	308	26	cells	cell	NOUN
aiua-12307	308	27	by	by	ADP
aiua-12307	308	28	the	the	DET
aiua-12307	308	29	immune	immune	ADJ
aiua-12307	308	30	system	system	NOUN
aiua-12307	308	31	is	be	AUX
aiua-12307	308	32	prevented	prevent	VERB
aiua-12307	308	33	.	.	PUNCT
aiua-12307	309	1	nivolumab	nivolumab	NOUN
aiua-12307	309	2	is	be	AUX
aiua-12307	309	3	an	an	DET
aiua-12307	309	4	igg4	igg4	NOUN
aiua-12307	309	5	monoclonal	monoclonal	NOUN
aiua-12307	309	6	antibody	antibody	NOUN
aiua-12307	309	7	that	that	PRON
aiua-12307	309	8	demonstrates	demonstrate	VERB
aiua-12307	309	9	antitumor	antitumor	PROPN
aiua-12307	309	10	response	response	NOUN
aiua-12307	309	11	by	by	ADP
aiua-12307	309	12	blocking	block	VERB
aiua-12307	309	13	pd-1	pd-1	ADP
aiua-12307	309	14	(	(	PUNCT
aiua-12307	309	15	80	80	NUM
aiua-12307	309	16	,	,	PUNCT
aiua-12307	309	17	81	81	NUM
aiua-12307	309	18	)	)	PUNCT
aiua-12307	309	19	.	.	PUNCT
aiua-12307	310	1	in	in	ADP
aiua-12307	310	2	the	the	DET
aiua-12307	310	3	checkmate	checkmate	NOUN
aiua-12307	310	4	650	650	NUM
aiua-12307	310	5	phase	phase	NOUN
aiua-12307	310	6	ii	ii	NOUN
aiua-12307	310	7	clinical	clinical	ADJ
aiua-12307	310	8	trial	trial	NOUN
aiua-12307	310	9	investigating	investigate	VERB
aiua-12307	310	10	the	the	DET
aiua-12307	310	11	combined	combine	VERB
aiua-12307	310	12	effects	effect	NOUN
aiua-12307	310	13	of	of	ADP
aiua-12307	310	14	ipilimumab	ipilimumab	NOUN
aiua-12307	310	15	and	and	CCONJ
aiua-12307	310	16	nivolumab	nivolumab	NOUN
aiua-12307	310	17	in	in	ADP
aiua-12307	310	18	patients	patient	NOUN
aiua-12307	310	19	with	with	ADP
aiua-12307	310	20	mcrpc	mcrpc	NOUN
aiua-12307	310	21	,	,	PUNCT
aiua-12307	310	22	combination	combination	NOUN
aiua-12307	310	23	therapy	therapy	NOUN
aiua-12307	310	24	demonstrated	demonstrate	VERB
aiua-12307	310	25	an	an	DET
aiua-12307	310	26	orr	orr	NOUN
aiua-12307	310	27	of	of	ADP
aiua-12307	310	28	25	25	NUM
aiua-12307	310	29	%	%	NOUN
aiua-12307	310	30	(	(	PUNCT
aiua-12307	310	31	81	81	NUM
aiua-12307	310	32	)	)	PUNCT
aiua-12307	310	33	.	.	PUNCT
aiua-12307	311	1	shenderov	shenderov	VERB
aiua-12307	311	2	et	et	PROPN
aiua-12307	311	3	al	al	PROPN
aiua-12307	311	4	.	.	PROPN
aiua-12307	311	5	,	,	PUNCT
aiua-12307	311	6	in	in	ADP
aiua-12307	311	7	patients	patient	NOUN
aiua-12307	311	8	with	with	ADP
aiua-12307	311	9	ar	ar	NOUN
aiua-12307	311	10	-	-	ADJ
aiua-12307	311	11	v7	v7	VERB
aiua-12307	311	12	positive	positive	ADJ
aiua-12307	311	13	mcrpc	mcrpc	NOUN
aiua-12307	311	14	,	,	PUNCT
aiua-12307	311	15	which	which	PRON
aiua-12307	311	16	is	be	AUX
aiua-12307	311	17	associated	associate	VERB
aiua-12307	311	18	with	with	ADP
aiua-12307	311	19	poor	poor	ADJ
aiua-12307	311	20	prognosis	prognosis	NOUN
aiua-12307	311	21	,	,	PUNCT
aiua-12307	311	22	investigated	investigate	VERB
aiua-12307	311	23	the	the	DET
aiua-12307	311	24	effectiveness	effectiveness	NOUN
aiua-12307	311	25	of	of	ADP
aiua-12307	311	26	nivolumab	nivolumab	NOUN
aiua-12307	311	27	/	/	SYM
aiua-12307	311	28	ipilimumab	ipilimumab	NOUN
aiua-12307	311	29	combination	combination	NOUN
aiua-12307	311	30	therapy	therapy	NOUN
aiua-12307	311	31	.	.	PUNCT
aiua-12307	312	1	although	although	SCONJ
aiua-12307	312	2	this	this	DET
aiua-12307	312	3	study	study	NOUN
aiua-12307	312	4	showed	show	VERB
aiua-12307	312	5	that	that	SCONJ
aiua-12307	312	6	combination	combination	NOUN
aiua-12307	312	7	therapy	therapy	NOUN
aiua-12307	312	8	may	may	AUX
aiua-12307	312	9	benefit	benefit	VERB
aiua-12307	312	10	ar	ar	NOUN
aiua-12307	312	11	-	-	ADJ
aiua-12307	312	12	v7	v7	VERB
aiua-12307	312	13	positive	positive	ADJ
aiua-12307	312	14	pca	pca	NOUN
aiua-12307	312	15	patients	patient	NOUN
aiua-12307	312	16	,	,	PUNCT
aiua-12307	312	17	sufficient	sufficient	ADJ
aiua-12307	312	18	evidence	evidence	NOUN
aiua-12307	312	19	was	be	AUX
aiua-12307	312	20	not	not	PART
aiua-12307	312	21	obtained	obtain	VERB
aiua-12307	312	22	for	for	ADP
aiua-12307	312	23	routine	routine	ADJ
aiua-12307	312	24	use	use	NOUN
aiua-12307	312	25	(	(	PUNCT
aiua-12307	312	26	82	82	NUM
aiua-12307	312	27	)	)	PUNCT
aiua-12307	312	28	.	.	PUNCT
aiua-12307	313	1	pembrolizumab	pembrolizumab	NOUN
aiua-12307	313	2	pembrolizumab	pembrolizumab	NOUN
aiua-12307	313	3	is	be	AUX
aiua-12307	313	4	an	an	DET
aiua-12307	313	5	anti	anti	ADJ
aiua-12307	313	6	-	-	ADJ
aiua-12307	313	7	pd-1	pd-1	ADJ
aiua-12307	313	8	antibody	antibody	NOUN
aiua-12307	313	9	that	that	PRON
aiua-12307	313	10	acts	act	VERB
aiua-12307	313	11	similarly	similarly	ADV
aiua-12307	313	12	to	to	ADP
aiua-12307	313	13	nivolumab	nivolumab	NOUN
aiua-12307	313	14	.	.	PUNCT
aiua-12307	314	1	in	in	ADP
aiua-12307	314	2	the	the	DET
aiua-12307	314	3	keynote-365	keynote-365	PROPN
aiua-12307	314	4	study	study	NOUN
aiua-12307	314	5	,	,	PUNCT
aiua-12307	314	6	ct	ct	PROPN
aiua-12307	314	7	-	-	PUNCT
aiua-12307	314	8	refractory	refractory	NOUN
aiua-12307	314	9	mcrpc	mcrpc	NOUN
aiua-12307	314	10	patients	patient	NOUN
aiua-12307	314	11	receiving	receive	VERB
aiua-12307	314	12	abiraterone	abiraterone	NOUN
aiua-12307	314	13	or	or	CCONJ
aiua-12307	314	14	enzalutamide	enzalutamide	NOUN
aiua-12307	314	15	were	be	AUX
aiua-12307	314	16	given	give	VERB
aiua-12307	314	17	pembrolizumab	pembrolizumab	NOUN
aiua-12307	314	18	/	/	SYM
aiua-12307	314	19	docetaxel	docetaxel	PROPN
aiua-12307	314	20	and	and	CCONJ
aiua-12307	314	21	prednisone	prednisone	NOUN
aiua-12307	314	22	combination	combination	NOUN
aiua-12307	314	23	therapy	therapy	NOUN
aiua-12307	314	24	.	.	PUNCT
aiua-12307	315	1	the	the	DET
aiua-12307	315	2	psa	psa	NOUN
aiua-12307	315	3	response	response	NOUN
aiua-12307	315	4	rate	rate	NOUN
aiua-12307	315	5	was	be	AUX
aiua-12307	315	6	34	34	NUM
aiua-12307	315	7	%	%	NOUN
aiua-12307	315	8	,	,	PUNCT
aiua-12307	315	9	the	the	DET
aiua-12307	315	10	radiological	radiological	ADJ
aiua-12307	315	11	mean	mean	NOUN
aiua-12307	315	12	pfs	pfs	PROPN
aiua-12307	315	13	was	be	AUX
aiua-12307	315	14	8.5	8.5	NUM
aiua-12307	315	15	mo	mo	NOUN
aiua-12307	315	16	.	.	PROPN
aiua-12307	315	17	,	,	PUNCT
aiua-12307	315	18	and	and	CCONJ
aiua-12307	315	19	the	the	DET
aiua-12307	315	20	os	os	NOUN
aiua-12307	315	21	was	be	AUX
aiua-12307	315	22	20.2	20.2	NUM
aiua-12307	315	23	mo	mo	NOUN
aiua-12307	315	24	.	.	PROPN
aiua-12307	316	1	(	(	PUNCT
aiua-12307	316	2	83	83	NUM
aiua-12307	316	3	)	)	PUNCT
aiua-12307	316	4	.	.	PUNCT
aiua-12307	317	1	in	in	ADP
aiua-12307	317	2	a	a	DET
aiua-12307	317	3	phase	phase	NOUN
aiua-12307	317	4	ii	ii	NOUN
aiua-12307	317	5	clinical	clinical	ADJ
aiua-12307	317	6	study	study	NOUN
aiua-12307	317	7	(	(	PUNCT
aiua-12307	317	8	keynote-199	keynote-199	NOUN
aiua-12307	317	9	)	)	PUNCT
aiua-12307	317	10	involving	involve	VERB
aiua-12307	317	11	multiple	multiple	ADJ
aiua-12307	317	12	cohorts	cohort	NOUN
aiua-12307	317	13	,	,	PUNCT
aiua-12307	317	14	pembrolizumab	pembrolizumab	NOUN
aiua-12307	317	15	monotherapy	monotherapy	NOUN
aiua-12307	317	16	was	be	AUX
aiua-12307	317	17	administered	administer	VERB
aiua-12307	317	18	to	to	ADP
aiua-12307	317	19	258	258	NUM
aiua-12307	317	20	patients	patient	NOUN
aiua-12307	317	21	diagnosed	diagnose	VERB
aiua-12307	317	22	with	with	ADP
aiua-12307	317	23	mcrpc	mcrpc	NOUN
aiua-12307	317	24	who	who	PRON
aiua-12307	317	25	had	have	VERB
aiua-12307	317	26	bone	bone	NOUN
aiua-12307	317	27	-	-	PUNCT
aiua-12307	317	28	predominant	predominant	ADJ
aiua-12307	317	29	metastases	metastasis	NOUN
aiua-12307	317	30	measurable	measurable	ADJ
aiua-12307	317	31	by	by	ADP
aiua-12307	317	32	response	response	NOUN
aiua-12307	317	33	evaluation	evaluation	NOUN
aiua-12307	317	34	criteria	criterion	NOUN
aiua-12307	317	35	in	in	ADP
aiua-12307	317	36	solid	solid	ADJ
aiua-12307	317	37	tumors	tumor	NOUN
aiua-12307	317	38	(	(	PUNCT
aiua-12307	317	39	recist	recist	NOUN
aiua-12307	317	40	)	)	PUNCT
aiua-12307	317	41	and	and	CCONJ
aiua-12307	317	42	received	receive	VERB
aiua-12307	317	43	docetaxel	docetaxel	NOUN
aiua-12307	317	44	and	and	CCONJ
aiua-12307	317	45	targeted	target	VERB
aiua-12307	317	46	endocrine	endocrine	NOUN
aiua-12307	317	47	therapy	therapy	NOUN
aiua-12307	317	48	.	.	PUNCT
aiua-12307	318	1	patients	patient	NOUN
aiua-12307	318	2	with	with	ADP
aiua-12307	318	3	positive	positive	ADJ
aiua-12307	318	4	pd	pd	ADJ
aiua-12307	318	5	-	-	PUNCT
aiua-12307	318	6	l1	l1	PROPN
aiua-12307	318	7	expression	expression	NOUN
aiua-12307	318	8	showed	show	VERB
aiua-12307	318	9	an	an	DET
aiua-12307	318	10	orr	orr	NOUN
aiua-12307	318	11	of	of	ADP
aiua-12307	318	12	5	5	NUM
aiua-12307	318	13	%	%	NOUN
aiua-12307	318	14	,	,	PUNCT
aiua-12307	318	15	and	and	CCONJ
aiua-12307	318	16	patients	patient	NOUN
aiua-12307	318	17	with	with	ADP
aiua-12307	318	18	negative	negative	ADJ
aiua-12307	318	19	expression	expression	NOUN
aiua-12307	318	20	showed	show	VERB
aiua-12307	318	21	an	an	DET
aiua-12307	318	22	orr	orr	NOUN
aiua-12307	318	23	of	of	ADP
aiua-12307	318	24	3	3	NUM
aiua-12307	318	25	%	%	NOUN
aiua-12307	318	26	.	.	PUNCT
aiua-12307	319	1	median	median	PROPN
aiua-12307	319	2	os	os	PROPN
aiua-12307	319	3	was	be	AUX
aiua-12307	319	4	reported	report	VERB
aiua-12307	319	5	as	as	ADP
aiua-12307	319	6	9.5	9.5	NUM
aiua-12307	319	7	mo	mo	NOUN
aiua-12307	319	8	.	.	PROPN
aiua-12307	320	1	in	in	ADP
aiua-12307	320	2	pd	pd	PROPN
aiua-12307	320	3	-	-	PROPN
aiua-12307	320	4	l1	l1	PROPN
aiua-12307	320	5	expressionpositive	expressionpositive	ADJ
aiua-12307	320	6	patients	patient	NOUN
aiua-12307	320	7	and	and	CCONJ
aiua-12307	320	8	7.9	7.9	NUM
aiua-12307	320	9	mo	mo	NOUN
aiua-12307	320	10	.	.	PROPN
aiua-12307	321	1	in	in	ADP
aiua-12307	321	2	negative	negative	ADJ
aiua-12307	321	3	patients	patient	NOUN
aiua-12307	321	4	(	(	PUNCT
aiua-12307	321	5	84	84	NUM
aiua-12307	321	6	)	)	PUNCT
aiua-12307	321	7	.	.	PUNCT
aiua-12307	322	1	with	with	ADP
aiua-12307	322	2	these	these	DET
aiua-12307	322	3	results	result	NOUN
aiua-12307	322	4	,	,	PUNCT
aiua-12307	322	5	it	it	PRON
aiua-12307	322	6	is	be	AUX
aiua-12307	322	7	thought	think	VERB
aiua-12307	322	8	that	that	SCONJ
aiua-12307	322	9	pembrolizumab	pembrolizumab	NOUN
aiua-12307	322	10	treatment	treatment	NOUN
aiua-12307	322	11	may	may	AUX
aiua-12307	322	12	be	be	AUX
aiua-12307	322	13	more	more	ADV
aiua-12307	322	14	effective	effective	ADJ
aiua-12307	322	15	in	in	ADP
aiua-12307	322	16	tumours	tumour	NOUN
aiua-12307	322	17	with	with	ADP
aiua-12307	322	18	high	high	ADJ
aiua-12307	322	19	pd	pd	PROPN
aiua-12307	322	20	-	-	PUNCT
aiua-12307	322	21	l1	l1	PROPN
aiua-12307	322	22	expression	expression	NOUN
aiua-12307	322	23	.	.	PUNCT
aiua-12307	323	1	atezolizumab	atezolizumab	PROPN
aiua-12307	323	2	atezolizumab	atezolizumab	PROPN
aiua-12307	323	3	,	,	PUNCT
aiua-12307	323	4	avelumab	avelumab	ADJ
aiua-12307	323	5	and	and	CCONJ
aiua-12307	323	6	durvalumab	durvalumab	PROPN
aiua-12307	323	7	,	,	PUNCT
aiua-12307	323	8	which	which	PRON
aiua-12307	323	9	target	target	VERB
aiua-12307	323	10	pd	pd	NOUN
aiua-12307	323	11	-	-	PUNCT
aiua-12307	323	12	l1	l1	PROPN
aiua-12307	323	13	,	,	PUNCT
aiua-12307	323	14	work	work	NOUN
aiua-12307	323	15	by	by	ADP
aiua-12307	323	16	blocking	block	VERB
aiua-12307	323	17	the	the	DET
aiua-12307	323	18	interaction	interaction	NOUN
aiua-12307	323	19	of	of	ADP
aiua-12307	323	20	pd	pd	PROPN
aiua-12307	323	21	-	-	PROPN
aiua-12307	323	22	l1	l1	PROPN
aiua-12307	323	23	with	with	ADP
aiua-12307	323	24	pd-1	pd-1	ADV
aiua-12307	323	25	.	.	PUNCT
aiua-12307	324	1	these	these	DET
aiua-12307	324	2	agents	agent	NOUN
aiua-12307	324	3	have	have	AUX
aiua-12307	324	4	been	be	AUX
aiua-12307	324	5	investigated	investigate	VERB
aiua-12307	324	6	as	as	ADP
aiua-12307	324	7	an	an	DET
aiua-12307	324	8	option	option	NOUN
aiua-12307	324	9	in	in	ADP
aiua-12307	324	10	the	the	DET
aiua-12307	324	11	treatment	treatment	NOUN
aiua-12307	324	12	of	of	ADP
aiua-12307	324	13	advanced	advanced	ADJ
aiua-12307	324	14	prostate	prostate	NOUN
aiua-12307	324	15	cancer	cancer	NOUN
aiua-12307	324	16	(	(	PUNCT
aiua-12307	324	17	85	85	NUM
aiua-12307	324	18	-	-	NUM
aiua-12307	324	19	89	89	NUM
aiua-12307	324	20	)	)	PUNCT
aiua-12307	324	21	.	.	PUNCT
aiua-12307	325	1	in	in	ADP
aiua-12307	325	2	imbassador	imbassador	PROPN
aiua-12307	325	3	250	250	NUM
aiua-12307	325	4	study	study	NOUN
aiua-12307	325	5	,	,	PUNCT
aiua-12307	325	6	759	759	NUM
aiua-12307	325	7	patients	patient	NOUN
aiua-12307	325	8	with	with	ADP
aiua-12307	325	9	mcrpc	mcrpc	PROPN
aiua-12307	325	10	or	or	CCONJ
aiua-12307	325	11	locally	locally	ADV
aiua-12307	325	12	advanced	advanced	ADJ
aiua-12307	325	13	crpc	crpc	ADJ
aiua-12307	325	14	refractory	refractory	NOUN
aiua-12307	325	15	to	to	ADP
aiua-12307	325	16	abiraterone	abiraterone	NOUN
aiua-12307	325	17	and	and	CCONJ
aiua-12307	325	18	doxetaxel	doxetaxel	PROPN
aiua-12307	325	19	were	be	AUX
aiua-12307	325	20	treated	treat	VERB
aiua-12307	325	21	with	with	ADP
aiua-12307	325	22	the	the	DET
aiua-12307	325	23	combination	combination	NOUN
aiua-12307	325	24	of	of	ADP
aiua-12307	325	25	atezolizumab	atezolizumab	ADJ
aiua-12307	325	26	table	table	NOUN
aiua-12307	325	27	6	6	NUM
aiua-12307	325	28	.	.	PUNCT
aiua-12307	326	1	clinical	clinical	ADJ
aiua-12307	326	2	trials	trial	NOUN
aiua-12307	326	3	of	of	ADP
aiua-12307	326	4	varying	vary	VERB
aiua-12307	326	5	treatment	treatment	NOUN
aiua-12307	326	6	plans	plan	NOUN
aiua-12307	326	7	for	for	ADP
aiua-12307	326	8	mcrpc	mcrpc	NOUN
aiua-12307	326	9	(	(	PUNCT
aiua-12307	326	10	91	91	NUM
aiua-12307	326	11	)	)	PUNCT
aiua-12307	326	12	.	.	PUNCT
aiua-12307	327	1	treatment	treatment	NOUN
aiua-12307	327	2	n	n	NOUN
aiua-12307	327	3	target	target	VERB
aiua-12307	327	4	dosing	dosing	NOUN
aiua-12307	327	5	interval	interval	NOUN
aiua-12307	327	6	results	result	NOUN
aiua-12307	327	7	article	article	NOUN
aiua-12307	327	8	ipilimumab	ipilimumab	VERB
aiua-12307	327	9	pembrolizumab	pembrolizumab	NOUN
aiua-12307	327	10	pembrolizumab	pembrolizumab	NOUN
aiua-12307	327	11	pembrolizumab	pembrolizumab	NOUN
aiua-12307	327	12	plus	plus	CCONJ
aiua-12307	327	13	docetaxel	docetaxel	NOUN
aiua-12307	327	14	and	and	CCONJ
aiua-12307	327	15	prednisone	prednisone	NOUN
aiua-12307	327	16	pembrolizumab	pembrolizumab	NOUN
aiua-12307	327	17	plus	plus	CCONJ
aiua-12307	327	18	enzalutamide	enzalutamide	ADP
aiua-12307	327	19	atezolizumab	atezolizumab	PROPN
aiua-12307	327	20	atezolizumab	atezolizumab	NOUN
aiua-12307	327	21	with	with	ADP
aiua-12307	327	22	sipuleucel	sipuleucel	NOUN
aiua-12307	327	23	-	-	PUNCT
aiua-12307	327	24	t	t	NOUN
aiua-12307	327	25	avelumab	avelumab	NOUN
aiua-12307	327	26	nivolumab	nivolumab	ADV
aiua-12307	327	27	plus	plus	CCONJ
aiua-12307	327	28	ipilimumab	ipilimumab	PROPN
aiua-12307	327	29	mcrpc	mcrpc	PROPN
aiua-12307	327	30	mcrpc	mcrpc	PROPN
aiua-12307	327	31	advanced	advanced	ADJ
aiua-12307	327	32	prostate	prostate	NOUN
aiua-12307	327	33	adenocarcinoma	adenocarcinoma	PROPN
aiua-12307	327	34	mcrpc	mcrpc	PROPN
aiua-12307	327	35	mcrpc	mcrpc	PROPN
aiua-12307	327	36	mcrpc	mcrpc	PROPN
aiua-12307	327	37	mcrpc	mcrpc	PROPN
aiua-12307	327	38	mcrpc	mcrpc	PROPN
aiua-12307	327	39	mcrpc	mcrpc	PROPN
aiua-12307	327	40	799	799	NUM
aiua-12307	327	41	258	258	NUM
aiua-12307	327	42	23	23	NUM
aiua-12307	327	43	104	104	NUM
aiua-12307	327	44	28	28	NUM
aiua-12307	327	45	35	35	NUM
aiua-12307	327	46	37	37	NUM
aiua-12307	327	47	15	15	NUM
aiua-12307	327	48	90	90	NUM
aiua-12307	327	49	one	one	NUM
aiua-12307	327	50	dose	dose	NOUN
aiua-12307	327	51	of	of	ADP
aiua-12307	327	52	rt	rt	PROPN
aiua-12307	327	53	followed	follow	VERB
aiua-12307	327	54	by	by	ADP
aiua-12307	327	55	10	10	NUM
aiua-12307	327	56	mg	mg	PROPN
aiua-12307	327	57	/	/	SYM
aiua-12307	327	58	kg	kg	PROPN
aiua-12307	327	59	ipilimumab	ipilimumab	NOUN
aiua-12307	327	60	every	every	DET
aiua-12307	327	61	3	3	NUM
aiua-12307	327	62	weeks	week	NOUN
aiua-12307	327	63	200	200	NUM
aiua-12307	327	64	mg	mg	NOUN
aiua-12307	327	65	every	every	DET
aiua-12307	327	66	3	3	NUM
aiua-12307	327	67	weeks	week	NOUN
aiua-12307	327	68	10	10	NUM
aiua-12307	327	69	mg	mg	NUM
aiua-12307	327	70	/	/	SYM
aiua-12307	327	71	kg	kg	NOUN
aiua-12307	327	72	every	every	DET
aiua-12307	327	73	2	2	NUM
aiua-12307	327	74	weeks	week	NOUN
aiua-12307	327	75	200	200	NUM
aiua-12307	327	76	mg	mg	NOUN
aiua-12307	327	77	pembrolizumab	pembrolizumab	NOUN
aiua-12307	327	78	and	and	CCONJ
aiua-12307	327	79	75	75	NUM
aiua-12307	327	80	mg	mg	PROPN
aiua-12307	327	81	/	/	SYM
aiua-12307	327	82	m2	m2	PROPN
aiua-12307	327	83	docetaxel	docetaxel	NOUN
aiua-12307	327	84	every	every	DET
aiua-12307	327	85	3	3	NUM
aiua-12307	327	86	weeks	week	NOUN
aiua-12307	327	87	,	,	PUNCT
aiua-12307	327	88	5	5	NUM
aiua-12307	327	89	mg	mg	PROPN
aiua-12307	327	90	prednisone	prednisone	PROPN
aiua-12307	327	91	bid	bid	VERB
aiua-12307	327	92	200	200	NUM
aiua-12307	327	93	mg	mg	PROPN
aiua-12307	327	94	pembrolizumab	pembrolizumab	NOUN
aiua-12307	327	95	every	every	DET
aiua-12307	327	96	3	3	NUM
aiua-12307	327	97	weeks	week	NOUN
aiua-12307	327	98	with	with	ADP
aiua-12307	327	99	4	4	NUM
aiua-12307	327	100	doses	dose	NOUN
aiua-12307	327	101	of	of	ADP
aiua-12307	327	102	enzalutamide	enzalutamide	NOUN
aiua-12307	327	103	every	every	DET
aiua-12307	327	104	3	3	NUM
aiua-12307	327	105	weeks	week	NOUN
aiua-12307	327	106	1200	1200	NUM
aiua-12307	327	107	mg	mg	PROPN
aiua-12307	327	108	azetolizumab	azetolizumab	NOUN
aiua-12307	327	109	every	every	DET
aiua-12307	327	110	3	3	NUM
aiua-12307	327	111	weeks	week	NOUN
aiua-12307	327	112	,	,	PUNCT
aiua-12307	327	113	sipuleucel	sipuleucel	NOUN
aiua-12307	327	114	-	-	PUNCT
aiua-12307	327	115	t	t	NOUN
aiua-12307	327	116	every	every	DET
aiua-12307	327	117	2	2	NUM
aiua-12307	327	118	weeks	week	NOUN
aiua-12307	327	119	10	10	NUM
aiua-12307	327	120	mg	mg	NUM
aiua-12307	327	121	/	/	SYM
aiua-12307	327	122	kg	kg	NOUN
aiua-12307	327	123	every	every	DET
aiua-12307	327	124	2	2	NUM
aiua-12307	327	125	weeks	week	NOUN
aiua-12307	327	126	1	1	NUM
aiua-12307	327	127	mg	mg	NUM
aiua-12307	327	128	/	/	SYM
aiua-12307	327	129	kg	kg	NOUN
aiua-12307	327	130	nivolumab	nivolumab	ADV
aiua-12307	327	131	and	and	CCONJ
aiua-12307	327	132	3	3	NUM
aiua-12307	327	133	mg	mg	PROPN
aiua-12307	327	134	/	/	SYM
aiua-12307	327	135	kg	kg	PROPN
aiua-12307	327	136	ipilimumab	ipilimumab	NOUN
aiua-12307	327	137	iv	iv	NUM
aiua-12307	327	138	followed	follow	VERB
aiua-12307	327	139	by	by	ADP
aiua-12307	327	140	480	480	NUM
aiua-12307	327	141	mg	mg	NOUN
aiua-12307	327	142	nivolumab	nivolumab	NOUN
aiua-12307	327	143	every	every	DET
aiua-12307	327	144	4	4	NUM
aiua-12307	327	145	weeks	week	NOUN
aiua-12307	327	146	overall	overall	ADJ
aiua-12307	327	147	increased	increase	VERB
aiua-12307	327	148	survival	survival	NOUN
aiua-12307	327	149	rates	rate	NOUN
aiua-12307	327	150	for	for	ADP
aiua-12307	327	151	patients	patient	NOUN
aiua-12307	327	152	given	give	VERB
aiua-12307	327	153	ipilimumab	ipilimumab	NOUN
aiua-12307	327	154	os	os	NOUN
aiua-12307	327	155	of	of	ADP
aiua-12307	327	156	14.1	14.1	NUM
aiua-12307	327	157	mo	mo	NOUN
aiua-12307	327	158	.	.	PROPN
aiua-12307	328	1	with	with	ADP
aiua-12307	328	2	acceptable	acceptable	ADJ
aiua-12307	328	3	safety	safety	NOUN
aiua-12307	328	4	os	os	NOUN
aiua-12307	328	5	of	of	ADP
aiua-12307	328	6	7.9	7.9	NUM
aiua-12307	328	7	mo	mo	PROPN
aiua-12307	328	8	.	.	PROPN
aiua-12307	328	9	os	os	NOUN
aiua-12307	328	10	of	of	ADP
aiua-12307	328	11	29.2	29.2	NUM
aiua-12307	328	12	mo	mo	NOUN
aiua-12307	328	13	.	.	PROPN
aiua-12307	329	1	with	with	ADP
aiua-12307	329	2	acceptable	acceptable	ADJ
aiua-12307	329	3	safety	safety	NOUN
aiua-12307	329	4	os	os	NOUN
aiua-12307	329	5	of	of	ADP
aiua-12307	329	6	41.7	41.7	NUM
aiua-12307	329	7	mo	mo	PROPN
aiua-12307	329	8	.	.	PROPN
aiua-12307	329	9	os	os	PROPN
aiua-12307	329	10	of	of	ADP
aiua-12307	329	11	14.7	14.7	NUM
aiua-12307	329	12	mo	mo	NOUN
aiua-12307	329	13	.	.	PROPN
aiua-12307	330	1	with	with	ADP
aiua-12307	330	2	acceptable	acceptable	ADJ
aiua-12307	330	3	safety	safety	NOUN
aiua-12307	330	4	os	os	NOUN
aiua-12307	330	5	of	of	ADP
aiua-12307	330	6	23.6	23.6	NUM
aiua-12307	330	7	mo	mo	NOUN
aiua-12307	330	8	.	.	PROPN
aiua-12307	330	9	os	os	NOUN
aiua-12307	330	10	of	of	ADP
aiua-12307	330	11	7.4	7.4	NUM
aiua-12307	330	12	mo	mo	NOUN
aiua-12307	330	13	.	.	PROPN
aiua-12307	330	14	os	os	NOUN
aiua-12307	330	15	of	of	ADP
aiua-12307	330	16	19.0	19.0	NUM
aiua-12307	330	17	mo	mo	PROPN
aiua-12307	330	18	.	.	PROPN
aiua-12307	330	19	fizazi	fizazi	PROPN
aiua-12307	330	20	et	et	PROPN
aiua-12307	330	21	al	al	PROPN
aiua-12307	330	22	.	.	PUNCT
aiua-12307	330	23	antonarakis	antonarakis	PROPN
aiua-12307	330	24	et	et	PROPN
aiua-12307	330	25	al	al	PROPN
aiua-12307	330	26	.	.	PUNCT
aiua-12307	330	27	hansen	hansen	PROPN
aiua-12307	330	28	et	et	PROPN
aiua-12307	330	29	al	al	PROPN
aiua-12307	330	30	.	.	PROPN
aiua-12307	330	31	yu	yu	PROPN
aiua-12307	330	32	et	et	PROPN
aiua-12307	330	33	al	al	PROPN
aiua-12307	330	34	.	.	PROPN
aiua-12307	330	35	graff	graff	VERB
aiua-12307	330	36	et	et	PROPN
aiua-12307	330	37	al	al	PROPN
aiua-12307	330	38	.	.	PROPN
aiua-12307	330	39	petrylak	petrylak	PROPN
aiua-12307	330	40	et	et	PROPN
aiua-12307	330	41	al	al	PROPN
aiua-12307	330	42	.	.	PUNCT
aiua-12307	331	1	dorff	dorff	PROPN
aiua-12307	331	2	et	et	PROPN
aiua-12307	331	3	al	al	PROPN
aiua-12307	331	4	.	.	PROPN
aiua-12307	331	5	brown	brown	PROPN
aiua-12307	331	6	et	et	PROPN
aiua-12307	331	7	al	al	PROPN
aiua-12307	331	8	.	.	PROPN
aiua-12307	332	1	sharma	sharma	PROPN
aiua-12307	332	2	et	et	PROPN
aiua-12307	332	3	al	al	PROPN
aiua-12307	332	4	.	.	PROPN
aiua-12307	332	5	archivio	archivio	PROPN
aiua-12307	332	6	italiano	italiano	PROPN
aiua-12307	332	7	di	di	PROPN
aiua-12307	332	8	urologia	urologia	PROPN
aiua-12307	332	9	e	e	PROPN
aiua-12307	332	10	andrologia	andrologia	NOUN
aiua-12307	332	11	2024	2024	NUM
aiua-12307	332	12	;	;	PUNCT
aiua-12307	332	13	96(2):12307	96(2):12307	NUM
aiua-12307	332	14	e.	e.	PROPN
aiua-12307	332	15	bosnali	bosnali	PROPN
aiua-12307	332	16	,	,	PUNCT
aiua-12307	332	17	e.	e.	PROPN
aiua-12307	332	18	malik	malik	PROPN
aiua-12307	332	19	akdas	akdas	PROPN
aiua-12307	332	20	,	,	PUNCT
aiua-12307	332	21	e.	e.	PROPN
aiua-12307	332	22	telli	telli	PROPN
aiua-12307	332	23	,	,	PUNCT
aiua-12307	332	24	k.	k.	PROPN
aiua-12307	332	25	teke	teke	PROPN
aiua-12307	332	26	,	,	PUNCT
aiua-12307	332	27	o.	o.	PROPN
aiua-12307	332	28	kara	kara	PROPN
aiua-12307	332	29	10	10	NUM
aiua-12307	332	30	and	and	CCONJ
aiua-12307	332	31	enzalutamide	enzalutamide	ADV
aiua-12307	332	32	or	or	CCONJ
aiua-12307	332	33	enzalutamide	enzalutamide	ADV
aiua-12307	332	34	alone	alone	ADV
aiua-12307	332	35	.	.	PUNCT
aiua-12307	333	1	similar	similar	ADJ
aiua-12307	333	2	os	os	NOUN
aiua-12307	333	3	rates	rate	NOUN
aiua-12307	333	4	were	be	AUX
aiua-12307	333	5	detected	detect	VERB
aiua-12307	333	6	in	in	ADP
aiua-12307	333	7	both	both	DET
aiua-12307	333	8	treatment	treatment	NOUN
aiua-12307	333	9	arms	arm	NOUN
aiua-12307	333	10	.	.	PUNCT
aiua-12307	334	1	subgroup	subgroup	PROPN
aiua-12307	334	2	analyses	analysis	NOUN
aiua-12307	334	3	reported	report	VERB
aiua-12307	334	4	that	that	SCONJ
aiua-12307	334	5	combination	combination	NOUN
aiua-12307	334	6	therapy	therapy	NOUN
aiua-12307	334	7	may	may	AUX
aiua-12307	334	8	benefit	benefit	VERB
aiua-12307	334	9	patients	patient	NOUN
aiua-12307	334	10	with	with	ADP
aiua-12307	334	11	high	high	ADJ
aiua-12307	334	12	pd	pd	PROPN
aiua-12307	334	13	-	-	PUNCT
aiua-12307	334	14	l1	l1	PROPN
aiua-12307	334	15	expression	expression	NOUN
aiua-12307	334	16	(	(	PUNCT
aiua-12307	334	17	86	86	NUM
aiua-12307	334	18	)	)	PUNCT
aiua-12307	334	19	.	.	PUNCT
aiua-12307	335	1	sipuleucel	sipuleucel	NOUN
aiua-12307	335	2	-	-	PUNCT
aiua-12307	335	3	t	t	NOUN
aiua-12307	335	4	there	there	PRON
aiua-12307	335	5	are	be	VERB
aiua-12307	335	6	also	also	ADV
aiua-12307	335	7	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	335	8	vaccines	vaccine	NOUN
aiua-12307	335	9	used	use	VERB
aiua-12307	335	10	in	in	ADP
aiua-12307	335	11	the	the	DET
aiua-12307	335	12	treatment	treatment	NOUN
aiua-12307	335	13	of	of	ADP
aiua-12307	335	14	prostate	prostate	NOUN
aiua-12307	335	15	cancer	cancer	NOUN
aiua-12307	335	16	.	.	PUNCT
aiua-12307	336	1	however	however	ADV
aiua-12307	336	2	,	,	PUNCT
aiua-12307	336	3	many	many	ADJ
aiua-12307	336	4	of	of	ADP
aiua-12307	336	5	these	these	DET
aiua-12307	336	6	vaccines	vaccine	NOUN
aiua-12307	336	7	are	be	AUX
aiua-12307	336	8	still	still	ADV
aiua-12307	336	9	in	in	ADP
aiua-12307	336	10	the	the	DET
aiua-12307	336	11	experimental	experimental	ADJ
aiua-12307	336	12	stage	stage	NOUN
aiua-12307	336	13	.	.	PUNCT
aiua-12307	337	1	fda	fda	PROPN
aiua-12307	337	2	approval	approval	NOUN
aiua-12307	337	3	of	of	ADP
aiua-12307	337	4	sipuleucel	sipuleucel	NOUN
aiua-12307	337	5	-	-	PUNCT
aiua-12307	337	6	t	t	PROPN
aiua-12307	337	7	is	be	AUX
aiua-12307	337	8	considered	consider	VERB
aiua-12307	337	9	the	the	DET
aiua-12307	337	10	first	first	ADJ
aiua-12307	337	11	application	application	NOUN
aiua-12307	337	12	of	of	ADP
aiua-12307	337	13	immunotherapy	immunotherapy	NOUN
aiua-12307	337	14	in	in	ADP
aiua-12307	337	15	prostate	prostate	NOUN
aiua-12307	337	16	cancer	cancer	NOUN
aiua-12307	337	17	.	.	PUNCT
aiua-12307	338	1	sipuleucel	sipuleucel	PROPN
aiua-12307	338	2	-	-	PUNCT
aiua-12307	338	3	t	t	PROPN
aiua-12307	338	4	is	be	AUX
aiua-12307	338	5	the	the	DET
aiua-12307	338	6	only	only	ADJ
aiua-12307	338	7	fda	fda	PROPN
aiua-12307	338	8	-	-	PUNCT
aiua-12307	338	9	approved	approve	VERB
aiua-12307	338	10	vaccine	vaccine	NOUN
aiua-12307	338	11	approved	approve	VERB
aiua-12307	338	12	for	for	ADP
aiua-12307	338	13	use	use	NOUN
aiua-12307	338	14	against	against	ADP
aiua-12307	338	15	prostate	prostate	NOUN
aiua-12307	338	16	cancer	cancer	NOUN
aiua-12307	338	17	.	.	PUNCT
aiua-12307	339	1	it	it	PRON
aiua-12307	339	2	has	have	AUX
aiua-12307	339	3	been	be	AUX
aiua-12307	339	4	shown	show	VERB
aiua-12307	339	5	in	in	ADP
aiua-12307	339	6	the	the	DET
aiua-12307	339	7	literature	literature	NOUN
aiua-12307	339	8	that	that	PRON
aiua-12307	339	9	sipuleucel	sipuleucel	NOUN
aiua-12307	339	10	-	-	PUNCT
aiua-12307	339	11	t	t	PROPN
aiua-12307	339	12	is	be	AUX
aiua-12307	339	13	effective	effective	ADJ
aiua-12307	339	14	in	in	ADP
aiua-12307	339	15	mcrpc	mcrpc	PROPN
aiua-12307	339	16	(	(	PUNCT
aiua-12307	339	17	69	69	NUM
aiua-12307	339	18	,	,	PUNCT
aiua-12307	339	19	90	90	NUM
aiua-12307	339	20	)	)	PUNCT
aiua-12307	339	21	.	.	PUNCT
aiua-12307	340	1	according	accord	VERB
aiua-12307	340	2	to	to	ADP
aiua-12307	340	3	a	a	DET
aiua-12307	340	4	study	study	NOUN
aiua-12307	340	5	conducted	conduct	VERB
aiua-12307	340	6	by	by	ADP
aiua-12307	340	7	kantoff	kantoff	PROPN
aiua-12307	340	8	et	et	PROPN
aiua-12307	340	9	al	al	PROPN
aiua-12307	340	10	.	.	PROPN
aiua-12307	341	1	in	in	ADP
aiua-12307	341	2	mcrpc	mcrpc	PROPN
aiua-12307	341	3	patients	patient	NOUN
aiua-12307	341	4	,	,	PUNCT
aiua-12307	341	5	sipuleucel	sipuleucel	NOUN
aiua-12307	341	6	-	-	PUNCT
aiua-12307	341	7	t	t	NOUN
aiua-12307	341	8	treatment	treatment	NOUN
aiua-12307	341	9	prolonged	prolong	VERB
aiua-12307	341	10	os	os	NOUN
aiua-12307	341	11	by	by	ADP
aiua-12307	341	12	an	an	DET
aiua-12307	341	13	average	average	NOUN
aiua-12307	341	14	of	of	ADP
aiua-12307	341	15	4.1	4.1	NUM
aiua-12307	341	16	mo	mo	NOUN
aiua-12307	341	17	.	.	PROPN
aiua-12307	341	18	and	and	CCONJ
aiua-12307	341	19	resulted	result	VERB
aiua-12307	341	20	in	in	ADP
aiua-12307	341	21	a	a	DET
aiua-12307	341	22	22	22	NUM
aiua-12307	341	23	%	%	NOUN
aiua-12307	341	24	reduction	reduction	NOUN
aiua-12307	341	25	in	in	ADP
aiua-12307	341	26	the	the	DET
aiua-12307	341	27	risk	risk	NOUN
aiua-12307	341	28	of	of	ADP
aiua-12307	341	29	death	death	NOUN
aiua-12307	341	30	(	(	PUNCT
aiua-12307	341	31	69	69	NUM
aiua-12307	341	32	)	)	PUNCT
aiua-12307	341	33	.	.	PUNCT
aiua-12307	342	1	these	these	DET
aiua-12307	342	2	results	result	NOUN
aiua-12307	342	3	may	may	AUX
aiua-12307	342	4	guide	guide	VERB
aiua-12307	342	5	new	new	ADJ
aiua-12307	342	6	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	342	7	vaccine	vaccine	NOUN
aiua-12307	342	8	trials	trial	NOUN
aiua-12307	342	9	.	.	PUNCT
aiua-12307	343	1	clinical	clinical	ADJ
aiua-12307	343	2	trials	trial	NOUN
aiua-12307	343	3	of	of	ADP
aiua-12307	343	4	various	various	ADJ
aiua-12307	343	5	prostate	prostate	NOUN
aiua-12307	343	6	cancer	cancer	NOUN
aiua-12307	343	7	immune	immune	ADJ
aiua-12307	343	8	therapies	therapy	NOUN
aiua-12307	343	9	were	be	AUX
aiua-12307	343	10	summarized	summarize	VERB
aiua-12307	343	11	in	in	ADP
aiua-12307	343	12	table	table	NOUN
aiua-12307	343	13	6	6	NUM
aiua-12307	343	14	(	(	PUNCT
aiua-12307	343	15	91	91	NUM
aiua-12307	343	16	)	)	PUNCT
aiua-12307	343	17	.	.	PUNCT
aiua-12307	344	1	role	role	NOUN
aiua-12307	344	2	of	of	ADP
aiua-12307	344	3	immunotherapy	immunotherapy	NOUN
aiua-12307	344	4	in	in	ADP
aiua-12307	344	5	prostate	prostate	NOUN
aiua-12307	344	6	cancer	cancer	NOUN
aiua-12307	344	7	as	as	SCONJ
aiua-12307	344	8	it	it	PRON
aiua-12307	344	9	is	be	AUX
aiua-12307	344	10	known	know	VERB
aiua-12307	344	11	,	,	PUNCT
aiua-12307	344	12	prostate	prostate	NOUN
aiua-12307	344	13	cancer	cancer	NOUN
aiua-12307	344	14	is	be	AUX
aiua-12307	344	15	in	in	ADP
aiua-12307	344	16	the	the	DET
aiua-12307	344	17	category	category	NOUN
aiua-12307	344	18	of	of	ADP
aiua-12307	344	19	immunologically	immunologically	ADV
aiua-12307	344	20	"	"	PUNCT
aiua-12307	344	21	cold	cold	ADJ
aiua-12307	344	22	"	"	PUNCT
aiua-12307	344	23	tumours	tumour	NOUN
aiua-12307	344	24	,	,	PUNCT
aiua-12307	344	25	so	so	SCONJ
aiua-12307	344	26	patients	patient	NOUN
aiua-12307	344	27	must	must	AUX
aiua-12307	344	28	be	be	AUX
aiua-12307	344	29	evaluated	evaluate	VERB
aiua-12307	344	30	according	accord	VERB
aiua-12307	344	31	to	to	ADP
aiua-12307	344	32	their	their	PRON
aiua-12307	344	33	individual	individual	ADJ
aiua-12307	344	34	immunogenicity	immunogenicity	NOUN
aiua-12307	344	35	status	status	NOUN
aiua-12307	344	36	in	in	ADP
aiua-12307	344	37	order	order	NOUN
aiua-12307	344	38	to	to	PART
aiua-12307	344	39	receive	receive	VERB
aiua-12307	344	40	effective	effective	ADJ
aiua-12307	344	41	immunotherapy	immunotherapy	NOUN
aiua-12307	344	42	treatment	treatment	NOUN
aiua-12307	344	43	(	(	PUNCT
aiua-12307	344	44	91	91	NUM
aiua-12307	344	45	)	)	PUNCT
aiua-12307	344	46	.	.	PUNCT
aiua-12307	345	1	more	more	ADV
aiua-12307	345	2	successful	successful	ADJ
aiua-12307	345	3	treatment	treatment	NOUN
aiua-12307	345	4	results	result	NOUN
aiua-12307	345	5	can	can	AUX
aiua-12307	345	6	be	be	AUX
aiua-12307	345	7	achieved	achieve	VERB
aiua-12307	345	8	in	in	ADP
aiua-12307	345	9	larger	large	ADJ
aiua-12307	345	10	patient	patient	ADJ
aiua-12307	345	11	populations	population	NOUN
aiua-12307	345	12	with	with	ADP
aiua-12307	345	13	combination	combination	NOUN
aiua-12307	345	14	treatments	treatment	NOUN
aiua-12307	345	15	with	with	ADP
aiua-12307	345	16	different	different	ADJ
aiua-12307	345	17	agents	agent	NOUN
aiua-12307	345	18	.	.	PUNCT
aiua-12307	346	1	another	another	DET
aiua-12307	346	2	critical	critical	ADJ
aiua-12307	346	3	issue	issue	NOUN
aiua-12307	346	4	is	be	AUX
aiua-12307	346	5	that	that	SCONJ
aiua-12307	346	6	immunological	immunological	ADJ
aiua-12307	346	7	interventions	intervention	NOUN
aiua-12307	346	8	are	be	AUX
aiua-12307	346	9	generally	generally	ADV
aiua-12307	346	10	applied	apply	VERB
aiua-12307	346	11	only	only	ADV
aiua-12307	346	12	to	to	ADP
aiua-12307	346	13	those	those	PRON
aiua-12307	346	14	with	with	ADP
aiua-12307	346	15	advanced	advanced	ADJ
aiua-12307	346	16	disease	disease	NOUN
aiua-12307	346	17	,	,	PUNCT
aiua-12307	346	18	although	although	SCONJ
aiua-12307	346	19	,	,	PUNCT
aiua-12307	346	20	as	as	SCONJ
aiua-12307	346	21	the	the	DET
aiua-12307	346	22	disease	disease	NOUN
aiua-12307	346	23	progresses	progress	VERB
aiua-12307	346	24	,	,	PUNCT
aiua-12307	346	25	the	the	DET
aiua-12307	346	26	number	number	NOUN
aiua-12307	346	27	of	of	ADP
aiua-12307	346	28	t	t	NOUN
aiua-12307	346	29	cells	cell	NOUN
aiua-12307	346	30	decreases	decrease	VERB
aiua-12307	346	31	.	.	PUNCT
aiua-12307	347	1	therefore	therefore	ADV
aiua-12307	347	2	,	,	PUNCT
aiua-12307	347	3	applying	apply	VERB
aiua-12307	347	4	immunotherapy	immunotherapy	NOUN
aiua-12307	347	5	at	at	ADP
aiua-12307	347	6	the	the	DET
aiua-12307	347	7	early	early	ADJ
aiua-12307	347	8	stage	stage	NOUN
aiua-12307	347	9	of	of	ADP
aiua-12307	347	10	the	the	DET
aiua-12307	347	11	disease	disease	NOUN
aiua-12307	347	12	may	may	AUX
aiua-12307	347	13	provide	provide	VERB
aiua-12307	347	14	a	a	DET
aiua-12307	347	15	more	more	ADV
aiua-12307	347	16	effective	effective	ADJ
aiua-12307	347	17	response	response	NOUN
aiua-12307	347	18	to	to	ADP
aiua-12307	347	19	treatment	treatment	NOUN
aiua-12307	347	20	.	.	PUNCT
aiua-12307	348	1	immunotherapy	immunotherapy	NOUN
aiua-12307	348	2	is	be	AUX
aiua-12307	348	3	a	a	DET
aiua-12307	348	4	promising	promising	ADJ
aiua-12307	348	5	alternative	alternative	ADJ
aiua-12307	348	6	treatment	treatment	NOUN
aiua-12307	348	7	option	option	NOUN
aiua-12307	348	8	,	,	PUNCT
aiua-12307	348	9	especially	especially	ADV
aiua-12307	348	10	in	in	ADP
aiua-12307	348	11	some	some	DET
aiua-12307	348	12	crpc	crpc	ADJ
aiua-12307	348	13	patients	patient	NOUN
aiua-12307	348	14	.	.	PUNCT
aiua-12307	349	1	ici	ici	PROPN
aiua-12307	349	2	treatment	treatment	NOUN
aiua-12307	349	3	success	success	NOUN
aiua-12307	349	4	is	be	AUX
aiua-12307	349	5	higher	high	ADJ
aiua-12307	349	6	in	in	ADP
aiua-12307	349	7	prostate	prostate	NOUN
aiua-12307	349	8	cancer	cancer	NOUN
aiua-12307	349	9	patients	patient	NOUN
aiua-12307	349	10	with	with	ADP
aiua-12307	349	11	high	high	ADJ
aiua-12307	349	12	msi	msi	NOUN
aiua-12307	349	13	/	/	SYM
aiua-12307	349	14	dmmr	dmmr	ADV
aiua-12307	349	15	or	or	CCONJ
aiua-12307	349	16	cdk12	cdk12	ADJ
aiua-12307	349	17	mutations	mutation	NOUN
aiua-12307	349	18	.	.	PUNCT
aiua-12307	350	1	a	a	DET
aiua-12307	350	2	better	well	ADJ
aiua-12307	350	3	understanding	understanding	NOUN
aiua-12307	350	4	of	of	ADP
aiua-12307	350	5	tme	tme	NOUN
aiua-12307	350	6	and	and	CCONJ
aiua-12307	350	7	ici	ici	NOUN
aiua-12307	350	8	mechanisms	mechanism	NOUN
aiua-12307	350	9	through	through	ADP
aiua-12307	350	10	high	high	ADJ
aiua-12307	350	11	-	-	PUNCT
aiua-12307	350	12	volume	volume	NOUN
aiua-12307	350	13	prospective	prospective	ADJ
aiua-12307	350	14	rcts	rct	NOUN
aiua-12307	350	15	may	may	AUX
aiua-12307	350	16	pave	pave	VERB
aiua-12307	350	17	the	the	DET
aiua-12307	350	18	way	way	NOUN
aiua-12307	350	19	for	for	ADP
aiua-12307	350	20	new	new	ADJ
aiua-12307	350	21	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	350	22	approaches	approach	NOUN
aiua-12307	350	23	in	in	ADP
aiua-12307	350	24	advanced	advanced	ADJ
aiua-12307	350	25	prostate	prostate	NOUN
aiua-12307	350	26	cancer	cancer	NOUN
aiua-12307	350	27	.	.	PUNCT
aiua-12307	351	1	conclusions	conclusion	NOUN
aiua-12307	351	2	given	give	VERB
aiua-12307	351	3	the	the	DET
aiua-12307	351	4	limited	limited	ADJ
aiua-12307	351	5	research	research	NOUN
aiua-12307	351	6	experience	experience	NOUN
aiua-12307	351	7	to	to	ADP
aiua-12307	351	8	date	date	NOUN
aiua-12307	351	9	,	,	PUNCT
aiua-12307	351	10	it	it	PRON
aiua-12307	351	11	remains	remain	VERB
aiua-12307	351	12	unclear	unclear	ADJ
aiua-12307	351	13	whether	whether	SCONJ
aiua-12307	351	14	the	the	DET
aiua-12307	351	15	persistence	persistence	NOUN
aiua-12307	351	16	of	of	ADP
aiua-12307	351	17	the	the	DET
aiua-12307	351	18	primary	primary	ADJ
aiua-12307	351	19	tumour	tumour	NOUN
aiua-12307	351	20	will	will	AUX
aiua-12307	351	21	impact	impact	VERB
aiua-12307	351	22	attempts	attempt	NOUN
aiua-12307	351	23	to	to	PART
aiua-12307	351	24	modulate	modulate	VERB
aiua-12307	351	25	the	the	DET
aiua-12307	351	26	metastatic	metastatic	ADJ
aiua-12307	351	27	cascade	cascade	NOUN
aiua-12307	351	28	or	or	CCONJ
aiua-12307	351	29	whether	whether	SCONJ
aiua-12307	351	30	different	different	ADJ
aiua-12307	351	31	immunotherapy	immunotherapy	NOUN
aiua-12307	351	32	agents	agent	NOUN
aiua-12307	351	33	have	have	VERB
aiua-12307	351	34	different	different	ADJ
aiua-12307	351	35	degrees	degree	NOUN
aiua-12307	351	36	of	of	ADP
aiua-12307	351	37	efficacy	efficacy	NOUN
aiua-12307	351	38	in	in	ADP
aiua-12307	351	39	adjuvant	adjuvant	NOUN
aiua-12307	351	40	or	or	CCONJ
aiua-12307	351	41	neoadjuvant	neoadjuvant	ADJ
aiua-12307	351	42	settings	setting	NOUN
aiua-12307	351	43	.	.	PUNCT
aiua-12307	352	1	cisplatin	cisplatin	NOUN
aiua-12307	352	2	-	-	PUNCT
aiua-12307	352	3	based	base	VERB
aiua-12307	352	4	ct	ct	PROPN
aiua-12307	352	5	has	have	AUX
aiua-12307	352	6	long	long	ADV
aiua-12307	352	7	been	be	AUX
aiua-12307	352	8	used	use	VERB
aiua-12307	352	9	as	as	ADP
aiua-12307	352	10	standard	standard	ADJ
aiua-12307	352	11	therapy	therapy	NOUN
aiua-12307	352	12	in	in	ADP
aiua-12307	352	13	the	the	DET
aiua-12307	352	14	treatment	treatment	NOUN
aiua-12307	352	15	of	of	ADP
aiua-12307	352	16	urothelial	urothelial	ADJ
aiua-12307	352	17	carcinoma	carcinoma	NOUN
aiua-12307	352	18	.	.	PUNCT
aiua-12307	353	1	with	with	ADP
aiua-12307	353	2	the	the	DET
aiua-12307	353	3	promising	promising	ADJ
aiua-12307	353	4	results	result	NOUN
aiua-12307	353	5	obtained	obtain	VERB
aiua-12307	353	6	in	in	ADP
aiua-12307	353	7	locally	locally	ADV
aiua-12307	353	8	advanced	advanced	ADJ
aiua-12307	353	9	and	and	CCONJ
aiua-12307	353	10	muc	muc	ADJ
aiua-12307	353	11	,	,	PUNCT
aiua-12307	353	12	systemic	systemic	ADJ
aiua-12307	353	13	immunotherapeutic	immunotherapeutic	ADJ
aiua-12307	353	14	agents	agent	NOUN
aiua-12307	353	15	have	have	AUX
aiua-12307	353	16	begun	begin	VERB
aiua-12307	353	17	to	to	PART
aiua-12307	353	18	take	take	VERB
aiua-12307	353	19	their	their	PRON
aiua-12307	353	20	place	place	NOUN
aiua-12307	353	21	in	in	ADP
aiua-12307	353	22	the	the	DET
aiua-12307	353	23	standard	standard	ADJ
aiua-12307	353	24	treatment	treatment	NOUN
aiua-12307	353	25	of	of	ADP
aiua-12307	353	26	the	the	DET
aiua-12307	353	27	disease	disease	NOUN
aiua-12307	353	28	.	.	PUNCT
aiua-12307	354	1	however	however	ADV
aiua-12307	354	2	,	,	PUNCT
aiua-12307	354	3	more	more	ADJ
aiua-12307	354	4	rct	rct	PROPN
aiua-12307	354	5	evidence	evidence	NOUN
aiua-12307	354	6	and	and	CCONJ
aiua-12307	354	7	extended	extended	ADJ
aiua-12307	354	8	follow	follow	NOUN
aiua-12307	354	9	-	-	PUNCT
aiua-12307	354	10	up	up	ADP
aiua-12307	354	11	periods	period	NOUN
aiua-12307	354	12	are	be	AUX
aiua-12307	354	13	needed	need	VERB
aiua-12307	354	14	.	.	PUNCT
aiua-12307	355	1	data	datum	NOUN
aiua-12307	355	2	from	from	ADP
aiua-12307	355	3	large	large	ADJ
aiua-12307	355	4	clinical	clinical	ADJ
aiua-12307	355	5	trials	trial	NOUN
aiua-12307	355	6	to	to	PART
aiua-12307	355	7	evaluate	evaluate	VERB
aiua-12307	355	8	immunotherapy	immunotherapy	NOUN
aiua-12307	355	9	and	and	CCONJ
aiua-12307	355	10	tkis	tkis	NOUN
aiua-12307	355	11	for	for	ADP
aiua-12307	355	12	treating	treat	VERB
aiua-12307	355	13	rcc	rcc	PROPN
aiua-12307	355	14	in	in	ADP
aiua-12307	355	15	the	the	DET
aiua-12307	355	16	adjuvant	adjuvant	ADJ
aiua-12307	355	17	setting	setting	NOUN
aiua-12307	355	18	remain	remain	VERB
aiua-12307	355	19	largely	largely	ADV
aiua-12307	355	20	conflicting	conflicting	ADJ
aiua-12307	355	21	regarding	regard	VERB
aiua-12307	355	22	the	the	DET
aiua-12307	355	23	dfs	dfs	PROPN
aiua-12307	355	24	benefit	benefit	NOUN
aiua-12307	355	25	of	of	ADP
aiua-12307	355	26	either	either	DET
aiua-12307	355	27	treatment	treatment	NOUN
aiua-12307	355	28	modality	modality	NOUN
aiua-12307	355	29	.	.	PUNCT
aiua-12307	356	1	however	however	ADV
aiua-12307	356	2	,	,	PUNCT
aiua-12307	356	3	a	a	DET
aiua-12307	356	4	comprehensive	comprehensive	ADJ
aiua-12307	356	5	biological	biological	ADJ
aiua-12307	356	6	rationale	rationale	NOUN
aiua-12307	356	7	exists	exist	VERB
aiua-12307	356	8	for	for	ADP
aiua-12307	356	9	administering	administer	VERB
aiua-12307	356	10	tkis	tkis	NOUN
aiua-12307	356	11	and	and	CCONJ
aiua-12307	356	12	immunotherapy	immunotherapy	NOUN
aiua-12307	356	13	agents	agent	NOUN
aiua-12307	356	14	in	in	ADP
aiua-12307	356	15	the	the	DET
aiua-12307	356	16	adjuvant	adjuvant	ADJ
aiua-12307	356	17	setting	setting	NOUN
aiua-12307	356	18	.	.	PUNCT
aiua-12307	357	1	however	however	ADV
aiua-12307	357	2	,	,	PUNCT
aiua-12307	357	3	questions	question	NOUN
aiua-12307	357	4	regarding	regard	VERB
aiua-12307	357	5	the	the	DET
aiua-12307	357	6	optimal	optimal	ADJ
aiua-12307	357	7	adjuvant	adjuvant	ADJ
aiua-12307	357	8	treatment	treatment	NOUN
aiua-12307	357	9	regimen	regiman	NOUN
aiua-12307	357	10	and	and	CCONJ
aiua-12307	357	11	appropriate	appropriate	ADJ
aiua-12307	357	12	method	method	NOUN
aiua-12307	357	13	in	in	ADP
aiua-12307	357	14	rcc	rcc	PROPN
aiua-12307	357	15	still	still	ADV
aiua-12307	357	16	remain	remain	VERB
aiua-12307	357	17	to	to	PART
aiua-12307	357	18	be	be	AUX
aiua-12307	357	19	answered	answer	VERB
aiua-12307	357	20	.	.	PUNCT
aiua-12307	358	1	prostate	prostate	NOUN
aiua-12307	358	2	cancer	cancer	NOUN
aiua-12307	358	3	,	,	PUNCT
aiua-12307	358	4	which	which	PRON
aiua-12307	358	5	is	be	AUX
aiua-12307	358	6	considered	consider	VERB
aiua-12307	358	7	an	an	DET
aiua-12307	358	8	immunological	immunological	ADJ
aiua-12307	358	9	"	"	PUNCT
aiua-12307	358	10	cold	cold	ADJ
aiua-12307	358	11	"	"	PUNCT
aiua-12307	358	12	tumour	tumour	NOUN
aiua-12307	358	13	,	,	PUNCT
aiua-12307	358	14	is	be	AUX
aiua-12307	358	15	not	not	PART
aiua-12307	358	16	as	as	ADV
aiua-12307	358	17	sensitive	sensitive	ADJ
aiua-12307	358	18	to	to	ADP
aiua-12307	358	19	immunotherapy	immunotherapy	NOUN
aiua-12307	358	20	as	as	ADP
aiua-12307	358	21	other	other	ADJ
aiua-12307	358	22	urological	urological	ADJ
aiua-12307	358	23	malignancies	malignancy	NOUN
aiua-12307	358	24	.	.	PUNCT
aiua-12307	359	1	however	however	ADV
aiua-12307	359	2	,	,	PUNCT
aiua-12307	359	3	promising	promising	ADJ
aiua-12307	359	4	results	result	NOUN
aiua-12307	359	5	have	have	AUX
aiua-12307	359	6	been	be	AUX
aiua-12307	359	7	obtained	obtain	VERB
aiua-12307	359	8	in	in	ADP
aiua-12307	359	9	some	some	DET
aiua-12307	359	10	identified	identify	VERB
aiua-12307	359	11	prostate	prostate	NOUN
aiua-12307	359	12	cancer	cancer	NOUN
aiua-12307	359	13	patients	patient	NOUN
aiua-12307	359	14	.	.	PUNCT
aiua-12307	360	1	in	in	ADP
aiua-12307	360	2	the	the	DET
aiua-12307	360	3	light	light	NOUN
aiua-12307	360	4	of	of	ADP
aiua-12307	360	5	new	new	ADJ
aiua-12307	360	6	prospective	prospective	ADJ
aiua-12307	360	7	rcts	rct	NOUN
aiua-12307	360	8	,	,	PUNCT
aiua-12307	360	9	treatment	treatment	NOUN
aiua-12307	360	10	procedures	procedure	NOUN
aiua-12307	360	11	that	that	PRON
aiua-12307	360	12	reach	reach	VERB
aiua-12307	360	13	sufficient	sufficient	ADJ
aiua-12307	360	14	evidence	evidence	NOUN
aiua-12307	360	15	levels	level	NOUN
aiua-12307	360	16	do	do	AUX
aiua-12307	360	17	not	not	PART
aiua-12307	360	18	seem	seem	VERB
aiua-12307	360	19	far	far	ADV
aiua-12307	360	20	away	away	ADV
aiua-12307	360	21	.	.	PUNCT
aiua-12307	361	1	to	to	PART
aiua-12307	361	2	make	make	VERB
aiua-12307	361	3	an	an	DET
aiua-12307	361	4	informed	informed	ADJ
aiua-12307	361	5	decision	decision	NOUN
aiua-12307	361	6	about	about	ADP
aiua-12307	361	7	the	the	DET
aiua-12307	361	8	individualized	individualized	ADJ
aiua-12307	361	9	use	use	NOUN
aiua-12307	361	10	of	of	ADP
aiua-12307	361	11	adjuvant	adjuvant	ADJ
aiua-12307	361	12	immunotherapy	immunotherapy	NOUN
aiua-12307	361	13	,	,	PUNCT
aiua-12307	361	14	clinicians	clinician	NOUN
aiua-12307	361	15	should	should	AUX
aiua-12307	361	16	discuss	discuss	VERB
aiua-12307	361	17	the	the	DET
aiua-12307	361	18	available	available	ADJ
aiua-12307	361	19	data	datum	NOUN
aiua-12307	361	20	with	with	ADP
aiua-12307	361	21	patients	patient	NOUN
aiua-12307	361	22	and	and	CCONJ
aiua-12307	361	23	actively	actively	ADV
aiua-12307	361	24	make	make	VERB
aiua-12307	361	25	the	the	DET
aiua-12307	361	26	decision	decision	NOUN
aiua-12307	361	27	.	.	PUNCT
aiua-12307	362	1	further	further	ADJ
aiua-12307	362	2	research	research	NOUN
aiua-12307	362	3	and	and	CCONJ
aiua-12307	362	4	development	development	NOUN
aiua-12307	362	5	of	of	ADP
aiua-12307	362	6	biomarkers	biomarker	NOUN
aiua-12307	362	7	are	be	AUX
aiua-12307	362	8	needed	need	VERB
aiua-12307	362	9	to	to	PART
aiua-12307	362	10	answer	answer	VERB
aiua-12307	362	11	these	these	DET
aiua-12307	362	12	questions	question	NOUN
aiua-12307	362	13	and	and	CCONJ
aiua-12307	362	14	improve	improve	VERB
aiua-12307	362	15	outcomes	outcome	NOUN
aiua-12307	362	16	for	for	ADP
aiua-12307	362	17	uro	uro	NOUN
aiua-12307	362	18	-	-	PUNCT
aiua-12307	362	19	oncology	oncology	NOUN
aiua-12307	362	20	.	.	PUNCT
aiua-12307	363	1	although	although	SCONJ
aiua-12307	363	2	it	it	PRON
aiua-12307	363	3	is	be	AUX
aiua-12307	363	4	challenging	challenge	VERB
aiua-12307	363	5	to	to	PART
aiua-12307	363	6	stay	stay	VERB
aiua-12307	363	7	up	up	ADP
aiua-12307	363	8	to	to	ADP
aiua-12307	363	9	date	date	NOUN
aiua-12307	363	10	on	on	ADP
aiua-12307	363	11	innovations	innovation	NOUN
aiua-12307	363	12	in	in	ADP
aiua-12307	363	13	immunotherapy	immunotherapy	NOUN
aiua-12307	363	14	,	,	PUNCT
aiua-12307	363	15	given	give	VERB
aiua-12307	363	16	the	the	DET
aiua-12307	363	17	ongoing	ongoing	ADJ
aiua-12307	363	18	rcts	rct	NOUN
aiua-12307	363	19	,	,	PUNCT
aiua-12307	363	20	there	there	PRON
aiua-12307	363	21	is	be	VERB
aiua-12307	363	22	no	no	DET
aiua-12307	363	23	doubt	doubt	NOUN
aiua-12307	363	24	that	that	SCONJ
aiua-12307	363	25	we	we	PRON
aiua-12307	363	26	will	will	AUX
aiua-12307	363	27	have	have	AUX
aiua-12307	363	28	more	more	ADJ
aiua-12307	363	29	options	option	NOUN
aiua-12307	363	30	available	available	ADJ
aiua-12307	363	31	to	to	ADP
aiua-12307	363	32	our	our	PRON
aiua-12307	363	33	patients	patient	NOUN
aiua-12307	363	34	who	who	PRON
aiua-12307	363	35	need	need	VERB
aiua-12307	363	36	this	this	DET
aiua-12307	363	37	treatment	treatment	NOUN
aiua-12307	363	38	in	in	ADP
aiua-12307	363	39	the	the	DET
aiua-12307	363	40	next	next	ADJ
aiua-12307	363	41	decade	decade	NOUN
aiua-12307	363	42	.	.	PUNCT
aiua-12307	364	1	references	reference	NOUN
aiua-12307	364	2	1	1	NUM
aiua-12307	364	3	.	.	X
aiua-12307	364	4	elena	elena	PROPN
aiua-12307	364	5	dreyzin	dreyzin	PROPN
aiua-12307	364	6	ak	ak	PROPN
aiua-12307	364	7	.	.	PROPN
aiua-12307	364	8	kidney	kidney	PROPN
aiua-12307	364	9	cancer	cancer	NOUN
aiua-12307	364	10	and	and	CCONJ
aiua-12307	364	11	its	its	PRON
aiua-12307	364	12	treatment	treatment	NOUN
aiua-12307	364	13	.	.	PUNCT
aiua-12307	365	1	in	in	ADP
aiua-12307	365	2	:	:	PUNCT
aiua-12307	365	3	edouard	edouard	PROPN
aiua-12307	365	4	j.	j.	PROPN
aiua-12307	365	5	trabulsi	trabulsi	PROPN
aiua-12307	365	6	cdl	cdl	PROPN
aiua-12307	365	7	,	,	PUNCT
aiua-12307	365	8	anne	anne	PROPN
aiua-12307	365	9	e.	e.	PROPN
aiua-12307	365	10	lizardi	lizardi	PROPN
aiua-12307	365	11	-	-	PUNCT
aiua-12307	365	12	calvaresi	calvaresi	PROPN
aiua-12307	365	13	,	,	PUNCT
aiua-12307	365	14	editor	editor	NOUN
aiua-12307	365	15	.	.	PUNCT
aiua-12307	366	1	chemotherapy	chemotherapy	NOUN
aiua-12307	366	2	and	and	CCONJ
aiua-12307	366	3	immunotherapy	immunotherapy	NOUN
aiua-12307	366	4	in	in	ADP
aiua-12307	366	5	urologic	urologic	ADJ
aiua-12307	366	6	oncology	oncology	NOUN
aiua-12307	366	7	.	.	PUNCT
aiua-12307	367	1	switzerland	switzerland	PROPN
aiua-12307	367	2	:	:	PUNCT
aiua-12307	367	3	springer	springer	NOUN
aiua-12307	367	4	nature	nature	NOUN
aiua-12307	367	5	;	;	PUNCT
aiua-12307	367	6	2021	2021	NUM
aiua-12307	367	7	.	.	PUNCT
aiua-12307	368	1	p.	p.	NOUN
aiua-12307	368	2	231	231	NUM
aiua-12307	368	3	-	-	SYM
aiua-12307	368	4	7	7	NUM
aiua-12307	368	5	.	.	NOUN
aiua-12307	368	6	2	2	NUM
aiua-12307	368	7	.	.	X
aiua-12307	369	1	morales	morale	NOUN
aiua-12307	369	2	a	a	PRON
aiua-12307	369	3	,	,	PUNCT
aiua-12307	369	4	eidinger	eidinger	NOUN
aiua-12307	369	5	d	d	NOUN
aiua-12307	369	6	,	,	PUNCT
aiua-12307	369	7	bruce	bruce	PROPN
aiua-12307	369	8	aw	aw	INTJ
aiua-12307	369	9	.	.	PROPN
aiua-12307	369	10	intracavitary	intracavitary	ADJ
aiua-12307	369	11	bacillus	bacillus	NOUN
aiua-12307	369	12	calmette	calmette	PROPN
aiua-12307	369	13	-	-	PUNCT
aiua-12307	369	14	guerin	guerin	PROPN
aiua-12307	369	15	in	in	ADP
aiua-12307	369	16	the	the	DET
aiua-12307	369	17	treatment	treatment	NOUN
aiua-12307	369	18	of	of	ADP
aiua-12307	369	19	superficial	superficial	ADJ
aiua-12307	369	20	bladder	bladder	NOUN
aiua-12307	369	21	tumors	tumor	NOUN
aiua-12307	369	22	.	.	PUNCT
aiua-12307	370	1	j	j	PROPN
aiua-12307	370	2	urol	urol	PROPN
aiua-12307	370	3	.	.	PUNCT
aiua-12307	370	4	1976	1976	NUM
aiua-12307	370	5	;	;	PUNCT
aiua-12307	370	6	116:180	116:180	NUM
aiua-12307	370	7	-	-	SYM
aiua-12307	370	8	3	3	NUM
aiua-12307	370	9	.	.	NOUN
aiua-12307	370	10	3	3	NUM
aiua-12307	370	11	.	.	X
aiua-12307	370	12	rosenberg	rosenberg	PROPN
aiua-12307	370	13	sa	sa	PROPN
aiua-12307	370	14	,	,	PUNCT
aiua-12307	370	15	lotze	lotze	PROPN
aiua-12307	370	16	mt	mt	PROPN
aiua-12307	370	17	,	,	PUNCT
aiua-12307	370	18	muul	muul	NOUN
aiua-12307	370	19	lm	lm	PROPN
aiua-12307	370	20	,	,	PUNCT
aiua-12307	370	21	et	et	PROPN
aiua-12307	370	22	al	al	PROPN
aiua-12307	370	23	.	.	PUNCT
aiua-12307	371	1	observations	observation	NOUN
aiua-12307	371	2	on	on	ADP
aiua-12307	371	3	the	the	DET
aiua-12307	371	4	systemic	systemic	ADJ
aiua-12307	371	5	administration	administration	NOUN
aiua-12307	371	6	of	of	ADP
aiua-12307	371	7	autologous	autologous	ADJ
aiua-12307	371	8	lymphokine	lymphokine	ADJ
aiua-12307	371	9	-	-	PUNCT
aiua-12307	371	10	activated	activate	VERB
aiua-12307	371	11	killer	killer	NOUN
aiua-12307	371	12	cells	cell	NOUN
aiua-12307	371	13	and	and	CCONJ
aiua-12307	371	14	recombinant	recombinant	ADJ
aiua-12307	371	15	interleukin-2	interleukin-2	NOUN
aiua-12307	371	16	to	to	ADP
aiua-12307	371	17	patients	patient	NOUN
aiua-12307	371	18	with	with	ADP
aiua-12307	371	19	metastatic	metastatic	ADJ
aiua-12307	371	20	cancer	cancer	NOUN
aiua-12307	371	21	.	.	PUNCT
aiua-12307	372	1	new	new	ADJ
aiua-12307	372	2	engl	engl	PROPN
aiua-12307	372	3	j	j	PROPN
aiua-12307	372	4	med	med	PROPN
aiua-12307	372	5	.	.	PUNCT
aiua-12307	372	6	1985	1985	NUM
aiua-12307	372	7	;	;	PUNCT
aiua-12307	372	8	313:1485	313:1485	NUM
aiua-12307	372	9	-	-	SYM
aiua-12307	372	10	92	92	NUM
aiua-12307	372	11	.	.	PUNCT
aiua-12307	373	1	4	4	X
aiua-12307	373	2	.	.	X
aiua-12307	373	3	cassell	cassell	PROPN
aiua-12307	373	4	a	a	PRON
aiua-12307	373	5	,	,	PUNCT
aiua-12307	373	6	3rd	3rd	NOUN
aiua-12307	373	7	,	,	PUNCT
aiua-12307	373	8	manobah	manobah	NOUN
aiua-12307	373	9	b	b	PROPN
aiua-12307	373	10	,	,	PUNCT
aiua-12307	373	11	willie	willie	PROPN
aiua-12307	373	12	s.	s.	PROPN
aiua-12307	373	13	diagnostic	diagnostic	ADJ
aiua-12307	373	14	and	and	CCONJ
aiua-12307	373	15	therapeutic	therapeutic	ADJ
aiua-12307	373	16	challenges	challenge	NOUN
aiua-12307	373	17	of	of	ADP
aiua-12307	373	18	rare	rare	ADJ
aiua-12307	373	19	urogenital	urogenital	ADJ
aiua-12307	373	20	cancers	cancer	NOUN
aiua-12307	373	21	:	:	PUNCT
aiua-12307	373	22	urothelial	urothelial	ADJ
aiua-12307	373	23	carcinoma	carcinoma	NOUN
aiua-12307	373	24	of	of	ADP
aiua-12307	373	25	the	the	DET
aiua-12307	373	26	renal	renal	ADJ
aiua-12307	373	27	pelvis	pelvis	NOUN
aiua-12307	373	28	,	,	PUNCT
aiua-12307	373	29	ureters	ureter	NOUN
aiua-12307	373	30	and	and	CCONJ
aiua-12307	373	31	urethra	urethra	NOUN
aiua-12307	373	32	.	.	PUNCT
aiua-12307	374	1	world	world	PROPN
aiua-12307	374	2	journal	journal	PROPN
aiua-12307	374	3	of	of	ADP
aiua-12307	374	4	oncology	oncology	NOUN
aiua-12307	374	5	.	.	PUNCT
aiua-12307	375	1	2021	2021	NUM
aiua-12307	375	2	;	;	PUNCT
aiua-12307	375	3	12:20	12:20	NUM
aiua-12307	375	4	-	-	SYM
aiua-12307	375	5	7	7	NUM
aiua-12307	375	6	.	.	NOUN
aiua-12307	375	7	5	5	NUM
aiua-12307	375	8	.	.	X
aiua-12307	376	1	bray	bray	PROPN
aiua-12307	376	2	f	f	PROPN
aiua-12307	376	3	,	,	PUNCT
aiua-12307	376	4	ferlay	ferlay	PROPN
aiua-12307	376	5	j	j	PROPN
aiua-12307	376	6	,	,	PUNCT
aiua-12307	376	7	soerjomataram	soerjomataram	PROPN
aiua-12307	376	8	i	i	PROPN
aiua-12307	376	9	,	,	PUNCT
aiua-12307	376	10	et	et	PROPN
aiua-12307	376	11	al	al	PROPN
aiua-12307	376	12	.	.	PUNCT
aiua-12307	377	1	global	global	ADJ
aiua-12307	377	2	cancer	cancer	NOUN
aiua-12307	377	3	statistics	statistic	NOUN
aiua-12307	377	4	2018	2018	NUM
aiua-12307	377	5	:	:	PUNCT
aiua-12307	377	6	globocan	globocan	PROPN
aiua-12307	377	7	estimates	estimate	NOUN
aiua-12307	377	8	of	of	ADP
aiua-12307	377	9	incidence	incidence	NOUN
aiua-12307	377	10	and	and	CCONJ
aiua-12307	377	11	mortality	mortality	NOUN
aiua-12307	377	12	worldwide	worldwide	ADV
aiua-12307	377	13	for	for	ADP
aiua-12307	377	14	36	36	NUM
aiua-12307	377	15	cancers	cancer	NOUN
aiua-12307	377	16	in	in	ADP
aiua-12307	377	17	185	185	NUM
aiua-12307	377	18	countries	country	NOUN
aiua-12307	377	19	.	.	PUNCT
aiua-12307	378	1	ca	can	AUX
aiua-12307	378	2	cancer	cancer	PROPN
aiua-12307	378	3	j	j	PROPN
aiua-12307	378	4	clin	clin	PROPN
aiua-12307	378	5	.	.	PUNCT
aiua-12307	379	1	2018	2018	NUM
aiua-12307	379	2	;	;	PUNCT
aiua-12307	379	3	68:394424	68:394424	NUM
aiua-12307	379	4	.	.	NOUN
aiua-12307	379	5	6	6	NUM
aiua-12307	379	6	.	.	X
aiua-12307	379	7	babjuk	babjuk	PROPN
aiua-12307	379	8	m	m	PROPN
aiua-12307	379	9	,	,	PUNCT
aiua-12307	379	10	burger	burger	PROPN
aiua-12307	379	11	m	m	PROPN
aiua-12307	379	12	,	,	PUNCT
aiua-12307	379	13	comperat	comperat	VERB
aiua-12307	379	14	em	em	PRON
aiua-12307	379	15	,	,	PUNCT
aiua-12307	379	16	et	et	PROPN
aiua-12307	379	17	al	al	PROPN
aiua-12307	379	18	.	.	PROPN
aiua-12307	380	1	european	european	PROPN
aiua-12307	380	2	association	association	PROPN
aiua-12307	380	3	of	of	ADP
aiua-12307	380	4	urology	urology	NOUN
aiua-12307	380	5	guidelines	guideline	NOUN
aiua-12307	380	6	on	on	ADP
aiua-12307	380	7	non	non	ADJ
aiua-12307	380	8	-	-	ADJ
aiua-12307	380	9	muscle	muscle	ADJ
aiua-12307	380	10	-	-	PUNCT
aiua-12307	380	11	invasive	invasive	ADJ
aiua-12307	380	12	bladder	bladder	NOUN
aiua-12307	380	13	cancer	cancer	NOUN
aiua-12307	380	14	(	(	PUNCT
aiua-12307	380	15	tat1	tat1	NOUN
aiua-12307	380	16	and	and	CCONJ
aiua-12307	380	17	carcinoma	carcinoma	NOUN
aiua-12307	380	18	in	in	ADP
aiua-12307	380	19	situ	situ	NOUN
aiua-12307	380	20	)	)	PUNCT
aiua-12307	380	21	2019	2019	NUM
aiua-12307	380	22	update	update	NOUN
aiua-12307	380	23	.	.	PUNCT
aiua-12307	381	1	eur	eur	PROPN
aiua-12307	381	2	urol	urol	PROPN
aiua-12307	381	3	.	.	PUNCT
aiua-12307	382	1	2019	2019	NUM
aiua-12307	382	2	;	;	PUNCT
aiua-12307	382	3	76:639	76:639	NUM
aiua-12307	382	4	-	-	SYM
aiua-12307	382	5	57	57	NUM
aiua-12307	382	6	.	.	PUNCT
aiua-12307	383	1	7	7	X
aiua-12307	383	2	.	.	X
aiua-12307	383	3	siegel	siegel	PROPN
aiua-12307	383	4	rl	rl	PROPN
aiua-12307	383	5	,	,	PUNCT
aiua-12307	383	6	miller	miller	PROPN
aiua-12307	383	7	kd	kd	PROPN
aiua-12307	383	8	,	,	PUNCT
aiua-12307	383	9	jemal	jemal	ADJ
aiua-12307	383	10	a.	a.	NOUN
aiua-12307	383	11	cancer	cancer	PROPN
aiua-12307	383	12	statistics	statistic	NOUN
aiua-12307	383	13	,	,	PUNCT
aiua-12307	383	14	2019	2019	NUM
aiua-12307	383	15	.	.	PUNCT
aiua-12307	384	1	ca	can	AUX
aiua-12307	384	2	cancer	cancer	PROPN
aiua-12307	384	3	j	j	PROPN
aiua-12307	384	4	clin	clin	PROPN
aiua-12307	384	5	.	.	PUNCT
aiua-12307	385	1	2019	2019	NUM
aiua-12307	385	2	;	;	PUNCT
aiua-12307	385	3	69:7	69:7	NUM
aiua-12307	385	4	-	-	SYM
aiua-12307	385	5	34	34	NUM
aiua-12307	385	6	.	.	NOUN
aiua-12307	385	7	8	8	NUM
aiua-12307	385	8	.	.	PUNCT
aiua-12307	386	1	petros	petros	PROPN
aiua-12307	386	2	fg	fg	PROPN
aiua-12307	386	3	.	.	PROPN
aiua-12307	386	4	epidemiology	epidemiology	NOUN
aiua-12307	386	5	,	,	PUNCT
aiua-12307	386	6	clinical	clinical	ADJ
aiua-12307	386	7	presentation	presentation	NOUN
aiua-12307	386	8	,	,	PUNCT
aiua-12307	386	9	and	and	CCONJ
aiua-12307	386	10	evaluation	evaluation	NOUN
aiua-12307	386	11	of	of	ADP
aiua-12307	386	12	upper	upper	ADJ
aiua-12307	386	13	-	-	PUNCT
aiua-12307	386	14	tract	tract	NOUN
aiua-12307	386	15	urothelial	urothelial	ADJ
aiua-12307	386	16	carcinoma	carcinoma	NOUN
aiua-12307	386	17	.	.	PUNCT
aiua-12307	387	1	transl	transl	PROPN
aiua-12307	387	2	androl	androl	PROPN
aiua-12307	387	3	urol	urol	PROPN
aiua-12307	387	4	.	.	PUNCT
aiua-12307	388	1	2020	2020	NUM
aiua-12307	388	2	;	;	PUNCT
aiua-12307	389	1	9:1794	9:1794	NUM
aiua-12307	389	2	-	-	SYM
aiua-12307	389	3	8	8	NUM
aiua-12307	389	4	.	.	NOUN
aiua-12307	389	5	9	9	NUM
aiua-12307	389	6	.	.	X
aiua-12307	389	7	ward	ward	PROPN
aiua-12307	389	8	grados	grados	PROPN
aiua-12307	389	9	df	df	PROPN
aiua-12307	389	10	,	,	PUNCT
aiua-12307	389	11	ahmadi	ahmadi	PROPN
aiua-12307	389	12	h	h	PROPN
aiua-12307	389	13	,	,	PUNCT
aiua-12307	389	14	griffith	griffith	PROPN
aiua-12307	389	15	ts	ts	PROPN
aiua-12307	389	16	,	,	PUNCT
aiua-12307	389	17	warlick	warlick	PROPN
aiua-12307	389	18	ca	can	AUX
aiua-12307	389	19	.	.	PUNCT
aiua-12307	390	1	immunotherapy	immunotherapy	NOUN
aiua-12307	390	2	for	for	ADP
aiua-12307	390	3	bladder	bladder	NOUN
aiua-12307	390	4	cancer	cancer	NOUN
aiua-12307	390	5	:	:	PUNCT
aiua-12307	390	6	latest	late	ADJ
aiua-12307	390	7	advances	advance	NOUN
aiua-12307	390	8	and	and	CCONJ
aiua-12307	390	9	ongoing	ongoing	ADJ
aiua-12307	390	10	clinical	clinical	ADJ
aiua-12307	390	11	trials	trial	NOUN
aiua-12307	390	12	.	.	PUNCT
aiua-12307	391	1	immunol	immunol	NOUN
aiua-12307	391	2	invest	invest	PROPN
aiua-12307	391	3	.	.	PUNCT
aiua-12307	392	1	2022	2022	NUM
aiua-12307	392	2	;	;	PUNCT
aiua-12307	392	3	51:2226	51:2226	NUM
aiua-12307	392	4	-	-	SYM
aiua-12307	392	5	51	51	NUM
aiua-12307	392	6	.	.	PUNCT
aiua-12307	393	1	10	10	NUM
aiua-12307	393	2	.	.	PUNCT
aiua-12307	394	1	naitoh	naitoh	PROPN
aiua-12307	394	2	j	j	PROPN
aiua-12307	394	3	,	,	PUNCT
aiua-12307	394	4	franklin	franklin	PROPN
aiua-12307	394	5	j	j	PROPN
aiua-12307	394	6	,	,	PUNCT
aiua-12307	394	7	o'donnell	o'donnell	PROPN
aiua-12307	394	8	ma	ma	PROPN
aiua-12307	394	9	,	,	PUNCT
aiua-12307	394	10	belldegrun	belldegrun	ADJ
aiua-12307	394	11	as	as	ADP
aiua-12307	394	12	.	.	PUNCT
aiua-12307	395	1	interferon	interferon	ADJ
aiua-12307	395	2	alpha	alpha	NOUN
aiua-12307	395	3	for	for	ADP
aiua-12307	395	4	the	the	DET
aiua-12307	395	5	treatment	treatment	NOUN
aiua-12307	395	6	of	of	ADP
aiua-12307	395	7	superficial	superficial	ADJ
aiua-12307	395	8	bladder	bladder	NOUN
aiua-12307	395	9	cancer	cancer	NOUN
aiua-12307	395	10	.	.	PUNCT
aiua-12307	396	1	adv	adv	PROPN
aiua-12307	396	2	exp	exp	NOUN
aiua-12307	396	3	med	med	ADJ
aiua-12307	396	4	biol	biol	NOUN
aiua-12307	396	5	.	.	PUNCT
aiua-12307	397	1	1999	1999	NUM
aiua-12307	397	2	;	;	PUNCT
aiua-12307	397	3	462:371	462:371	NOUN
aiua-12307	397	4	-	-	SYM
aiua-12307	397	5	86	86	NUM
aiua-12307	397	6	.	.	PUNCT
aiua-12307	398	1	11	11	NUM
aiua-12307	398	2	.	.	PUNCT
aiua-12307	399	1	balar	balar	PROPN
aiua-12307	399	2	av	av	PROPN
aiua-12307	399	3	,	,	PUNCT
aiua-12307	399	4	kamat	kamat	PROPN
aiua-12307	399	5	am	am	PROPN
aiua-12307	399	6	,	,	PUNCT
aiua-12307	399	7	kulkarni	kulkarni	PROPN
aiua-12307	399	8	gs	gs	PROPN
aiua-12307	399	9	,	,	PUNCT
aiua-12307	399	10	et	et	PROPN
aiua-12307	399	11	al	al	PROPN
aiua-12307	399	12	.	.	PROPN
aiua-12307	399	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	399	14	archivio	archivio	NOUN
aiua-12307	399	15	italiano	italiano	X
aiua-12307	399	16	di	di	X
aiua-12307	399	17	urologia	urologia	PROPN
aiua-12307	399	18	e	e	PROPN
aiua-12307	399	19	andrologia	andrologia	NOUN
aiua-12307	399	20	2024	2024	NUM
aiua-12307	399	21	;	;	PUNCT
aiua-12307	399	22	96(2):12307	96(2):12307	NUM
aiua-12307	399	23	11	11	NUM
aiua-12307	399	24	the	the	DET
aiua-12307	399	25	role	role	NOUN
aiua-12307	399	26	of	of	ADP
aiua-12307	399	27	immunotherapy	immunotherapy	NOUN
aiua-12307	399	28	in	in	ADP
aiua-12307	399	29	urological	urological	ADJ
aiua-12307	399	30	cancers	cancer	NOUN
aiua-12307	399	31	monotherapy	monotherapy	NOUN
aiua-12307	399	32	for	for	ADP
aiua-12307	399	33	the	the	DET
aiua-12307	399	34	treatment	treatment	NOUN
aiua-12307	399	35	of	of	ADP
aiua-12307	399	36	high	high	ADJ
aiua-12307	399	37	-	-	PUNCT
aiua-12307	399	38	risk	risk	NOUN
aiua-12307	399	39	non	non	ADJ
aiua-12307	399	40	-	-	ADJ
aiua-12307	399	41	muscle	muscle	ADJ
aiua-12307	399	42	-	-	PUNCT
aiua-12307	399	43	invasive	invasive	ADJ
aiua-12307	399	44	bladder	bladder	NOUN
aiua-12307	399	45	cancer	cancer	NOUN
aiua-12307	399	46	unresponsive	unresponsive	ADJ
aiua-12307	399	47	to	to	ADP
aiua-12307	399	48	bcg	bcg	PROPN
aiua-12307	399	49	(	(	PUNCT
aiua-12307	399	50	keynote-057	keynote-057	NOUN
aiua-12307	399	51	):	):	PUNCT
aiua-12307	399	52	an	an	DET
aiua-12307	399	53	openlabel	openlabel	NOUN
aiua-12307	399	54	,	,	PUNCT
aiua-12307	399	55	single	single	ADJ
aiua-12307	399	56	-	-	PUNCT
aiua-12307	399	57	arm	arm	NOUN
aiua-12307	399	58	,	,	PUNCT
aiua-12307	399	59	multicentre	multicentre	NOUN
aiua-12307	399	60	,	,	PUNCT
aiua-12307	399	61	phase	phase	NOUN
aiua-12307	399	62	2	2	NUM
aiua-12307	399	63	study	study	NOUN
aiua-12307	399	64	.	.	PUNCT
aiua-12307	400	1	lancet	lancet	PROPN
aiua-12307	400	2	oncol	oncol	PROPN
aiua-12307	400	3	.	.	PUNCT
aiua-12307	401	1	2021	2021	NUM
aiua-12307	401	2	;	;	PUNCT
aiua-12307	401	3	22:919	22:919	NUM
aiua-12307	401	4	-	-	SYM
aiua-12307	401	5	30	30	NUM
aiua-12307	401	6	.	.	PUNCT
aiua-12307	402	1	12	12	NUM
aiua-12307	402	2	.	.	PUNCT
aiua-12307	403	1	balar	balar	PROPN
aiua-12307	403	2	av	av	PROPN
aiua-12307	403	3	,	,	PUNCT
aiua-12307	403	4	castellano	castellano	PROPN
aiua-12307	403	5	d	d	PROPN
aiua-12307	403	6	,	,	PUNCT
aiua-12307	403	7	o'donnell	o'donnell	PROPN
aiua-12307	403	8	ph	ph	VERB
aiua-12307	403	9	,	,	PUNCT
aiua-12307	403	10	et	et	PROPN
aiua-12307	403	11	al	al	PROPN
aiua-12307	403	12	.	.	PUNCT
aiua-12307	404	1	first	first	ADJ
aiua-12307	404	2	-	-	PUNCT
aiua-12307	404	3	line	line	NOUN
aiua-12307	404	4	pembrolizumab	pembrolizumab	NOUN
aiua-12307	404	5	in	in	ADP
aiua-12307	404	6	cisplatin	cisplatin	NOUN
aiua-12307	404	7	-	-	PUNCT
aiua-12307	404	8	ineligible	ineligible	ADJ
aiua-12307	404	9	patients	patient	NOUN
aiua-12307	404	10	with	with	ADP
aiua-12307	404	11	locally	locally	ADV
aiua-12307	404	12	advanced	advanced	ADJ
aiua-12307	404	13	and	and	CCONJ
aiua-12307	404	14	unresectable	unresectable	ADJ
aiua-12307	404	15	or	or	CCONJ
aiua-12307	404	16	metastatic	metastatic	ADJ
aiua-12307	404	17	urothelial	urothelial	ADJ
aiua-12307	404	18	cancer	cancer	NOUN
aiua-12307	404	19	(	(	PUNCT
aiua-12307	404	20	keynote-052	keynote-052	NOUN
aiua-12307	404	21	):	):	PUNCT
aiua-12307	404	22	a	a	DET
aiua-12307	404	23	multicentre	multicentre	NOUN
aiua-12307	404	24	,	,	PUNCT
aiua-12307	404	25	single	single	ADJ
aiua-12307	404	26	-	-	PUNCT
aiua-12307	404	27	arm	arm	NOUN
aiua-12307	404	28	,	,	PUNCT
aiua-12307	404	29	phase	phase	NOUN
aiua-12307	404	30	2	2	NUM
aiua-12307	404	31	study	study	NOUN
aiua-12307	404	32	.	.	PUNCT
aiua-12307	405	1	lancet	lancet	PROPN
aiua-12307	405	2	oncol	oncol	PROPN
aiua-12307	405	3	2017	2017	NUM
aiua-12307	405	4	;	;	PUNCT
aiua-12307	405	5	18:1483	18:1483	NUM
aiua-12307	405	6	-	-	SYM
aiua-12307	405	7	92	92	NUM
aiua-12307	405	8	.	.	PUNCT
aiua-12307	405	9	13	13	NUM
aiua-12307	405	10	.	.	PUNCT
aiua-12307	406	1	necchi	necchi	PROPN
aiua-12307	406	2	a	a	PRON
aiua-12307	406	3	,	,	PUNCT
aiua-12307	406	4	anichini	anichini	ADV
aiua-12307	406	5	a	a	PRON
aiua-12307	406	6	,	,	PUNCT
aiua-12307	406	7	raggi	raggi	NOUN
aiua-12307	406	8	d	d	PROPN
aiua-12307	406	9	,	,	PUNCT
aiua-12307	406	10	et	et	PROPN
aiua-12307	406	11	al	al	PROPN
aiua-12307	406	12	.	.	PROPN
aiua-12307	406	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	406	14	as	as	ADP
aiua-12307	406	15	neoadjuvant	neoadjuvant	ADJ
aiua-12307	406	16	therapy	therapy	NOUN
aiua-12307	406	17	before	before	ADP
aiua-12307	406	18	radical	radical	ADJ
aiua-12307	406	19	cystectomy	cystectomy	NOUN
aiua-12307	406	20	in	in	ADP
aiua-12307	406	21	patients	patient	NOUN
aiua-12307	406	22	with	with	ADP
aiua-12307	406	23	muscle	muscle	NOUN
aiua-12307	406	24	-	-	PUNCT
aiua-12307	406	25	invasive	invasive	ADJ
aiua-12307	406	26	urothelial	urothelial	ADJ
aiua-12307	406	27	bladder	bladder	NOUN
aiua-12307	406	28	carcinoma	carcinoma	NOUN
aiua-12307	406	29	(	(	PUNCT
aiua-12307	406	30	pure-01	pure-01	VERB
aiua-12307	406	31	):	):	PUNCT
aiua-12307	406	32	an	an	DET
aiua-12307	406	33	open	open	ADJ
aiua-12307	406	34	-	-	PUNCT
aiua-12307	406	35	label	label	NOUN
aiua-12307	406	36	,	,	PUNCT
aiua-12307	406	37	single	single	ADJ
aiua-12307	406	38	-	-	PUNCT
aiua-12307	406	39	arm	arm	NOUN
aiua-12307	406	40	,	,	PUNCT
aiua-12307	406	41	phase	phase	NOUN
aiua-12307	406	42	ii	ii	PROPN
aiua-12307	406	43	study	study	NOUN
aiua-12307	406	44	.	.	PUNCT
aiua-12307	407	1	j	j	PROPN
aiua-12307	407	2	clin	clin	PROPN
aiua-12307	407	3	oncol	oncol	PROPN
aiua-12307	407	4	2018	2018	NUM
aiua-12307	407	5	;	;	PUNCT
aiua-12307	407	6	36:3353	36:3353	NUM
aiua-12307	407	7	-	-	SYM
aiua-12307	407	8	60	60	NUM
aiua-12307	407	9	.	.	PUNCT
aiua-12307	407	10	14	14	NUM
aiua-12307	407	11	.	.	PUNCT
aiua-12307	407	12	rose	rise	VERB
aiua-12307	407	13	tl	tl	PROPN
aiua-12307	407	14	,	,	PUNCT
aiua-12307	407	15	harrison	harrison	PROPN
aiua-12307	407	16	mr	mr	PROPN
aiua-12307	407	17	,	,	PUNCT
aiua-12307	407	18	deal	deal	NOUN
aiua-12307	407	19	am	be	AUX
aiua-12307	407	20	,	,	PUNCT
aiua-12307	407	21	et	et	PROPN
aiua-12307	407	22	al	al	PROPN
aiua-12307	407	23	.	.	PROPN
aiua-12307	407	24	phase	phase	PROPN
aiua-12307	407	25	ii	ii	PROPN
aiua-12307	407	26	study	study	NOUN
aiua-12307	407	27	of	of	ADP
aiua-12307	407	28	gemcitabine	gemcitabine	NOUN
aiua-12307	407	29	and	and	CCONJ
aiua-12307	407	30	split	split	NOUN
aiua-12307	407	31	-	-	PUNCT
aiua-12307	407	32	dose	dose	NOUN
aiua-12307	407	33	cisplatin	cisplatin	NOUN
aiua-12307	407	34	plus	plus	CCONJ
aiua-12307	407	35	pembrolizumab	pembrolizumab	NOUN
aiua-12307	407	36	as	as	ADP
aiua-12307	407	37	neoadjuvant	neoadjuvant	ADJ
aiua-12307	407	38	therapy	therapy	NOUN
aiua-12307	407	39	before	before	ADP
aiua-12307	407	40	radical	radical	ADJ
aiua-12307	407	41	cystectomy	cystectomy	NOUN
aiua-12307	407	42	in	in	ADP
aiua-12307	407	43	patients	patient	NOUN
aiua-12307	407	44	with	with	ADP
aiua-12307	407	45	muscle	muscle	NOUN
aiua-12307	407	46	-	-	PUNCT
aiua-12307	407	47	invasive	invasive	ADJ
aiua-12307	407	48	bladder	bladder	NOUN
aiua-12307	407	49	cancer	cancer	NOUN
aiua-12307	407	50	.	.	PUNCT
aiua-12307	408	1	j	j	PROPN
aiua-12307	408	2	clin	clin	PROPN
aiua-12307	408	3	oncol	oncol	PROPN
aiua-12307	408	4	.	.	PUNCT
aiua-12307	409	1	2021	2021	NUM
aiua-12307	409	2	;	;	PUNCT
aiua-12307	409	3	39:3140	39:3140	NUM
aiua-12307	409	4	-	-	SYM
aiua-12307	409	5	8	8	NUM
aiua-12307	409	6	.	.	NOUN
aiua-12307	409	7	15	15	NUM
aiua-12307	409	8	.	.	PUNCT
aiua-12307	410	1	galsky	galsky	PROPN
aiua-12307	410	2	md	md	PROPN
aiua-12307	410	3	,	,	PUNCT
aiua-12307	410	4	mortazavi	mortazavi	VERB
aiua-12307	410	5	a	a	DET
aiua-12307	410	6	,	,	PUNCT
aiua-12307	410	7	milowsky	milowsky	PROPN
aiua-12307	410	8	mi	mi	PROPN
aiua-12307	410	9	,	,	PUNCT
aiua-12307	410	10	et	et	PROPN
aiua-12307	410	11	al	al	PROPN
aiua-12307	410	12	.	.	PROPN
aiua-12307	410	13	randomized	randomize	VERB
aiua-12307	410	14	double	double	ADJ
aiua-12307	410	15	-	-	PUNCT
aiua-12307	410	16	blind	blind	ADJ
aiua-12307	410	17	phase	phase	NOUN
aiua-12307	410	18	ii	ii	NOUN
aiua-12307	410	19	study	study	NOUN
aiua-12307	410	20	of	of	ADP
aiua-12307	410	21	maintenance	maintenance	NOUN
aiua-12307	410	22	pembrolizumab	pembrolizumab	NOUN
aiua-12307	410	23	versus	versus	ADP
aiua-12307	410	24	placebo	placebo	NOUN
aiua-12307	410	25	after	after	ADP
aiua-12307	410	26	first	first	ADJ
aiua-12307	410	27	-	-	PUNCT
aiua-12307	410	28	line	line	NOUN
aiua-12307	410	29	chemotherapy	chemotherapy	NOUN
aiua-12307	410	30	in	in	ADP
aiua-12307	410	31	patients	patient	NOUN
aiua-12307	410	32	with	with	ADP
aiua-12307	410	33	metastatic	metastatic	ADJ
aiua-12307	410	34	urothelial	urothelial	ADJ
aiua-12307	410	35	cancer	cancer	NOUN
aiua-12307	410	36	.	.	PUNCT
aiua-12307	411	1	j	j	PROPN
aiua-12307	411	2	clin	clin	PROPN
aiua-12307	411	3	oncol	oncol	PROPN
aiua-12307	411	4	2020	2020	NUM
aiua-12307	411	5	;	;	PUNCT
aiua-12307	411	6	38:1797	38:1797	NUM
aiua-12307	411	7	-	-	SYM
aiua-12307	411	8	806	806	NUM
aiua-12307	411	9	.	.	PUNCT
aiua-12307	412	1	16	16	NUM
aiua-12307	412	2	.	.	PUNCT
aiua-12307	413	1	bellmunt	bellmunt	PROPN
aiua-12307	413	2	j	j	PROPN
aiua-12307	413	3	,	,	PUNCT
aiua-12307	413	4	de	de	X
aiua-12307	413	5	wit	wit	ADJ
aiua-12307	413	6	r	r	PROPN
aiua-12307	413	7	,	,	PUNCT
aiua-12307	413	8	vaughn	vaughn	PROPN
aiua-12307	413	9	dj	dj	PROPN
aiua-12307	413	10	,	,	PUNCT
aiua-12307	413	11	et	et	PROPN
aiua-12307	413	12	al	al	PROPN
aiua-12307	413	13	.	.	PROPN
aiua-12307	413	14	pembrolizumab	pembrolizumab	NOUN
aiua-12307	413	15	as	as	ADP
aiua-12307	413	16	second	second	ADJ
aiua-12307	413	17	-	-	PUNCT
aiua-12307	413	18	line	line	NOUN
aiua-12307	413	19	therapy	therapy	NOUN
aiua-12307	413	20	for	for	ADP
aiua-12307	413	21	advanced	advanced	ADJ
aiua-12307	413	22	urothelial	urothelial	ADJ
aiua-12307	413	23	carcinoma	carcinoma	NOUN
aiua-12307	413	24	.	.	PUNCT
aiua-12307	414	1	new	new	ADJ
aiua-12307	414	2	engl	engl	PROPN
aiua-12307	414	3	j	j	PROPN
aiua-12307	414	4	med	med	PROPN
aiua-12307	414	5	2017	2017	NUM
aiua-12307	414	6	;	;	PUNCT
aiua-12307	414	7	376:1015	376:1015	X
aiua-12307	414	8	-	-	SYM
aiua-12307	414	9	26	26	NUM
aiua-12307	414	10	.	.	PUNCT
aiua-12307	414	11	17	17	NUM
aiua-12307	414	12	.	.	PUNCT
aiua-12307	415	1	sharma	sharma	PROPN
aiua-12307	415	2	p	p	PROPN
aiua-12307	415	3	,	,	PUNCT
aiua-12307	415	4	retz	retz	PROPN
aiua-12307	415	5	m	m	PROPN
aiua-12307	415	6	,	,	PUNCT
aiua-12307	415	7	siefker	siefker	NOUN
aiua-12307	415	8	-	-	PUNCT
aiua-12307	415	9	radtke	radtke	NOUN
aiua-12307	415	10	a	a	DET
aiua-12307	415	11	,	,	PUNCT
aiua-12307	415	12	et	et	PROPN
aiua-12307	415	13	al	al	PROPN
aiua-12307	415	14	.	.	PROPN
aiua-12307	415	15	nivolumab	nivolumab	PROPN
aiua-12307	415	16	in	in	ADP
aiua-12307	415	17	metastatic	metastatic	ADJ
aiua-12307	415	18	urothelial	urothelial	ADJ
aiua-12307	415	19	carcinoma	carcinoma	NOUN
aiua-12307	415	20	after	after	ADP
aiua-12307	415	21	platinum	platinum	NOUN
aiua-12307	415	22	therapy	therapy	NOUN
aiua-12307	415	23	(	(	PUNCT
aiua-12307	415	24	checkmate	checkmate	VERB
aiua-12307	415	25	275	275	NUM
aiua-12307	415	26	):	):	PUNCT
aiua-12307	415	27	a	a	DET
aiua-12307	415	28	multicentre	multicentre	NOUN
aiua-12307	415	29	,	,	PUNCT
aiua-12307	415	30	single	single	ADJ
aiua-12307	415	31	-	-	PUNCT
aiua-12307	415	32	arm	arm	NOUN
aiua-12307	415	33	,	,	PUNCT
aiua-12307	415	34	phase	phase	NOUN
aiua-12307	415	35	2	2	NUM
aiua-12307	415	36	trial	trial	NOUN
aiua-12307	415	37	.	.	PUNCT
aiua-12307	416	1	lancet	lancet	PROPN
aiua-12307	416	2	oncol	oncol	PROPN
aiua-12307	416	3	.	.	PUNCT
aiua-12307	417	1	2017	2017	NUM
aiua-12307	417	2	;	;	PUNCT
aiua-12307	417	3	18:312	18:312	NUM
aiua-12307	417	4	-	-	SYM
aiua-12307	417	5	22	22	NUM
aiua-12307	417	6	.	.	PUNCT
aiua-12307	418	1	18	18	NUM
aiua-12307	418	2	.	.	PUNCT
aiua-12307	419	1	sharma	sharma	PROPN
aiua-12307	419	2	p	p	PROPN
aiua-12307	419	3	,	,	PUNCT
aiua-12307	419	4	siefker	siefker	NOUN
aiua-12307	419	5	-	-	PUNCT
aiua-12307	419	6	radtke	radtke	NOUN
aiua-12307	419	7	a	a	DET
aiua-12307	419	8	,	,	PUNCT
aiua-12307	419	9	de	de	X
aiua-12307	419	10	braud	braud	VERB
aiua-12307	419	11	f	f	PROPN
aiua-12307	419	12	,	,	PUNCT
aiua-12307	420	1	et	et	PROPN
aiua-12307	420	2	al	al	PROPN
aiua-12307	420	3	.	.	PROPN
aiua-12307	420	4	nivolumab	nivolumab	PROPN
aiua-12307	420	5	alone	alone	ADV
aiua-12307	420	6	and	and	CCONJ
aiua-12307	420	7	with	with	ADP
aiua-12307	420	8	ipilimumab	ipilimumab	NOUN
aiua-12307	420	9	in	in	ADP
aiua-12307	420	10	previously	previously	ADV
aiua-12307	420	11	treated	treat	VERB
aiua-12307	420	12	metastatic	metastatic	ADJ
aiua-12307	420	13	urothelial	urothelial	ADJ
aiua-12307	420	14	carcinoma	carcinoma	NOUN
aiua-12307	420	15	:	:	PUNCT
aiua-12307	420	16	checkmate	checkmate	VERB
aiua-12307	420	17	032	032	NUM
aiua-12307	420	18	nivolumab	nivolumab	NOUN
aiua-12307	420	19	1	1	NUM
aiua-12307	420	20	mg	mg	PROPN
aiua-12307	420	21	/	/	SYM
aiua-12307	420	22	kg	kg	PROPN
aiua-12307	420	23	plus	plus	CCONJ
aiua-12307	420	24	ipilimumab	ipilimumab	VERB
aiua-12307	420	25	3	3	NUM
aiua-12307	420	26	mg	mg	PROPN
aiua-12307	420	27	/	/	SYM
aiua-12307	420	28	kg	kg	PROPN
aiua-12307	420	29	expansion	expansion	NOUN
aiua-12307	420	30	cohort	cohort	NOUN
aiua-12307	420	31	results	result	VERB
aiua-12307	420	32	.	.	PUNCT
aiua-12307	421	1	j	j	PROPN
aiua-12307	421	2	clin	clin	PROPN
aiua-12307	421	3	oncol	oncol	PROPN
aiua-12307	421	4	.	.	PUNCT
aiua-12307	422	1	2019	2019	NUM
aiua-12307	422	2	;	;	PUNCT
aiua-12307	422	3	37:1608	37:1608	X
aiua-12307	422	4	-	-	SYM
aiua-12307	422	5	16	16	NUM
aiua-12307	422	6	.	.	PUNCT
aiua-12307	423	1	19	19	NUM
aiua-12307	423	2	.	.	PUNCT
aiua-12307	424	1	rouprêt	rouprêt	PROPN
aiua-12307	424	2	m	m	PROPN
aiua-12307	424	3	,	,	PUNCT
aiua-12307	424	4	seisen	seisen	VERB
aiua-12307	424	5	t	t	PROPN
aiua-12307	424	6	,	,	PUNCT
aiua-12307	424	7	birtle	birtle	PROPN
aiua-12307	424	8	aj	aj	PROPN
aiua-12307	424	9	,	,	PUNCT
aiua-12307	424	10	et	et	PROPN
aiua-12307	424	11	al	al	PROPN
aiua-12307	424	12	.	.	PROPN
aiua-12307	424	13	european	european	PROPN
aiua-12307	424	14	association	association	PROPN
aiua-12307	424	15	of	of	ADP
aiua-12307	424	16	urology	urology	NOUN
aiua-12307	424	17	guidelines	guideline	NOUN
aiua-12307	424	18	on	on	ADP
aiua-12307	424	19	upper	upper	ADJ
aiua-12307	424	20	urinary	urinary	ADJ
aiua-12307	424	21	tract	tract	NOUN
aiua-12307	424	22	urothelial	urothelial	ADJ
aiua-12307	424	23	carcinoma	carcinoma	NOUN
aiua-12307	424	24	:	:	PUNCT
aiua-12307	424	25	2023	2023	NUM
aiua-12307	424	26	update	update	NOUN
aiua-12307	424	27	.	.	PUNCT
aiua-12307	425	1	eur	eur	PROPN
aiua-12307	425	2	urol	urol	PROPN
aiua-12307	425	3	.	.	PUNCT
aiua-12307	426	1	2023	2023	NUM
aiua-12307	426	2	;	;	PUNCT
aiua-12307	426	3	84:49	84:49	NUM
aiua-12307	426	4	-	-	SYM
aiua-12307	426	5	64	64	NUM
aiua-12307	426	6	.	.	PUNCT
aiua-12307	427	1	20	20	NUM
aiua-12307	427	2	.	.	PUNCT
aiua-12307	427	3	bajorin	bajorin	PROPN
aiua-12307	427	4	df	df	PROPN
aiua-12307	427	5	,	,	PUNCT
aiua-12307	427	6	witjes	witjes	PROPN
aiua-12307	427	7	ja	ja	PROPN
aiua-12307	427	8	,	,	PUNCT
aiua-12307	427	9	gschwend	gschwend	PROPN
aiua-12307	427	10	je	je	PROPN
aiua-12307	427	11	,	,	PUNCT
aiua-12307	427	12	et	et	PROPN
aiua-12307	427	13	al	al	PROPN
aiua-12307	427	14	.	.	PROPN
aiua-12307	428	1	adjuvant	adjuvant	ADJ
aiua-12307	428	2	nivolumab	nivolumab	NOUN
aiua-12307	428	3	versus	versus	ADP
aiua-12307	428	4	placebo	placebo	NOUN
aiua-12307	428	5	in	in	ADP
aiua-12307	428	6	muscle	muscle	NOUN
aiua-12307	428	7	-	-	PUNCT
aiua-12307	428	8	invasive	invasive	ADJ
aiua-12307	428	9	urothelial	urothelial	ADJ
aiua-12307	428	10	carcinoma	carcinoma	NOUN
aiua-12307	428	11	.	.	PUNCT
aiua-12307	429	1	new	new	ADJ
aiua-12307	429	2	engl	engl	PROPN
aiua-12307	429	3	j	j	PROPN
aiua-12307	429	4	med	med	PROPN
aiua-12307	429	5	2021	2021	NUM
aiua-12307	429	6	;	;	PUNCT
aiua-12307	429	7	384:2102	384:2102	NUM
aiua-12307	429	8	-	-	SYM
aiua-12307	429	9	14	14	NUM
aiua-12307	429	10	.	.	PUNCT
aiua-12307	430	1	21	21	NUM
aiua-12307	430	2	.	.	PUNCT
aiua-12307	431	1	rosenberg	rosenberg	PROPN
aiua-12307	431	2	je	je	PROPN
aiua-12307	431	3	,	,	PUNCT
aiua-12307	431	4	hoffman	hoffman	NOUN
aiua-12307	431	5	-	-	PUNCT
aiua-12307	431	6	censits	censit	NOUN
aiua-12307	431	7	j	j	PROPN
aiua-12307	431	8	,	,	PUNCT
aiua-12307	431	9	powles	powle	VERB
aiua-12307	431	10	t	t	PROPN
aiua-12307	431	11	,	,	PUNCT
aiua-12307	431	12	et	et	PROPN
aiua-12307	431	13	al	al	PROPN
aiua-12307	431	14	.	.	PROPN
aiua-12307	431	15	atezolizumab	atezolizumab	PROPN
aiua-12307	431	16	in	in	ADP
aiua-12307	431	17	patients	patient	NOUN
aiua-12307	431	18	with	with	ADP
aiua-12307	431	19	locally	locally	ADV
aiua-12307	431	20	advanced	advanced	ADJ
aiua-12307	431	21	and	and	CCONJ
aiua-12307	431	22	metastatic	metastatic	ADJ
aiua-12307	431	23	urothelial	urothelial	ADJ
aiua-12307	431	24	carcinoma	carcinoma	NOUN
aiua-12307	431	25	who	who	PRON
aiua-12307	431	26	have	have	AUX
aiua-12307	431	27	progressed	progress	VERB
aiua-12307	431	28	following	follow	VERB
aiua-12307	431	29	treatment	treatment	NOUN
aiua-12307	431	30	with	with	ADP
aiua-12307	431	31	platinum	platinum	NOUN
aiua-12307	431	32	-	-	PUNCT
aiua-12307	431	33	based	base	VERB
aiua-12307	431	34	chemotherapy	chemotherapy	NOUN
aiua-12307	431	35	:	:	PUNCT
aiua-12307	431	36	a	a	DET
aiua-12307	431	37	single	single	ADJ
aiua-12307	431	38	-	-	PUNCT
aiua-12307	431	39	arm	arm	NOUN
aiua-12307	431	40	,	,	PUNCT
aiua-12307	431	41	multicentre	multicentre	NOUN
aiua-12307	431	42	,	,	PUNCT
aiua-12307	431	43	phase	phase	NOUN
aiua-12307	431	44	2	2	NUM
aiua-12307	431	45	trial	trial	NOUN
aiua-12307	431	46	.	.	PUNCT
aiua-12307	432	1	lancet	lancet	PROPN
aiua-12307	432	2	2016	2016	NUM
aiua-12307	432	3	;	;	PUNCT
aiua-12307	432	4	387:1909	387:1909	NUM
aiua-12307	432	5	-	-	SYM
aiua-12307	432	6	20	20	NUM
aiua-12307	432	7	.	.	PUNCT
aiua-12307	432	8	22	22	NUM
aiua-12307	432	9	.	.	PUNCT
aiua-12307	433	1	balar	balar	PROPN
aiua-12307	433	2	av	av	PROPN
aiua-12307	433	3	,	,	PUNCT
aiua-12307	433	4	galsky	galsky	PROPN
aiua-12307	433	5	md	md	PROPN
aiua-12307	433	6	,	,	PUNCT
aiua-12307	433	7	rosenberg	rosenberg	PROPN
aiua-12307	433	8	je	je	PROPN
aiua-12307	433	9	,	,	PUNCT
aiua-12307	433	10	et	et	PROPN
aiua-12307	433	11	al	al	PROPN
aiua-12307	433	12	.	.	PROPN
aiua-12307	433	13	atezolizumab	atezolizumab	PROPN
aiua-12307	433	14	as	as	ADP
aiua-12307	433	15	firstline	firstline	ADJ
aiua-12307	433	16	treatment	treatment	NOUN
aiua-12307	433	17	in	in	ADP
aiua-12307	433	18	cisplatin	cisplatin	NOUN
aiua-12307	433	19	-	-	PUNCT
aiua-12307	433	20	ineligible	ineligible	ADJ
aiua-12307	433	21	patients	patient	NOUN
aiua-12307	433	22	with	with	ADP
aiua-12307	433	23	locally	locally	ADV
aiua-12307	433	24	advanced	advanced	ADJ
aiua-12307	433	25	and	and	CCONJ
aiua-12307	433	26	metastatic	metastatic	ADJ
aiua-12307	433	27	urothelial	urothelial	ADJ
aiua-12307	433	28	carcinoma	carcinoma	NOUN
aiua-12307	433	29	:	:	PUNCT
aiua-12307	433	30	a	a	DET
aiua-12307	433	31	single	single	ADJ
aiua-12307	433	32	-	-	PUNCT
aiua-12307	433	33	arm	arm	NOUN
aiua-12307	433	34	,	,	PUNCT
aiua-12307	433	35	multicentre	multicentre	NOUN
aiua-12307	433	36	,	,	PUNCT
aiua-12307	433	37	phase	phase	NOUN
aiua-12307	433	38	2	2	NUM
aiua-12307	433	39	trial	trial	NOUN
aiua-12307	433	40	.	.	PUNCT
aiua-12307	434	1	lancet	lancet	NOUN
aiua-12307	434	2	2017	2017	NUM
aiua-12307	434	3	;	;	PUNCT
aiua-12307	434	4	389:67	389:67	NUM
aiua-12307	434	5	-	-	SYM
aiua-12307	434	6	76	76	NUM
aiua-12307	434	7	.	.	PUNCT
aiua-12307	434	8	23	23	NUM
aiua-12307	434	9	.	.	PUNCT
aiua-12307	435	1	funt	funt	PROPN
aiua-12307	435	2	sa	sa	PROPN
aiua-12307	435	3	,	,	PUNCT
aiua-12307	435	4	lattanzi	lattanzi	PROPN
aiua-12307	435	5	m	m	PROPN
aiua-12307	435	6	,	,	PUNCT
aiua-12307	435	7	whiting	white	VERB
aiua-12307	435	8	k	k	PROPN
aiua-12307	435	9	,	,	PUNCT
aiua-12307	435	10	et	et	PROPN
aiua-12307	435	11	al	al	PROPN
aiua-12307	435	12	.	.	PROPN
aiua-12307	435	13	neoadjuvant	neoadjuvant	PROPN
aiua-12307	435	14	atezolizumab	atezolizumab	NOUN
aiua-12307	435	15	with	with	ADP
aiua-12307	435	16	gemcitabine	gemcitabine	NOUN
aiua-12307	435	17	and	and	CCONJ
aiua-12307	435	18	cisplatin	cisplatin	NOUN
aiua-12307	435	19	in	in	ADP
aiua-12307	435	20	patients	patient	NOUN
aiua-12307	435	21	with	with	ADP
aiua-12307	435	22	muscle	muscle	NOUN
aiua-12307	435	23	-	-	PUNCT
aiua-12307	435	24	invasive	invasive	ADJ
aiua-12307	435	25	bladder	bladder	NOUN
aiua-12307	435	26	cancer	cancer	NOUN
aiua-12307	435	27	:	:	PUNCT
aiua-12307	435	28	a	a	DET
aiua-12307	435	29	multicenter	multicenter	NOUN
aiua-12307	435	30	,	,	PUNCT
aiua-12307	435	31	single	single	ADJ
aiua-12307	435	32	-	-	PUNCT
aiua-12307	435	33	arm	arm	NOUN
aiua-12307	435	34	,	,	PUNCT
aiua-12307	435	35	phase	phase	NOUN
aiua-12307	435	36	ii	ii	NOUN
aiua-12307	435	37	trial	trial	NOUN
aiua-12307	435	38	.	.	PUNCT
aiua-12307	436	1	j	j	PROPN
aiua-12307	436	2	clin	clin	PROPN
aiua-12307	436	3	oncol	oncol	PROPN
aiua-12307	436	4	.	.	PUNCT
aiua-12307	437	1	2022	2022	NUM
aiua-12307	437	2	;	;	PUNCT
aiua-12307	437	3	40:1312	40:1312	NUM
aiua-12307	437	4	-	-	SYM
aiua-12307	437	5	22	22	NUM
aiua-12307	437	6	.	.	PUNCT
aiua-12307	438	1	24	24	NUM
aiua-12307	438	2	.	.	PUNCT
aiua-12307	439	1	galsky	galsky	PROPN
aiua-12307	439	2	md	md	PROPN
aiua-12307	439	3	,	,	PUNCT
aiua-12307	439	4	arija	arija	PROPN
aiua-12307	439	5	jaa	jaa	PROPN
aiua-12307	439	6	,	,	PUNCT
aiua-12307	439	7	bamias	bamias	PROPN
aiua-12307	439	8	a	a	PRON
aiua-12307	439	9	,	,	PUNCT
aiua-12307	439	10	et	et	PROPN
aiua-12307	439	11	al	al	PROPN
aiua-12307	439	12	.	.	PROPN
aiua-12307	439	13	atezolizumab	atezolizumab	PROPN
aiua-12307	439	14	with	with	ADP
aiua-12307	439	15	or	or	CCONJ
aiua-12307	439	16	without	without	ADP
aiua-12307	439	17	chemotherapy	chemotherapy	NOUN
aiua-12307	439	18	in	in	ADP
aiua-12307	439	19	metastatic	metastatic	ADJ
aiua-12307	439	20	urothelial	urothelial	ADJ
aiua-12307	439	21	cancer	cancer	NOUN
aiua-12307	439	22	(	(	PUNCT
aiua-12307	439	23	imvigor130	imvigor130	PROPN
aiua-12307	439	24	):	):	PUNCT
aiua-12307	439	25	a	a	DET
aiua-12307	439	26	multicentre	multicentre	NOUN
aiua-12307	439	27	,	,	PUNCT
aiua-12307	439	28	randomised	randomise	VERB
aiua-12307	439	29	,	,	PUNCT
aiua-12307	439	30	placebo	placebo	NOUN
aiua-12307	439	31	-	-	PUNCT
aiua-12307	439	32	controlled	control	VERB
aiua-12307	439	33	phase	phase	NOUN
aiua-12307	439	34	3	3	NUM
aiua-12307	439	35	trial	trial	NOUN
aiua-12307	439	36	.	.	PUNCT
aiua-12307	440	1	lancet	lancet	PROPN
aiua-12307	440	2	2020	2020	NUM
aiua-12307	440	3	;	;	PUNCT
aiua-12307	440	4	395:1547	395:1547	NUM
aiua-12307	440	5	-	-	SYM
aiua-12307	440	6	57	57	NUM
aiua-12307	440	7	.	.	PUNCT
aiua-12307	440	8	25	25	NUM
aiua-12307	440	9	.	.	PUNCT
aiua-12307	441	1	powles	powle	NOUN
aiua-12307	441	2	t	t	PROPN
aiua-12307	441	3	,	,	PUNCT
aiua-12307	441	4	park	park	PROPN
aiua-12307	441	5	sh	sh	PROPN
aiua-12307	441	6	,	,	PUNCT
aiua-12307	441	7	voog	voog	NOUN
aiua-12307	441	8	e	e	NOUN
aiua-12307	441	9	,	,	PUNCT
aiua-12307	441	10	et	et	PROPN
aiua-12307	441	11	al	al	PROPN
aiua-12307	441	12	.	.	PROPN
aiua-12307	441	13	avelumab	avelumab	PROPN
aiua-12307	441	14	maintenance	maintenance	NOUN
aiua-12307	441	15	therapy	therapy	NOUN
aiua-12307	441	16	for	for	ADP
aiua-12307	441	17	advanced	advanced	ADJ
aiua-12307	441	18	or	or	CCONJ
aiua-12307	441	19	metastatic	metastatic	ADJ
aiua-12307	441	20	urothelial	urothelial	ADJ
aiua-12307	441	21	carcinoma	carcinoma	NOUN
aiua-12307	441	22	.	.	PUNCT
aiua-12307	442	1	new	new	ADJ
aiua-12307	442	2	engl	engl	PROPN
aiua-12307	442	3	j	j	PROPN
aiua-12307	442	4	med	med	PROPN
aiua-12307	442	5	.	.	PUNCT
aiua-12307	443	1	2020	2020	NUM
aiua-12307	443	2	;	;	PUNCT
aiua-12307	443	3	383:1218	383:1218	NUM
aiua-12307	443	4	-	-	SYM
aiua-12307	443	5	30	30	NUM
aiua-12307	443	6	.	.	PUNCT
aiua-12307	444	1	26	26	NUM
aiua-12307	444	2	.	.	PUNCT
aiua-12307	444	3	erck	erck	PROPN
aiua-12307	444	4	a	a	PROPN
aiua-12307	444	5	,	,	PUNCT
aiua-12307	444	6	aragon	aragon	PROPN
aiua-12307	444	7	-	-	PUNCT
aiua-12307	444	8	ching	ching	PROPN
aiua-12307	444	9	jb	jb	PROPN
aiua-12307	444	10	.	.	PUNCT
aiua-12307	445	1	maintenance	maintenance	NOUN
aiua-12307	445	2	avelumab	avelumab	ADJ
aiua-12307	445	3	for	for	ADP
aiua-12307	445	4	metastatic	metastatic	ADJ
aiua-12307	445	5	urothelial	urothelial	ADJ
aiua-12307	445	6	cancer	cancer	NOUN
aiua-12307	445	7	:	:	PUNCT
aiua-12307	445	8	a	a	DET
aiua-12307	445	9	new	new	ADJ
aiua-12307	445	10	standard	standard	NOUN
aiua-12307	445	11	of	of	ADP
aiua-12307	445	12	care	care	NOUN
aiua-12307	445	13	.	.	PUNCT
aiua-12307	446	1	cancer	cancer	NOUN
aiua-12307	446	2	biol	biol	PROPN
aiua-12307	446	3	ther	ther	ADV
aiua-12307	446	4	.	.	PUNCT
aiua-12307	447	1	2020	2020	NUM
aiua-12307	447	2	;	;	PUNCT
aiua-12307	447	3	21:1095	21:1095	NUM
aiua-12307	447	4	-	-	SYM
aiua-12307	447	5	6	6	NUM
aiua-12307	447	6	.	.	NOUN
aiua-12307	447	7	27	27	NUM
aiua-12307	447	8	.	.	PUNCT
aiua-12307	448	1	powles	powle	NOUN
aiua-12307	448	2	t	t	PROPN
aiua-12307	448	3	,	,	PUNCT
aiua-12307	448	4	van	van	PROPN
aiua-12307	448	5	der	der	PROPN
aiua-12307	448	6	heijden	heijden	PROPN
aiua-12307	448	7	ms	ms	PROPN
aiua-12307	448	8	,	,	PUNCT
aiua-12307	448	9	castellano	castellano	PROPN
aiua-12307	448	10	d	d	PROPN
aiua-12307	448	11	,	,	PUNCT
aiua-12307	448	12	et	et	PROPN
aiua-12307	448	13	al	al	PROPN
aiua-12307	448	14	.	.	PROPN
aiua-12307	448	15	durvalumab	durvalumab	PROPN
aiua-12307	448	16	alone	alone	ADV
aiua-12307	448	17	and	and	CCONJ
aiua-12307	448	18	durvalumab	durvalumab	NOUN
aiua-12307	448	19	plus	plus	CCONJ
aiua-12307	448	20	tremelimumab	tremelimumab	NOUN
aiua-12307	448	21	versus	versus	ADP
aiua-12307	448	22	chemotherapy	chemotherapy	NOUN
aiua-12307	448	23	in	in	ADP
aiua-12307	448	24	previously	previously	ADV
aiua-12307	448	25	untreated	untreated	ADJ
aiua-12307	448	26	patients	patient	NOUN
aiua-12307	448	27	with	with	ADP
aiua-12307	448	28	unresectable	unresectable	ADJ
aiua-12307	448	29	,	,	PUNCT
aiua-12307	448	30	locally	locally	ADV
aiua-12307	448	31	advanced	advanced	ADJ
aiua-12307	448	32	or	or	CCONJ
aiua-12307	448	33	metastatic	metastatic	ADJ
aiua-12307	448	34	urothelial	urothelial	ADJ
aiua-12307	448	35	carcinoma	carcinoma	NOUN
aiua-12307	448	36	(	(	PUNCT
aiua-12307	448	37	danube	danube	NOUN
aiua-12307	448	38	):	):	PUNCT
aiua-12307	448	39	a	a	DET
aiua-12307	448	40	randomised	randomised	ADJ
aiua-12307	448	41	,	,	PUNCT
aiua-12307	448	42	openlabel	openlabel	NOUN
aiua-12307	448	43	,	,	PUNCT
aiua-12307	448	44	multicentre	multicentre	NOUN
aiua-12307	448	45	,	,	PUNCT
aiua-12307	448	46	phase	phase	NOUN
aiua-12307	448	47	3	3	NUM
aiua-12307	448	48	trial	trial	NOUN
aiua-12307	448	49	.	.	PUNCT
aiua-12307	449	1	lancet	lancet	PROPN
aiua-12307	449	2	oncol	oncol	PROPN
aiua-12307	449	3	.	.	PUNCT
aiua-12307	450	1	2020	2020	NUM
aiua-12307	450	2	;	;	PUNCT
aiua-12307	450	3	21:1574	21:1574	NUM
aiua-12307	450	4	-	-	SYM
aiua-12307	450	5	88	88	NUM
aiua-12307	450	6	.	.	PUNCT
aiua-12307	451	1	28	28	NUM
aiua-12307	451	2	.	.	PUNCT
aiua-12307	452	1	rhea	rhea	PROPN
aiua-12307	452	2	lp	lp	PROPN
aiua-12307	452	3	,	,	PUNCT
aiua-12307	452	4	aragon	aragon	PROPN
aiua-12307	452	5	-	-	PUNCT
aiua-12307	452	6	ching	ching	PROPN
aiua-12307	452	7	jb	jb	PROPN
aiua-12307	452	8	.	.	PROPN
aiua-12307	453	1	advances	advance	NOUN
aiua-12307	453	2	and	and	CCONJ
aiua-12307	453	3	controversies	controversy	NOUN
aiua-12307	453	4	with	with	ADP
aiua-12307	453	5	checkpoint	checkpoint	NOUN
aiua-12307	453	6	inhibitors	inhibitor	NOUN
aiua-12307	453	7	in	in	ADP
aiua-12307	453	8	bladder	bladder	NOUN
aiua-12307	453	9	cancer	cancer	NOUN
aiua-12307	453	10	.	.	PUNCT
aiua-12307	454	1	clin	clin	PROPN
aiua-12307	454	2	med	med	PROPN
aiua-12307	454	3	insights	insight	NOUN
aiua-12307	454	4	oncol	oncol	ADJ
aiua-12307	454	5	.	.	PUNCT
aiua-12307	454	6	2021	2021	NUM
aiua-12307	454	7	;	;	PUNCT
aiua-12307	454	8	15:11795549211044963	15:11795549211044963	NUM
aiua-12307	454	9	.	.	X
aiua-12307	454	10	29	29	NUM
aiua-12307	454	11	.	.	PUNCT
aiua-12307	455	1	abd	abd	PROPN
aiua-12307	455	2	el	el	PROPN
aiua-12307	455	3	-	-	PROPN
aiua-12307	455	4	salam	salam	PROPN
aiua-12307	455	5	ma	ma	PROPN
aiua-12307	455	6	,	,	PUNCT
aiua-12307	455	7	smith	smith	PROPN
aiua-12307	455	8	cep	cep	PROPN
aiua-12307	455	9	,	,	PUNCT
aiua-12307	455	10	pan	pan	PROPN
aiua-12307	455	11	cx	cx	PROPN
aiua-12307	455	12	.	.	PUNCT
aiua-12307	456	1	insights	insight	NOUN
aiua-12307	456	2	on	on	ADP
aiua-12307	456	3	recent	recent	ADJ
aiua-12307	456	4	innovations	innovation	NOUN
aiua-12307	456	5	in	in	ADP
aiua-12307	456	6	bladder	bladder	NOUN
aiua-12307	456	7	cancer	cancer	NOUN
aiua-12307	456	8	immunotherapy	immunotherapy	NOUN
aiua-12307	456	9	.	.	PUNCT
aiua-12307	457	1	cancer	cancer	NOUN
aiua-12307	457	2	cytopathol	cytopathol	NOUN
aiua-12307	457	3	.	.	PUNCT
aiua-12307	458	1	2022	2022	NUM
aiua-12307	458	2	;	;	PUNCT
aiua-12307	458	3	130:667	130:667	NOUN
aiua-12307	458	4	-	-	PUNCT
aiua-12307	458	5	83	83	NUM
aiua-12307	458	6	.	.	PUNCT
aiua-12307	458	7	30	30	NUM
aiua-12307	458	8	.	.	PUNCT
aiua-12307	459	1	ferlay	ferlay	PROPN
aiua-12307	459	2	j	j	PROPN
aiua-12307	459	3	,	,	PUNCT
aiua-12307	459	4	colombet	colombet	PROPN
aiua-12307	459	5	m	m	PROPN
aiua-12307	459	6	,	,	PUNCT
aiua-12307	459	7	soerjomataram	soerjomataram	PROPN
aiua-12307	459	8	i	i	PROPN
aiua-12307	459	9	,	,	PUNCT
aiua-12307	459	10	et	et	PROPN
aiua-12307	459	11	al	al	PROPN
aiua-12307	459	12	.	.	PUNCT
aiua-12307	459	13	cancer	cancer	NOUN
aiua-12307	459	14	incidence	incidence	NOUN
aiua-12307	459	15	and	and	CCONJ
aiua-12307	459	16	mortality	mortality	NOUN
aiua-12307	459	17	patterns	pattern	NOUN
aiua-12307	459	18	in	in	ADP
aiua-12307	459	19	europe	europe	PROPN
aiua-12307	459	20	:	:	PUNCT
aiua-12307	459	21	estimates	estimate	NOUN
aiua-12307	459	22	for	for	ADP
aiua-12307	459	23	40	40	NUM
aiua-12307	459	24	countries	country	NOUN
aiua-12307	459	25	and	and	CCONJ
aiua-12307	459	26	25	25	NUM
aiua-12307	459	27	major	major	ADJ
aiua-12307	459	28	cancers	cancer	NOUN
aiua-12307	459	29	in	in	ADP
aiua-12307	459	30	2018	2018	NUM
aiua-12307	459	31	.	.	PUNCT
aiua-12307	460	1	eur	eur	PROPN
aiua-12307	460	2	j	j	PROPN
aiua-12307	460	3	cancer	cancer	NOUN
aiua-12307	460	4	.	.	PUNCT
aiua-12307	461	1	2018	2018	NUM
aiua-12307	461	2	;	;	PUNCT
aiua-12307	461	3	103:356	103:356	NOUN
aiua-12307	461	4	-	-	SYM
aiua-12307	461	5	87	87	NUM
aiua-12307	461	6	.	.	PUNCT
aiua-12307	462	1	31	31	NUM
aiua-12307	462	2	.	.	PUNCT
aiua-12307	463	1	siegel	siegel	PROPN
aiua-12307	463	2	rl	rl	PROPN
aiua-12307	463	3	,	,	PUNCT
aiua-12307	463	4	miller	miller	PROPN
aiua-12307	463	5	kd	kd	PROPN
aiua-12307	463	6	,	,	PUNCT
aiua-12307	463	7	wagle	wagle	NOUN
aiua-12307	463	8	ns	ns	ADJ
aiua-12307	463	9	,	,	PUNCT
aiua-12307	463	10	jemal	jemal	ADJ
aiua-12307	463	11	a.	a.	NOUN
aiua-12307	463	12	cancer	cancer	NOUN
aiua-12307	463	13	statistics	statistic	NOUN
aiua-12307	463	14	,	,	PUNCT
aiua-12307	463	15	2023	2023	NUM
aiua-12307	463	16	.	.	PUNCT
aiua-12307	464	1	ca	can	AUX
aiua-12307	464	2	cancer	cancer	PROPN
aiua-12307	464	3	j	j	PROPN
aiua-12307	464	4	clin	clin	PROPN
aiua-12307	464	5	.	.	PUNCT
aiua-12307	465	1	2023	2023	NUM
aiua-12307	465	2	;	;	PUNCT
aiua-12307	465	3	73:17	73:17	NUM
aiua-12307	465	4	-	-	SYM
aiua-12307	465	5	48	48	NUM
aiua-12307	465	6	.	.	PUNCT
aiua-12307	466	1	32	32	NUM
aiua-12307	466	2	.	.	PUNCT
aiua-12307	467	1	kaur	kaur	PROPN
aiua-12307	467	2	j	j	PROPN
aiua-12307	467	3	,	,	PUNCT
aiua-12307	467	4	patil	patil	PROPN
aiua-12307	467	5	g	g	PROPN
aiua-12307	467	6	,	,	PUNCT
aiua-12307	467	7	geynisman	geynisman	PROPN
aiua-12307	467	8	dm	dm	PROPN
aiua-12307	467	9	,	,	PUNCT
aiua-12307	467	10	ghatalia	ghatalia	PROPN
aiua-12307	467	11	p.	p.	NOUN
aiua-12307	467	12	role	role	NOUN
aiua-12307	467	13	of	of	ADP
aiua-12307	467	14	perioperative	perioperative	ADJ
aiua-12307	467	15	immunotherapy	immunotherapy	NOUN
aiua-12307	467	16	in	in	ADP
aiua-12307	467	17	localized	localized	ADJ
aiua-12307	467	18	renal	renal	ADJ
aiua-12307	467	19	cell	cell	NOUN
aiua-12307	467	20	carcinoma	carcinoma	NOUN
aiua-12307	467	21	.	.	PUNCT
aiua-12307	468	1	ther	ther	VERB
aiua-12307	468	2	adv	adv	PROPN
aiua-12307	468	3	med	med	PROPN
aiua-12307	468	4	oncol	oncol	ADJ
aiua-12307	468	5	.	.	PUNCT
aiua-12307	469	1	2023	2023	NUM
aiua-12307	469	2	;	;	PUNCT
aiua-12307	469	3	15:17588359231181497	15:17588359231181497	NUM
aiua-12307	469	4	.	.	PROPN
aiua-12307	470	1	33	33	NUM
aiua-12307	470	2	.	.	PUNCT
aiua-12307	471	1	gill	gill	PROPN
aiua-12307	471	2	dm	dm	PROPN
aiua-12307	471	3	,	,	PUNCT
aiua-12307	471	4	hahn	hahn	PROPN
aiua-12307	471	5	aw	aw	PROPN
aiua-12307	471	6	,	,	PUNCT
aiua-12307	471	7	hale	hale	PROPN
aiua-12307	471	8	p	p	PROPN
aiua-12307	471	9	,	,	PUNCT
aiua-12307	471	10	maughan	maughan	PROPN
aiua-12307	471	11	bl	bl	PROPN
aiua-12307	471	12	.	.	PUNCT
aiua-12307	472	1	overview	overview	NOUN
aiua-12307	472	2	of	of	ADP
aiua-12307	472	3	current	current	ADJ
aiua-12307	472	4	and	and	CCONJ
aiua-12307	472	5	future	future	ADJ
aiua-12307	472	6	first	first	ADJ
aiua-12307	472	7	-	-	PUNCT
aiua-12307	472	8	line	line	NOUN
aiua-12307	472	9	systemic	systemic	ADJ
aiua-12307	472	10	therapy	therapy	NOUN
aiua-12307	472	11	for	for	ADP
aiua-12307	472	12	metastatic	metastatic	ADJ
aiua-12307	472	13	clear	clear	ADJ
aiua-12307	472	14	cell	cell	NOUN
aiua-12307	472	15	renal	renal	ADJ
aiua-12307	472	16	cell	cell	NOUN
aiua-12307	472	17	carcinoma	carcinoma	NOUN
aiua-12307	472	18	.	.	PUNCT
aiua-12307	473	1	curr	curr	PROPN
aiua-12307	473	2	treat	treat	PROPN
aiua-12307	473	3	options	option	NOUN
aiua-12307	473	4	oncol	oncol	ADJ
aiua-12307	473	5	.	.	PUNCT
aiua-12307	474	1	2018	2018	NUM
aiua-12307	474	2	;	;	PUNCT
aiua-12307	474	3	19:6	19:6	NUM
aiua-12307	474	4	.	.	X
aiua-12307	474	5	34	34	NUM
aiua-12307	474	6	.	.	PUNCT
aiua-12307	474	7	tykodi	tykodi	PROPN
aiua-12307	474	8	ss	ss	PROPN
aiua-12307	474	9	,	,	PUNCT
aiua-12307	474	10	pichler	pichler	PROPN
aiua-12307	474	11	r.	r.	PROPN
aiua-12307	474	12	editorial	editorial	PROPN
aiua-12307	474	13	:	:	PUNCT
aiua-12307	474	14	immune	immune	ADJ
aiua-12307	474	15	checkpoint	checkpoint	NOUN
aiua-12307	474	16	inhibitors	inhibitor	NOUN
aiua-12307	474	17	in	in	ADP
aiua-12307	474	18	renal	renal	ADJ
aiua-12307	474	19	cell	cell	NOUN
aiua-12307	474	20	carcinoma	carcinoma	NOUN
aiua-12307	474	21	.	.	PUNCT
aiua-12307	475	1	front	front	ADJ
aiua-12307	475	2	oncol	oncol	ADJ
aiua-12307	475	3	.	.	PUNCT
aiua-12307	476	1	2023	2023	NUM
aiua-12307	476	2	;	;	PUNCT
aiua-12307	476	3	13:1203463	13:1203463	NUM
aiua-12307	476	4	.	.	PROPN
aiua-12307	476	5	35	35	NUM
aiua-12307	476	6	.	.	PUNCT
aiua-12307	477	1	quhal	quhal	PROPN
aiua-12307	477	2	f	f	PROPN
aiua-12307	477	3	,	,	PUNCT
aiua-12307	477	4	mori	mori	PROPN
aiua-12307	478	1	k	k	PROPN
aiua-12307	478	2	,	,	PUNCT
aiua-12307	478	3	bruchbacher	bruchbacher	NOUN
aiua-12307	478	4	a	a	X
aiua-12307	478	5	,	,	PUNCT
aiua-12307	478	6	et	et	PROPN
aiua-12307	478	7	al	al	PROPN
aiua-12307	478	8	.	.	PUNCT
aiua-12307	479	1	first	first	ADJ
aiua-12307	479	2	-	-	PUNCT
aiua-12307	479	3	line	line	NOUN
aiua-12307	479	4	immunotherapy	immunotherapy	NOUN
aiua-12307	479	5	-	-	PUNCT
aiua-12307	479	6	based	base	VERB
aiua-12307	479	7	combinations	combination	NOUN
aiua-12307	479	8	for	for	ADP
aiua-12307	479	9	metastatic	metastatic	ADJ
aiua-12307	479	10	renal	renal	ADJ
aiua-12307	479	11	cell	cell	NOUN
aiua-12307	479	12	carcinoma	carcinoma	NOUN
aiua-12307	479	13	:	:	PUNCT
aiua-12307	479	14	a	a	DET
aiua-12307	479	15	systematic	systematic	ADJ
aiua-12307	479	16	review	review	NOUN
aiua-12307	479	17	and	and	CCONJ
aiua-12307	479	18	network	network	NOUN
aiua-12307	479	19	meta	meta	ADJ
aiua-12307	479	20	-	-	PUNCT
aiua-12307	479	21	analysis	analysis	NOUN
aiua-12307	479	22	.	.	PUNCT
aiua-12307	480	1	eur	eur	PROPN
aiua-12307	480	2	urol	urol	PROPN
aiua-12307	480	3	oncol	oncol	PROPN
aiua-12307	480	4	.	.	PUNCT
aiua-12307	481	1	2021	2021	NUM
aiua-12307	482	1	;	;	PUNCT
aiua-12307	482	2	4:755	4:755	NUM
aiua-12307	482	3	-	-	SYM
aiua-12307	482	4	65	65	NUM
aiua-12307	482	5	.	.	PUNCT
aiua-12307	482	6	36	36	NUM
aiua-12307	482	7	.	.	PUNCT
aiua-12307	483	1	sharma	sharma	PROPN
aiua-12307	483	2	p	p	PROPN
aiua-12307	483	3	,	,	PUNCT
aiua-12307	483	4	allison	allison	PROPN
aiua-12307	483	5	jp	jp	PROPN
aiua-12307	483	6	.	.	PROPN
aiua-12307	483	7	immune	immune	ADJ
aiua-12307	483	8	checkpoint	checkpoint	NOUN
aiua-12307	483	9	targeting	target	VERB
aiua-12307	483	10	in	in	ADP
aiua-12307	483	11	cancer	cancer	NOUN
aiua-12307	483	12	therapy	therapy	NOUN
aiua-12307	483	13	:	:	PUNCT
aiua-12307	483	14	toward	toward	ADP
aiua-12307	483	15	combination	combination	NOUN
aiua-12307	483	16	strategies	strategy	NOUN
aiua-12307	483	17	with	with	ADP
aiua-12307	483	18	curative	curative	ADJ
aiua-12307	483	19	potential	potential	NOUN
aiua-12307	483	20	.	.	PUNCT
aiua-12307	484	1	cell	cell	NOUN
aiua-12307	484	2	.	.	PUNCT
aiua-12307	485	1	2015	2015	NUM
aiua-12307	485	2	;	;	PUNCT
aiua-12307	485	3	161:205	161:205	X
aiua-12307	485	4	-	-	SYM
aiua-12307	485	5	14	14	NUM
aiua-12307	485	6	.	.	PUNCT
aiua-12307	486	1	37	37	NUM
aiua-12307	486	2	.	.	PUNCT
aiua-12307	487	1	allaf	allaf	PROPN
aiua-12307	487	2	m	m	PROPN
aiua-12307	487	3	,	,	PUNCT
aiua-12307	487	4	kim	kim	PROPN
aiua-12307	487	5	s	s	PROPN
aiua-12307	487	6	,	,	PUNCT
aiua-12307	487	7	harshman	harshman	PROPN
aiua-12307	487	8	l	l	PROPN
aiua-12307	487	9	,	,	PUNCT
aiua-12307	487	10	et	et	PROPN
aiua-12307	487	11	al	al	PROPN
aiua-12307	487	12	.	.	PROPN
aiua-12307	487	13	phase	phase	NOUN
aiua-12307	487	14	iii	iii	NUM
aiua-12307	487	15	randomized	randomized	ADJ
aiua-12307	487	16	study	study	NOUN
aiua-12307	487	17	comparing	compare	VERB
aiua-12307	487	18	perioperative	perioperative	ADJ
aiua-12307	487	19	nivolumab	nivolumab	NOUN
aiua-12307	487	20	(	(	PUNCT
aiua-12307	487	21	nivo	nivo	NOUN
aiua-12307	487	22	)	)	PUNCT
aiua-12307	487	23	versus	versus	ADP
aiua-12307	487	24	observation	observation	NOUN
aiua-12307	487	25	in	in	ADP
aiua-12307	487	26	patients	patient	NOUN
aiua-12307	487	27	with	with	ADP
aiua-12307	487	28	renal	renal	ADJ
aiua-12307	487	29	cell	cell	NOUN
aiua-12307	487	30	carcinoma	carcinoma	NOUN
aiua-12307	487	31	undergoing	undergo	VERB
aiua-12307	487	32	nephrectomy	nephrectomy	ADV
aiua-12307	487	33	(	(	PUNCT
aiua-12307	487	34	prosper	prosper	NOUN
aiua-12307	487	35	,	,	PUNCT
aiua-12307	487	36	ecog	ecog	NOUN
aiua-12307	487	37	-	-	PUNCT
aiua-12307	487	38	acrin	acrin	NOUN
aiua-12307	487	39	ea8143	ea8143	NOUN
aiua-12307	487	40	)	)	PUNCT
aiua-12307	487	41	,	,	PUNCT
aiua-12307	487	42	a	a	DET
aiua-12307	487	43	national	national	ADJ
aiua-12307	487	44	clinical	clinical	ADJ
aiua-12307	487	45	trials	trial	NOUN
aiua-12307	487	46	network	network	VERB
aiua-12307	487	47	trial.annal	trial.annal	X
aiua-12307	487	48	oncol	oncol	ADJ
aiua-12307	487	49	2022	2022	NUM
aiua-12307	487	50	;	;	PUNCT
aiua-12307	487	51	23	23	NUM
aiua-12307	487	52	:	:	PUNCT
aiua-12307	487	53	s1432	s1432	NOUN
aiua-12307	487	54	-	-	NOUN
aiua-12307	487	55	33	33	NUM
aiua-12307	487	56	.	.	PUNCT
aiua-12307	488	1	38	38	NUM
aiua-12307	488	2	.	.	PUNCT
aiua-12307	489	1	tacconi	tacconi	PROPN
aiua-12307	489	2	emc	emc	PROPN
aiua-12307	489	3	,	,	PUNCT
aiua-12307	489	4	tuthill	tuthill	NOUN
aiua-12307	489	5	m	m	PROPN
aiua-12307	489	6	,	,	PUNCT
aiua-12307	489	7	protheroe	protheroe	PROPN
aiua-12307	489	8	a.	a.	NOUN
aiua-12307	489	9	review	review	NOUN
aiua-12307	489	10	of	of	ADP
aiua-12307	489	11	adjuvant	adjuvant	ADJ
aiua-12307	489	12	therapies	therapy	NOUN
aiua-12307	489	13	in	in	ADP
aiua-12307	489	14	renal	renal	ADJ
aiua-12307	489	15	cell	cell	NOUN
aiua-12307	489	16	carcinoma	carcinoma	NOUN
aiua-12307	489	17	:	:	PUNCT
aiua-12307	489	18	evidence	evidence	NOUN
aiua-12307	489	19	to	to	ADP
aiua-12307	489	20	date	date	NOUN
aiua-12307	489	21	.	.	PUNCT
aiua-12307	490	1	onco	onco	NOUN
aiua-12307	490	2	targets	target	NOUN
aiua-12307	490	3	ther	ther	ADV
aiua-12307	490	4	.	.	PUNCT
aiua-12307	491	1	2020	2020	NUM
aiua-12307	491	2	;	;	PUNCT
aiua-12307	491	3	13:12301	13:12301	NUM
aiua-12307	491	4	-	-	SYM
aiua-12307	491	5	16	16	NUM
aiua-12307	491	6	.	.	PUNCT
aiua-12307	491	7	39	39	NUM
aiua-12307	491	8	.	.	PUNCT
aiua-12307	492	1	powles	powle	NOUN
aiua-12307	492	2	t	t	PROPN
aiua-12307	492	3	,	,	PUNCT
aiua-12307	492	4	tomczak	tomczak	NOUN
aiua-12307	492	5	p	p	NOUN
aiua-12307	492	6	,	,	PUNCT
aiua-12307	492	7	park	park	NOUN
aiua-12307	492	8	sh	sh	PROPN
aiua-12307	492	9	,	,	PUNCT
aiua-12307	492	10	et	et	PROPN
aiua-12307	492	11	al	al	PROPN
aiua-12307	492	12	.	.	PROPN
aiua-12307	492	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	492	14	versus	versus	ADP
aiua-12307	492	15	placebo	placebo	NOUN
aiua-12307	492	16	as	as	ADP
aiua-12307	492	17	post	post	ADJ
aiua-12307	492	18	-	-	ADJ
aiua-12307	492	19	nephrectomy	nephrectomy	ADJ
aiua-12307	492	20	adjuvant	adjuvant	ADJ
aiua-12307	492	21	therapy	therapy	NOUN
aiua-12307	492	22	for	for	ADP
aiua-12307	492	23	clear	clear	ADJ
aiua-12307	492	24	cell	cell	NOUN
aiua-12307	492	25	renal	renal	ADJ
aiua-12307	492	26	cell	cell	NOUN
aiua-12307	492	27	carcinoma	carcinoma	NOUN
aiua-12307	492	28	(	(	PUNCT
aiua-12307	492	29	keynote-564	keynote-564	NOUN
aiua-12307	492	30	):	):	PUNCT
aiua-12307	492	31	30	30	NUM
aiua-12307	492	32	-	-	PUNCT
aiua-12307	492	33	month	month	NOUN
aiua-12307	492	34	follow	follow	NOUN
aiua-12307	492	35	-	-	PUNCT
aiua-12307	492	36	up	up	NOUN
aiua-12307	492	37	analysis	analysis	NOUN
aiua-12307	492	38	of	of	ADP
aiua-12307	492	39	a	a	DET
aiua-12307	492	40	multicentre	multicentre	NOUN
aiua-12307	492	41	,	,	PUNCT
aiua-12307	492	42	randomised	randomise	VERB
aiua-12307	492	43	,	,	PUNCT
aiua-12307	492	44	double	double	ADJ
aiua-12307	492	45	-	-	PUNCT
aiua-12307	492	46	blind	blind	ADJ
aiua-12307	492	47	,	,	PUNCT
aiua-12307	492	48	placebo	placebo	NOUN
aiua-12307	492	49	-	-	PUNCT
aiua-12307	492	50	controlled	control	VERB
aiua-12307	492	51	,	,	PUNCT
aiua-12307	492	52	phase	phase	NOUN
aiua-12307	492	53	3	3	NUM
aiua-12307	492	54	trial	trial	NOUN
aiua-12307	492	55	.	.	PUNCT
aiua-12307	493	1	lancet	lancet	PROPN
aiua-12307	493	2	oncol	oncol	PROPN
aiua-12307	493	3	.	.	PUNCT
aiua-12307	494	1	2022	2022	NUM
aiua-12307	494	2	;	;	PUNCT
aiua-12307	494	3	23:1133	23:1133	NUM
aiua-12307	494	4	-	-	SYM
aiua-12307	494	5	44	44	NUM
aiua-12307	494	6	.	.	PUNCT
aiua-12307	495	1	40	40	NUM
aiua-12307	495	2	.	.	PUNCT
aiua-12307	495	3	choueiri	choueiri	NOUN
aiua-12307	495	4	tk	tk	PROPN
aiua-12307	495	5	,	,	PUNCT
aiua-12307	495	6	tomczak	tomczak	NOUN
aiua-12307	495	7	p	p	NOUN
aiua-12307	495	8	,	,	PUNCT
aiua-12307	495	9	park	park	NOUN
aiua-12307	495	10	sh	sh	PROPN
aiua-12307	495	11	,	,	PUNCT
aiua-12307	495	12	et	et	PROPN
aiua-12307	495	13	al	al	PROPN
aiua-12307	495	14	.	.	PROPN
aiua-12307	496	1	adjuvant	adjuvant	PROPN
aiua-12307	496	2	pembrolizumab	pembrolizumab	NOUN
aiua-12307	496	3	after	after	ADP
aiua-12307	496	4	nephrectomy	nephrectomy	NOUN
aiua-12307	496	5	in	in	ADP
aiua-12307	496	6	renal	renal	ADJ
aiua-12307	496	7	-	-	PUNCT
aiua-12307	496	8	cell	cell	NOUN
aiua-12307	496	9	carcinoma	carcinoma	NOUN
aiua-12307	496	10	.	.	PUNCT
aiua-12307	497	1	new	new	ADJ
aiua-12307	497	2	engl	engl	PROPN
aiua-12307	497	3	j	j	PROPN
aiua-12307	497	4	med	med	PROPN
aiua-12307	497	5	.	.	PROPN
aiua-12307	497	6	2021	2021	NUM
aiua-12307	497	7	;	;	PUNCT
aiua-12307	497	8	385:683	385:683	PROPN
aiua-12307	497	9	-	-	PUNCT
aiua-12307	497	10	94	94	NUM
aiua-12307	497	11	.	.	PUNCT
aiua-12307	498	1	41	41	NUM
aiua-12307	498	2	.	.	PUNCT
aiua-12307	499	1	fitzgerald	fitzgerald	PROPN
aiua-12307	499	2	kn	kn	PROPN
aiua-12307	499	3	,	,	PUNCT
aiua-12307	499	4	motzer	motzer	PROPN
aiua-12307	499	5	rj	rj	PROPN
aiua-12307	499	6	,	,	PUNCT
aiua-12307	499	7	lee	lee	PROPN
aiua-12307	499	8	c	c	PROPN
aiua-12307	499	9	-	-	PUNCT
aiua-12307	499	10	h.	h.	PROPN
aiua-12307	499	11	adjuvant	adjuvant	PROPN
aiua-12307	499	12	therapy	therapy	NOUN
aiua-12307	499	13	options	option	NOUN
aiua-12307	499	14	in	in	ADP
aiua-12307	499	15	renal	renal	ADJ
aiua-12307	499	16	cell	cell	NOUN
aiua-12307	499	17	carcinoma	carcinoma	NOUN
aiua-12307	499	18	—	—	PUNCT
aiua-12307	499	19	targeting	target	VERB
aiua-12307	499	20	the	the	DET
aiua-12307	499	21	metastatic	metastatic	ADJ
aiua-12307	499	22	cascade	cascade	NOUN
aiua-12307	499	23	.	.	PUNCT
aiua-12307	500	1	nat	nat	PROPN
aiua-12307	500	2	rev	rev	VERB
aiua-12307	500	3	urol	urol	PROPN
aiua-12307	500	4	.	.	PUNCT
aiua-12307	500	5	2023	2023	NUM
aiua-12307	500	6	;	;	PUNCT
aiua-12307	500	7	20:179	20:179	NUM
aiua-12307	500	8	-	-	SYM
aiua-12307	500	9	93	93	NUM
aiua-12307	500	10	.	.	PUNCT
aiua-12307	501	1	42	42	NUM
aiua-12307	501	2	.	.	PUNCT
aiua-12307	502	1	bex	bex	PROPN
aiua-12307	502	2	a	a	PRON
aiua-12307	502	3	,	,	PUNCT
aiua-12307	502	4	uzzo	uzzo	ADJ
aiua-12307	502	5	r	r	NOUN
aiua-12307	502	6	,	,	PUNCT
aiua-12307	502	7	karam	karam	PROPN
aiua-12307	502	8	j	j	PROPN
aiua-12307	502	9	,	,	PUNCT
aiua-12307	502	10	et	et	PROPN
aiua-12307	502	11	al	al	PROPN
aiua-12307	502	12	.	.	PUNCT
aiua-12307	503	1	lba66	lba66	PROPN
aiua-12307	503	2	immotion010	immotion010	PROPN
aiua-12307	503	3	:	:	PUNCT
aiua-12307	503	4	efficacy	efficacy	NOUN
aiua-12307	503	5	and	and	CCONJ
aiua-12307	503	6	safety	safety	NOUN
aiua-12307	503	7	from	from	ADP
aiua-12307	503	8	the	the	DET
aiua-12307	503	9	phase	phase	NOUN
aiua-12307	503	10	iii	iii	NUM
aiua-12307	503	11	study	study	NOUN
aiua-12307	503	12	of	of	ADP
aiua-12307	503	13	atezolizumab	atezolizumab	PROPN
aiua-12307	503	14	(	(	PUNCT
aiua-12307	503	15	atezo	atezo	PROPN
aiua-12307	503	16	)	)	PUNCT
aiua-12307	503	17	vs	vs	ADP
aiua-12307	503	18	placebo	placebo	NOUN
aiua-12307	503	19	(	(	PUNCT
aiua-12307	503	20	pbo	pbo	NOUN
aiua-12307	503	21	)	)	PUNCT
aiua-12307	503	22	as	as	ADP
aiua-12307	503	23	adjuvant	adjuvant	ADJ
aiua-12307	503	24	therapy	therapy	NOUN
aiua-12307	503	25	in	in	ADP
aiua-12307	503	26	patients	patient	NOUN
aiua-12307	503	27	with	with	ADP
aiua-12307	503	28	renal	renal	ADJ
aiua-12307	503	29	cell	cell	NOUN
aiua-12307	503	30	carcinoma	carcinoma	NOUN
aiua-12307	503	31	(	(	PUNCT
aiua-12307	503	32	rcc	rcc	PROPN
aiua-12307	503	33	)	)	PUNCT
aiua-12307	503	34	at	at	ADP
aiua-12307	503	35	increased	increase	VERB
aiua-12307	503	36	risk	risk	NOUN
aiua-12307	503	37	of	of	ADP
aiua-12307	503	38	recurrence	recurrence	NOUN
aiua-12307	503	39	after	after	ADP
aiua-12307	503	40	resection	resection	NOUN
aiua-12307	503	41	.	.	PUNCT
aiua-12307	504	1	ann	ann	PROPN
aiua-12307	504	2	oncol	oncol	PROPN
aiua-12307	504	3	.	.	PUNCT
aiua-12307	505	1	2022	2022	NUM
aiua-12307	505	2	;	;	PUNCT
aiua-12307	505	3	33	33	NUM
aiua-12307	505	4	:	:	PUNCT
aiua-12307	505	5	s1431	s1431	NOUN
aiua-12307	505	6	-	-	PUNCT
aiua-12307	505	7	s2	s2	NOUN
aiua-12307	505	8	.	.	PUNCT
aiua-12307	506	1	43	43	NUM
aiua-12307	506	2	.	.	PUNCT
aiua-12307	507	1	pal	pal	ADJ
aiua-12307	507	2	sk	sk	X
aiua-12307	507	3	,	,	PUNCT
aiua-12307	507	4	uzzo	uzzo	ADJ
aiua-12307	507	5	r	r	NOUN
aiua-12307	507	6	,	,	PUNCT
aiua-12307	507	7	karam	karam	PROPN
aiua-12307	507	8	ja	ja	PROPN
aiua-12307	507	9	,	,	PUNCT
aiua-12307	507	10	et	et	PROPN
aiua-12307	507	11	al	al	PROPN
aiua-12307	507	12	.	.	PROPN
aiua-12307	508	1	adjuvant	adjuvant	PROPN
aiua-12307	508	2	atezolizumab	atezolizumab	PROPN
aiua-12307	508	3	versus	versus	ADP
aiua-12307	508	4	archivio	archivio	NOUN
aiua-12307	508	5	italiano	italiano	X
aiua-12307	508	6	di	di	X
aiua-12307	508	7	urologia	urologia	PROPN
aiua-12307	508	8	e	e	PROPN
aiua-12307	508	9	andrologia	andrologia	NOUN
aiua-12307	508	10	2024	2024	NUM
aiua-12307	508	11	;	;	PUNCT
aiua-12307	508	12	96(2):12307	96(2):12307	NUM
aiua-12307	508	13	e.	e.	PROPN
aiua-12307	508	14	bosnali	bosnali	PROPN
aiua-12307	508	15	,	,	PUNCT
aiua-12307	508	16	e.	e.	PROPN
aiua-12307	508	17	malik	malik	PROPN
aiua-12307	508	18	akdas	akdas	PROPN
aiua-12307	508	19	,	,	PUNCT
aiua-12307	508	20	e.	e.	PROPN
aiua-12307	508	21	telli	telli	PROPN
aiua-12307	508	22	,	,	PUNCT
aiua-12307	508	23	k.	k.	PROPN
aiua-12307	508	24	teke	teke	PROPN
aiua-12307	508	25	,	,	PUNCT
aiua-12307	508	26	o.	o.	PROPN
aiua-12307	508	27	kara	kara	PROPN
aiua-12307	508	28	12	12	NUM
aiua-12307	508	29	placebo	placebo	NOUN
aiua-12307	508	30	for	for	ADP
aiua-12307	508	31	patients	patient	NOUN
aiua-12307	508	32	with	with	ADP
aiua-12307	508	33	renal	renal	ADJ
aiua-12307	508	34	cell	cell	NOUN
aiua-12307	508	35	carcinoma	carcinoma	NOUN
aiua-12307	508	36	at	at	ADP
aiua-12307	508	37	increased	increase	VERB
aiua-12307	508	38	risk	risk	NOUN
aiua-12307	508	39	of	of	ADP
aiua-12307	508	40	recurrence	recurrence	NOUN
aiua-12307	508	41	following	follow	VERB
aiua-12307	508	42	resection	resection	NOUN
aiua-12307	508	43	(	(	PUNCT
aiua-12307	508	44	immotion010	immotion010	PROPN
aiua-12307	508	45	):	):	PUNCT
aiua-12307	508	46	a	a	DET
aiua-12307	508	47	multicentre	multicentre	NOUN
aiua-12307	508	48	,	,	PUNCT
aiua-12307	508	49	randomised	randomise	VERB
aiua-12307	508	50	,	,	PUNCT
aiua-12307	508	51	double	double	ADJ
aiua-12307	508	52	-	-	PUNCT
aiua-12307	508	53	blind	blind	ADJ
aiua-12307	508	54	,	,	PUNCT
aiua-12307	508	55	phase	phase	NOUN
aiua-12307	508	56	3	3	NUM
aiua-12307	508	57	trial	trial	NOUN
aiua-12307	508	58	.	.	PUNCT
aiua-12307	509	1	lancet	lancet	NOUN
aiua-12307	509	2	2022	2022	NUM
aiua-12307	509	3	;	;	PUNCT
aiua-12307	509	4	400:1103	400:1103	X
aiua-12307	509	5	-	-	SYM
aiua-12307	509	6	16	16	NUM
aiua-12307	509	7	.	.	PUNCT
aiua-12307	509	8	44	44	NUM
aiua-12307	509	9	.	.	PUNCT
aiua-12307	510	1	bex	bex	PROPN
aiua-12307	510	2	a	a	PRON
aiua-12307	510	3	,	,	PUNCT
aiua-12307	510	4	russo	russo	PROPN
aiua-12307	510	5	p	p	X
aiua-12307	510	6	,	,	PUNCT
aiua-12307	510	7	tomita	tomita	PROPN
aiua-12307	510	8	y	y	PROPN
aiua-12307	510	9	,	,	PUNCT
aiua-12307	510	10	et	et	PROPN
aiua-12307	510	11	al	al	PROPN
aiua-12307	510	12	.	.	PUNCT
aiua-12307	511	1	a	a	DET
aiua-12307	511	2	phase	phase	NOUN
aiua-12307	511	3	iii	iii	NOUN
aiua-12307	511	4	,	,	PUNCT
aiua-12307	511	5	randomized	randomize	VERB
aiua-12307	511	6	,	,	PUNCT
aiua-12307	511	7	placebo	placebo	NOUN
aiua-12307	511	8	-	-	PUNCT
aiua-12307	511	9	controlled	control	VERB
aiua-12307	511	10	trial	trial	NOUN
aiua-12307	511	11	of	of	ADP
aiua-12307	511	12	nivolumab	nivolumab	NOUN
aiua-12307	511	13	or	or	CCONJ
aiua-12307	511	14	nivolumab	nivolumab	NOUN
aiua-12307	511	15	plus	plus	CCONJ
aiua-12307	511	16	ipilimumab	ipilimumab	VERB
aiua-12307	511	17	in	in	ADP
aiua-12307	511	18	patients	patient	NOUN
aiua-12307	511	19	with	with	ADP
aiua-12307	511	20	localized	localized	ADJ
aiua-12307	511	21	renal	renal	ADJ
aiua-12307	511	22	cell	cell	NOUN
aiua-12307	511	23	carcinoma	carcinoma	NOUN
aiua-12307	511	24	at	at	ADP
aiua-12307	511	25	high	high	ADJ
aiua-12307	511	26	-	-	PUNCT
aiua-12307	511	27	risk	risk	NOUN
aiua-12307	511	28	of	of	ADP
aiua-12307	511	29	relapse	relapse	NOUN
aiua-12307	511	30	after	after	ADP
aiua-12307	511	31	radical	radical	ADJ
aiua-12307	511	32	or	or	CCONJ
aiua-12307	511	33	partial	partial	ADJ
aiua-12307	511	34	nephrectomy	nephrectomy	NOUN
aiua-12307	511	35	(	(	PUNCT
aiua-12307	511	36	checkmate	checkmate	VERB
aiua-12307	511	37	914	914	NUM
aiua-12307	511	38	)	)	PUNCT
aiua-12307	511	39	.	.	PUNCT
aiua-12307	512	1	j	j	PROPN
aiua-12307	512	2	clin	clin	PROPN
aiua-12307	512	3	oncol	oncol	PROPN
aiua-12307	512	4	2018	2018	NUM
aiua-12307	512	5	;	;	PUNCT
aiua-12307	512	6	29	29	NUM
aiua-12307	512	7	(	(	PUNCT
aiua-12307	512	8	suppl	suppl	ADJ
aiua-12307	512	9	8):viii330	8):viii330	PROPN
aiua-12307	512	10	.	.	PROPN
aiua-12307	513	1	45	45	NUM
aiua-12307	513	2	.	.	PUNCT
aiua-12307	513	3	motzer	motzer	PROPN
aiua-12307	513	4	rj	rj	PROPN
aiua-12307	513	5	,	,	PUNCT
aiua-12307	513	6	russo	russo	PROPN
aiua-12307	513	7	p	p	X
aiua-12307	513	8	,	,	PUNCT
aiua-12307	513	9	grunwald	grunwald	PROPN
aiua-12307	513	10	v	v	PROPN
aiua-12307	513	11	,	,	PUNCT
aiua-12307	513	12	et	et	PROPN
aiua-12307	513	13	al	al	PROPN
aiua-12307	513	14	.	.	PROPN
aiua-12307	514	1	adjuvant	adjuvant	PROPN
aiua-12307	514	2	nivolumab	nivolumab	ADV
aiua-12307	514	3	plus	plus	CCONJ
aiua-12307	514	4	ipilimumab	ipilimumab	VERB
aiua-12307	514	5	versus	versus	ADP
aiua-12307	514	6	placebo	placebo	NOUN
aiua-12307	514	7	for	for	ADP
aiua-12307	514	8	localised	localise	VERB
aiua-12307	514	9	renal	renal	ADJ
aiua-12307	514	10	cell	cell	NOUN
aiua-12307	514	11	carcinoma	carcinoma	NOUN
aiua-12307	514	12	after	after	ADP
aiua-12307	514	13	nephrectomy	nephrectomy	NOUN
aiua-12307	514	14	(	(	PUNCT
aiua-12307	514	15	checkmate	checkmate	VERB
aiua-12307	514	16	914	914	NUM
aiua-12307	514	17	):	):	PUNCT
aiua-12307	514	18	a	a	DET
aiua-12307	514	19	double	double	ADJ
aiua-12307	514	20	-	-	PUNCT
aiua-12307	514	21	blind	blind	ADJ
aiua-12307	514	22	,	,	PUNCT
aiua-12307	514	23	randomised	randomise	VERB
aiua-12307	514	24	,	,	PUNCT
aiua-12307	514	25	phase	phase	NOUN
aiua-12307	514	26	3	3	NUM
aiua-12307	514	27	trial	trial	NOUN
aiua-12307	514	28	.	.	PUNCT
aiua-12307	515	1	lancet	lancet	PROPN
aiua-12307	515	2	2023	2023	NUM
aiua-12307	515	3	;	;	PUNCT
aiua-12307	515	4	401:821	401:821	NOUN
aiua-12307	515	5	-	-	PUNCT
aiua-12307	515	6	32	32	NUM
aiua-12307	515	7	.	.	PUNCT
aiua-12307	515	8	46	46	NUM
aiua-12307	515	9	.	.	PUNCT
aiua-12307	516	1	motzer	motzer	NOUN
aiua-12307	516	2	r	r	NOUN
aiua-12307	516	3	,	,	PUNCT
aiua-12307	516	4	russo	russo	NOUN
aiua-12307	516	5	p	p	X
aiua-12307	516	6	,	,	PUNCT
aiua-12307	516	7	gruenwald	gruenwald	NOUN
aiua-12307	516	8	v	v	NOUN
aiua-12307	516	9	,	,	PUNCT
aiua-12307	516	10	et	et	PROPN
aiua-12307	516	11	al	al	PROPN
aiua-12307	516	12	.	.	PUNCT
aiua-12307	516	13	lba4	lba4	PROPN
aiua-12307	516	14	adjuvant	adjuvant	ADJ
aiua-12307	516	15	nivolumab	nivolumab	ADP
aiua-12307	516	16	plus	plus	CCONJ
aiua-12307	516	17	ipilimumab	ipilimumab	NOUN
aiua-12307	516	18	(	(	PUNCT
aiua-12307	516	19	nivo+	nivo+	X
aiua-12307	516	20	ipi	ipi	PROPN
aiua-12307	516	21	)	)	PUNCT
aiua-12307	516	22	vs	vs	ADP
aiua-12307	516	23	placebo	placebo	NOUN
aiua-12307	516	24	(	(	PUNCT
aiua-12307	516	25	pbo	pbo	NOUN
aiua-12307	516	26	)	)	PUNCT
aiua-12307	516	27	for	for	ADP
aiua-12307	516	28	localized	localized	ADJ
aiua-12307	516	29	renal	renal	ADJ
aiua-12307	516	30	cell	cell	NOUN
aiua-12307	516	31	carcinoma	carcinoma	NOUN
aiua-12307	516	32	(	(	PUNCT
aiua-12307	516	33	rcc	rcc	PROPN
aiua-12307	516	34	)	)	PUNCT
aiua-12307	516	35	at	at	ADP
aiua-12307	516	36	high	high	ADJ
aiua-12307	516	37	risk	risk	NOUN
aiua-12307	516	38	of	of	ADP
aiua-12307	516	39	relapse	relapse	NOUN
aiua-12307	516	40	after	after	ADP
aiua-12307	516	41	nephrectomy	nephrectomy	NOUN
aiua-12307	516	42	:	:	PUNCT
aiua-12307	516	43	results	result	NOUN
aiua-12307	516	44	from	from	ADP
aiua-12307	516	45	the	the	DET
aiua-12307	516	46	randomized	randomized	ADJ
aiua-12307	516	47	,	,	PUNCT
aiua-12307	516	48	phase	phase	NOUN
aiua-12307	516	49	iii	iii	NUM
aiua-12307	516	50	checkmate	checkmate	VERB
aiua-12307	516	51	914	914	NUM
aiua-12307	516	52	trial	trial	NOUN
aiua-12307	516	53	.	.	PUNCT
aiua-12307	517	1	ann	ann	PROPN
aiua-12307	517	2	oncol	oncol	PROPN
aiua-12307	517	3	.	.	PUNCT
aiua-12307	518	1	2022	2022	NUM
aiua-12307	518	2	;	;	PUNCT
aiua-12307	518	3	33	33	NUM
aiua-12307	518	4	:	:	PUNCT
aiua-12307	518	5	s1430	s1430	PROPN
aiua-12307	518	6	.	.	PROPN
aiua-12307	519	1	47	47	NUM
aiua-12307	519	2	.	.	PUNCT
aiua-12307	520	1	motzer	motzer	PROPN
aiua-12307	520	2	rj	rj	PROPN
aiua-12307	520	3	,	,	PUNCT
aiua-12307	520	4	jonasch	jonasch	PROPN
aiua-12307	520	5	e	e	PROPN
aiua-12307	520	6	,	,	PUNCT
aiua-12307	520	7	agarwal	agarwal	PROPN
aiua-12307	520	8	n	n	CCONJ
aiua-12307	520	9	,	,	PUNCT
aiua-12307	520	10	et	et	PROPN
aiua-12307	520	11	al	al	PROPN
aiua-12307	520	12	.	.	PROPN
aiua-12307	520	13	kidney	kidney	PROPN
aiua-12307	520	14	cancer	cancer	NOUN
aiua-12307	520	15	,	,	PUNCT
aiua-12307	520	16	version	version	NOUN
aiua-12307	520	17	3.2022	3.2022	NUM
aiua-12307	520	18	,	,	PUNCT
aiua-12307	520	19	nccn	nccn	ADJ
aiua-12307	520	20	clinical	clinical	ADJ
aiua-12307	520	21	practice	practice	NOUN
aiua-12307	520	22	guidelines	guideline	NOUN
aiua-12307	520	23	in	in	ADP
aiua-12307	520	24	oncology	oncology	NOUN
aiua-12307	520	25	.	.	PUNCT
aiua-12307	521	1	j	j	PROPN
aiua-12307	521	2	natl	natl	PROPN
aiua-12307	521	3	compr	compr	PROPN
aiua-12307	521	4	canc	canc	PROPN
aiua-12307	521	5	netw	netw	PROPN
aiua-12307	521	6	2022	2022	NUM
aiua-12307	521	7	;	;	PUNCT
aiua-12307	521	8	20:71	20:71	NUM
aiua-12307	521	9	-	-	SYM
aiua-12307	521	10	90	90	NUM
aiua-12307	521	11	.	.	PUNCT
aiua-12307	521	12	48	48	NUM
aiua-12307	521	13	.	.	PUNCT
aiua-12307	522	1	ljungberg	ljungberg	PROPN
aiua-12307	522	2	b	b	PROPN
aiua-12307	522	3	,	,	PUNCT
aiua-12307	522	4	albiges	albige	NOUN
aiua-12307	522	5	l	l	NOUN
aiua-12307	522	6	,	,	PUNCT
aiua-12307	522	7	abu	abu	PROPN
aiua-12307	522	8	-	-	PUNCT
aiua-12307	522	9	ghanem	ghanem	PROPN
aiua-12307	522	10	y	y	PROPN
aiua-12307	522	11	,	,	PUNCT
aiua-12307	522	12	et	et	PROPN
aiua-12307	522	13	al	al	PROPN
aiua-12307	522	14	.	.	PROPN
aiua-12307	523	1	european	european	PROPN
aiua-12307	523	2	association	association	PROPN
aiua-12307	523	3	of	of	ADP
aiua-12307	523	4	urology	urology	NOUN
aiua-12307	523	5	guidelines	guideline	NOUN
aiua-12307	523	6	on	on	ADP
aiua-12307	523	7	renal	renal	ADJ
aiua-12307	523	8	cell	cell	NOUN
aiua-12307	523	9	carcinoma	carcinoma	NOUN
aiua-12307	523	10	:	:	PUNCT
aiua-12307	523	11	the	the	DET
aiua-12307	523	12	2022	2022	NUM
aiua-12307	523	13	update	update	NOUN
aiua-12307	523	14	.	.	PUNCT
aiua-12307	524	1	eur	eur	PROPN
aiua-12307	524	2	urol	urol	PROPN
aiua-12307	524	3	.	.	PUNCT
aiua-12307	524	4	2022	2022	NUM
aiua-12307	524	5	;	;	PUNCT
aiua-12307	524	6	82:399	82:399	NUM
aiua-12307	524	7	-	-	SYM
aiua-12307	524	8	410	410	NUM
aiua-12307	524	9	.	.	PUNCT
aiua-12307	524	10	49	49	NUM
aiua-12307	524	11	.	.	PUNCT
aiua-12307	525	1	fitzgerald	fitzgerald	PROPN
aiua-12307	525	2	kn	kn	PROPN
aiua-12307	525	3	,	,	PUNCT
aiua-12307	525	4	lee	lee	PROPN
aiua-12307	525	5	ch	ch	PROPN
aiua-12307	525	6	.	.	PUNCT
aiua-12307	526	1	personalizing	personalize	VERB
aiua-12307	526	2	first	first	ADJ
aiua-12307	526	3	-	-	PUNCT
aiua-12307	526	4	line	line	NOUN
aiua-12307	526	5	management	management	NOUN
aiua-12307	526	6	of	of	ADP
aiua-12307	526	7	metastatic	metastatic	ADJ
aiua-12307	526	8	renal	renal	ADJ
aiua-12307	526	9	cell	cell	NOUN
aiua-12307	526	10	carcinoma	carcinoma	NOUN
aiua-12307	526	11	:	:	PUNCT
aiua-12307	526	12	leveraging	leverage	VERB
aiua-12307	526	13	current	current	ADJ
aiua-12307	526	14	and	and	CCONJ
aiua-12307	526	15	novel	novel	ADJ
aiua-12307	526	16	therapeutic	therapeutic	ADJ
aiua-12307	526	17	options	option	NOUN
aiua-12307	526	18	.	.	PUNCT
aiua-12307	527	1	j	j	PROPN
aiua-12307	527	2	natl	natl	PROPN
aiua-12307	527	3	compr	compr	PROPN
aiua-12307	527	4	canc	canc	PROPN
aiua-12307	527	5	netw	netw	PROPN
aiua-12307	527	6	2022	2022	NUM
aiua-12307	527	7	;	;	PUNCT
aiua-12307	527	8	20(13	20(13	NUM
aiua-12307	527	9	)	)	PUNCT
aiua-12307	527	10	.	.	PUNCT
aiua-12307	528	1	50	50	NUM
aiua-12307	528	2	.	.	X
aiua-12307	528	3	motzer	motzer	PROPN
aiua-12307	528	4	rj	rj	PROPN
aiua-12307	528	5	,	,	PUNCT
aiua-12307	528	6	escudier	escudier	PROPN
aiua-12307	528	7	b	b	PROPN
aiua-12307	528	8	,	,	PUNCT
aiua-12307	528	9	mcdermott	mcdermott	PROPN
aiua-12307	528	10	df	df	PROPN
aiua-12307	528	11	,	,	PUNCT
aiua-12307	528	12	et	et	PROPN
aiua-12307	528	13	al	al	PROPN
aiua-12307	528	14	.	.	PROPN
aiua-12307	528	15	nivolumab	nivolumab	PROPN
aiua-12307	528	16	versus	versus	ADP
aiua-12307	528	17	everolimus	everolimus	NOUN
aiua-12307	528	18	in	in	ADP
aiua-12307	528	19	advanced	advanced	ADJ
aiua-12307	528	20	renal	renal	ADJ
aiua-12307	528	21	-	-	PUNCT
aiua-12307	528	22	cell	cell	NOUN
aiua-12307	528	23	carcinoma	carcinoma	NOUN
aiua-12307	528	24	.	.	PUNCT
aiua-12307	529	1	new	new	ADJ
aiua-12307	529	2	engl	engl	PROPN
aiua-12307	529	3	j	j	PROPN
aiua-12307	529	4	med	med	PROPN
aiua-12307	529	5	2015	2015	NUM
aiua-12307	529	6	;	;	PUNCT
aiua-12307	529	7	373:1803	373:1803	NUM
aiua-12307	529	8	-	-	SYM
aiua-12307	529	9	13	13	NUM
aiua-12307	529	10	.	.	PUNCT
aiua-12307	530	1	51	51	NUM
aiua-12307	530	2	.	.	PUNCT
aiua-12307	530	3	mcdermott	mcdermott	PROPN
aiua-12307	530	4	df	df	PROPN
aiua-12307	530	5	,	,	PUNCT
aiua-12307	530	6	lee	lee	PROPN
aiua-12307	530	7	j	j	PROPN
aiua-12307	530	8	-	-	PROPN
aiua-12307	530	9	l	l	PROPN
aiua-12307	530	10	,	,	PUNCT
aiua-12307	530	11	bjarnason	bjarnason	PROPN
aiua-12307	530	12	ga	ga	PROPN
aiua-12307	530	13	,	,	PUNCT
aiua-12307	530	14	et	et	PROPN
aiua-12307	530	15	al	al	PROPN
aiua-12307	530	16	.	.	PROPN
aiua-12307	531	1	open	open	ADJ
aiua-12307	531	2	-	-	PUNCT
aiua-12307	531	3	label	label	NOUN
aiua-12307	531	4	,	,	PUNCT
aiua-12307	531	5	singlearm	singlearm	ADJ
aiua-12307	531	6	phase	phase	NOUN
aiua-12307	531	7	ii	ii	PROPN
aiua-12307	531	8	study	study	NOUN
aiua-12307	531	9	of	of	ADP
aiua-12307	531	10	pembrolizumab	pembrolizumab	NOUN
aiua-12307	531	11	monotherapy	monotherapy	NOUN
aiua-12307	531	12	as	as	ADP
aiua-12307	531	13	first	first	ADJ
aiua-12307	531	14	-	-	PUNCT
aiua-12307	531	15	line	line	NOUN
aiua-12307	531	16	therapy	therapy	NOUN
aiua-12307	531	17	in	in	ADP
aiua-12307	531	18	patients	patient	NOUN
aiua-12307	531	19	with	with	ADP
aiua-12307	531	20	advanced	advanced	ADJ
aiua-12307	531	21	clear	clear	ADJ
aiua-12307	531	22	cell	cell	NOUN
aiua-12307	531	23	renal	renal	ADJ
aiua-12307	531	24	cell	cell	NOUN
aiua-12307	531	25	carcinoma	carcinoma	NOUN
aiua-12307	531	26	.	.	PUNCT
aiua-12307	532	1	j	j	PROPN
aiua-12307	532	2	clin	clin	PROPN
aiua-12307	532	3	oncol	oncol	PROPN
aiua-12307	532	4	2021	2021	NUM
aiua-12307	532	5	;	;	PUNCT
aiua-12307	532	6	39:1020	39:1020	NUM
aiua-12307	532	7	.	.	PROPN
aiua-12307	532	8	52	52	NUM
aiua-12307	532	9	.	.	PUNCT
aiua-12307	533	1	vogelzang	vogelzang	PROPN
aiua-12307	533	2	nj	nj	PROPN
aiua-12307	533	3	,	,	PUNCT
aiua-12307	533	4	olsen	olsen	PROPN
aiua-12307	533	5	mr	mr	PROPN
aiua-12307	533	6	,	,	PUNCT
aiua-12307	533	7	mcfarlane	mcfarlane	PROPN
aiua-12307	533	8	jj	jj	PROPN
aiua-12307	533	9	,	,	PUNCT
aiua-12307	533	10	et	et	PROPN
aiua-12307	533	11	al	al	PROPN
aiua-12307	533	12	.	.	PROPN
aiua-12307	533	13	safety	safety	NOUN
aiua-12307	533	14	and	and	CCONJ
aiua-12307	533	15	efficacy	efficacy	NOUN
aiua-12307	533	16	of	of	ADP
aiua-12307	533	17	nivolumab	nivolumab	NOUN
aiua-12307	533	18	in	in	ADP
aiua-12307	533	19	patients	patient	NOUN
aiua-12307	533	20	with	with	ADP
aiua-12307	533	21	advanced	advanced	ADJ
aiua-12307	533	22	non	non	ADJ
aiua-12307	533	23	–	–	ADJ
aiua-12307	533	24	clear	clear	ADJ
aiua-12307	533	25	cell	cell	NOUN
aiua-12307	533	26	renal	renal	ADJ
aiua-12307	533	27	cell	cell	NOUN
aiua-12307	533	28	carcinoma	carcinoma	NOUN
aiua-12307	533	29	:	:	PUNCT
aiua-12307	533	30	results	result	NOUN
aiua-12307	533	31	from	from	ADP
aiua-12307	533	32	the	the	DET
aiua-12307	533	33	phase	phase	NOUN
aiua-12307	533	34	iiib	iiib	NOUN
aiua-12307	533	35	/	/	SYM
aiua-12307	533	36	iv	iv	NOUN
aiua-12307	533	37	checkmate	checkmate	VERB
aiua-12307	533	38	374	374	NUM
aiua-12307	533	39	study	study	NOUN
aiua-12307	533	40	.	.	PUNCT
aiua-12307	534	1	clin	clin	PROPN
aiua-12307	534	2	genitourin	genitourin	PROPN
aiua-12307	534	3	cancer	cancer	NOUN
aiua-12307	534	4	.	.	PUNCT
aiua-12307	535	1	2020	2020	NUM
aiua-12307	535	2	;	;	PUNCT
aiua-12307	535	3	18:461	18:461	NUM
aiua-12307	535	4	-	-	SYM
aiua-12307	535	5	8	8	NUM
aiua-12307	535	6	.	.	PUNCT
aiua-12307	536	1	e3	e3	NOUN
aiua-12307	536	2	.	.	PUNCT
aiua-12307	537	1	53	53	NUM
aiua-12307	537	2	.	.	PUNCT
aiua-12307	538	1	kadowaki	kadowaki	PROPN
aiua-12307	538	2	n.	n.	PROPN
aiua-12307	539	1	[	[	X
aiua-12307	539	2	combination	combination	NOUN
aiua-12307	539	3	of	of	ADP
aiua-12307	539	4	targeted	target	VERB
aiua-12307	539	5	therapy	therapy	NOUN
aiua-12307	539	6	and	and	CCONJ
aiua-12307	539	7	immunotherapy	immunotherapy	NOUN
aiua-12307	539	8	for	for	ADP
aiua-12307	539	9	cancer	cancer	NOUN
aiua-12307	539	10	]	]	PUNCT
aiua-12307	539	11	.	.	PUNCT
aiua-12307	540	1	gan	gan	PROPN
aiua-12307	540	2	to	to	ADP
aiua-12307	540	3	kagaku	kagaku	PROPN
aiua-12307	540	4	ryoho	ryoho	PROPN
aiua-12307	540	5	.	.	PUNCT
aiua-12307	541	1	2015	2015	NUM
aiua-12307	541	2	;	;	PUNCT
aiua-12307	541	3	42:1046	42:1046	NUM
aiua-12307	541	4	-	-	SYM
aiua-12307	541	5	9	9	NUM
aiua-12307	541	6	.	.	NUM
aiua-12307	542	1	54	54	NUM
aiua-12307	542	2	.	.	PUNCT
aiua-12307	543	1	rathmell	rathmell	PROPN
aiua-12307	543	2	wk	wk	PROPN
aiua-12307	543	3	,	,	PUNCT
aiua-12307	543	4	rumble	rumble	ADJ
aiua-12307	543	5	rb	rb	NOUN
aiua-12307	543	6	,	,	PUNCT
aiua-12307	543	7	van	van	PROPN
aiua-12307	543	8	veldhuizen	veldhuizen	NOUN
aiua-12307	543	9	pj	pj	PROPN
aiua-12307	543	10	,	,	PUNCT
aiua-12307	543	11	et	et	PROPN
aiua-12307	543	12	al	al	PROPN
aiua-12307	543	13	.	.	PUNCT
aiua-12307	543	14	management	management	NOUN
aiua-12307	543	15	of	of	ADP
aiua-12307	543	16	metastatic	metastatic	ADJ
aiua-12307	543	17	clear	clear	ADJ
aiua-12307	543	18	cell	cell	NOUN
aiua-12307	543	19	renal	renal	ADJ
aiua-12307	543	20	cell	cell	NOUN
aiua-12307	543	21	carcinoma	carcinoma	NOUN
aiua-12307	543	22	:	:	PUNCT
aiua-12307	543	23	asco	asco	PROPN
aiua-12307	543	24	guideline	guideline	NOUN
aiua-12307	543	25	.	.	PUNCT
aiua-12307	544	1	j	j	PROPN
aiua-12307	544	2	clin	clin	PROPN
aiua-12307	544	3	oncol	oncol	PROPN
aiua-12307	544	4	2022	2022	NUM
aiua-12307	544	5	;	;	PUNCT
aiua-12307	544	6	40:2957	40:2957	NOUN
aiua-12307	544	7	-	-	SYM
aiua-12307	544	8	95	95	NUM
aiua-12307	544	9	.	.	PUNCT
aiua-12307	545	1	55	55	NUM
aiua-12307	545	2	.	.	PUNCT
aiua-12307	546	1	motzer	motzer	NOUN
aiua-12307	546	2	r	r	NOUN
aiua-12307	546	3	,	,	PUNCT
aiua-12307	546	4	alekseev	alekseev	PROPN
aiua-12307	546	5	b	b	PROPN
aiua-12307	546	6	,	,	PUNCT
aiua-12307	546	7	rha	rha	PROPN
aiua-12307	546	8	sy	sy	PROPN
aiua-12307	546	9	,	,	PUNCT
aiua-12307	546	10	et	et	PROPN
aiua-12307	546	11	al	al	PROPN
aiua-12307	546	12	.	.	PROPN
aiua-12307	546	13	lenvatinib	lenvatinib	PROPN
aiua-12307	546	14	plus	plus	CCONJ
aiua-12307	546	15	pembrolizumab	pembrolizumab	NOUN
aiua-12307	546	16	or	or	CCONJ
aiua-12307	546	17	everolimus	everolimus	NOUN
aiua-12307	546	18	for	for	ADP
aiua-12307	546	19	advanced	advanced	ADJ
aiua-12307	546	20	renal	renal	ADJ
aiua-12307	546	21	cell	cell	NOUN
aiua-12307	546	22	carcinoma	carcinoma	NOUN
aiua-12307	546	23	.	.	PUNCT
aiua-12307	547	1	new	new	ADJ
aiua-12307	547	2	engl	engl	PROPN
aiua-12307	547	3	j	j	PROPN
aiua-12307	547	4	med	med	PROPN
aiua-12307	547	5	.	.	PROPN
aiua-12307	547	6	2021	2021	NUM
aiua-12307	547	7	;	;	PUNCT
aiua-12307	548	1	384:1289	384:1289	NUM
aiua-12307	548	2	-	-	SYM
aiua-12307	548	3	300	300	NUM
aiua-12307	548	4	.	.	PUNCT
aiua-12307	549	1	56	56	NUM
aiua-12307	549	2	.	.	PUNCT
aiua-12307	549	3	motzer	motzer	PROPN
aiua-12307	549	4	rj	rj	PROPN
aiua-12307	549	5	,	,	PUNCT
aiua-12307	549	6	tannir	tannir	PROPN
aiua-12307	549	7	nm	nm	PROPN
aiua-12307	549	8	,	,	PUNCT
aiua-12307	549	9	mcdermott	mcdermott	PROPN
aiua-12307	549	10	df	df	PROPN
aiua-12307	549	11	,	,	PUNCT
aiua-12307	549	12	et	et	PROPN
aiua-12307	549	13	al	al	PROPN
aiua-12307	549	14	.	.	PROPN
aiua-12307	549	15	nivolumab	nivolumab	PROPN
aiua-12307	549	16	plus	plus	CCONJ
aiua-12307	549	17	ipilimumab	ipilimumab	X
aiua-12307	549	18	versus	versus	ADP
aiua-12307	549	19	sunitinib	sunitinib	NOUN
aiua-12307	549	20	in	in	ADP
aiua-12307	549	21	advanced	advanced	ADJ
aiua-12307	549	22	renal	renal	ADJ
aiua-12307	549	23	-	-	PUNCT
aiua-12307	549	24	cell	cell	NOUN
aiua-12307	549	25	carcinoma	carcinoma	NOUN
aiua-12307	549	26	.	.	PUNCT
aiua-12307	550	1	new	new	ADJ
aiua-12307	550	2	engl	engl	PROPN
aiua-12307	550	3	j	j	PROPN
aiua-12307	550	4	med	med	PROPN
aiua-12307	550	5	.	.	PROPN
aiua-12307	550	6	2018	2018	NUM
aiua-12307	550	7	;	;	PUNCT
aiua-12307	550	8	378:1277	378:1277	NUM
aiua-12307	550	9	-	-	SYM
aiua-12307	550	10	90	90	NUM
aiua-12307	550	11	.	.	PUNCT
aiua-12307	551	1	57	57	NUM
aiua-12307	551	2	.	.	PUNCT
aiua-12307	552	1	rini	rini	PROPN
aiua-12307	552	2	bi	bi	PROPN
aiua-12307	552	3	,	,	PUNCT
aiua-12307	552	4	plimack	plimack	NOUN
aiua-12307	552	5	er	er	INTJ
aiua-12307	552	6	,	,	PUNCT
aiua-12307	552	7	stus	stus	PROPN
aiua-12307	552	8	v	v	PROPN
aiua-12307	552	9	,	,	PUNCT
aiua-12307	552	10	et	et	PROPN
aiua-12307	552	11	al	al	PROPN
aiua-12307	552	12	.	.	PROPN
aiua-12307	552	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	552	14	plus	plus	CCONJ
aiua-12307	552	15	axitinib	axitinib	NOUN
aiua-12307	552	16	versus	versus	ADP
aiua-12307	552	17	sunitinib	sunitinib	NOUN
aiua-12307	552	18	for	for	ADP
aiua-12307	552	19	advanced	advanced	ADJ
aiua-12307	552	20	renal	renal	ADJ
aiua-12307	552	21	-	-	PUNCT
aiua-12307	552	22	cell	cell	NOUN
aiua-12307	552	23	carcinoma	carcinoma	NOUN
aiua-12307	552	24	.	.	PUNCT
aiua-12307	553	1	new	new	ADJ
aiua-12307	553	2	engl	engl	PROPN
aiua-12307	553	3	j	j	PROPN
aiua-12307	553	4	med	med	PROPN
aiua-12307	553	5	.	.	PROPN
aiua-12307	553	6	2019	2019	NUM
aiua-12307	553	7	;	;	PUNCT
aiua-12307	553	8	380:1116	380:1116	NUM
aiua-12307	553	9	-	-	SYM
aiua-12307	553	10	27	27	NUM
aiua-12307	553	11	.	.	PUNCT
aiua-12307	554	1	58	58	NUM
aiua-12307	554	2	.	.	PUNCT
aiua-12307	554	3	choueiri	choueiri	PROPN
aiua-12307	554	4	tk	tk	PROPN
aiua-12307	554	5	,	,	PUNCT
aiua-12307	554	6	powles	powle	VERB
aiua-12307	554	7	t	t	PROPN
aiua-12307	554	8	,	,	PUNCT
aiua-12307	554	9	burotto	burotto	NOUN
aiua-12307	554	10	m	m	PROPN
aiua-12307	554	11	,	,	PUNCT
aiua-12307	554	12	et	et	PROPN
aiua-12307	554	13	al	al	PROPN
aiua-12307	554	14	.	.	PROPN
aiua-12307	554	15	nivolumab	nivolumab	PROPN
aiua-12307	554	16	plus	plus	CCONJ
aiua-12307	554	17	cabozantinib	cabozantinib	NOUN
aiua-12307	554	18	versus	versus	ADP
aiua-12307	554	19	sunitinib	sunitinib	NOUN
aiua-12307	554	20	for	for	ADP
aiua-12307	554	21	advanced	advanced	ADJ
aiua-12307	554	22	renal	renal	ADJ
aiua-12307	554	23	-	-	PUNCT
aiua-12307	554	24	cell	cell	NOUN
aiua-12307	554	25	carcinoma.new	carcinoma.new	PART
aiua-12307	554	26	engl	engl	PROPN
aiua-12307	554	27	j	j	PROPN
aiua-12307	554	28	med	med	PROPN
aiua-12307	554	29	.	.	PROPN
aiua-12307	554	30	2021	2021	NUM
aiua-12307	554	31	;	;	PUNCT
aiua-12307	554	32	384:829	384:829	NUM
aiua-12307	554	33	-	-	SYM
aiua-12307	554	34	41	41	NUM
aiua-12307	554	35	.	.	PUNCT
aiua-12307	555	1	59	59	NUM
aiua-12307	555	2	.	.	PUNCT
aiua-12307	556	1	ljungberg	ljungberg	PROPN
aiua-12307	556	2	b	b	PROPN
aiua-12307	556	3	,	,	PUNCT
aiua-12307	556	4	albiges	albige	NOUN
aiua-12307	556	5	l	l	NOUN
aiua-12307	556	6	,	,	PUNCT
aiua-12307	556	7	bedke	bedke	PROPN
aiua-12307	556	8	j	j	PROPN
aiua-12307	556	9	,	,	PUNCT
aiua-12307	556	10	et	et	PROPN
aiua-12307	556	11	al	al	PROPN
aiua-12307	556	12	.	.	PUNCT
aiua-12307	557	1	eau	eau	PROPN
aiua-12307	557	2	guidelines	guideline	NOUN
aiua-12307	557	3	on	on	ADP
aiua-12307	557	4	renal	renal	ADJ
aiua-12307	557	5	cell	cell	NOUN
aiua-12307	557	6	carcinoma	carcinoma	NOUN
aiua-12307	557	7	.	.	PUNCT
aiua-12307	558	1	limited	limited	ADJ
aiua-12307	558	2	march	march	PROPN
aiua-12307	558	3	2023	2023	NUM
aiua-12307	558	4	ed	ed	NOUN
aiua-12307	558	5	.	.	PUNCT
aiua-12307	558	6	arnhem	arnhem	PROPN
aiua-12307	558	7	,	,	PUNCT
aiua-12307	558	8	the	the	DET
aiua-12307	558	9	netherlands	netherlands	PROPN
aiua-12307	558	10	.	.	PUNCT
aiua-12307	558	11	:	:	PUNCT
aiua-12307	559	1	eau	eau	PROPN
aiua-12307	559	2	guidelines	guideline	VERB
aiua-12307	559	3	office	office	NOUN
aiua-12307	559	4	;	;	PUNCT
aiua-12307	559	5	2023	2023	NUM
aiua-12307	559	6	;	;	PUNCT
aiua-12307	559	7	p.	p.	NOUN
aiua-12307	559	8	29	29	NUM
aiua-12307	559	9	-	-	SYM
aiua-12307	559	10	62	62	NUM
aiua-12307	559	11	.	.	PUNCT
aiua-12307	560	1	60	60	NUM
aiua-12307	560	2	.	.	PUNCT
aiua-12307	561	1	climent	climent	PROPN
aiua-12307	561	2	c	c	X
aiua-12307	561	3	,	,	PUNCT
aiua-12307	561	4	soriano	soriano	PROPN
aiua-12307	561	5	s	s	PROPN
aiua-12307	561	6	,	,	PUNCT
aiua-12307	561	7	bonfill	bonfill	PROPN
aiua-12307	561	8	t	t	PROPN
aiua-12307	561	9	,	,	PUNCT
aiua-12307	561	10	et	et	PROPN
aiua-12307	561	11	al	al	PROPN
aiua-12307	561	12	.	.	PUNCT
aiua-12307	562	1	the	the	DET
aiua-12307	562	2	role	role	NOUN
aiua-12307	562	3	of	of	ADP
aiua-12307	562	4	immunotherapy	immunotherapy	NOUN
aiua-12307	562	5	in	in	ADP
aiua-12307	562	6	non	non	ADJ
aiua-12307	562	7	-	-	ADJ
aiua-12307	562	8	clear	clear	ADJ
aiua-12307	562	9	cell	cell	NOUN
aiua-12307	562	10	renal	renal	ADJ
aiua-12307	562	11	cell	cell	NOUN
aiua-12307	562	12	carcinoma	carcinoma	NOUN
aiua-12307	562	13	.	.	PUNCT
aiua-12307	563	1	front	front	ADJ
aiua-12307	563	2	oncol	oncol	ADJ
aiua-12307	563	3	.	.	PUNCT
aiua-12307	564	1	2023	2023	NUM
aiua-12307	564	2	;	;	PUNCT
aiua-12307	564	3	13:941835	13:941835	NUM
aiua-12307	564	4	.	.	PUNCT
aiua-12307	565	1	61	61	NUM
aiua-12307	565	2	.	.	PUNCT
aiua-12307	566	1	bergmann	bergmann	PROPN
aiua-12307	566	2	l	l	PROPN
aiua-12307	566	3	,	,	PUNCT
aiua-12307	566	4	weber	weber	PROPN
aiua-12307	566	5	s	s	PROPN
aiua-12307	566	6	,	,	PUNCT
aiua-12307	566	7	hartmann	hartmann	PROPN
aiua-12307	566	8	a	a	PROPN
aiua-12307	566	9	,	,	PUNCT
aiua-12307	566	10	ahrens	ahrens	PROPN
aiua-12307	566	11	m.	m.	NOUN
aiua-12307	566	12	pathology	pathology	NOUN
aiua-12307	566	13	and	and	CCONJ
aiua-12307	566	14	systemic	systemic	ADJ
aiua-12307	566	15	therapy	therapy	NOUN
aiua-12307	566	16	of	of	ADP
aiua-12307	566	17	non	non	ADJ
aiua-12307	566	18	-	-	ADJ
aiua-12307	566	19	clear	clear	ADJ
aiua-12307	566	20	cell	cell	NOUN
aiua-12307	566	21	renal	renal	ADJ
aiua-12307	566	22	cell	cell	NOUN
aiua-12307	566	23	carcinoma	carcinoma	NOUN
aiua-12307	566	24	:	:	PUNCT
aiua-12307	566	25	an	an	DET
aiua-12307	566	26	overview	overview	NOUN
aiua-12307	566	27	.	.	PUNCT
aiua-12307	567	1	expert	expert	NOUN
aiua-12307	567	2	rev	rev	PROPN
aiua-12307	567	3	anticancer	anticancer	NOUN
aiua-12307	567	4	ther	ther	ADV
aiua-12307	567	5	.	.	PUNCT
aiua-12307	568	1	2021	2021	NUM
aiua-12307	568	2	;	;	PUNCT
aiua-12307	568	3	21:1273	21:1273	NUM
aiua-12307	568	4	-	-	SYM
aiua-12307	568	5	86	86	NUM
aiua-12307	568	6	.	.	PUNCT
aiua-12307	569	1	62	62	NUM
aiua-12307	569	2	.	.	PUNCT
aiua-12307	570	1	liu	liu	PROPN
aiua-12307	570	2	k	k	PROPN
aiua-12307	570	3	,	,	PUNCT
aiua-12307	570	4	qin	qin	PROPN
aiua-12307	571	1	z	z	X
aiua-12307	571	2	,	,	PUNCT
aiua-12307	571	3	xu	xu	PROPN
aiua-12307	571	4	x	x	PROPN
aiua-12307	571	5	,	,	PUNCT
aiua-12307	571	6	et	et	PROPN
aiua-12307	571	7	al	al	PROPN
aiua-12307	571	8	.	.	PROPN
aiua-12307	571	9	comparative	comparative	ADJ
aiua-12307	571	10	risk	risk	NOUN
aiua-12307	571	11	of	of	ADP
aiua-12307	571	12	renal	renal	ADJ
aiua-12307	571	13	adverse	adverse	ADJ
aiua-12307	571	14	events	event	NOUN
aiua-12307	571	15	in	in	ADP
aiua-12307	571	16	patients	patient	NOUN
aiua-12307	571	17	receiving	receive	VERB
aiua-12307	571	18	immune	immune	ADJ
aiua-12307	571	19	checkpoint	checkpoint	NOUN
aiua-12307	571	20	inhibitors	inhibitor	NOUN
aiua-12307	571	21	:	:	PUNCT
aiua-12307	571	22	a	a	DET
aiua-12307	571	23	bayesian	bayesian	NOUN
aiua-12307	571	24	network	network	NOUN
aiua-12307	571	25	meta	meta	ADJ
aiua-12307	571	26	-	-	PUNCT
aiua-12307	571	27	analysis	analysis	NOUN
aiua-12307	571	28	.	.	PUNCT
aiua-12307	572	1	front	front	ADJ
aiua-12307	572	2	oncol	oncol	ADJ
aiua-12307	572	3	.	.	PUNCT
aiua-12307	573	1	2021	2021	NUM
aiua-12307	573	2	;	;	PUNCT
aiua-12307	574	1	11:662731	11:662731	NUM
aiua-12307	574	2	.	.	PROPN
aiua-12307	574	3	63	63	NUM
aiua-12307	574	4	.	.	PUNCT
aiua-12307	575	1	sung	sung	PROPN
aiua-12307	575	2	h	h	PROPN
aiua-12307	575	3	,	,	PUNCT
aiua-12307	575	4	ferlay	ferlay	PROPN
aiua-12307	575	5	j	j	PROPN
aiua-12307	575	6	,	,	PUNCT
aiua-12307	575	7	siegel	siegel	PROPN
aiua-12307	575	8	rl	rl	PROPN
aiua-12307	575	9	,	,	PUNCT
aiua-12307	575	10	et	et	PROPN
aiua-12307	575	11	al	al	PROPN
aiua-12307	575	12	.	.	PUNCT
aiua-12307	576	1	global	global	ADJ
aiua-12307	576	2	cancer	cancer	NOUN
aiua-12307	576	3	statistics	statistic	NOUN
aiua-12307	576	4	2020	2020	NUM
aiua-12307	576	5	:	:	PUNCT
aiua-12307	576	6	globocan	globocan	PROPN
aiua-12307	576	7	estimates	estimate	NOUN
aiua-12307	576	8	of	of	ADP
aiua-12307	576	9	incidence	incidence	NOUN
aiua-12307	576	10	and	and	CCONJ
aiua-12307	576	11	mortality	mortality	NOUN
aiua-12307	576	12	worldwide	worldwide	ADV
aiua-12307	576	13	for	for	ADP
aiua-12307	576	14	36	36	NUM
aiua-12307	576	15	cancers	cancer	NOUN
aiua-12307	576	16	in	in	ADP
aiua-12307	576	17	185	185	NUM
aiua-12307	576	18	countries	country	NOUN
aiua-12307	576	19	.	.	PUNCT
aiua-12307	577	1	ca	can	AUX
aiua-12307	577	2	cancer	cancer	PROPN
aiua-12307	577	3	j	j	PROPN
aiua-12307	577	4	clin	clin	PROPN
aiua-12307	577	5	.	.	PUNCT
aiua-12307	578	1	2021	2021	NUM
aiua-12307	578	2	;	;	PUNCT
aiua-12307	578	3	71:209	71:209	NUM
aiua-12307	578	4	-	-	SYM
aiua-12307	578	5	49	49	NUM
aiua-12307	578	6	.	.	PUNCT
aiua-12307	579	1	64	64	NUM
aiua-12307	579	2	.	.	PUNCT
aiua-12307	579	3	welch	welch	PROPN
aiua-12307	579	4	hg	hg	PROPN
aiua-12307	579	5	,	,	PUNCT
aiua-12307	579	6	albertsen	albertsen	VERB
aiua-12307	579	7	pc	pc	NOUN
aiua-12307	579	8	.	.	PUNCT
aiua-12307	580	1	prostate	prostate	NOUN
aiua-12307	580	2	cancer	cancer	NOUN
aiua-12307	580	3	diagnosis	diagnosis	NOUN
aiua-12307	580	4	and	and	CCONJ
aiua-12307	580	5	treatment	treatment	NOUN
aiua-12307	580	6	after	after	ADP
aiua-12307	580	7	the	the	DET
aiua-12307	580	8	introduction	introduction	NOUN
aiua-12307	580	9	of	of	ADP
aiua-12307	580	10	prostate	prostate	NOUN
aiua-12307	580	11	-	-	PUNCT
aiua-12307	580	12	specific	specific	ADJ
aiua-12307	580	13	antigen	antigen	NOUN
aiua-12307	580	14	screening	screening	NOUN
aiua-12307	580	15	:	:	PUNCT
aiua-12307	580	16	1986	1986	NUM
aiua-12307	580	17	-	-	SYM
aiua-12307	580	18	2005	2005	NUM
aiua-12307	580	19	.	.	PUNCT
aiua-12307	581	1	j	j	PROPN
aiua-12307	581	2	natl	natl	PROPN
aiua-12307	581	3	cancer	cancer	PROPN
aiua-12307	581	4	inst	inst	PROPN
aiua-12307	581	5	.	.	PUNCT
aiua-12307	581	6	2009	2009	NUM
aiua-12307	581	7	;	;	PUNCT
aiua-12307	581	8	101:1325	101:1325	NUM
aiua-12307	581	9	-	-	SYM
aiua-12307	581	10	9	9	NUM
aiua-12307	581	11	.	.	NOUN
aiua-12307	581	12	65	65	NUM
aiua-12307	581	13	.	.	PUNCT
aiua-12307	582	1	bratt	bratt	PROPN
aiua-12307	582	2	o	o	PROPN
aiua-12307	582	3	,	,	PUNCT
aiua-12307	582	4	drevin	drevin	PROPN
aiua-12307	582	5	l	l	PROPN
aiua-12307	582	6	,	,	PUNCT
aiua-12307	582	7	akre	akre	ADJ
aiua-12307	582	8	o	o	NOUN
aiua-12307	582	9	,	,	PUNCT
aiua-12307	582	10	et	et	PROPN
aiua-12307	582	11	al	al	PROPN
aiua-12307	582	12	.	.	PUNCT
aiua-12307	582	13	family	family	NOUN
aiua-12307	582	14	history	history	NOUN
aiua-12307	582	15	and	and	CCONJ
aiua-12307	582	16	probability	probability	NOUN
aiua-12307	582	17	of	of	ADP
aiua-12307	582	18	prostate	prostate	NOUN
aiua-12307	582	19	cancer	cancer	NOUN
aiua-12307	582	20	,	,	PUNCT
aiua-12307	582	21	differentiated	differentiate	VERB
aiua-12307	582	22	by	by	ADP
aiua-12307	582	23	risk	risk	NOUN
aiua-12307	582	24	category	category	NOUN
aiua-12307	582	25	:	:	PUNCT
aiua-12307	582	26	a	a	DET
aiua-12307	582	27	nationwide	nationwide	ADJ
aiua-12307	582	28	population	population	NOUN
aiua-12307	582	29	-	-	PUNCT
aiua-12307	582	30	based	base	VERB
aiua-12307	582	31	study	study	NOUN
aiua-12307	582	32	.	.	PUNCT
aiua-12307	583	1	j	j	PROPN
aiua-12307	583	2	natl	natl	PROPN
aiua-12307	583	3	cancer	cancer	PROPN
aiua-12307	583	4	inst	inst	PROPN
aiua-12307	583	5	.	.	PROPN
aiua-12307	583	6	2016	2016	NUM
aiua-12307	583	7	;	;	PUNCT
aiua-12307	583	8	108	108	NUM
aiua-12307	583	9	:	:	PUNCT
aiua-12307	583	10	djw110	djw110	PROPN
aiua-12307	583	11	.	.	PROPN
aiua-12307	584	1	66	66	NUM
aiua-12307	584	2	.	.	PUNCT
aiua-12307	585	1	krstev	krstev	PROPN
aiua-12307	585	2	s	s	PROPN
aiua-12307	585	3	,	,	PUNCT
aiua-12307	585	4	knutsson	knutsson	PROPN
aiua-12307	585	5	a.	a.	PROPN
aiua-12307	585	6	occupational	occupational	ADJ
aiua-12307	585	7	risk	risk	NOUN
aiua-12307	585	8	factors	factor	NOUN
aiua-12307	585	9	for	for	ADP
aiua-12307	585	10	prostate	prostate	NOUN
aiua-12307	585	11	cancer	cancer	NOUN
aiua-12307	585	12	:	:	PUNCT
aiua-12307	585	13	a	a	DET
aiua-12307	585	14	meta	meta	ADJ
aiua-12307	585	15	-	-	PUNCT
aiua-12307	585	16	analysis	analysis	NOUN
aiua-12307	585	17	.	.	PUNCT
aiua-12307	586	1	j	j	PROPN
aiua-12307	586	2	cancer	cancer	NOUN
aiua-12307	586	3	prev	prev	PROPN
aiua-12307	586	4	.	.	PROPN
aiua-12307	586	5	2019	2019	NUM
aiua-12307	586	6	;	;	PUNCT
aiua-12307	586	7	24:91	24:91	NUM
aiua-12307	586	8	-	-	SYM
aiua-12307	586	9	111	111	NUM
aiua-12307	586	10	.	.	PUNCT
aiua-12307	586	11	67	67	NUM
aiua-12307	586	12	.	.	PUNCT
aiua-12307	587	1	campi	campi	VERB
aiua-12307	587	2	r	r	NOUN
aiua-12307	587	3	,	,	PUNCT
aiua-12307	587	4	brookman	brookman	NOUN
aiua-12307	587	5	-	-	PUNCT
aiua-12307	587	6	may	may	PROPN
aiua-12307	587	7	sd	sd	NOUN
aiua-12307	587	8	,	,	PUNCT
aiua-12307	587	9	subiela	subiela	PROPN
aiua-12307	587	10	henriquez	henriquez	PROPN
aiua-12307	587	11	jd	jd	PROPN
aiua-12307	587	12	,	,	PUNCT
aiua-12307	587	13	et	et	PROPN
aiua-12307	587	14	al	al	PROPN
aiua-12307	587	15	.	.	PROPN
aiua-12307	587	16	impact	impact	NOUN
aiua-12307	587	17	of	of	ADP
aiua-12307	587	18	metabolic	metabolic	NOUN
aiua-12307	587	19	diseases	disease	NOUN
aiua-12307	587	20	,	,	PUNCT
aiua-12307	587	21	drugs	drug	NOUN
aiua-12307	587	22	,	,	PUNCT
aiua-12307	587	23	and	and	CCONJ
aiua-12307	587	24	dietary	dietary	ADJ
aiua-12307	587	25	factors	factor	NOUN
aiua-12307	587	26	on	on	ADP
aiua-12307	587	27	prostate	prostate	NOUN
aiua-12307	587	28	cancer	cancer	NOUN
aiua-12307	587	29	risk	risk	NOUN
aiua-12307	587	30	,	,	PUNCT
aiua-12307	587	31	recurrence	recurrence	NOUN
aiua-12307	587	32	,	,	PUNCT
aiua-12307	587	33	and	and	CCONJ
aiua-12307	587	34	survival	survival	NOUN
aiua-12307	587	35	:	:	PUNCT
aiua-12307	587	36	a	a	DET
aiua-12307	587	37	systematic	systematic	ADJ
aiua-12307	587	38	review	review	NOUN
aiua-12307	587	39	by	by	ADP
aiua-12307	587	40	the	the	DET
aiua-12307	587	41	european	european	PROPN
aiua-12307	587	42	association	association	PROPN
aiua-12307	587	43	of	of	ADP
aiua-12307	587	44	urology	urology	NOUN
aiua-12307	587	45	section	section	NOUN
aiua-12307	587	46	of	of	ADP
aiua-12307	587	47	oncological	oncological	ADJ
aiua-12307	587	48	urology	urology	NOUN
aiua-12307	587	49	.	.	PUNCT
aiua-12307	588	1	eur	eur	PROPN
aiua-12307	588	2	urol	urol	PROPN
aiua-12307	588	3	focus	focus	NOUN
aiua-12307	588	4	.	.	PUNCT
aiua-12307	589	1	2019	2019	NUM
aiua-12307	589	2	;	;	PUNCT
aiua-12307	589	3	5:1029	5:1029	NUM
aiua-12307	589	4	-	-	SYM
aiua-12307	589	5	57	57	NUM
aiua-12307	589	6	.	.	PUNCT
aiua-12307	590	1	68	68	NUM
aiua-12307	590	2	.	.	PUNCT
aiua-12307	591	1	bilusic	bilusic	PROPN
aiua-12307	591	2	m	m	PROPN
aiua-12307	591	3	,	,	PUNCT
aiua-12307	591	4	madan	madan	PROPN
aiua-12307	591	5	ra	ra	PROPN
aiua-12307	591	6	,	,	PUNCT
aiua-12307	591	7	gulley	gulley	PROPN
aiua-12307	591	8	jl	jl	PROPN
aiua-12307	591	9	.	.	PUNCT
aiua-12307	592	1	immunotherapy	immunotherapy	NOUN
aiua-12307	592	2	of	of	ADP
aiua-12307	592	3	prostate	prostate	NOUN
aiua-12307	592	4	cancer	cancer	NOUN
aiua-12307	592	5	:	:	PUNCT
aiua-12307	592	6	facts	fact	NOUN
aiua-12307	592	7	and	and	CCONJ
aiua-12307	592	8	hopes	hope	NOUN
aiua-12307	592	9	.	.	PUNCT
aiua-12307	593	1	clin	clin	PROPN
aiua-12307	593	2	cancer	cancer	NOUN
aiua-12307	593	3	res	re	NOUN
aiua-12307	593	4	.	.	PROPN
aiua-12307	593	5	2017	2017	NUM
aiua-12307	593	6	;	;	PUNCT
aiua-12307	593	7	23:6764	23:6764	NUM
aiua-12307	593	8	-	-	SYM
aiua-12307	593	9	70	70	NUM
aiua-12307	593	10	.	.	PUNCT
aiua-12307	594	1	69	69	NUM
aiua-12307	594	2	.	.	PUNCT
aiua-12307	595	1	kantoff	kantoff	PROPN
aiua-12307	595	2	pw	pw	PROPN
aiua-12307	595	3	,	,	PUNCT
aiua-12307	595	4	higano	higano	NOUN
aiua-12307	595	5	cs	cs	PROPN
aiua-12307	595	6	,	,	PUNCT
aiua-12307	595	7	shore	shore	PROPN
aiua-12307	595	8	nd	nd	NUM
aiua-12307	595	9	,	,	PUNCT
aiua-12307	595	10	et	et	PROPN
aiua-12307	595	11	al	al	PROPN
aiua-12307	595	12	.	.	PROPN
aiua-12307	595	13	sipuleucel	sipuleucel	PROPN
aiua-12307	595	14	-	-	PUNCT
aiua-12307	595	15	t	t	NOUN
aiua-12307	595	16	immunotherapy	immunotherapy	NOUN
aiua-12307	595	17	for	for	ADP
aiua-12307	595	18	castration	castration	NOUN
aiua-12307	595	19	-	-	PUNCT
aiua-12307	595	20	resistant	resistant	ADJ
aiua-12307	595	21	prostate	prostate	NOUN
aiua-12307	595	22	cancer	cancer	NOUN
aiua-12307	595	23	.	.	PUNCT
aiua-12307	596	1	new	new	ADJ
aiua-12307	596	2	engl	engl	PROPN
aiua-12307	596	3	j	j	PROPN
aiua-12307	596	4	med	med	PROPN
aiua-12307	596	5	.	.	PUNCT
aiua-12307	596	6	2010	2010	NUM
aiua-12307	596	7	;	;	PUNCT
aiua-12307	596	8	363:411	363:411	NOUN
aiua-12307	596	9	-	-	SYM
aiua-12307	596	10	22	22	NUM
aiua-12307	596	11	.	.	PUNCT
aiua-12307	597	1	70	70	NUM
aiua-12307	597	2	.	.	PUNCT
aiua-12307	598	1	kwon	kwon	PROPN
aiua-12307	598	2	ed	ed	PROPN
aiua-12307	598	3	,	,	PUNCT
aiua-12307	598	4	drake	drake	PROPN
aiua-12307	598	5	cg	cg	PROPN
aiua-12307	598	6	,	,	PUNCT
aiua-12307	598	7	scher	scher	PROPN
aiua-12307	598	8	hi	hi	PROPN
aiua-12307	598	9	,	,	PUNCT
aiua-12307	598	10	et	et	PROPN
aiua-12307	598	11	al	al	PROPN
aiua-12307	598	12	.	.	PROPN
aiua-12307	598	13	ipilimumab	ipilimumab	PROPN
aiua-12307	598	14	versus	versus	ADP
aiua-12307	598	15	placebo	placebo	NOUN
aiua-12307	598	16	after	after	ADP
aiua-12307	598	17	radiotherapy	radiotherapy	NOUN
aiua-12307	598	18	in	in	ADP
aiua-12307	598	19	patients	patient	NOUN
aiua-12307	598	20	with	with	ADP
aiua-12307	598	21	metastatic	metastatic	ADJ
aiua-12307	598	22	castration	castration	NOUN
aiua-12307	598	23	-	-	PUNCT
aiua-12307	598	24	resistant	resistant	ADJ
aiua-12307	598	25	prostate	prostate	NOUN
aiua-12307	598	26	cancer	cancer	NOUN
aiua-12307	598	27	that	that	PRON
aiua-12307	598	28	had	have	AUX
aiua-12307	598	29	progressed	progress	VERB
aiua-12307	598	30	after	after	SCONJ
aiua-12307	598	31	docetaxel	docetaxel	NOUN
aiua-12307	598	32	chemotherapy	chemotherapy	NOUN
aiua-12307	598	33	(	(	PUNCT
aiua-12307	598	34	ca184	ca184	PROPN
aiua-12307	598	35	-	-	PUNCT
aiua-12307	598	36	043	043	NUM
aiua-12307	598	37	):	):	PUNCT
aiua-12307	598	38	a	a	DET
aiua-12307	598	39	multicentre	multicentre	NOUN
aiua-12307	598	40	,	,	PUNCT
aiua-12307	598	41	randomised	randomise	VERB
aiua-12307	598	42	,	,	PUNCT
aiua-12307	598	43	double	double	ADJ
aiua-12307	598	44	-	-	PUNCT
aiua-12307	598	45	blind	blind	ADJ
aiua-12307	598	46	,	,	PUNCT
aiua-12307	598	47	phase	phase	NOUN
aiua-12307	598	48	3	3	NUM
aiua-12307	598	49	trial	trial	NOUN
aiua-12307	598	50	.	.	PUNCT
aiua-12307	599	1	lancet	lancet	PROPN
aiua-12307	599	2	oncol	oncol	PROPN
aiua-12307	599	3	.	.	PUNCT
aiua-12307	600	1	2014	2014	NUM
aiua-12307	600	2	;	;	PUNCT
aiua-12307	600	3	15:700	15:700	NUM
aiua-12307	600	4	-	-	SYM
aiua-12307	600	5	12	12	NUM
aiua-12307	600	6	.	.	PUNCT
aiua-12307	601	1	71	71	NUM
aiua-12307	601	2	.	.	PUNCT
aiua-12307	601	3	markowski	markowski	PROPN
aiua-12307	601	4	mc	mc	PROPN
aiua-12307	601	5	,	,	PUNCT
aiua-12307	601	6	shenderov	shenderov	NOUN
aiua-12307	601	7	e	e	NOUN
aiua-12307	601	8	,	,	PUNCT
aiua-12307	601	9	eisenberger	eisenberger	PROPN
aiua-12307	601	10	ma	ma	PROPN
aiua-12307	601	11	,	,	PUNCT
aiua-12307	601	12	et	et	PROPN
aiua-12307	601	13	al	al	PROPN
aiua-12307	601	14	.	.	PUNCT
aiua-12307	602	1	extreme	extreme	ADJ
aiua-12307	602	2	responses	response	NOUN
aiua-12307	602	3	to	to	ADP
aiua-12307	602	4	immune	immune	ADJ
aiua-12307	602	5	checkpoint	checkpoint	NOUN
aiua-12307	602	6	blockade	blockade	NOUN
aiua-12307	602	7	following	follow	VERB
aiua-12307	602	8	bipolar	bipolar	ADJ
aiua-12307	602	9	androgen	androgen	NOUN
aiua-12307	602	10	therapy	therapy	NOUN
aiua-12307	602	11	and	and	CCONJ
aiua-12307	602	12	enzalutamide	enzalutamide	ADV
aiua-12307	602	13	in	in	ADP
aiua-12307	602	14	patients	patient	NOUN
aiua-12307	602	15	with	with	ADP
aiua-12307	602	16	metastatic	metastatic	ADJ
aiua-12307	602	17	castration	castration	NOUN
aiua-12307	602	18	resistant	resistant	ADJ
aiua-12307	602	19	prostate	prostate	NOUN
aiua-12307	602	20	cancer	cancer	NOUN
aiua-12307	602	21	.	.	PUNCT
aiua-12307	603	1	prostate	prostate	NOUN
aiua-12307	603	2	.	.	PUNCT
aiua-12307	604	1	2020	2020	NUM
aiua-12307	604	2	;	;	PUNCT
aiua-12307	604	3	80:407	80:407	NUM
aiua-12307	604	4	-	-	SYM
aiua-12307	604	5	11	11	NUM
aiua-12307	604	6	.	.	PUNCT
aiua-12307	605	1	72	72	NUM
aiua-12307	605	2	.	.	PUNCT
aiua-12307	605	3	fellner	fellner	PROPN
aiua-12307	605	4	c.	c.	PROPN
aiua-12307	605	5	ipilimumab	ipilimumab	PROPN
aiua-12307	605	6	(	(	PUNCT
aiua-12307	605	7	yervoy	yervoy	NOUN
aiua-12307	605	8	)	)	PUNCT
aiua-12307	605	9	prolongs	prolong	VERB
aiua-12307	605	10	survival	survival	NOUN
aiua-12307	605	11	in	in	ADP
aiua-12307	605	12	advanced	advanced	ADJ
aiua-12307	605	13	melanoma	melanoma	NOUN
aiua-12307	605	14	:	:	PUNCT
aiua-12307	605	15	serious	serious	ADJ
aiua-12307	605	16	side	side	NOUN
aiua-12307	605	17	effects	effect	NOUN
aiua-12307	605	18	and	and	CCONJ
aiua-12307	605	19	a	a	DET
aiua-12307	605	20	hefty	hefty	ADJ
aiua-12307	605	21	price	price	NOUN
aiua-12307	605	22	tag	tag	NOUN
aiua-12307	605	23	may	may	AUX
aiua-12307	605	24	limit	limit	VERB
aiua-12307	605	25	its	its	PRON
aiua-12307	605	26	use	use	NOUN
aiua-12307	605	27	.	.	PUNCT
aiua-12307	606	1	p.t	p.t	PROPN
aiua-12307	606	2	.	.	PROPN
aiua-12307	606	3	2012	2012	NUM
aiua-12307	606	4	;	;	PUNCT
aiua-12307	606	5	37:503	37:503	NUM
aiua-12307	606	6	-	-	SYM
aiua-12307	606	7	30	30	NUM
aiua-12307	606	8	.	.	PUNCT
aiua-12307	607	1	73	73	NUM
aiua-12307	607	2	.	.	PUNCT
aiua-12307	608	1	small	small	ADJ
aiua-12307	608	2	ej	ej	PROPN
aiua-12307	608	3	,	,	PUNCT
aiua-12307	608	4	tchekmedyian	tchekmedyian	PROPN
aiua-12307	608	5	ns	ns	PROPN
aiua-12307	608	6	,	,	PUNCT
aiua-12307	608	7	rini	rini	PROPN
aiua-12307	608	8	bi	bi	PROPN
aiua-12307	608	9	,	,	PUNCT
aiua-12307	608	10	et	et	PROPN
aiua-12307	608	11	al	al	PROPN
aiua-12307	608	12	.	.	PUNCT
aiua-12307	609	1	a	a	DET
aiua-12307	609	2	pilot	pilot	NOUN
aiua-12307	609	3	trial	trial	NOUN
aiua-12307	609	4	of	of	ADP
aiua-12307	609	5	ctla4	ctla4	NOUN
aiua-12307	609	6	blockade	blockade	NOUN
aiua-12307	609	7	with	with	ADP
aiua-12307	609	8	human	human	ADJ
aiua-12307	609	9	anti	anti	NOUN
aiua-12307	609	10	-	-	NOUN
aiua-12307	609	11	ctla-4	ctla-4	NOUN
aiua-12307	609	12	in	in	ADP
aiua-12307	609	13	patients	patient	NOUN
aiua-12307	609	14	with	with	ADP
aiua-12307	609	15	hormonerefractory	hormonerefractory	ADJ
aiua-12307	609	16	prostate	prostate	NOUN
aiua-12307	609	17	cancer	cancer	NOUN
aiua-12307	609	18	.	.	PUNCT
aiua-12307	610	1	clin	clin	PROPN
aiua-12307	610	2	cancer	cancer	NOUN
aiua-12307	610	3	res	re	NOUN
aiua-12307	610	4	2007	2007	NUM
aiua-12307	610	5	;	;	PUNCT
aiua-12307	610	6	13:1810	13:1810	NUM
aiua-12307	610	7	-	-	SYM
aiua-12307	610	8	5	5	NUM
aiua-12307	610	9	.	.	NOUN
aiua-12307	610	10	74	74	NUM
aiua-12307	610	11	.	.	PUNCT
aiua-12307	610	12	mcneel	mcneel	PROPN
aiua-12307	610	13	dg	dg	PROPN
aiua-12307	610	14	,	,	PUNCT
aiua-12307	610	15	smith	smith	PROPN
aiua-12307	610	16	ha	ha	PROPN
aiua-12307	610	17	,	,	PUNCT
aiua-12307	610	18	eickhoff	eickhoff	PROPN
aiua-12307	610	19	jc	jc	PROPN
aiua-12307	610	20	,	,	PUNCT
aiua-12307	610	21	et	et	PROPN
aiua-12307	610	22	al	al	PROPN
aiua-12307	610	23	.	.	PROPN
aiua-12307	610	24	phase	phase	NOUN
aiua-12307	610	25	i	i	PRON
aiua-12307	610	26	trial	trial	NOUN
aiua-12307	610	27	of	of	ADP
aiua-12307	610	28	tremelimumab	tremelimumab	NOUN
aiua-12307	610	29	in	in	ADP
aiua-12307	610	30	combination	combination	NOUN
aiua-12307	610	31	with	with	ADP
aiua-12307	610	32	short	short	ADJ
aiua-12307	610	33	-	-	PUNCT
aiua-12307	610	34	term	term	NOUN
aiua-12307	610	35	androgen	androgen	NOUN
aiua-12307	610	36	deprivation	deprivation	NOUN
aiua-12307	610	37	in	in	ADP
aiua-12307	610	38	patients	patient	NOUN
aiua-12307	610	39	with	with	ADP
aiua-12307	610	40	psa	psa	NOUN
aiua-12307	610	41	-	-	PUNCT
aiua-12307	610	42	recurrent	recurrent	NOUN
aiua-12307	610	43	prostate	prostate	NOUN
aiua-12307	610	44	cancer	cancer	NOUN
aiua-12307	610	45	.	.	PUNCT
aiua-12307	611	1	cancer	cancer	NOUN
aiua-12307	611	2	immunol	immunol	PROPN
aiua-12307	611	3	immunother	immunother	PROPN
aiua-12307	611	4	.	.	PUNCT
aiua-12307	612	1	2012	2012	NUM
aiua-12307	612	2	;	;	PUNCT
aiua-12307	612	3	61:1137	61:1137	NUM
aiua-12307	612	4	-	-	SYM
aiua-12307	612	5	47	47	NUM
aiua-12307	612	6	.	.	PUNCT
aiua-12307	613	1	75	75	NUM
aiua-12307	613	2	.	.	PUNCT
aiua-12307	613	3	jochems	jochem	NOUN
aiua-12307	613	4	c	c	VERB
aiua-12307	613	5	,	,	PUNCT
aiua-12307	613	6	tucker	tucker	PROPN
aiua-12307	613	7	ja	ja	PROPN
aiua-12307	613	8	,	,	PUNCT
aiua-12307	613	9	tsang	tsang	PROPN
aiua-12307	613	10	ky	ky	PROPN
aiua-12307	613	11	,	,	PUNCT
aiua-12307	613	12	et	et	PROPN
aiua-12307	613	13	al	al	PROPN
aiua-12307	613	14	.	.	PUNCT
aiua-12307	614	1	a	a	DET
aiua-12307	614	2	combination	combination	NOUN
aiua-12307	614	3	trial	trial	NOUN
aiua-12307	614	4	of	of	ADP
aiua-12307	614	5	vaccine	vaccine	NOUN
aiua-12307	614	6	plus	plus	CCONJ
aiua-12307	614	7	ipilimumab	ipilimumab	VERB
aiua-12307	614	8	in	in	ADP
aiua-12307	614	9	metastatic	metastatic	ADJ
aiua-12307	614	10	castration	castration	NOUN
aiua-12307	614	11	-	-	PUNCT
aiua-12307	614	12	resistant	resistant	ADJ
aiua-12307	614	13	prostate	prostate	NOUN
aiua-12307	614	14	cancer	cancer	NOUN
aiua-12307	614	15	patients	patient	NOUN
aiua-12307	614	16	:	:	PUNCT
aiua-12307	614	17	immune	immune	ADJ
aiua-12307	614	18	correlates	correlate	VERB
aiua-12307	614	19	.	.	PUNCT
aiua-12307	615	1	cancer	cancer	NOUN
aiua-12307	615	2	immunol	immunol	PROPN
aiua-12307	615	3	immunother	immunother	PROPN
aiua-12307	615	4	.	.	PUNCT
aiua-12307	616	1	2014	2014	NUM
aiua-12307	616	2	;	;	PUNCT
aiua-12307	616	3	63:407	63:407	NUM
aiua-12307	616	4	-	-	SYM
aiua-12307	616	5	18	18	NUM
aiua-12307	616	6	.	.	PUNCT
aiua-12307	616	7	76	76	NUM
aiua-12307	616	8	.	.	PUNCT
aiua-12307	617	1	hegde	hegde	PROPN
aiua-12307	617	2	a	a	PROPN
aiua-12307	617	3	,	,	PUNCT
aiua-12307	617	4	jayaprakash	jayaprakash	ADJ
aiua-12307	617	5	p	p	NOUN
aiua-12307	617	6	,	,	PUNCT
aiua-12307	617	7	couillault	couillault	NOUN
aiua-12307	617	8	ca	ca	NOUN
aiua-12307	617	9	,	,	PUNCT
aiua-12307	617	10	et	et	PROPN
aiua-12307	617	11	al	al	PROPN
aiua-12307	617	12	.	.	PUNCT
aiua-12307	618	1	a	a	DET
aiua-12307	618	2	phase	phase	NOUN
aiua-12307	618	3	i	i	PRON
aiua-12307	618	4	doseescalation	doseescalation	NOUN
aiua-12307	618	5	study	study	NOUN
aiua-12307	618	6	to	to	PART
aiua-12307	618	7	evaluate	evaluate	VERB
aiua-12307	618	8	the	the	DET
aiua-12307	618	9	safety	safety	NOUN
aiua-12307	618	10	and	and	CCONJ
aiua-12307	618	11	tolerability	tolerability	NOUN
aiua-12307	618	12	of	of	ADP
aiua-12307	618	13	evofosfamide	evofosfamide	ADV
aiua-12307	618	14	in	in	ADP
aiua-12307	618	15	combination	combination	NOUN
aiua-12307	618	16	with	with	ADP
aiua-12307	618	17	ipilimumab	ipilimumab	NOUN
aiua-12307	618	18	in	in	ADP
aiua-12307	618	19	advanced	advanced	ADJ
aiua-12307	618	20	solid	solid	ADJ
aiua-12307	618	21	malignancies	malignancy	NOUN
aiua-12307	618	22	.	.	PUNCT
aiua-12307	619	1	clin	clin	PROPN
aiua-12307	619	2	cancer	cancer	NOUN
aiua-12307	619	3	res	re	NOUN
aiua-12307	619	4	.	.	PUNCT
aiua-12307	619	5	2021	2021	NUM
aiua-12307	619	6	;	;	PUNCT
aiua-12307	619	7	27:3050	27:3050	NUM
aiua-12307	619	8	-	-	SYM
aiua-12307	619	9	60	60	NUM
aiua-12307	619	10	.	.	PUNCT
aiua-12307	620	1	77	77	NUM
aiua-12307	620	2	.	.	PUNCT
aiua-12307	621	1	slovin	slovin	PROPN
aiua-12307	621	2	sf	sf	PROPN
aiua-12307	621	3	,	,	PUNCT
aiua-12307	621	4	higano	higano	NOUN
aiua-12307	621	5	cs	cs	PROPN
aiua-12307	621	6	,	,	PUNCT
aiua-12307	621	7	hamid	hamid	PROPN
aiua-12307	621	8	o	o	PROPN
aiua-12307	621	9	,	,	PUNCT
aiua-12307	621	10	et	et	PROPN
aiua-12307	621	11	al	al	PROPN
aiua-12307	621	12	.	.	PROPN
aiua-12307	621	13	ipilimumab	ipilimumab	PROPN
aiua-12307	621	14	alone	alone	ADV
aiua-12307	621	15	or	or	CCONJ
aiua-12307	621	16	in	in	ADP
aiua-12307	621	17	archivio	archivio	NOUN
aiua-12307	621	18	italiano	italiano	X
aiua-12307	621	19	di	di	X
aiua-12307	621	20	urologia	urologia	PROPN
aiua-12307	621	21	e	e	PROPN
aiua-12307	621	22	andrologia	andrologia	NOUN
aiua-12307	621	23	2024	2024	NUM
aiua-12307	621	24	;	;	PUNCT
aiua-12307	621	25	96(2):12307	96(2):12307	NUM
aiua-12307	621	26	13	13	NUM
aiua-12307	621	27	the	the	DET
aiua-12307	621	28	role	role	NOUN
aiua-12307	621	29	of	of	ADP
aiua-12307	621	30	immunotherapy	immunotherapy	NOUN
aiua-12307	621	31	in	in	ADP
aiua-12307	621	32	urological	urological	ADJ
aiua-12307	621	33	cancers	cancer	NOUN
aiua-12307	621	34	combination	combination	NOUN
aiua-12307	621	35	with	with	ADP
aiua-12307	621	36	radiotherapy	radiotherapy	NOUN
aiua-12307	621	37	in	in	ADP
aiua-12307	621	38	metastatic	metastatic	ADJ
aiua-12307	621	39	castration	castration	NOUN
aiua-12307	621	40	-	-	PUNCT
aiua-12307	621	41	resistant	resistant	ADJ
aiua-12307	621	42	prostate	prostate	NOUN
aiua-12307	621	43	cancer	cancer	NOUN
aiua-12307	621	44	:	:	PUNCT
aiua-12307	621	45	results	result	NOUN
aiua-12307	621	46	from	from	ADP
aiua-12307	621	47	an	an	DET
aiua-12307	621	48	open	open	ADJ
aiua-12307	621	49	-	-	PUNCT
aiua-12307	621	50	label	label	NOUN
aiua-12307	621	51	,	,	PUNCT
aiua-12307	621	52	multicenter	multicenter	NOUN
aiua-12307	621	53	phase	phase	NOUN
aiua-12307	621	54	i	i	PROPN
aiua-12307	621	55	/	/	SYM
aiua-12307	621	56	ii	ii	PROPN
aiua-12307	621	57	study	study	NOUN
aiua-12307	621	58	.	.	PUNCT
aiua-12307	622	1	ann	ann	PROPN
aiua-12307	622	2	oncol	oncol	PROPN
aiua-12307	622	3	.	.	PUNCT
aiua-12307	623	1	2013	2013	NUM
aiua-12307	623	2	;	;	PUNCT
aiua-12307	623	3	24:1813	24:1813	NUM
aiua-12307	623	4	-	-	SYM
aiua-12307	623	5	21	21	NUM
aiua-12307	623	6	.	.	PUNCT
aiua-12307	624	1	78	78	NUM
aiua-12307	624	2	.	.	PUNCT
aiua-12307	625	1	fizazi	fizazi	PROPN
aiua-12307	625	2	k	k	PROPN
aiua-12307	625	3	,	,	PUNCT
aiua-12307	625	4	drake	drake	PROPN
aiua-12307	625	5	cg	cg	PROPN
aiua-12307	625	6	,	,	PUNCT
aiua-12307	625	7	beer	beer	NOUN
aiua-12307	625	8	tm	tm	PROPN
aiua-12307	625	9	,	,	PUNCT
aiua-12307	625	10	et	et	PROPN
aiua-12307	625	11	al	al	PROPN
aiua-12307	625	12	.	.	PROPN
aiua-12307	625	13	final	final	ADJ
aiua-12307	625	14	analysis	analysis	NOUN
aiua-12307	625	15	of	of	ADP
aiua-12307	625	16	the	the	DET
aiua-12307	625	17	ipilimumab	ipilimumab	NOUN
aiua-12307	625	18	versus	versus	ADP
aiua-12307	625	19	placebo	placebo	NOUN
aiua-12307	625	20	following	follow	VERB
aiua-12307	625	21	radiotherapy	radiotherapy	NOUN
aiua-12307	625	22	phase	phase	NOUN
aiua-12307	625	23	iii	iii	NUM
aiua-12307	625	24	trial	trial	NOUN
aiua-12307	625	25	in	in	ADP
aiua-12307	625	26	postdocetaxel	postdocetaxel	ADJ
aiua-12307	625	27	metastatic	metastatic	ADJ
aiua-12307	625	28	castration	castration	NOUN
aiua-12307	625	29	-	-	PUNCT
aiua-12307	625	30	resistant	resistant	ADJ
aiua-12307	625	31	prostate	prostate	NOUN
aiua-12307	625	32	cancer	cancer	NOUN
aiua-12307	625	33	identifies	identify	VERB
aiua-12307	625	34	an	an	DET
aiua-12307	625	35	excess	excess	NOUN
aiua-12307	625	36	of	of	ADP
aiua-12307	625	37	long	long	ADJ
aiua-12307	625	38	-	-	PUNCT
aiua-12307	625	39	term	term	NOUN
aiua-12307	625	40	survivors	survivor	NOUN
aiua-12307	625	41	.	.	PUNCT
aiua-12307	626	1	eur	eur	PROPN
aiua-12307	626	2	urol	urol	PROPN
aiua-12307	626	3	.	.	PUNCT
aiua-12307	627	1	2020	2020	NUM
aiua-12307	627	2	;	;	PUNCT
aiua-12307	628	1	78:822	78:822	NUM
aiua-12307	628	2	-	-	SYM
aiua-12307	628	3	30	30	NUM
aiua-12307	628	4	.	.	PUNCT
aiua-12307	628	5	79	79	NUM
aiua-12307	628	6	.	.	PUNCT
aiua-12307	629	1	beer	beer	PROPN
aiua-12307	629	2	tm	tm	PROPN
aiua-12307	629	3	,	,	PUNCT
aiua-12307	629	4	kwon	kwon	VERB
aiua-12307	629	5	ed	ed	PROPN
aiua-12307	629	6	,	,	PUNCT
aiua-12307	629	7	drake	drake	PROPN
aiua-12307	629	8	cg	cg	PROPN
aiua-12307	629	9	,	,	PUNCT
aiua-12307	629	10	et	et	PROPN
aiua-12307	629	11	al	al	PROPN
aiua-12307	629	12	.	.	PROPN
aiua-12307	629	13	randomized	randomize	VERB
aiua-12307	629	14	,	,	PUNCT
aiua-12307	629	15	doubleblind	doubleblind	NOUN
aiua-12307	629	16	,	,	PUNCT
aiua-12307	629	17	phase	phase	NOUN
aiua-12307	629	18	iii	iii	NOUN
aiua-12307	629	19	trial	trial	NOUN
aiua-12307	629	20	of	of	ADP
aiua-12307	629	21	ipilimumab	ipilimumab	NOUN
aiua-12307	629	22	versus	versus	ADP
aiua-12307	629	23	placebo	placebo	NOUN
aiua-12307	629	24	in	in	ADP
aiua-12307	629	25	asymptomatic	asymptomatic	ADJ
aiua-12307	629	26	or	or	CCONJ
aiua-12307	629	27	minimally	minimally	ADV
aiua-12307	629	28	symptomatic	symptomatic	ADJ
aiua-12307	629	29	patients	patient	NOUN
aiua-12307	629	30	with	with	ADP
aiua-12307	629	31	metastatic	metastatic	ADJ
aiua-12307	629	32	chemotherapynaive	chemotherapynaive	ADJ
aiua-12307	629	33	castration	castration	NOUN
aiua-12307	629	34	-	-	PUNCT
aiua-12307	629	35	resistant	resistant	ADJ
aiua-12307	629	36	prostate	prostate	NOUN
aiua-12307	629	37	cancer	cancer	NOUN
aiua-12307	629	38	.	.	PUNCT
aiua-12307	630	1	j	j	PROPN
aiua-12307	630	2	clin	clin	PROPN
aiua-12307	630	3	oncol	oncol	PROPN
aiua-12307	630	4	2017	2017	NUM
aiua-12307	630	5	;	;	PUNCT
aiua-12307	630	6	35:40	35:40	NUM
aiua-12307	630	7	-	-	SYM
aiua-12307	630	8	7	7	NUM
aiua-12307	630	9	.	.	NUM
aiua-12307	630	10	80	80	NUM
aiua-12307	630	11	.	.	PUNCT
aiua-12307	631	1	sharma	sharma	PROPN
aiua-12307	631	2	p	p	PROPN
aiua-12307	631	3	,	,	PUNCT
aiua-12307	631	4	pachynski	pachynski	ADJ
aiua-12307	631	5	rk	rk	PROPN
aiua-12307	631	6	,	,	PUNCT
aiua-12307	631	7	narayan	narayan	PROPN
aiua-12307	631	8	v	v	NOUN
aiua-12307	631	9	,	,	PUNCT
aiua-12307	631	10	et	et	PROPN
aiua-12307	631	11	al	al	PROPN
aiua-12307	631	12	.	.	PROPN
aiua-12307	631	13	initial	initial	ADJ
aiua-12307	631	14	results	result	NOUN
aiua-12307	631	15	from	from	ADP
aiua-12307	631	16	a	a	DET
aiua-12307	631	17	phase	phase	NOUN
aiua-12307	631	18	ii	ii	NOUN
aiua-12307	631	19	study	study	NOUN
aiua-12307	631	20	of	of	ADP
aiua-12307	631	21	nivolumab	nivolumab	NOUN
aiua-12307	631	22	(	(	PUNCT
aiua-12307	631	23	nivo	nivo	PROPN
aiua-12307	631	24	)	)	PUNCT
aiua-12307	631	25	plus	plus	CCONJ
aiua-12307	631	26	ipilimumab	ipilimumab	X
aiua-12307	631	27	(	(	PUNCT
aiua-12307	631	28	ipi	ipi	PROPN
aiua-12307	631	29	)	)	PUNCT
aiua-12307	631	30	for	for	ADP
aiua-12307	631	31	the	the	DET
aiua-12307	631	32	treatment	treatment	NOUN
aiua-12307	631	33	of	of	ADP
aiua-12307	631	34	metastatic	metastatic	ADJ
aiua-12307	631	35	castration	castration	NOUN
aiua-12307	631	36	-	-	PUNCT
aiua-12307	631	37	resistant	resistant	ADJ
aiua-12307	631	38	prostate	prostate	NOUN
aiua-12307	631	39	cancer	cancer	NOUN
aiua-12307	631	40	(	(	PUNCT
aiua-12307	631	41	mcrpc	mcrpc	NOUN
aiua-12307	631	42	;	;	PUNCT
aiua-12307	631	43	checkmate	checkmate	VERB
aiua-12307	631	44	650	650	NUM
aiua-12307	631	45	)	)	PUNCT
aiua-12307	631	46	.	.	PUNCT
aiua-12307	632	1	j	j	PROPN
aiua-12307	632	2	clin	clin	PROPN
aiua-12307	632	3	oncol	oncol	PROPN
aiua-12307	632	4	.	.	PUNCT
aiua-12307	633	1	2019	2019	NUM
aiua-12307	633	2	;	;	PUNCT
aiua-12307	634	1	37(7	37(7	PROPN
aiua-12307	634	2	suppl):142	suppl):142	PROPN
aiua-12307	634	3	.	.	PUNCT
aiua-12307	635	1	81	81	NUM
aiua-12307	635	2	.	.	PUNCT
aiua-12307	636	1	caruso	caruso	PROPN
aiua-12307	636	2	c.	c.	PROPN
aiua-12307	636	3	anti	anti	PROPN
aiua-12307	636	4	–	–	PUNCT
aiua-12307	636	5	pd-1	pd-1	ADJ
aiua-12307	636	6	–	–	PUNCT
aiua-12307	636	7	ctla4	ctla4	NOUN
aiua-12307	636	8	combo	combo	NOUN
aiua-12307	636	9	hits	hit	VERB
aiua-12307	636	10	prostate	prostate	NOUN
aiua-12307	636	11	cancer	cancer	NOUN
aiua-12307	636	12	.	.	PUNCT
aiua-12307	637	1	cancer	cancer	NOUN
aiua-12307	637	2	discov	discov	NOUN
aiua-12307	637	3	.	.	PUNCT
aiua-12307	638	1	2019	2019	NUM
aiua-12307	638	2	;	;	PUNCT
aiua-12307	638	3	9:569	9:569	NUM
aiua-12307	638	4	-	-	SYM
aiua-12307	638	5	70	70	NUM
aiua-12307	638	6	.	.	PUNCT
aiua-12307	639	1	82	82	NUM
aiua-12307	639	2	.	.	PUNCT
aiua-12307	640	1	shenderov	shenderov	PROPN
aiua-12307	640	2	e	e	NOUN
aiua-12307	640	3	,	,	PUNCT
aiua-12307	640	4	boudadi	boudadi	PROPN
aiua-12307	640	5	k	k	PROPN
aiua-12307	640	6	,	,	PUNCT
aiua-12307	640	7	fu	fu	PROPN
aiua-12307	640	8	w	w	PROPN
aiua-12307	640	9	,	,	PUNCT
aiua-12307	640	10	et	et	PROPN
aiua-12307	640	11	al	al	PROPN
aiua-12307	640	12	.	.	PROPN
aiua-12307	640	13	nivolumab	nivolumab	PROPN
aiua-12307	640	14	plus	plus	CCONJ
aiua-12307	640	15	ipilimumab	ipilimumab	ADV
aiua-12307	640	16	,	,	PUNCT
aiua-12307	640	17	with	with	ADP
aiua-12307	640	18	or	or	CCONJ
aiua-12307	640	19	without	without	ADP
aiua-12307	640	20	enzalutamide	enzalutamide	NOUN
aiua-12307	640	21	,	,	PUNCT
aiua-12307	640	22	in	in	ADP
aiua-12307	640	23	ar	ar	NOUN
aiua-12307	640	24	-	-	PUNCT
aiua-12307	640	25	v7	v7	VERB
aiua-12307	640	26	-	-	PUNCT
aiua-12307	640	27	expressing	express	VERB
aiua-12307	640	28	metastatic	metastatic	ADJ
aiua-12307	640	29	castration	castration	NOUN
aiua-12307	640	30	-	-	PUNCT
aiua-12307	640	31	resistant	resistant	ADJ
aiua-12307	640	32	prostate	prostate	NOUN
aiua-12307	640	33	cancer	cancer	NOUN
aiua-12307	640	34	:	:	PUNCT
aiua-12307	640	35	a	a	DET
aiua-12307	640	36	phase-2	phase-2	PROPN
aiua-12307	640	37	nonrandomized	nonrandomize	VERB
aiua-12307	640	38	clinical	clinical	ADJ
aiua-12307	640	39	trial	trial	NOUN
aiua-12307	640	40	.	.	PUNCT
aiua-12307	641	1	prostate	prostate	NOUN
aiua-12307	641	2	.	.	PUNCT
aiua-12307	641	3	2021	2021	NUM
aiua-12307	641	4	;	;	PUNCT
aiua-12307	641	5	81:326	81:326	NUM
aiua-12307	641	6	-	-	SYM
aiua-12307	641	7	38	38	NUM
aiua-12307	641	8	.	.	PUNCT
aiua-12307	641	9	83	83	NUM
aiua-12307	641	10	.	.	PUNCT
aiua-12307	642	1	evan	evan	PROPN
aiua-12307	642	2	yy	yy	PROPN
aiua-12307	642	3	,	,	PUNCT
aiua-12307	642	4	kolinsky	kolinsky	PROPN
aiua-12307	642	5	mp	mp	PROPN
aiua-12307	642	6	,	,	PUNCT
aiua-12307	642	7	berry	berry	VERB
aiua-12307	642	8	wr	wr	PROPN
aiua-12307	642	9	,	,	PUNCT
aiua-12307	642	10	et	et	PROPN
aiua-12307	642	11	al	al	PROPN
aiua-12307	642	12	.	.	PROPN
aiua-12307	642	13	pembrolizumab	pembrolizumab	NOUN
aiua-12307	642	14	plus	plus	CCONJ
aiua-12307	642	15	docetaxel	docetaxel	NOUN
aiua-12307	642	16	and	and	CCONJ
aiua-12307	642	17	prednisone	prednisone	NOUN
aiua-12307	642	18	in	in	ADP
aiua-12307	642	19	patients	patient	NOUN
aiua-12307	642	20	with	with	ADP
aiua-12307	642	21	metastatic	metastatic	ADJ
aiua-12307	642	22	castrationresistant	castrationresistant	NOUN
aiua-12307	642	23	prostate	prostate	NOUN
aiua-12307	642	24	cancer	cancer	NOUN
aiua-12307	642	25	:	:	PUNCT
aiua-12307	642	26	long	long	ADJ
aiua-12307	642	27	-	-	PUNCT
aiua-12307	642	28	term	term	NOUN
aiua-12307	642	29	results	result	NOUN
aiua-12307	642	30	from	from	ADP
aiua-12307	642	31	the	the	DET
aiua-12307	642	32	phase	phase	NOUN
aiua-12307	642	33	1b/2	1b/2	NUM
aiua-12307	642	34	keynote-365	keynote-365	NOUN
aiua-12307	642	35	cohort	cohort	NOUN
aiua-12307	642	36	b	b	PROPN
aiua-12307	642	37	study	study	NOUN
aiua-12307	642	38	.	.	PUNCT
aiua-12307	643	1	eur	eur	PROPN
aiua-12307	643	2	urol	urol	PROPN
aiua-12307	643	3	.	.	PUNCT
aiua-12307	643	4	2022	2022	NUM
aiua-12307	643	5	;	;	PUNCT
aiua-12307	643	6	82:22	82:22	NUM
aiua-12307	643	7	-	-	SYM
aiua-12307	643	8	30	30	NUM
aiua-12307	643	9	.	.	PUNCT
aiua-12307	643	10	84	84	NUM
aiua-12307	643	11	.	.	PUNCT
aiua-12307	644	1	antonarakis	antonarakis	PROPN
aiua-12307	644	2	es	es	PROPN
aiua-12307	644	3	,	,	PUNCT
aiua-12307	644	4	piulats	piulat	VERB
aiua-12307	644	5	jm	jm	PROPN
aiua-12307	644	6	,	,	PUNCT
aiua-12307	644	7	gross	gross	ADJ
aiua-12307	644	8	-	-	PUNCT
aiua-12307	644	9	goupil	goupil	NOUN
aiua-12307	644	10	m	m	NOUN
aiua-12307	644	11	,	,	PUNCT
aiua-12307	644	12	et	et	PROPN
aiua-12307	644	13	al	al	PROPN
aiua-12307	644	14	.	.	PROPN
aiua-12307	644	15	pembrolizumab	pembrolizumab	NOUN
aiua-12307	644	16	for	for	ADP
aiua-12307	644	17	treatment	treatment	NOUN
aiua-12307	644	18	-	-	PUNCT
aiua-12307	644	19	refractory	refractory	NOUN
aiua-12307	644	20	metastatic	metastatic	ADJ
aiua-12307	644	21	castration	castration	NOUN
aiua-12307	644	22	-	-	PUNCT
aiua-12307	644	23	resistant	resistant	ADJ
aiua-12307	644	24	prostate	prostate	NOUN
aiua-12307	644	25	cancer	cancer	NOUN
aiua-12307	644	26	:	:	PUNCT
aiua-12307	644	27	multicohort	multicohort	NOUN
aiua-12307	644	28	,	,	PUNCT
aiua-12307	644	29	open	open	ADJ
aiua-12307	644	30	-	-	PUNCT
aiua-12307	644	31	label	label	NOUN
aiua-12307	644	32	phase	phase	NOUN
aiua-12307	644	33	ii	ii	PROPN
aiua-12307	644	34	keynote-199	keynote-199	NOUN
aiua-12307	644	35	study	study	NOUN
aiua-12307	644	36	.	.	PUNCT
aiua-12307	645	1	j	j	PROPN
aiua-12307	645	2	clin	clin	PROPN
aiua-12307	645	3	oncol	oncol	PROPN
aiua-12307	645	4	.	.	PUNCT
aiua-12307	646	1	2020	2020	NUM
aiua-12307	646	2	;	;	PUNCT
aiua-12307	646	3	38:395	38:395	NUM
aiua-12307	646	4	-	-	SYM
aiua-12307	646	5	405	405	NUM
aiua-12307	646	6	.	.	PUNCT
aiua-12307	646	7	85	85	NUM
aiua-12307	646	8	.	.	PUNCT
aiua-12307	646	9	petrylak	petrylak	ADJ
aiua-12307	646	10	dp	dp	PROPN
aiua-12307	646	11	,	,	PUNCT
aiua-12307	646	12	loriot	loriot	PROPN
aiua-12307	646	13	y	y	PROPN
aiua-12307	646	14	,	,	PUNCT
aiua-12307	646	15	shaffer	shaffer	PROPN
aiua-12307	646	16	dr	dr	PROPN
aiua-12307	646	17	,	,	PUNCT
aiua-12307	646	18	et	et	PROPN
aiua-12307	647	1	al	al	PROPN
aiua-12307	647	2	.	.	PROPN
aiua-12307	647	3	safety	safety	NOUN
aiua-12307	647	4	and	and	CCONJ
aiua-12307	647	5	clinical	clinical	ADJ
aiua-12307	647	6	activity	activity	NOUN
aiua-12307	647	7	of	of	ADP
aiua-12307	647	8	atezolizumab	atezolizumab	NOUN
aiua-12307	647	9	in	in	ADP
aiua-12307	647	10	patients	patient	NOUN
aiua-12307	647	11	with	with	ADP
aiua-12307	647	12	metastatic	metastatic	ADJ
aiua-12307	647	13	castrationresistant	castrationresistant	NOUN
aiua-12307	647	14	prostate	prostate	NOUN
aiua-12307	647	15	cancer	cancer	NOUN
aiua-12307	647	16	:	:	PUNCT
aiua-12307	647	17	a	a	DET
aiua-12307	647	18	phase	phase	NOUN
aiua-12307	647	19	i	i	PRON
aiua-12307	647	20	study	study	VERB
aiua-12307	647	21	.	.	PUNCT
aiua-12307	648	1	clin	clin	PROPN
aiua-12307	648	2	cancer	cancer	NOUN
aiua-12307	648	3	res	re	NOUN
aiua-12307	648	4	2021	2021	NUM
aiua-12307	648	5	;	;	PUNCT
aiua-12307	648	6	27:3360	27:3360	NUM
aiua-12307	648	7	-	-	SYM
aiua-12307	648	8	9	9	NUM
aiua-12307	648	9	.	.	NOUN
aiua-12307	648	10	86	86	NUM
aiua-12307	648	11	.	.	PUNCT
aiua-12307	649	1	powles	powle	NOUN
aiua-12307	649	2	t	t	PROPN
aiua-12307	649	3	,	,	PUNCT
aiua-12307	649	4	yuen	yuen	PROPN
aiua-12307	649	5	kc	kc	PROPN
aiua-12307	649	6	,	,	PUNCT
aiua-12307	649	7	gillessen	gillessen	NOUN
aiua-12307	649	8	s	s	PROPN
aiua-12307	649	9	,	,	PUNCT
aiua-12307	649	10	,	,	PUNCT
aiua-12307	649	11	et	et	PROPN
aiua-12307	649	12	al	al	PROPN
aiua-12307	649	13	.	.	PROPN
aiua-12307	649	14	atezolizumab	atezolizumab	PROPN
aiua-12307	649	15	with	with	ADP
aiua-12307	649	16	enzalutamide	enzalutamide	NOUN
aiua-12307	649	17	versus	versus	ADP
aiua-12307	649	18	enzalutamide	enzalutamide	ADV
aiua-12307	649	19	alone	alone	ADV
aiua-12307	649	20	in	in	ADP
aiua-12307	649	21	metastatic	metastatic	ADJ
aiua-12307	649	22	castration	castration	NOUN
aiua-12307	649	23	-	-	PUNCT
aiua-12307	649	24	resistant	resistant	ADJ
aiua-12307	649	25	prostate	prostate	NOUN
aiua-12307	649	26	cancer	cancer	NOUN
aiua-12307	649	27	:	:	PUNCT
aiua-12307	649	28	a	a	DET
aiua-12307	649	29	randomized	randomized	ADJ
aiua-12307	649	30	phase	phase	NOUN
aiua-12307	649	31	3	3	NUM
aiua-12307	649	32	trial	trial	NOUN
aiua-12307	649	33	.	.	PUNCT
aiua-12307	650	1	nat	nat	PROPN
aiua-12307	650	2	med	med	PROPN
aiua-12307	650	3	.	.	PUNCT
aiua-12307	650	4	2022	2022	NUM
aiua-12307	650	5	;	;	PUNCT
aiua-12307	650	6	28:144	28:144	NUM
aiua-12307	650	7	-	-	SYM
aiua-12307	650	8	53	53	NUM
aiua-12307	650	9	.	.	PUNCT
aiua-12307	651	1	87	87	NUM
aiua-12307	651	2	.	.	PUNCT
aiua-12307	652	1	fong	fong	PROPN
aiua-12307	652	2	l	l	PROPN
aiua-12307	652	3	,	,	PUNCT
aiua-12307	652	4	morris	morris	PROPN
aiua-12307	652	5	mj	mj	PROPN
aiua-12307	652	6	,	,	PUNCT
aiua-12307	652	7	sartor	sartor	PROPN
aiua-12307	652	8	o	o	PROPN
aiua-12307	652	9	,	,	PUNCT
aiua-12307	652	10	et	et	PROPN
aiua-12307	652	11	al	al	PROPN
aiua-12307	652	12	.	.	PUNCT
aiua-12307	653	1	a	a	DET
aiua-12307	653	2	phase	phase	NOUN
aiua-12307	653	3	ib	ib	PROPN
aiua-12307	653	4	study	study	NOUN
aiua-12307	653	5	of	of	ADP
aiua-12307	653	6	atezolizumab	atezolizumab	NOUN
aiua-12307	653	7	with	with	ADP
aiua-12307	653	8	radium-223	radium-223	NOUN
aiua-12307	653	9	dichloride	dichloride	NOUN
aiua-12307	653	10	in	in	ADP
aiua-12307	653	11	men	man	NOUN
aiua-12307	653	12	with	with	ADP
aiua-12307	653	13	metastatic	metastatic	ADJ
aiua-12307	653	14	castration	castration	NOUN
aiua-12307	653	15	-	-	PUNCT
aiua-12307	653	16	resistant	resistant	ADJ
aiua-12307	653	17	prostate	prostate	NOUN
aiua-12307	653	18	cancer	cancer	NOUN
aiua-12307	653	19	.	.	PUNCT
aiua-12307	654	1	clin	clin	PROPN
aiua-12307	654	2	cancer	cancer	NOUN
aiua-12307	654	3	res	re	NOUN
aiua-12307	654	4	.	.	PUNCT
aiua-12307	654	5	2021	2021	NUM
aiua-12307	654	6	;	;	PUNCT
aiua-12307	654	7	27:4746	27:4746	PROPN
aiua-12307	654	8	-	-	SYM
aiua-12307	654	9	56	56	NUM
aiua-12307	654	10	.	.	NUM
aiua-12307	654	11	88	88	NUM
aiua-12307	654	12	.	.	PUNCT
aiua-12307	655	1	kwan	kwan	PROPN
aiua-12307	655	2	em	em	PRON
aiua-12307	655	3	,	,	PUNCT
aiua-12307	655	4	spain	spain	PROPN
aiua-12307	655	5	l	l	PROPN
aiua-12307	655	6	,	,	PUNCT
aiua-12307	655	7	anton	anton	PROPN
aiua-12307	655	8	a	a	PRON
aiua-12307	655	9	,	,	PUNCT
aiua-12307	655	10	et	et	PROPN
aiua-12307	655	11	al	al	PROPN
aiua-12307	655	12	.	.	PROPN
aiua-12307	655	13	avelumab	avelumab	PROPN
aiua-12307	655	14	combined	combine	VERB
aiua-12307	655	15	with	with	ADP
aiua-12307	655	16	stereotactic	stereotactic	ADJ
aiua-12307	655	17	ablative	ablative	ADJ
aiua-12307	655	18	body	body	NOUN
aiua-12307	655	19	radiotherapy	radiotherapy	NOUN
aiua-12307	655	20	in	in	ADP
aiua-12307	655	21	metastatic	metastatic	ADJ
aiua-12307	655	22	castrationresistant	castrationresistant	NOUN
aiua-12307	655	23	prostate	prostate	NOUN
aiua-12307	655	24	cancer	cancer	NOUN
aiua-12307	655	25	:	:	PUNCT
aiua-12307	655	26	the	the	DET
aiua-12307	655	27	phase	phase	NOUN
aiua-12307	655	28	2	2	NUM
aiua-12307	655	29	ice	ice	NOUN
aiua-12307	655	30	-	-	PUNCT
aiua-12307	655	31	pac	pac	NOUN
aiua-12307	655	32	clinical	clinical	ADJ
aiua-12307	655	33	trial	trial	NOUN
aiua-12307	655	34	.	.	PUNCT
aiua-12307	656	1	eur	eur	PROPN
aiua-12307	656	2	urol	urol	PROPN
aiua-12307	656	3	.	.	PUNCT
aiua-12307	656	4	2022	2022	NUM
aiua-12307	656	5	;	;	PUNCT
aiua-12307	656	6	81:253	81:253	NUM
aiua-12307	656	7	-	-	SYM
aiua-12307	656	8	62	62	NUM
aiua-12307	656	9	.	.	PUNCT
aiua-12307	656	10	89	89	NUM
aiua-12307	656	11	.	.	PUNCT
aiua-12307	657	1	karzai	karzai	PROPN
aiua-12307	657	2	f	f	PROPN
aiua-12307	657	3	,	,	PUNCT
aiua-12307	657	4	vanderweele	vanderweele	PROPN
aiua-12307	657	5	d	d	PROPN
aiua-12307	657	6	,	,	PUNCT
aiua-12307	657	7	madan	madan	PROPN
aiua-12307	657	8	ra	ra	PROPN
aiua-12307	657	9	,	,	PUNCT
aiua-12307	657	10	et	et	PROPN
aiua-12307	657	11	al	al	PROPN
aiua-12307	657	12	.	.	PUNCT
aiua-12307	657	13	activity	activity	NOUN
aiua-12307	657	14	of	of	ADP
aiua-12307	657	15	durvalumab	durvalumab	NOUN
aiua-12307	657	16	plus	plus	CCONJ
aiua-12307	657	17	olaparib	olaparib	VERB
aiua-12307	657	18	in	in	ADP
aiua-12307	657	19	metastatic	metastatic	ADJ
aiua-12307	657	20	castration	castration	NOUN
aiua-12307	657	21	-	-	PUNCT
aiua-12307	657	22	resistant	resistant	ADJ
aiua-12307	657	23	prostate	prostate	NOUN
aiua-12307	657	24	cancer	cancer	NOUN
aiua-12307	657	25	in	in	ADP
aiua-12307	657	26	men	man	NOUN
aiua-12307	657	27	with	with	ADP
aiua-12307	657	28	and	and	CCONJ
aiua-12307	657	29	without	without	ADP
aiua-12307	657	30	dna	dna	PROPN
aiua-12307	657	31	damage	damage	NOUN
aiua-12307	657	32	repair	repair	NOUN
aiua-12307	657	33	mutations	mutation	NOUN
aiua-12307	657	34	.	.	PUNCT
aiua-12307	658	1	j	j	PROPN
aiua-12307	658	2	immunother	immunother	ADJ
aiua-12307	658	3	cancer	cancer	NOUN
aiua-12307	658	4	.	.	PUNCT
aiua-12307	659	1	2018	2018	NUM
aiua-12307	659	2	;	;	PUNCT
aiua-12307	659	3	6:1	6:1	NUM
aiua-12307	659	4	-	-	SYM
aiua-12307	659	5	12	12	NUM
aiua-12307	659	6	.	.	PUNCT
aiua-12307	660	1	90	90	NUM
aiua-12307	660	2	.	.	PUNCT
aiua-12307	661	1	cheever	cheever	PROPN
aiua-12307	661	2	ma	ma	PROPN
aiua-12307	661	3	,	,	PUNCT
aiua-12307	661	4	higano	higano	NOUN
aiua-12307	661	5	cs	cs	PROPN
aiua-12307	661	6	.	.	PROPN
aiua-12307	661	7	provenge	provenge	PROPN
aiua-12307	661	8	(	(	PUNCT
aiua-12307	661	9	sipuleucel	sipuleucel	PROPN
aiua-12307	661	10	-	-	PUNCT
aiua-12307	661	11	t	t	NOUN
aiua-12307	661	12	)	)	PUNCT
aiua-12307	661	13	in	in	ADP
aiua-12307	661	14	prostate	prostate	NOUN
aiua-12307	661	15	cancer	cancer	NOUN
aiua-12307	661	16	:	:	PUNCT
aiua-12307	661	17	the	the	DET
aiua-12307	661	18	first	first	ADJ
aiua-12307	661	19	fda	fda	PROPN
aiua-12307	661	20	-	-	PUNCT
aiua-12307	661	21	approved	approve	VERB
aiua-12307	661	22	therapeutic	therapeutic	ADJ
aiua-12307	661	23	cancer	cancer	NOUN
aiua-12307	661	24	vaccine	vaccine	NOUN
aiua-12307	661	25	.	.	PUNCT
aiua-12307	662	1	clin	clin	PROPN
aiua-12307	662	2	cancer	cancer	NOUN
aiua-12307	662	3	res	re	NOUN
aiua-12307	662	4	.	.	PUNCT
aiua-12307	662	5	2011	2011	NUM
aiua-12307	662	6	;	;	PUNCT
aiua-12307	662	7	17:3520	17:3520	NUM
aiua-12307	662	8	-	-	SYM
aiua-12307	662	9	6	6	NUM
aiua-12307	662	10	.	.	NOUN
aiua-12307	662	11	91	91	NUM
aiua-12307	662	12	.	.	PUNCT
aiua-12307	663	1	wang	wang	PROPN
aiua-12307	663	2	i	i	PROPN
aiua-12307	663	3	,	,	PUNCT
aiua-12307	663	4	song	song	PROPN
aiua-12307	663	5	l	l	PROPN
aiua-12307	663	6	,	,	PUNCT
aiua-12307	663	7	wang	wang	PROPN
aiua-12307	663	8	by	by	ADV
aiua-12307	663	9	,	,	PUNCT
aiua-12307	663	10	et	et	PROPN
aiua-12307	663	11	al	al	PROPN
aiua-12307	663	12	.	.	PROPN
aiua-12307	663	13	prostate	prostate	NOUN
aiua-12307	663	14	cancer	cancer	NOUN
aiua-12307	663	15	immunotherapy	immunotherapy	NOUN
aiua-12307	663	16	:	:	PUNCT
aiua-12307	663	17	a	a	DET
aiua-12307	663	18	review	review	NOUN
aiua-12307	663	19	of	of	ADP
aiua-12307	663	20	recent	recent	ADJ
aiua-12307	663	21	advancements	advancement	NOUN
aiua-12307	663	22	with	with	ADP
aiua-12307	663	23	novel	novel	ADJ
aiua-12307	663	24	treatment	treatment	NOUN
aiua-12307	663	25	methods	method	NOUN
aiua-12307	663	26	and	and	CCONJ
aiua-12307	663	27	efficacy	efficacy	NOUN
aiua-12307	663	28	.	.	PUNCT
aiua-12307	664	1	am	be	AUX
aiua-12307	664	2	j	j	PROPN
aiua-12307	664	3	clin	clin	PROPN
aiua-12307	664	4	exp	exp	PROPN
aiua-12307	664	5	urol	urol	PROPN
aiua-12307	664	6	.	.	PUNCT
aiua-12307	665	1	2022	2022	NUM
aiua-12307	665	2	;	;	PUNCT
aiua-12307	665	3	10:210	10:210	NUM
aiua-12307	665	4	-	-	SYM
aiua-12307	665	5	33	33	NUM
aiua-12307	665	6	.	.	PUNCT
aiua-12307	666	1	correspondence	correspondence	NOUN
aiua-12307	666	2	efe	efe	PROPN
aiua-12307	666	3	bosnalı	bosnalı	PROPN
aiua-12307	666	4	,	,	PUNCT
aiua-12307	666	5	md	md	PROPN
aiua-12307	666	6	(	(	PUNCT
aiua-12307	666	7	corresponding	correspond	VERB
aiua-12307	666	8	author	author	NOUN
aiua-12307	666	9	)	)	PUNCT
aiua-12307	666	10	efebosnali415@gmail.com	efebosnali415@gmail.com	X
aiua-12307	666	11	department	department	NOUN
aiua-12307	666	12	of	of	ADP
aiua-12307	666	13	urology	urology	NOUN
aiua-12307	666	14	,	,	PUNCT
aiua-12307	666	15	university	university	NOUN
aiua-12307	666	16	of	of	ADP
aiua-12307	666	17	health	health	PROPN
aiua-12307	666	18	sciences	sciences	PROPN
aiua-12307	666	19	,	,	PUNCT
aiua-12307	666	20	derince	derince	NOUN
aiua-12307	666	21	training	training	NOUN
aiua-12307	666	22	and	and	CCONJ
aiua-12307	666	23	research	research	NOUN
aiua-12307	666	24	hospital	hospital	NOUN
aiua-12307	666	25	,	,	PUNCT
aiua-12307	666	26	turkey	turkey	PROPN
aiua-12307	666	27	,	,	PUNCT
aiua-12307	666	28	41380	41380	NUM
aiua-12307	666	29	enes	enes	PROPN
aiua-12307	666	30	malik	malik	PROPN
aiua-12307	666	31	akdas	akdas	PROPN
aiua-12307	666	32	,	,	PUNCT
aiua-12307	666	33	md	md	PROPN
aiua-12307	666	34	turkey	turkey	PROPN
aiua-12307	666	35	enesmalikakdas@gmail.com	enesmalikakdas@gmail.com	PROPN
aiua-12307	667	1	engin	engin	PROPN
aiua-12307	667	2	telli	telli	PROPN
aiua-12307	667	3	,	,	PUNCT
aiua-12307	667	4	md	md	PROPN
aiua-12307	667	5	turkey	turkey	PROPN
aiua-12307	667	6	engintelli@gmail.com	engintelli@gmail.com	PROPN
aiua-12307	668	1	kerem	kerem	PROPN
aiua-12307	668	2	teke	teke	PROPN
aiua-12307	668	3	,	,	PUNCT
aiua-12307	668	4	md	md	PROPN
aiua-12307	668	5	turkey	turkey	PROPN
aiua-12307	668	6	drtekekerem@gmail.com	drtekekerem@gmail.com	PROPN
aiua-12307	669	1	onder	onder	PROPN
aiua-12307	669	2	kara	kara	PROPN
aiua-12307	669	3	,	,	PUNCT
aiua-12307	669	4	md	md	PROPN
aiua-12307	669	5	turkey	turkey	PROPN
aiua-12307	670	1	onerkara@yahoo.com	onerkara@yahoo.com	PROPN
aiua-12307	671	1	kocaeli	kocaeli	PROPN
aiua-12307	671	2	university	university	PROPN
aiua-12307	671	3	,	,	PUNCT
aiua-12307	671	4	school	school	NOUN
aiua-12307	671	5	of	of	ADP
aiua-12307	671	6	medicine	medicine	NOUN
aiua-12307	671	7	,	,	PUNCT
aiua-12307	671	8	department	department	NOUN
aiua-12307	671	9	of	of	ADP
aiua-12307	671	10	urology	urology	NOUN
aiua-12307	671	11	,	,	PUNCT
aiua-12307	671	12	kocaeli	kocaeli	VERB
aiua-12307	671	13	,	,	PUNCT
aiua-12307	671	14	turkey	turkey	NOUN
aiua-12307	671	15	conflict	conflict	NOUN
aiua-12307	671	16	of	of	ADP
aiua-12307	671	17	interest	interest	NOUN
aiua-12307	671	18	:	:	PUNCT
aiua-12307	671	19	the	the	DET
aiua-12307	671	20	authors	author	NOUN
aiua-12307	671	21	declare	declare	VERB
aiua-12307	671	22	no	no	DET
aiua-12307	671	23	potential	potential	ADJ
aiua-12307	671	24	conflict	conflict	NOUN
aiua-12307	671	25	of	of	ADP
aiua-12307	671	26	interest	interest	NOUN
aiua-12307	671	27	.	.	PUNCT